bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Arbeit is an umlsterm, Stickstoffmonoxid is an umlsterm, ischaemiebedingten is an umlsterm, Zelltod is an umlsterm, Feten is an umlsterm, Herz - Kreislauf - System is an umlsterm, Gewebeschnittmodell is an umlsterm, Marker is an umlsterm, Energiestoffwechsels is an umlsterm, Proteinbiosynthese is an umlsterm, Methode is an umlsterm, Meerschweinchenfeten is an umlsterm, Halothan is an umlsterm, Gehirns is an umlsterm, Gewebescheiben is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, glukosefreien is an umlsterm, Gewebeschnitte is an umlsterm, NO - Synthase is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gewebekonzentration is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, Konzentration is an umlsterm, HPLC is an umlsterm, Proteinbiosynthese is an umlsterm, Leucin is an umlsterm, Gewebeproteine is an umlsterm, Varianzanalyse is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Konzentration is an umlsterm, Gewebescheiben is an umlsterm, Protein is an umlsterm, Protein is an umlsterm, Ischaemie is an umlsterm, Energiestoffwechsel is an umlsterm, Proteinbiosynthese is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm, Stickstoffmonoxid is an umlsterm, Herz - Kreislauf - System is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm	PerinatalMedizin.80100016.ger.abstr_task0	Sentence: In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben .	[ "In", "der", "vorliegenden", "Arbeit", "sollte", "die", "Bedeutung", "von", "Stickstoffmonoxid", "(", "NO", ")", "fuer", "den", "ischaemiebedingten", "neuronalen", "Zelltod", "beim", "Feten", "unabhaengig", "vom", "Herz", "-", "Kreislauf", "-", "System", "untersucht", "werden", ".", "Hierzu", "verwendeten", "wir", "ein", "hippokampales", "Gewebeschnittmodell", ".", "Als", "Marker", "fuer", "den", "neuronalen", "Zellschaden", "waehlten", "wir", "die", "postischaemische", "Beeintraechtigung", "des", "Energiestoffwechsels", "und", "der", "Proteinbiosynthese", ".", "Methode", ":", "Reife", "Meerschweinchenfeten", "wurden", "mit", "Halothan", "narkotisiert", ".", "Das", "Hippokampusareal", "des", "Gehirns", "wurde", "entnommen", "und", "in", "500", "µm", "dicke", "Scheiben", "geschnitten", ".", "Die", "Gewebescheiben", "wurden", "in", "artifizielle", "Liquorfluessigkeit", "(", "aCSF", ")", "transferiert", "und", "mit", "O2", "/", "CO2", "(", "95%/5", "%", ")", "in", "einer", "Inkubationskammer", "begast", ".", "Zur", "Induktion", "der", "Ischaemie", "in", "vitro", "wurden", "die", "Gewebescheiben", "in", "einen", "glukosefreien", "aCSF", "transferiert", "und", "fuer", "10", "-", "40", "min", "mit", "N2", "/", "CO2", "(", "95%/5", "%", ")", "begast", ".", "Bei", "einem", "Teil", "der", "Gewebeschnitte", "wurde", "die", "NO", "-", "Synthase", "mit", "100", "µM", "N", "-", "Nitro", "-", "L", "-", "Arginin", "(", "NNLA", ")", "geblockt", ".", "Die", "Aktivierung", "der", "NO", "-", "Synthase", "waehrend", "der", "Ischaemie", "wurde", "ueber", "die", "Gewebekonzentration", "von", "cGMP", "bestimmt", ".", "cGMP", "wurde", "mit", "einem", "Radioimmunoassay", "gemessen", "12", ";", "h", "nach", "Ischaemie", "in", "vitro", "wurden", "die", "Adenylate", "und", "die", "Proteinbiosyntheses", "in", "den", "Gewebescheiben", "bestimmt", ".", "Die", "Konzentration", "der", "Adenylate", "wurde", "mit", "HPLC", "nach", "Extraktion", "mit", "Perchloressigsaeure", "gemessen", ".", "Die", "Proteinbiosynthese", "wurde", "als", "Inkorporationsrate", "von", "L-", "[", "1", "-", "14C", "]", "Leucin", "in", "Gewebeproteine", "ermittelt", ".", "Unterschiede", "innerhalb", "und", "zwischen", "den", "Gruppen", "wurden", "mit", "einer", "zweifaktoriellen", "Varianzanalyse", "und", "Scheffé", "-", "post", "-", "hoc", "-", "Test", "auf", "Signifikanz", "(", "p", "0.05", ")", "geprueft", ".", "Ergebnisse", ":", "Waehrend", "einer", "40minuetigen", "Ischaemie", "in", "vitro", "stieg", "die", "Konzentration", "von", "cGMP", "in", "den", "Gewebescheiben", "signifikant", "an", "(", "Kontrolle", ";", "1,35", "+", "/-", "0,38", "pmol", "/", "mg", "Protein", "vs", ".", "I", "40", ":", "18,6", "+", "/-", "1,04", "pmol", "/", "mg", "Protein", ":", "p", "0.05", ")", ".", "Der", "cGMP", "-", "Anstieg", "waehrend", "der", "Ischaemie", "konnte", "durch", "NNLA", "nahezu", "vollstaendig", "inhibiert", "werden", ".", "Allerdings", "gelang", "es", "nicht", "durch", "NNLA", "den", "Energiestoffwechsel", "oder", "die", "Proteinbiosynthese", "12", "h", "nach", "40minue", "-", "tiger", "Ischaemie", "in", "vitro", "zu", "verbessern", ".", "Schlussfolgerung", ":", "Die", "NO", "-", "Synthase", "wird", "waehrend", "einer", "Ischaemie", "im", "fetalen", "Gehirn", "erheblich", "aktiviert", ".", "Stickstoffmonoxid", "scheint", "dabei", "unabhaengig", "von", "seinen", "Wirkungen", "auf", "das", "Herz", "-", "Kreislauf", "-", "System", "fuer", "die", "Genese", "des", "neuronalen", "Zelltodes", "nach", "einer", "transienten", "Ischaemie", "im", "unreifen", "Gehirn", "keine", "groessere", "Bedeutung", "zu", "haben", "." ]	[ "umlsterm" ]
Arbeit is an umlsterm, Stickstoffmonoxid is an umlsterm, ischaemiebedingten is an umlsterm, Zelltod is an umlsterm, Feten is an umlsterm, Herz - Kreislauf - System is an umlsterm, Gewebeschnittmodell is an umlsterm, Marker is an umlsterm, Energiestoffwechsels is an umlsterm, Proteinbiosynthese is an umlsterm, Methode is an umlsterm, Meerschweinchenfeten is an umlsterm, Halothan is an umlsterm, Gehirns is an umlsterm, Gewebescheiben is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, glukosefreien is an umlsterm, Gewebeschnitte is an umlsterm, NO - Synthase is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gewebekonzentration is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, Konzentration is an umlsterm, HPLC is an umlsterm, Proteinbiosynthese is an umlsterm, Leucin is an umlsterm, Gewebeproteine is an umlsterm, Varianzanalyse is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Konzentration is an umlsterm, Gewebescheiben is an umlsterm, Protein is an umlsterm, Protein is an umlsterm, Ischaemie is an umlsterm, Energiestoffwechsel is an umlsterm, Proteinbiosynthese is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm, Stickstoffmonoxid is an umlsterm, Herz - Kreislauf - System is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm	PerinatalMedizin.80100016.ger.abstr_task1	Sentence: In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben . Instructions: please typing these entity words according to sentence: Arbeit, Stickstoffmonoxid, ischaemiebedingten, Zelltod, Feten, Herz - Kreislauf - System, Gewebeschnittmodell, Marker, Energiestoffwechsels, Proteinbiosynthese, Methode, Meerschweinchenfeten, Halothan, Gehirns, Gewebescheiben, Ischaemie, in vitro, Gewebescheiben, glukosefreien, Gewebeschnitte, NO - Synthase, NO - Synthase, Ischaemie, Gewebekonzentration, Ischaemie, in vitro, Gewebescheiben, Konzentration, HPLC, Proteinbiosynthese, Leucin, Gewebeproteine, Varianzanalyse, Ischaemie, in vitro, Konzentration, Gewebescheiben, Protein, Protein, Ischaemie, Energiestoffwechsel, Proteinbiosynthese, Ischaemie, in vitro, NO - Synthase, Ischaemie, Gehirn, Stickstoffmonoxid, Herz - Kreislauf - System, Ischaemie, Gehirn Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben .	[ "In", "der", "vorliegenden", "Arbeit", "sollte", "die", "Bedeutung", "von", "Stickstoffmonoxid", "(", "NO", ")", "fuer", "den", "ischaemiebedingten", "neuronalen", "Zelltod", "beim", "Feten", "unabhaengig", "vom", "Herz", "-", "Kreislauf", "-", "System", "untersucht", "werden", ".", "Hierzu", "verwendeten", "wir", "ein", "hippokampales", "Gewebeschnittmodell", ".", "Als", "Marker", "fuer", "den", "neuronalen", "Zellschaden", "waehlten", "wir", "die", "postischaemische", "Beeintraechtigung", "des", "Energiestoffwechsels", "und", "der", "Proteinbiosynthese", ".", "Methode", ":", "Reife", "Meerschweinchenfeten", "wurden", "mit", "Halothan", "narkotisiert", ".", "Das", "Hippokampusareal", "des", "Gehirns", "wurde", "entnommen", "und", "in", "500", "µm", "dicke", "Scheiben", "geschnitten", ".", "Die", "Gewebescheiben", "wurden", "in", "artifizielle", "Liquorfluessigkeit", "(", "aCSF", ")", "transferiert", "und", "mit", "O2", "/", "CO2", "(", "95%/5", "%", ")", "in", "einer", "Inkubationskammer", "begast", ".", "Zur", "Induktion", "der", "Ischaemie", "in", "vitro", "wurden", "die", "Gewebescheiben", "in", "einen", "glukosefreien", "aCSF", "transferiert", "und", "fuer", "10", "-", "40", "min", "mit", "N2", "/", "CO2", "(", "95%/5", "%", ")", "begast", ".", "Bei", "einem", "Teil", "der", "Gewebeschnitte", "wurde", "die", "NO", "-", "Synthase", "mit", "100", "µM", "N", "-", "Nitro", "-", "L", "-", "Arginin", "(", "NNLA", ")", "geblockt", ".", "Die", "Aktivierung", "der", "NO", "-", "Synthase", "waehrend", "der", "Ischaemie", "wurde", "ueber", "die", "Gewebekonzentration", "von", "cGMP", "bestimmt", ".", "cGMP", "wurde", "mit", "einem", "Radioimmunoassay", "gemessen", "12", ";", "h", "nach", "Ischaemie", "in", "vitro", "wurden", "die", "Adenylate", "und", "die", "Proteinbiosyntheses", "in", "den", "Gewebescheiben", "bestimmt", ".", "Die", "Konzentration", "der", "Adenylate", "wurde", "mit", "HPLC", "nach", "Extraktion", "mit", "Perchloressigsaeure", "gemessen", ".", "Die", "Proteinbiosynthese", "wurde", "als", "Inkorporationsrate", "von", "L-", "[", "1", "-", "14C", "]", "Leucin", "in", "Gewebeproteine", "ermittelt", ".", "Unterschiede", "innerhalb", "und", "zwischen", "den", "Gruppen", "wurden", "mit", "einer", "zweifaktoriellen", "Varianzanalyse", "und", "Scheffé", "-", "post", "-", "hoc", "-", "Test", "auf", "Signifikanz", "(", "p", "0.05", ")", "geprueft", ".", "Ergebnisse", ":", "Waehrend", "einer", "40minuetigen", "Ischaemie", "in", "vitro", "stieg", "die", "Konzentration", "von", "cGMP", "in", "den", "Gewebescheiben", "signifikant", "an", "(", "Kontrolle", ";", "1,35", "+", "/-", "0,38", "pmol", "/", "mg", "Protein", "vs", ".", "I", "40", ":", "18,6", "+", "/-", "1,04", "pmol", "/", "mg", "Protein", ":", "p", "0.05", ")", ".", "Der", "cGMP", "-", "Anstieg", "waehrend", "der", "Ischaemie", "konnte", "durch", "NNLA", "nahezu", "vollstaendig", "inhibiert", "werden", ".", "Allerdings", "gelang", "es", "nicht", "durch", "NNLA", "den", "Energiestoffwechsel", "oder", "die", "Proteinbiosynthese", "12", "h", "nach", "40minue", "-", "tiger", "Ischaemie", "in", "vitro", "zu", "verbessern", ".", "Schlussfolgerung", ":", "Die", "NO", "-", "Synthase", "wird", "waehrend", "einer", "Ischaemie", "im", "fetalen", "Gehirn", "erheblich", "aktiviert", ".", "Stickstoffmonoxid", "scheint", "dabei", "unabhaengig", "von", "seinen", "Wirkungen", "auf", "das", "Herz", "-", "Kreislauf", "-", "System", "fuer", "die", "Genese", "des", "neuronalen", "Zelltodes", "nach", "einer", "transienten", "Ischaemie", "im", "unreifen", "Gehirn", "keine", "groessere", "Bedeutung", "zu", "haben", "." ]	[ "umlsterm" ]
Arbeit, Stickstoffmonoxid, ischaemiebedingten, Zelltod, Feten, Herz - Kreislauf - System, Gewebeschnittmodell, Marker, Energiestoffwechsels, Proteinbiosynthese, Methode, Meerschweinchenfeten, Halothan, Gehirns, Gewebescheiben, Ischaemie, in vitro, Gewebescheiben, glukosefreien, Gewebeschnitte, NO - Synthase, NO - Synthase, Ischaemie, Gewebekonzentration, Ischaemie, in vitro, Gewebescheiben, Konzentration, HPLC, Proteinbiosynthese, Leucin, Gewebeproteine, Varianzanalyse, Ischaemie, in vitro, Konzentration, Gewebescheiben, Protein, Protein, Ischaemie, Energiestoffwechsel, Proteinbiosynthese, Ischaemie, in vitro, NO - Synthase, Ischaemie, Gehirn, Stickstoffmonoxid, Herz - Kreislauf - System, Ischaemie, Gehirn	PerinatalMedizin.80100016.ger.abstr_task2	Sentence: In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben .	[ "In", "der", "vorliegenden", "Arbeit", "sollte", "die", "Bedeutung", "von", "Stickstoffmonoxid", "(", "NO", ")", "fuer", "den", "ischaemiebedingten", "neuronalen", "Zelltod", "beim", "Feten", "unabhaengig", "vom", "Herz", "-", "Kreislauf", "-", "System", "untersucht", "werden", ".", "Hierzu", "verwendeten", "wir", "ein", "hippokampales", "Gewebeschnittmodell", ".", "Als", "Marker", "fuer", "den", "neuronalen", "Zellschaden", "waehlten", "wir", "die", "postischaemische", "Beeintraechtigung", "des", "Energiestoffwechsels", "und", "der", "Proteinbiosynthese", ".", "Methode", ":", "Reife", "Meerschweinchenfeten", "wurden", "mit", "Halothan", "narkotisiert", ".", "Das", "Hippokampusareal", "des", "Gehirns", "wurde", "entnommen", "und", "in", "500", "µm", "dicke", "Scheiben", "geschnitten", ".", "Die", "Gewebescheiben", "wurden", "in", "artifizielle", "Liquorfluessigkeit", "(", "aCSF", ")", "transferiert", "und", "mit", "O2", "/", "CO2", "(", "95%/5", "%", ")", "in", "einer", "Inkubationskammer", "begast", ".", "Zur", "Induktion", "der", "Ischaemie", "in", "vitro", "wurden", "die", "Gewebescheiben", "in", "einen", "glukosefreien", "aCSF", "transferiert", "und", "fuer", "10", "-", "40", "min", "mit", "N2", "/", "CO2", "(", "95%/5", "%", ")", "begast", ".", "Bei", "einem", "Teil", "der", "Gewebeschnitte", "wurde", "die", "NO", "-", "Synthase", "mit", "100", "µM", "N", "-", "Nitro", "-", "L", "-", "Arginin", "(", "NNLA", ")", "geblockt", ".", "Die", "Aktivierung", "der", "NO", "-", "Synthase", "waehrend", "der", "Ischaemie", "wurde", "ueber", "die", "Gewebekonzentration", "von", "cGMP", "bestimmt", ".", "cGMP", "wurde", "mit", "einem", "Radioimmunoassay", "gemessen", "12", ";", "h", "nach", "Ischaemie", "in", "vitro", "wurden", "die", "Adenylate", "und", "die", "Proteinbiosyntheses", "in", "den", "Gewebescheiben", "bestimmt", ".", "Die", "Konzentration", "der", "Adenylate", "wurde", "mit", "HPLC", "nach", "Extraktion", "mit", "Perchloressigsaeure", "gemessen", ".", "Die", "Proteinbiosynthese", "wurde", "als", "Inkorporationsrate", "von", "L-", "[", "1", "-", "14C", "]", "Leucin", "in", "Gewebeproteine", "ermittelt", ".", "Unterschiede", "innerhalb", "und", "zwischen", "den", "Gruppen", "wurden", "mit", "einer", "zweifaktoriellen", "Varianzanalyse", "und", "Scheffé", "-", "post", "-", "hoc", "-", "Test", "auf", "Signifikanz", "(", "p", "0.05", ")", "geprueft", ".", "Ergebnisse", ":", "Waehrend", "einer", "40minuetigen", "Ischaemie", "in", "vitro", "stieg", "die", "Konzentration", "von", "cGMP", "in", "den", "Gewebescheiben", "signifikant", "an", "(", "Kontrolle", ";", "1,35", "+", "/-", "0,38", "pmol", "/", "mg", "Protein", "vs", ".", "I", "40", ":", "18,6", "+", "/-", "1,04", "pmol", "/", "mg", "Protein", ":", "p", "0.05", ")", ".", "Der", "cGMP", "-", "Anstieg", "waehrend", "der", "Ischaemie", "konnte", "durch", "NNLA", "nahezu", "vollstaendig", "inhibiert", "werden", ".", "Allerdings", "gelang", "es", "nicht", "durch", "NNLA", "den", "Energiestoffwechsel", "oder", "die", "Proteinbiosynthese", "12", "h", "nach", "40minue", "-", "tiger", "Ischaemie", "in", "vitro", "zu", "verbessern", ".", "Schlussfolgerung", ":", "Die", "NO", "-", "Synthase", "wird", "waehrend", "einer", "Ischaemie", "im", "fetalen", "Gehirn", "erheblich", "aktiviert", ".", "Stickstoffmonoxid", "scheint", "dabei", "unabhaengig", "von", "seinen", "Wirkungen", "auf", "das", "Herz", "-", "Kreislauf", "-", "System", "fuer", "die", "Genese", "des", "neuronalen", "Zelltodes", "nach", "einer", "transienten", "Ischaemie", "im", "unreifen", "Gehirn", "keine", "groessere", "Bedeutung", "zu", "haben", "." ]	[ "umlsterm" ]
Empyemhoehlenrevision is an umlsterm, Drainagetherapie is an umlsterm, Empyeme is an umlsterm, Therapieverfahren is an umlsterm, Thoraxdrainage is an umlsterm, Geschlechtsverteilung is an umlsterm, Drainagegruppe is an umlsterm, Drainagedauer is an umlsterm, Drainage is an umlsterm, Rezidivrate is an umlsterm, Therapieversagern is an umlsterm, Drainagebehandlungen is an umlsterm	DerChirurg.90700464.ger.abstr_task0	Sentence: Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern .	[ "Zusammenfassung", ".", "Im", "fibropurulenten", "Stadium", "des", "Pleuraempyems", "gewinnt", "die", "videoassistierte", "thoracoskopische", "(", "VAT", ")", "Empyemhoehlenrevision", "im", "Sinne", "der", "Fruehdecortication", "an", "Bedeutung", ".", "Dieser", "Zugang", "ist", "bisher", "im", "Vergleich", "zur", "Drainagetherapie", "oder", "Thoracotomie", "nicht", "befriedigend", "evaluiert", ".", "356", "parapneumonische", "Empyeme", "aus", "den", "Jahren", "1986", "bis", "1997", "wurden", "retrospektiv", "im", "Hinblick", "auf", "die", "Ergebnisse", "nach", "den", "verschiedenen", "primaeren", "Therapieverfahren", "(", "225", "Thoraxdrainage", ",", "80", "Thoracotomie", ",", "51", "VAT", ")", "ausgewertet", ".", "Bezueglich", "Geschlechtsverteilung", "und", "Begleiterkrankungen", "waren", "die", "3", "Gruppen", "vergleichbar", ".", "Das", "mediane", "Alter", "der", "Drainagegruppe", "(", "54", "Jahre", ")", "lag", "aber", "hoeher", "als", "bei", "Thoracotomie", "(", "43,5", ")", "oder", "VAT", "(", "39", ")", ".", "Die", "mediane", "Drainagedauer", "nach", "Thoracotomie", "(", "7", "Tage", ")", "war", "kuerzer", "als", "nach", "VAT", "(", "13Tage", "oder", "Drainage", "(", ")", "20", "Tage", ")", "(", "p", "0,0001", ")", ".", "Auch", "bzgl", ".", "Liegedauer", ",", "Rezidivrate", "und", "Therapieversagern", "waren", "die", "jeweils", "invasiveren", "den", "weniger", "invasiven", "Verfahren", "ueberlegen", ".", "Trotz", "der", "besseren", "Ergebnisse", "wird", "die", "Thoracotomie", "beim", "Pleuraempyem", "durch", "die", "VAT", "zurueckgedraengt", "werden", ".", "Die", "Akzeptanz", "der", "VAT", "spiegelt", "sich", "in", "steigenden", "Zuweisungszahlen", "und", "kann", "protrahierte", "Drainagebehandlungen", "vermeiden", ".", "Auf", "der", "Basis", "dieser", "retrospektiven", "Daten", "planen", "wir", "eine", "prospektive", "multizentrische", "Studie", ",", "um", "die", "Indikation", "zur", "VAT", "beim", "Pleuraempyem", "abzusichern", "." ]	[ "umlsterm" ]
Empyemhoehlenrevision is an umlsterm, Drainagetherapie is an umlsterm, Empyeme is an umlsterm, Therapieverfahren is an umlsterm, Thoraxdrainage is an umlsterm, Geschlechtsverteilung is an umlsterm, Drainagegruppe is an umlsterm, Drainagedauer is an umlsterm, Drainage is an umlsterm, Rezidivrate is an umlsterm, Therapieversagern is an umlsterm, Drainagebehandlungen is an umlsterm	DerChirurg.90700464.ger.abstr_task1	Sentence: Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern . Instructions: please typing these entity words according to sentence: Empyemhoehlenrevision, Drainagetherapie, Empyeme, Therapieverfahren, Thoraxdrainage, Geschlechtsverteilung, Drainagegruppe, Drainagedauer, Drainage, Rezidivrate, Therapieversagern, Drainagebehandlungen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern .	[ "Zusammenfassung", ".", "Im", "fibropurulenten", "Stadium", "des", "Pleuraempyems", "gewinnt", "die", "videoassistierte", "thoracoskopische", "(", "VAT", ")", "Empyemhoehlenrevision", "im", "Sinne", "der", "Fruehdecortication", "an", "Bedeutung", ".", "Dieser", "Zugang", "ist", "bisher", "im", "Vergleich", "zur", "Drainagetherapie", "oder", "Thoracotomie", "nicht", "befriedigend", "evaluiert", ".", "356", "parapneumonische", "Empyeme", "aus", "den", "Jahren", "1986", "bis", "1997", "wurden", "retrospektiv", "im", "Hinblick", "auf", "die", "Ergebnisse", "nach", "den", "verschiedenen", "primaeren", "Therapieverfahren", "(", "225", "Thoraxdrainage", ",", "80", "Thoracotomie", ",", "51", "VAT", ")", "ausgewertet", ".", "Bezueglich", "Geschlechtsverteilung", "und", "Begleiterkrankungen", "waren", "die", "3", "Gruppen", "vergleichbar", ".", "Das", "mediane", "Alter", "der", "Drainagegruppe", "(", "54", "Jahre", ")", "lag", "aber", "hoeher", "als", "bei", "Thoracotomie", "(", "43,5", ")", "oder", "VAT", "(", "39", ")", ".", "Die", "mediane", "Drainagedauer", "nach", "Thoracotomie", "(", "7", "Tage", ")", "war", "kuerzer", "als", "nach", "VAT", "(", "13Tage", "oder", "Drainage", "(", ")", "20", "Tage", ")", "(", "p", "0,0001", ")", ".", "Auch", "bzgl", ".", "Liegedauer", ",", "Rezidivrate", "und", "Therapieversagern", "waren", "die", "jeweils", "invasiveren", "den", "weniger", "invasiven", "Verfahren", "ueberlegen", ".", "Trotz", "der", "besseren", "Ergebnisse", "wird", "die", "Thoracotomie", "beim", "Pleuraempyem", "durch", "die", "VAT", "zurueckgedraengt", "werden", ".", "Die", "Akzeptanz", "der", "VAT", "spiegelt", "sich", "in", "steigenden", "Zuweisungszahlen", "und", "kann", "protrahierte", "Drainagebehandlungen", "vermeiden", ".", "Auf", "der", "Basis", "dieser", "retrospektiven", "Daten", "planen", "wir", "eine", "prospektive", "multizentrische", "Studie", ",", "um", "die", "Indikation", "zur", "VAT", "beim", "Pleuraempyem", "abzusichern", "." ]	[ "umlsterm" ]
Empyemhoehlenrevision, Drainagetherapie, Empyeme, Therapieverfahren, Thoraxdrainage, Geschlechtsverteilung, Drainagegruppe, Drainagedauer, Drainage, Rezidivrate, Therapieversagern, Drainagebehandlungen	DerChirurg.90700464.ger.abstr_task2	Sentence: Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern .	[ "Zusammenfassung", ".", "Im", "fibropurulenten", "Stadium", "des", "Pleuraempyems", "gewinnt", "die", "videoassistierte", "thoracoskopische", "(", "VAT", ")", "Empyemhoehlenrevision", "im", "Sinne", "der", "Fruehdecortication", "an", "Bedeutung", ".", "Dieser", "Zugang", "ist", "bisher", "im", "Vergleich", "zur", "Drainagetherapie", "oder", "Thoracotomie", "nicht", "befriedigend", "evaluiert", ".", "356", "parapneumonische", "Empyeme", "aus", "den", "Jahren", "1986", "bis", "1997", "wurden", "retrospektiv", "im", "Hinblick", "auf", "die", "Ergebnisse", "nach", "den", "verschiedenen", "primaeren", "Therapieverfahren", "(", "225", "Thoraxdrainage", ",", "80", "Thoracotomie", ",", "51", "VAT", ")", "ausgewertet", ".", "Bezueglich", "Geschlechtsverteilung", "und", "Begleiterkrankungen", "waren", "die", "3", "Gruppen", "vergleichbar", ".", "Das", "mediane", "Alter", "der", "Drainagegruppe", "(", "54", "Jahre", ")", "lag", "aber", "hoeher", "als", "bei", "Thoracotomie", "(", "43,5", ")", "oder", "VAT", "(", "39", ")", ".", "Die", "mediane", "Drainagedauer", "nach", "Thoracotomie", "(", "7", "Tage", ")", "war", "kuerzer", "als", "nach", "VAT", "(", "13Tage", "oder", "Drainage", "(", ")", "20", "Tage", ")", "(", "p", "0,0001", ")", ".", "Auch", "bzgl", ".", "Liegedauer", ",", "Rezidivrate", "und", "Therapieversagern", "waren", "die", "jeweils", "invasiveren", "den", "weniger", "invasiven", "Verfahren", "ueberlegen", ".", "Trotz", "der", "besseren", "Ergebnisse", "wird", "die", "Thoracotomie", "beim", "Pleuraempyem", "durch", "die", "VAT", "zurueckgedraengt", "werden", ".", "Die", "Akzeptanz", "der", "VAT", "spiegelt", "sich", "in", "steigenden", "Zuweisungszahlen", "und", "kann", "protrahierte", "Drainagebehandlungen", "vermeiden", ".", "Auf", "der", "Basis", "dieser", "retrospektiven", "Daten", "planen", "wir", "eine", "prospektive", "multizentrische", "Studie", ",", "um", "die", "Indikation", "zur", "VAT", "beim", "Pleuraempyem", "abzusichern", "." ]	[ "umlsterm" ]
heparin - binding EGF - like growth factor is a GENE-Y, EGF receptor is a GENE-Y, imatinib mesylate is a CHEMICAL	15887238_task0	Sentence: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.	[ "Induction", "of", "heparin", "-", "binding", "EGF", "-", "like", "growth", "factor", "and", "activation", "of", "EGF", "receptor", "in", "imatinib", "mesylate", "-", "treated", "squamous", "carcinoma", "cells", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
heparin - binding EGF - like growth factor is a GENE-Y, EGF receptor is a GENE-Y, imatinib mesylate is a CHEMICAL	15887238_task1	Sentence: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Instructions: please typing these entity words according to sentence: heparin - binding EGF - like growth factor, EGF receptor, imatinib mesylate Options: GENE-Y, CHEMICAL	[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.	[ "Induction", "of", "heparin", "-", "binding", "EGF", "-", "like", "growth", "factor", "and", "activation", "of", "EGF", "receptor", "in", "imatinib", "mesylate", "-", "treated", "squamous", "carcinoma", "cells", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
heparin - binding EGF - like growth factor, EGF receptor, imatinib mesylate	15887238_task2	Sentence: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.	[ "Induction", "of", "heparin", "-", "binding", "EGF", "-", "like", "growth", "factor", "and", "activation", "of", "EGF", "receptor", "in", "imatinib", "mesylate", "-", "treated", "squamous", "carcinoma", "cells", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Gehirns is an umlsterm, Zeit is an umlsterm, Methoden is an umlsterm, SPECT is an umlsterm, Kontrastmittelapplikationen is an umlsterm, Magnetresonanztomographie is an umlsterm, kontrastmittelunterstuetzten is an umlsterm, Gewebeperfusion is an umlsterm, Mikrozirkulation is an umlsterm, Permeabilitaet is an umlsterm, Blut - Hirn - Schranke is an umlsterm, Nuklearmedizin is an umlsterm, Eigendiffusion is an umlsterm, Wassermolekuelen is an umlsterm, Gewebe is an umlsterm, Techniken is an umlsterm, Natur is an umlsterm, Gewebe is an umlsterm, Stoffwechselvorgaenge is an umlsterm, Strahlenbelastung is an umlsterm, Methoden is an umlsterm, Methoden is an umlsterm, zerebralen Ischaemie is an umlsterm, Schlaganfall is an umlsterm, Gefaessmissbildungen is an umlsterm, Tumordiagnostik is an umlsterm, Therapiefindung is an umlsterm, Therapieplanung is an umlsterm, Methoden is an umlsterm, Demenzen is an umlsterm, Psychosen is an umlsterm	DerRadiologe.00400849.ger.abstr_task0	Sentence: Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen .	[ "Funktionelle", "Untersuchungen", "des", "Gehirns", "waren", "lange", "Zeit", "lediglich", "mit", "nuklearmedizinischen", "Methoden", "wie", "der", "Positronenemissionstomographie", "(", "PET", ")", "und", "der", "Single", "-", "Photonen", "-", "Emission", "-", "Computed", "-", "Tomography", "(", "SPECT", ")", "moeglich", ".", "Durch", "den", "Einsatz", "schneller", "Bildgebungssequenzen", ",", "optimierter", "Kontrastmittelapplikationen", "und", "spezieller", "Nachverarbeitungsmethoden", "wurde", "es", "moeglich", "physiologische", "und", "pathophysiologische", "Prozesse", ",", "mittels", "der", "Magnetresonanztomographie", "(", "MRT", ")", "zu", "beobachten", ".", "Mit", "T1-", "und", "T2", "*", "-gewichteten", "kontrastmittelunterstuetzten", "Bildgebungssequenzen", "koennen", "Informationen", "ueber", "die", "Gewebeperfusion", ",", "Mikrozirkulation", "und", "die", "Permeabilitaet", "der", "Blut", "-", "Hirn", "-", "Schranke", "unter", "Anwendung", "spezieller", "z", ".", ",", "T.", "aus", "der", "Nuklearmedizin", "stammender", "Modelle", "erfasst", "werden", ".", "Die", "Eigendiffusion", "von", "Wassermolekuelen", "im", "Gewebe", "ist", "mit", "diffusionsgewichteter", "MRT", ",", "die", "Markrovaskulatur", ",", "zeitlich", "aufgeloest", ",", "mit", "MR", "-", "angiographischen", "Techniken", "darstellbar", ".", "Auch", "eine", "neuronale", "Aktivitaet", "einfacher", "oder", "komplexer", "Natur", "kann", "mit", "funktionellen", "MR", "-", "Techniken", "visualisiert", "werden", ".", "Mit", "MR", "-", "spektroskopischen", "Untersuchungen", "koennen", "metabolische", "Verteilungen", "in", "normalem", "und", "pathologischem", "Gewebe", "mehrdimensional", "erfasst", "und", "Stoffwechselvorgaenge", "im", "Verlauf", "beobachtet", "werden", ".", "Vorteile", "der", "MRT", "ist", "die", "geringe", "Invasivitaet", ",", "die", "Moeglichkeit", "einer", "dreidimensionalen", "Darstellung", "der", "Daten", "und", "eine", "beliebige", "Wiederholbarkeit", "der", "Untersuchung", "bei", "fehlender", "Strahlenbelastung", ".", "Die", "bereits", "klinisch", "einsetzbaren", "funktionellen", "Methoden", "werden", "beschrieben", "und", "ihr", "Einsatz", "in", "der", "Neuroradiologie", "auch", "in", "Bezug", "auf", "die", "Wertigkeit", "im", "Vergleich", "zu", "nuklearmedizinischen", "Methoden", "diskutiert", ".", "Perfusions-", "und", "Diffusions", "-", "MRT", "liefern", "wichtige", "Zusatzinformationen", "im", "akuten", "und", "chronischen", "Stadium", "der", "zerebralen", "Ischaemie", "und", "werden", "bereits", "routinemaessig", "bei", "akutem", "Schlaganfall", "eingesetzt", ".", "Dynamische", "MR", "-", "Angiographien", "erlauben", "eine", "haemodynamische", "Einstufung", "von", "Gefaessmissbildungen", ".", "In", "der", "Tumordiagnostik", "liefern", "die", "funktionellen", "MR", "-", "Techniken", "wichtige", "Zusatzinformationen", "fuer", "die", "Therapiefindung", ",", "Therapieplanung", "und", "das", "Therapiemonitoring", ".", "Die", "Untersuchung", "psychiatrischen", "Erkrankungen", "wurde", "durch", "die", "funktionelle", "MRT", "revolutioniert", ",", "obwohl", "der", "klinische", "Einsatz", "noch", "limitiert", "ist", ".", "Erste", "Untersuchungen", "konnten", "zeigen", ",", "dass", "die", "Methoden", "in", "der", "Lage", "sind", ",", "pathophysiologische", "Veraenderungen", "bei", "Demenzen", "und", "Psychosen", "sensitiv", "zu", "erfassen", "." ]	[ "umlsterm" ]
Gehirns is an umlsterm, Zeit is an umlsterm, Methoden is an umlsterm, SPECT is an umlsterm, Kontrastmittelapplikationen is an umlsterm, Magnetresonanztomographie is an umlsterm, kontrastmittelunterstuetzten is an umlsterm, Gewebeperfusion is an umlsterm, Mikrozirkulation is an umlsterm, Permeabilitaet is an umlsterm, Blut - Hirn - Schranke is an umlsterm, Nuklearmedizin is an umlsterm, Eigendiffusion is an umlsterm, Wassermolekuelen is an umlsterm, Gewebe is an umlsterm, Techniken is an umlsterm, Natur is an umlsterm, Gewebe is an umlsterm, Stoffwechselvorgaenge is an umlsterm, Strahlenbelastung is an umlsterm, Methoden is an umlsterm, Methoden is an umlsterm, zerebralen Ischaemie is an umlsterm, Schlaganfall is an umlsterm, Gefaessmissbildungen is an umlsterm, Tumordiagnostik is an umlsterm, Therapiefindung is an umlsterm, Therapieplanung is an umlsterm, Methoden is an umlsterm, Demenzen is an umlsterm, Psychosen is an umlsterm	DerRadiologe.00400849.ger.abstr_task1	Sentence: Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen . Instructions: please typing these entity words according to sentence: Gehirns, Zeit, Methoden, SPECT, Kontrastmittelapplikationen, Magnetresonanztomographie, kontrastmittelunterstuetzten, Gewebeperfusion, Mikrozirkulation, Permeabilitaet, Blut - Hirn - Schranke, Nuklearmedizin, Eigendiffusion, Wassermolekuelen, Gewebe, Techniken, Natur, Gewebe, Stoffwechselvorgaenge, Strahlenbelastung, Methoden, Methoden, zerebralen Ischaemie, Schlaganfall, Gefaessmissbildungen, Tumordiagnostik, Therapiefindung, Therapieplanung, Methoden, Demenzen, Psychosen Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen .	[ "Funktionelle", "Untersuchungen", "des", "Gehirns", "waren", "lange", "Zeit", "lediglich", "mit", "nuklearmedizinischen", "Methoden", "wie", "der", "Positronenemissionstomographie", "(", "PET", ")", "und", "der", "Single", "-", "Photonen", "-", "Emission", "-", "Computed", "-", "Tomography", "(", "SPECT", ")", "moeglich", ".", "Durch", "den", "Einsatz", "schneller", "Bildgebungssequenzen", ",", "optimierter", "Kontrastmittelapplikationen", "und", "spezieller", "Nachverarbeitungsmethoden", "wurde", "es", "moeglich", "physiologische", "und", "pathophysiologische", "Prozesse", ",", "mittels", "der", "Magnetresonanztomographie", "(", "MRT", ")", "zu", "beobachten", ".", "Mit", "T1-", "und", "T2", "*", "-gewichteten", "kontrastmittelunterstuetzten", "Bildgebungssequenzen", "koennen", "Informationen", "ueber", "die", "Gewebeperfusion", ",", "Mikrozirkulation", "und", "die", "Permeabilitaet", "der", "Blut", "-", "Hirn", "-", "Schranke", "unter", "Anwendung", "spezieller", "z", ".", ",", "T.", "aus", "der", "Nuklearmedizin", "stammender", "Modelle", "erfasst", "werden", ".", "Die", "Eigendiffusion", "von", "Wassermolekuelen", "im", "Gewebe", "ist", "mit", "diffusionsgewichteter", "MRT", ",", "die", "Markrovaskulatur", ",", "zeitlich", "aufgeloest", ",", "mit", "MR", "-", "angiographischen", "Techniken", "darstellbar", ".", "Auch", "eine", "neuronale", "Aktivitaet", "einfacher", "oder", "komplexer", "Natur", "kann", "mit", "funktionellen", "MR", "-", "Techniken", "visualisiert", "werden", ".", "Mit", "MR", "-", "spektroskopischen", "Untersuchungen", "koennen", "metabolische", "Verteilungen", "in", "normalem", "und", "pathologischem", "Gewebe", "mehrdimensional", "erfasst", "und", "Stoffwechselvorgaenge", "im", "Verlauf", "beobachtet", "werden", ".", "Vorteile", "der", "MRT", "ist", "die", "geringe", "Invasivitaet", ",", "die", "Moeglichkeit", "einer", "dreidimensionalen", "Darstellung", "der", "Daten", "und", "eine", "beliebige", "Wiederholbarkeit", "der", "Untersuchung", "bei", "fehlender", "Strahlenbelastung", ".", "Die", "bereits", "klinisch", "einsetzbaren", "funktionellen", "Methoden", "werden", "beschrieben", "und", "ihr", "Einsatz", "in", "der", "Neuroradiologie", "auch", "in", "Bezug", "auf", "die", "Wertigkeit", "im", "Vergleich", "zu", "nuklearmedizinischen", "Methoden", "diskutiert", ".", "Perfusions-", "und", "Diffusions", "-", "MRT", "liefern", "wichtige", "Zusatzinformationen", "im", "akuten", "und", "chronischen", "Stadium", "der", "zerebralen", "Ischaemie", "und", "werden", "bereits", "routinemaessig", "bei", "akutem", "Schlaganfall", "eingesetzt", ".", "Dynamische", "MR", "-", "Angiographien", "erlauben", "eine", "haemodynamische", "Einstufung", "von", "Gefaessmissbildungen", ".", "In", "der", "Tumordiagnostik", "liefern", "die", "funktionellen", "MR", "-", "Techniken", "wichtige", "Zusatzinformationen", "fuer", "die", "Therapiefindung", ",", "Therapieplanung", "und", "das", "Therapiemonitoring", ".", "Die", "Untersuchung", "psychiatrischen", "Erkrankungen", "wurde", "durch", "die", "funktionelle", "MRT", "revolutioniert", ",", "obwohl", "der", "klinische", "Einsatz", "noch", "limitiert", "ist", ".", "Erste", "Untersuchungen", "konnten", "zeigen", ",", "dass", "die", "Methoden", "in", "der", "Lage", "sind", ",", "pathophysiologische", "Veraenderungen", "bei", "Demenzen", "und", "Psychosen", "sensitiv", "zu", "erfassen", "." ]	[ "umlsterm" ]
Gehirns, Zeit, Methoden, SPECT, Kontrastmittelapplikationen, Magnetresonanztomographie, kontrastmittelunterstuetzten, Gewebeperfusion, Mikrozirkulation, Permeabilitaet, Blut - Hirn - Schranke, Nuklearmedizin, Eigendiffusion, Wassermolekuelen, Gewebe, Techniken, Natur, Gewebe, Stoffwechselvorgaenge, Strahlenbelastung, Methoden, Methoden, zerebralen Ischaemie, Schlaganfall, Gefaessmissbildungen, Tumordiagnostik, Therapiefindung, Therapieplanung, Methoden, Demenzen, Psychosen	DerRadiologe.00400849.ger.abstr_task2	Sentence: Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen .	[ "Funktionelle", "Untersuchungen", "des", "Gehirns", "waren", "lange", "Zeit", "lediglich", "mit", "nuklearmedizinischen", "Methoden", "wie", "der", "Positronenemissionstomographie", "(", "PET", ")", "und", "der", "Single", "-", "Photonen", "-", "Emission", "-", "Computed", "-", "Tomography", "(", "SPECT", ")", "moeglich", ".", "Durch", "den", "Einsatz", "schneller", "Bildgebungssequenzen", ",", "optimierter", "Kontrastmittelapplikationen", "und", "spezieller", "Nachverarbeitungsmethoden", "wurde", "es", "moeglich", "physiologische", "und", "pathophysiologische", "Prozesse", ",", "mittels", "der", "Magnetresonanztomographie", "(", "MRT", ")", "zu", "beobachten", ".", "Mit", "T1-", "und", "T2", "*", "-gewichteten", "kontrastmittelunterstuetzten", "Bildgebungssequenzen", "koennen", "Informationen", "ueber", "die", "Gewebeperfusion", ",", "Mikrozirkulation", "und", "die", "Permeabilitaet", "der", "Blut", "-", "Hirn", "-", "Schranke", "unter", "Anwendung", "spezieller", "z", ".", ",", "T.", "aus", "der", "Nuklearmedizin", "stammender", "Modelle", "erfasst", "werden", ".", "Die", "Eigendiffusion", "von", "Wassermolekuelen", "im", "Gewebe", "ist", "mit", "diffusionsgewichteter", "MRT", ",", "die", "Markrovaskulatur", ",", "zeitlich", "aufgeloest", ",", "mit", "MR", "-", "angiographischen", "Techniken", "darstellbar", ".", "Auch", "eine", "neuronale", "Aktivitaet", "einfacher", "oder", "komplexer", "Natur", "kann", "mit", "funktionellen", "MR", "-", "Techniken", "visualisiert", "werden", ".", "Mit", "MR", "-", "spektroskopischen", "Untersuchungen", "koennen", "metabolische", "Verteilungen", "in", "normalem", "und", "pathologischem", "Gewebe", "mehrdimensional", "erfasst", "und", "Stoffwechselvorgaenge", "im", "Verlauf", "beobachtet", "werden", ".", "Vorteile", "der", "MRT", "ist", "die", "geringe", "Invasivitaet", ",", "die", "Moeglichkeit", "einer", "dreidimensionalen", "Darstellung", "der", "Daten", "und", "eine", "beliebige", "Wiederholbarkeit", "der", "Untersuchung", "bei", "fehlender", "Strahlenbelastung", ".", "Die", "bereits", "klinisch", "einsetzbaren", "funktionellen", "Methoden", "werden", "beschrieben", "und", "ihr", "Einsatz", "in", "der", "Neuroradiologie", "auch", "in", "Bezug", "auf", "die", "Wertigkeit", "im", "Vergleich", "zu", "nuklearmedizinischen", "Methoden", "diskutiert", ".", "Perfusions-", "und", "Diffusions", "-", "MRT", "liefern", "wichtige", "Zusatzinformationen", "im", "akuten", "und", "chronischen", "Stadium", "der", "zerebralen", "Ischaemie", "und", "werden", "bereits", "routinemaessig", "bei", "akutem", "Schlaganfall", "eingesetzt", ".", "Dynamische", "MR", "-", "Angiographien", "erlauben", "eine", "haemodynamische", "Einstufung", "von", "Gefaessmissbildungen", ".", "In", "der", "Tumordiagnostik", "liefern", "die", "funktionellen", "MR", "-", "Techniken", "wichtige", "Zusatzinformationen", "fuer", "die", "Therapiefindung", ",", "Therapieplanung", "und", "das", "Therapiemonitoring", ".", "Die", "Untersuchung", "psychiatrischen", "Erkrankungen", "wurde", "durch", "die", "funktionelle", "MRT", "revolutioniert", ",", "obwohl", "der", "klinische", "Einsatz", "noch", "limitiert", "ist", ".", "Erste", "Untersuchungen", "konnten", "zeigen", ",", "dass", "die", "Methoden", "in", "der", "Lage", "sind", ",", "pathophysiologische", "Veraenderungen", "bei", "Demenzen", "und", "Psychosen", "sensitiv", "zu", "erfassen", "." ]	[ "umlsterm" ]
ProTon is an umlsterm, Tiermodell is an umlsterm	DerOpthalmologe.00970788.ger.abstr_task0	Sentence: Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell .	[ "Fragestellung", ".", "Untersuchung", "des", "lageunabhaengigen", "Applanationstonometers", "ProTon", "im", "Tiermodell", "." ]	[ "umlsterm" ]
ProTon is an umlsterm, Tiermodell is an umlsterm	DerOpthalmologe.00970788.ger.abstr_task1	Sentence: Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell . Instructions: please typing these entity words according to sentence: ProTon, Tiermodell Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell .	[ "Fragestellung", ".", "Untersuchung", "des", "lageunabhaengigen", "Applanationstonometers", "ProTon", "im", "Tiermodell", "." ]	[ "umlsterm" ]
ProTon, Tiermodell	DerOpthalmologe.00970788.ger.abstr_task2	Sentence: Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell .	[ "Fragestellung", ".", "Untersuchung", "des", "lageunabhaengigen", "Applanationstonometers", "ProTon", "im", "Tiermodell", "." ]	[ "umlsterm" ]
18 55 years is a Value, age is a Person, History is a Observation, good health is a Condition, Medical Assessment is a Procedure, Medical History is a Observation, Physical Examination is a Procedure, Vital Signs is a Measurement, EKG is a Procedure, oral HIV test is a Procedure, height is a Measurement, urinalysis is a Procedure, blood sample is a Procedure, CBC is a Procedure, complete metabolic profile is a Procedure, TSH is a Procedure, ESR is a Procedure, STS is a Procedure, HIV is a Procedure, positive is a Value, salivary test for HIV is a Measurement, disqualify is a Negation, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 + is a Scope, Serum glucose over 140 mg / dl is a Scope, fasting serum glucose assessment is a Procedure, Right - handed is a Condition, Edinburgh Handedness Inventory is a Procedure, Estimated IQ is a Measurement, greater than or equal to 85 is a Value, Wechsler Abbreviated Scale of Intelligence is a Procedure	NCT02231892_inc_task0	Sentence: Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Observation, Procedure, Negation, Scope, Measurement	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Measurement", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O" ]	Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence.	[ "Subjects", "must", ":", "\n", "1", ".", "Be", "able", "to", "give", "valid", "informed", "consent", "\n", "2", ".", "Be", "18", "55", "years", "of", "age", ".", "\n", "1", ".", "Justification", ":", "Many", "neural", "processes", "change", "with", "age", ",", "and", "these", "changes", "could", "introduce", "unwanted", "variability", "in", "both", "behavioral", "and", "MRI", "signals", ".", "In", "addition", ",", "the", "risk", "of", "difficult", "-", "to", "-", "detect", "medical", "abnormalities", "such", "as", "silent", "cerebral", "infarcts", "increases", "with", "age", ".", "\n", "2", ".", "Screening", "tool", ":", "History", ".", "Government", "-", "issued", "forms", "of", "identification", "(", "e.g", ".", "driver", "s", "license", ",", "birth", "certificate", ")", "will", "be", "required", "when", "participant", "appears", "to", "be", "out", "of", "age", "range", ".", "\n", "3", ".", "Be", "in", "good", "health", ".", "\n", "1", ".", "Justification", ":", "Many", "illnesses", "may", "alter", "neural", "functioning", "as", "well", "as", "fMRI", "signals", ".", "\n", "2", ".", "Screening", "tools", ":", "Medical", "Assessment", ",", "Medical", "History", "and", "Physical", "Examination", ".", "Medical", "assessments", "include", ":", "Vital", "Signs", ",", "EKG", ",", "oral", "HIV", "test", ",", "height", "/", "weight", "measurements", ",", "urinalysis", "and", "blood", "sample", ".", "Tests", "on", "the", "blood", "sample", "include", "CBC", ",", "complete", "metabolic", "profile", ",", "TSH", ",", "ESR", ",", "STS", "and", "HIV", "(", "if", "needed", "to", "confirm", "a", "positive", "salivary", "test", "for", "HIV", ")", ".", "The", "following", "individual", "laboratory", "results", "will", "independently", "disqualify", "individuals", ":", "Cholesterol", ">", "250", "mg", "/", "dl", ",", "Hemoglobin", "<", "10.5", "g", "/", "dl", ",", "WBC", "<", "2400", "/", "microl", ",", "LFTs", ">", "3Xnormal", ",", "HCG", "positive", ",", "Casual", "serum", "glucose", ">", "200", "mg", "/", "dl", ",", "Urine", "protein", ">", "1", "+", ".", "The", "MAI", "will", "retain", "discretion", "to", "exclude", "at", "less", "extreme", "values", ",", "depending", "on", "the", "clinical", "presentation", ".", "(", "Serum", "glucose", "over", "140", "mg", "/", "dl", "will", "be", "followed", "up", "with", "a", "fasting", "serum", "glucose", "assessment", ".", "Those", "with", "fasting", "glucose", "below", "100", "mg", "/", "dl", "may", "be", "considered", "for", "the", "protocol", ".", "Others", "will", "be", "rejected", "and", "referred", "for", "work", "-", "up", ".", ")", "MAI", "will", "make", "the", "final", "judgment", "on", "any", "questionable", "lab", "results", ".", "\n", "4", ".", "Right", "-", "handed", ".", "\n", "1", ".", "Justification", ":", "Using", "right", "-", "handed", "individuals", "will", "reduce", "variability", "in", "BOLD", "MRI", "data", ".", "\n", "2", ".", "Screening", "tool", ":", "Edinburgh", "Handedness", "Inventory", ".", "\n", "5", ".", "Estimated", "IQ", "greater", "than", "or", "equal", "to", "85", "\n", "1", ".", "Justification", ":", "Subjects", "must", "be", "able", "to", "perform", "a", "cognitively", "challenging", "task", "to", "a", "high", "standard", ".", "\n", "2", ".", "Screening", "tool", ":", "Wechsler", "Abbreviated", "Scale", "of", "Intelligence", ".", "\n" ]	[ "Scope", "Procedure", "Value", "Measurement", "Observation", "Condition", "Negation", "Person" ]
18 55 years is a Value, age is a Person, History is a Observation, good health is a Condition, Medical Assessment is a Procedure, Medical History is a Observation, Physical Examination is a Procedure, Vital Signs is a Measurement, EKG is a Procedure, oral HIV test is a Procedure, height is a Measurement, urinalysis is a Procedure, blood sample is a Procedure, CBC is a Procedure, complete metabolic profile is a Procedure, TSH is a Procedure, ESR is a Procedure, STS is a Procedure, HIV is a Procedure, positive is a Value, salivary test for HIV is a Measurement, disqualify is a Negation, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 + is a Scope, Serum glucose over 140 mg / dl is a Scope, fasting serum glucose assessment is a Procedure, Right - handed is a Condition, Edinburgh Handedness Inventory is a Procedure, Estimated IQ is a Measurement, greater than or equal to 85 is a Value, Wechsler Abbreviated Scale of Intelligence is a Procedure	NCT02231892_inc_task1	Sentence: Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence. Instructions: please typing these entity words according to sentence: 18 55 years, age, History, good health, Medical Assessment, Medical History, Physical Examination, Vital Signs, EKG, oral HIV test, height, urinalysis, blood sample, CBC, complete metabolic profile, TSH, ESR, STS, HIV, positive, salivary test for HIV, disqualify, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 +, Serum glucose over 140 mg / dl, fasting serum glucose assessment, Right - handed, Edinburgh Handedness Inventory, Estimated IQ, greater than or equal to 85, Wechsler Abbreviated Scale of Intelligence Options: Condition, Value, Person, Observation, Procedure, Negation, Scope, Measurement	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Measurement", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O" ]	Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence.	[ "Subjects", "must", ":", "\n", "1", ".", "Be", "able", "to", "give", "valid", "informed", "consent", "\n", "2", ".", "Be", "18", "55", "years", "of", "age", ".", "\n", "1", ".", "Justification", ":", "Many", "neural", "processes", "change", "with", "age", ",", "and", "these", "changes", "could", "introduce", "unwanted", "variability", "in", "both", "behavioral", "and", "MRI", "signals", ".", "In", "addition", ",", "the", "risk", "of", "difficult", "-", "to", "-", "detect", "medical", "abnormalities", "such", "as", "silent", "cerebral", "infarcts", "increases", "with", "age", ".", "\n", "2", ".", "Screening", "tool", ":", "History", ".", "Government", "-", "issued", "forms", "of", "identification", "(", "e.g", ".", "driver", "s", "license", ",", "birth", "certificate", ")", "will", "be", "required", "when", "participant", "appears", "to", "be", "out", "of", "age", "range", ".", "\n", "3", ".", "Be", "in", "good", "health", ".", "\n", "1", ".", "Justification", ":", "Many", "illnesses", "may", "alter", "neural", "functioning", "as", "well", "as", "fMRI", "signals", ".", "\n", "2", ".", "Screening", "tools", ":", "Medical", "Assessment", ",", "Medical", "History", "and", "Physical", "Examination", ".", "Medical", "assessments", "include", ":", "Vital", "Signs", ",", "EKG", ",", "oral", "HIV", "test", ",", "height", "/", "weight", "measurements", ",", "urinalysis", "and", "blood", "sample", ".", "Tests", "on", "the", "blood", "sample", "include", "CBC", ",", "complete", "metabolic", "profile", ",", "TSH", ",", "ESR", ",", "STS", "and", "HIV", "(", "if", "needed", "to", "confirm", "a", "positive", "salivary", "test", "for", "HIV", ")", ".", "The", "following", "individual", "laboratory", "results", "will", "independently", "disqualify", "individuals", ":", "Cholesterol", ">", "250", "mg", "/", "dl", ",", "Hemoglobin", "<", "10.5", "g", "/", "dl", ",", "WBC", "<", "2400", "/", "microl", ",", "LFTs", ">", "3Xnormal", ",", "HCG", "positive", ",", "Casual", "serum", "glucose", ">", "200", "mg", "/", "dl", ",", "Urine", "protein", ">", "1", "+", ".", "The", "MAI", "will", "retain", "discretion", "to", "exclude", "at", "less", "extreme", "values", ",", "depending", "on", "the", "clinical", "presentation", ".", "(", "Serum", "glucose", "over", "140", "mg", "/", "dl", "will", "be", "followed", "up", "with", "a", "fasting", "serum", "glucose", "assessment", ".", "Those", "with", "fasting", "glucose", "below", "100", "mg", "/", "dl", "may", "be", "considered", "for", "the", "protocol", ".", "Others", "will", "be", "rejected", "and", "referred", "for", "work", "-", "up", ".", ")", "MAI", "will", "make", "the", "final", "judgment", "on", "any", "questionable", "lab", "results", ".", "\n", "4", ".", "Right", "-", "handed", ".", "\n", "1", ".", "Justification", ":", "Using", "right", "-", "handed", "individuals", "will", "reduce", "variability", "in", "BOLD", "MRI", "data", ".", "\n", "2", ".", "Screening", "tool", ":", "Edinburgh", "Handedness", "Inventory", ".", "\n", "5", ".", "Estimated", "IQ", "greater", "than", "or", "equal", "to", "85", "\n", "1", ".", "Justification", ":", "Subjects", "must", "be", "able", "to", "perform", "a", "cognitively", "challenging", "task", "to", "a", "high", "standard", ".", "\n", "2", ".", "Screening", "tool", ":", "Wechsler", "Abbreviated", "Scale", "of", "Intelligence", ".", "\n" ]	[ "Scope", "Procedure", "Value", "Measurement", "Observation", "Condition", "Negation", "Person" ]
18 55 years, age, History, good health, Medical Assessment, Medical History, Physical Examination, Vital Signs, EKG, oral HIV test, height, urinalysis, blood sample, CBC, complete metabolic profile, TSH, ESR, STS, HIV, positive, salivary test for HIV, disqualify, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 +, Serum glucose over 140 mg / dl, fasting serum glucose assessment, Right - handed, Edinburgh Handedness Inventory, Estimated IQ, greater than or equal to 85, Wechsler Abbreviated Scale of Intelligence	NCT02231892_inc_task2	Sentence: Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Measurement", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O" ]	Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence.	[ "Subjects", "must", ":", "\n", "1", ".", "Be", "able", "to", "give", "valid", "informed", "consent", "\n", "2", ".", "Be", "18", "55", "years", "of", "age", ".", "\n", "1", ".", "Justification", ":", "Many", "neural", "processes", "change", "with", "age", ",", "and", "these", "changes", "could", "introduce", "unwanted", "variability", "in", "both", "behavioral", "and", "MRI", "signals", ".", "In", "addition", ",", "the", "risk", "of", "difficult", "-", "to", "-", "detect", "medical", "abnormalities", "such", "as", "silent", "cerebral", "infarcts", "increases", "with", "age", ".", "\n", "2", ".", "Screening", "tool", ":", "History", ".", "Government", "-", "issued", "forms", "of", "identification", "(", "e.g", ".", "driver", "s", "license", ",", "birth", "certificate", ")", "will", "be", "required", "when", "participant", "appears", "to", "be", "out", "of", "age", "range", ".", "\n", "3", ".", "Be", "in", "good", "health", ".", "\n", "1", ".", "Justification", ":", "Many", "illnesses", "may", "alter", "neural", "functioning", "as", "well", "as", "fMRI", "signals", ".", "\n", "2", ".", "Screening", "tools", ":", "Medical", "Assessment", ",", "Medical", "History", "and", "Physical", "Examination", ".", "Medical", "assessments", "include", ":", "Vital", "Signs", ",", "EKG", ",", "oral", "HIV", "test", ",", "height", "/", "weight", "measurements", ",", "urinalysis", "and", "blood", "sample", ".", "Tests", "on", "the", "blood", "sample", "include", "CBC", ",", "complete", "metabolic", "profile", ",", "TSH", ",", "ESR", ",", "STS", "and", "HIV", "(", "if", "needed", "to", "confirm", "a", "positive", "salivary", "test", "for", "HIV", ")", ".", "The", "following", "individual", "laboratory", "results", "will", "independently", "disqualify", "individuals", ":", "Cholesterol", ">", "250", "mg", "/", "dl", ",", "Hemoglobin", "<", "10.5", "g", "/", "dl", ",", "WBC", "<", "2400", "/", "microl", ",", "LFTs", ">", "3Xnormal", ",", "HCG", "positive", ",", "Casual", "serum", "glucose", ">", "200", "mg", "/", "dl", ",", "Urine", "protein", ">", "1", "+", ".", "The", "MAI", "will", "retain", "discretion", "to", "exclude", "at", "less", "extreme", "values", ",", "depending", "on", "the", "clinical", "presentation", ".", "(", "Serum", "glucose", "over", "140", "mg", "/", "dl", "will", "be", "followed", "up", "with", "a", "fasting", "serum", "glucose", "assessment", ".", "Those", "with", "fasting", "glucose", "below", "100", "mg", "/", "dl", "may", "be", "considered", "for", "the", "protocol", ".", "Others", "will", "be", "rejected", "and", "referred", "for", "work", "-", "up", ".", ")", "MAI", "will", "make", "the", "final", "judgment", "on", "any", "questionable", "lab", "results", ".", "\n", "4", ".", "Right", "-", "handed", ".", "\n", "1", ".", "Justification", ":", "Using", "right", "-", "handed", "individuals", "will", "reduce", "variability", "in", "BOLD", "MRI", "data", ".", "\n", "2", ".", "Screening", "tool", ":", "Edinburgh", "Handedness", "Inventory", ".", "\n", "5", ".", "Estimated", "IQ", "greater", "than", "or", "equal", "to", "85", "\n", "1", ".", "Justification", ":", "Subjects", "must", "be", "able", "to", "perform", "a", "cognitively", "challenging", "task", "to", "a", "high", "standard", ".", "\n", "2", ".", "Screening", "tool", ":", "Wechsler", "Abbreviated", "Scale", "of", "Intelligence", ".", "\n" ]	[ "Scope", "Procedure", "Value", "Measurement", "Observation", "Condition", "Negation", "Person" ]
survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, Survivin is a Gene_or_gene_product, p53 is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, pRB is a Gene_or_gene_product, p130 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, E2F3 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product	128_task0	Sentence: Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene_or_gene_product	[ "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O" ]	Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.	[ "Aberrant", "regulation", "of", "survivin", "by", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "\n", "Survivin", "is", "a", "putative", "oncogene", "that", "is", "aberrantly", "expressed", "in", "cancer", "cells", ".", "It", "has", "been", "hypothesized", "to", "play", "a", "central", "role", "in", "cancer", "progression", "and", "resistance", "to", "therapy", "in", "diverse", "tumor", "types", ".", "Although", "some", "of", "the", "transcriptional", "processes", "regulating", "its", "expression", "have", "been", "established", ",", "the", "diversity", "of", "genes", "that", "may", "be", "controlling", "the", "levels", "of", "its", "expression", "in", "both", "normal", "cells", "as", "well", "as", "in", "cancer", "cells", "has", "not", "been", "fully", "explored", ".", "The", "most", "common", "genetically", "mutated", "pathways", "in", "human", "malignancies", "are", "the", "p53", "tumor", "suppressor", "pathway", "and", "the", "RB", "/", "E2F", "pathway", ".", "Both", "of", "these", "pathways", ",", "when", "intact", ",", "provide", "essential", "checkpoints", "in", "the", "maintenance", "of", "normal", "cell", "growth", "and", "protect", "the", "cell", "from", "DNA", "damage", ".", "Using", "non", "-", "transformed", "embryonic", "fibroblasts", ",", "we", "provide", "evidence", "of", "a", "molecular", "link", "between", "the", "regulation", "of", "survivin", "transcription", "and", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "We", "demonstrate", "that", "both", "pRB", "and", "p130", "can", "interact", "with", "the", "survivin", "promoter", "and", "can", "repress", "survivin", "transcription", ".", "We", "also", "show", "that", "the", "E2F", "activators", "(", "E2F1", ",", "E2F2", ",", "and", "E2F3", ")", "can", "bind", "to", "the", "survivin", "promoter", "and", "induce", "survivin", "transcription", ".", "Genetically", "modified", "cells", "that", "harbor", "deletions", "in", "various", "members", "of", "the", "RB", "/", "E2F", "family", "confirm", "our", "data", "from", "the", "wild", "-", "type", "cells", ".", "Our", "findings", "implicate", "several", "members", "of", "the", "RB", "/", "E2F", "pathway", "in", "an", "intricate", "mechanism", "of", "survivin", "gene", "regulation", "that", ",", "when", "genetically", "altered", "during", "the", "process", "of", "tumorigenesis", ",", "may", "function", "within", "cancer", "cells", "to", "aberrantly", "alter", "survivin", "levels", "and", "enhance", "tumor", "progression", ".", "\n" ]	[ "Gene_or_gene_product" ]
survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, Survivin is a Gene_or_gene_product, p53 is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, pRB is a Gene_or_gene_product, p130 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, E2F3 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product	128_task1	Sentence: Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression. Instructions: please typing these entity words according to sentence: survivin, RB, E2F, Survivin, p53, RB, E2F, survivin, RB, E2F, pRB, p130, survivin, survivin, E2F, E2F1, E2F2, E2F3, survivin, survivin, RB, E2F, RB, E2F, survivin, survivin Options: Gene_or_gene_product	[ "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O" ]	Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.	[ "Aberrant", "regulation", "of", "survivin", "by", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "\n", "Survivin", "is", "a", "putative", "oncogene", "that", "is", "aberrantly", "expressed", "in", "cancer", "cells", ".", "It", "has", "been", "hypothesized", "to", "play", "a", "central", "role", "in", "cancer", "progression", "and", "resistance", "to", "therapy", "in", "diverse", "tumor", "types", ".", "Although", "some", "of", "the", "transcriptional", "processes", "regulating", "its", "expression", "have", "been", "established", ",", "the", "diversity", "of", "genes", "that", "may", "be", "controlling", "the", "levels", "of", "its", "expression", "in", "both", "normal", "cells", "as", "well", "as", "in", "cancer", "cells", "has", "not", "been", "fully", "explored", ".", "The", "most", "common", "genetically", "mutated", "pathways", "in", "human", "malignancies", "are", "the", "p53", "tumor", "suppressor", "pathway", "and", "the", "RB", "/", "E2F", "pathway", ".", "Both", "of", "these", "pathways", ",", "when", "intact", ",", "provide", "essential", "checkpoints", "in", "the", "maintenance", "of", "normal", "cell", "growth", "and", "protect", "the", "cell", "from", "DNA", "damage", ".", "Using", "non", "-", "transformed", "embryonic", "fibroblasts", ",", "we", "provide", "evidence", "of", "a", "molecular", "link", "between", "the", "regulation", "of", "survivin", "transcription", "and", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "We", "demonstrate", "that", "both", "pRB", "and", "p130", "can", "interact", "with", "the", "survivin", "promoter", "and", "can", "repress", "survivin", "transcription", ".", "We", "also", "show", "that", "the", "E2F", "activators", "(", "E2F1", ",", "E2F2", ",", "and", "E2F3", ")", "can", "bind", "to", "the", "survivin", "promoter", "and", "induce", "survivin", "transcription", ".", "Genetically", "modified", "cells", "that", "harbor", "deletions", "in", "various", "members", "of", "the", "RB", "/", "E2F", "family", "confirm", "our", "data", "from", "the", "wild", "-", "type", "cells", ".", "Our", "findings", "implicate", "several", "members", "of", "the", "RB", "/", "E2F", "pathway", "in", "an", "intricate", "mechanism", "of", "survivin", "gene", "regulation", "that", ",", "when", "genetically", "altered", "during", "the", "process", "of", "tumorigenesis", ",", "may", "function", "within", "cancer", "cells", "to", "aberrantly", "alter", "survivin", "levels", "and", "enhance", "tumor", "progression", ".", "\n" ]	[ "Gene_or_gene_product" ]
survivin, RB, E2F, Survivin, p53, RB, E2F, survivin, RB, E2F, pRB, p130, survivin, survivin, E2F, E2F1, E2F2, E2F3, survivin, survivin, RB, E2F, RB, E2F, survivin, survivin	128_task2	Sentence: Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O" ]	Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.	[ "Aberrant", "regulation", "of", "survivin", "by", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "\n", "Survivin", "is", "a", "putative", "oncogene", "that", "is", "aberrantly", "expressed", "in", "cancer", "cells", ".", "It", "has", "been", "hypothesized", "to", "play", "a", "central", "role", "in", "cancer", "progression", "and", "resistance", "to", "therapy", "in", "diverse", "tumor", "types", ".", "Although", "some", "of", "the", "transcriptional", "processes", "regulating", "its", "expression", "have", "been", "established", ",", "the", "diversity", "of", "genes", "that", "may", "be", "controlling", "the", "levels", "of", "its", "expression", "in", "both", "normal", "cells", "as", "well", "as", "in", "cancer", "cells", "has", "not", "been", "fully", "explored", ".", "The", "most", "common", "genetically", "mutated", "pathways", "in", "human", "malignancies", "are", "the", "p53", "tumor", "suppressor", "pathway", "and", "the", "RB", "/", "E2F", "pathway", ".", "Both", "of", "these", "pathways", ",", "when", "intact", ",", "provide", "essential", "checkpoints", "in", "the", "maintenance", "of", "normal", "cell", "growth", "and", "protect", "the", "cell", "from", "DNA", "damage", ".", "Using", "non", "-", "transformed", "embryonic", "fibroblasts", ",", "we", "provide", "evidence", "of", "a", "molecular", "link", "between", "the", "regulation", "of", "survivin", "transcription", "and", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "We", "demonstrate", "that", "both", "pRB", "and", "p130", "can", "interact", "with", "the", "survivin", "promoter", "and", "can", "repress", "survivin", "transcription", ".", "We", "also", "show", "that", "the", "E2F", "activators", "(", "E2F1", ",", "E2F2", ",", "and", "E2F3", ")", "can", "bind", "to", "the", "survivin", "promoter", "and", "induce", "survivin", "transcription", ".", "Genetically", "modified", "cells", "that", "harbor", "deletions", "in", "various", "members", "of", "the", "RB", "/", "E2F", "family", "confirm", "our", "data", "from", "the", "wild", "-", "type", "cells", ".", "Our", "findings", "implicate", "several", "members", "of", "the", "RB", "/", "E2F", "pathway", "in", "an", "intricate", "mechanism", "of", "survivin", "gene", "regulation", "that", ",", "when", "genetically", "altered", "during", "the", "process", "of", "tumorigenesis", ",", "may", "function", "within", "cancer", "cells", "to", "aberrantly", "alter", "survivin", "levels", "and", "enhance", "tumor", "progression", ".", "\n" ]	[ "Gene_or_gene_product" ]
IL-2 is a protein_molecule, IL-7 is a protein_molecule, heterodimerization is an other_name, STAT5 isoforms is a protein_family_or_group, human peripheral blood T lymphoblasts is a cell_type	56266_task0	Sentence: IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name, protein_family_or_group, protein_molecule	[ "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts.	[ "IL-2", "and", "IL-7", "induce", "heterodimerization", "of", "STAT5", "isoforms", "in", "human", "peripheral", "blood", "T", "lymphoblasts", "." ]	[ "protein_family_or_group", "cell_type", "DNA_domain_or_region", "(AND other_name other_name)", "other_name", "(OR cell_line cell_line)", "protein_molecule", "", "cell_line", "protein_complex", "amino_acid_monomer" ]
IL-2 is a protein_molecule, IL-7 is a protein_molecule, heterodimerization is an other_name, STAT5 isoforms is a protein_family_or_group, human peripheral blood T lymphoblasts is a cell_type	56266_task1	Sentence: IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Instructions: please typing these entity words according to sentence: IL-2, IL-7, heterodimerization, STAT5 isoforms, human peripheral blood T lymphoblasts Options: cell_type, other_name, protein_family_or_group, protein_molecule	[ "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts.	[ "IL-2", "and", "IL-7", "induce", "heterodimerization", "of", "STAT5", "isoforms", "in", "human", "peripheral", "blood", "T", "lymphoblasts", "." ]	[ "protein_family_or_group", "cell_type", "DNA_domain_or_region", "(AND other_name other_name)", "other_name", "(OR cell_line cell_line)", "protein_molecule", "", "cell_line", "protein_complex", "amino_acid_monomer" ]
IL-2, IL-7, heterodimerization, STAT5 isoforms, human peripheral blood T lymphoblasts	56266_task2	Sentence: IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Instructions: please extract entity words from the input sentence	[ "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]	IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts.	[ "IL-2", "and", "IL-7", "induce", "heterodimerization", "of", "STAT5", "isoforms", "in", "human", "peripheral", "blood", "T", "lymphoblasts", "." ]	[ "protein_family_or_group", "cell_type", "DNA_domain_or_region", "(AND other_name other_name)", "other_name", "(OR cell_line cell_line)", "protein_molecule", "", "cell_line", "protein_complex", "amino_acid_monomer" ]
tetanus immune globulin is a Intervention_Pharmacological, immune response is a Outcome_Physical, tetanus - diphtheria vaccine is a Intervention_Pharmacological, adults is a Participant_Age, tetanus - diphtheria ( Td ) vaccine is a Intervention_Pharmacological, tetanus immune globulin ( TIG ) is a Intervention_Pharmacological, Sixty and 59 is a Participant_Sample-size, healthy is a Participant_Condition, young adults is a Participant_Age, previously immunized against tetanus ( T ) and diphtheria ( D ) is a Participant_Condition, Td vaccine alone is a Intervention_Control, ( group 1 ) is a Intervention_Pharmacological, Td vaccine plus 500 IU of TIG is a Intervention_Pharmacological, Antitoxin response is a Outcome_Physical, antibody titers is a Outcome_Physical, circulating T and D antitoxin levels is a Outcome_Physical, T antitoxin levels is a Outcome_Physical	81674_task0	Sentence: Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size	[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Condition", "B-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "Does", "tetanus", "immune", "globulin", "interfere", "with", "the", "immune", "response", "to", "simultaneous", "administration", "of", "tetanus", "-", "diphtheria", "vaccine", "?", "A", "comparative", "clinical", "trial", "in", "adults", ".", "In", "the", "management", "of", "wounds", ",", "sometimes", "it", "is", "recommended", "to", "give", "an", "adult", "-", "type", "tetanus", "-", "diphtheria", "(", "Td", ")", "vaccine", "dose", "plus", "tetanus", "immune", "globulin", "(", "TIG", ")", ".", "Sixty", "and", "59", "healthy", "young", "adults", "previously", "immunized", "against", "tetanus", "(", "T", ")", "and", "diphtheria", "(", "D", ")", "were", "randomized", "to", "receive", "intramuscularly", "either", "Td", "vaccine", "alone", "(", "group", "1", ")", "or", "Td", "vaccine", "plus", "500", "IU", "of", "TIG", "(", "group", "2", ")", "simultaneously", ".", "Antitoxin", "response", "was", "assessed", "after", "4", "weeks", "and", "4", "months", ".", "Circulating", "antibodies", "were", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "The", "cutoff", "of", "these", "tests", "was", "0.1", "IU", "/", "mL", ".", "Titers", "of", "0.1", "IU", "/", "mL", "or", "greater", "were", "considered", "protective", ".", "For", "geometric", "mean", "titers", "(", "GMT", ")", ",", "antibody", "titers", "below", "the", "cutoff", "of", "the", "assay", "were", "given", ",", "arbitrarily", ",", "0.05", "IU", "/", "mL", ".", "At", "4", "weeks", ",", "98", "%", "or", "more", "of", "the", "subjects", "in", "group", "1", "had", "circulating", "T", "and", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ";", "in", "group", "2", ",", "95", "%", "and", "90", "%", "of", "the", "subjects", "had", "titers", "above", "this", "limit", "for", "T", "and", "D", ",", "respectively", ".", "At", "4", "months", ",", "these", "percentages", "were", "98", "%", "and", "95", "%", "for", "T", "antitoxin", "levels", "in", "groups", "1", "and", "2", ",", "respectively", ";", "whereas", "96", "%", "and", "88", "%", "of", "the", "subjects", "in", "groups", "1", "and", "2", "had", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ",", "respectively", ".", "Significantly", "(", "P", "<", ".05", ")", "higher", "GMTs", "were", "seen", "at", "the", "4-week", "assessment", "(", "but", "not", "at", "4", "months", ")", "in", "group", "1", ",", "as", "compared", "with", "group", "2", ",", "in", "both", "T", "and", "D", "antitoxin", "levels", "(", "9.91", "IU", "/", "mL", "versus", "5.60", "IU", "/", "mL", "for", "T", "antitoxin", ",", "and", "2.86", "IU", "/", "mL", "versus", "1.45", "IU", "/", "mL", "for", "D", "antitoxin", ")", ".", "This", "finding", "resulted", "from", "those", "participants", "with", "low", "(", "<", "0.1", "IU", "/", "mL", ")", "prevaccination", "antibody", "titers", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age" ]
tetanus immune globulin is a Intervention_Pharmacological, immune response is a Outcome_Physical, tetanus - diphtheria vaccine is a Intervention_Pharmacological, adults is a Participant_Age, tetanus - diphtheria ( Td ) vaccine is a Intervention_Pharmacological, tetanus immune globulin ( TIG ) is a Intervention_Pharmacological, Sixty and 59 is a Participant_Sample-size, healthy is a Participant_Condition, young adults is a Participant_Age, previously immunized against tetanus ( T ) and diphtheria ( D ) is a Participant_Condition, Td vaccine alone is a Intervention_Control, ( group 1 ) is a Intervention_Pharmacological, Td vaccine plus 500 IU of TIG is a Intervention_Pharmacological, Antitoxin response is a Outcome_Physical, antibody titers is a Outcome_Physical, circulating T and D antitoxin levels is a Outcome_Physical, T antitoxin levels is a Outcome_Physical	81674_task1	Sentence: Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please typing these entity words according to sentence: tetanus immune globulin, immune response, tetanus - diphtheria vaccine, adults, tetanus - diphtheria ( Td ) vaccine, tetanus immune globulin ( TIG ), Sixty and 59, healthy, young adults, previously immunized against tetanus ( T ) and diphtheria ( D ), Td vaccine alone, ( group 1 ), Td vaccine plus 500 IU of TIG, Antitoxin response, antibody titers, circulating T and D antitoxin levels, T antitoxin levels Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size	[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Condition", "B-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "Does", "tetanus", "immune", "globulin", "interfere", "with", "the", "immune", "response", "to", "simultaneous", "administration", "of", "tetanus", "-", "diphtheria", "vaccine", "?", "A", "comparative", "clinical", "trial", "in", "adults", ".", "In", "the", "management", "of", "wounds", ",", "sometimes", "it", "is", "recommended", "to", "give", "an", "adult", "-", "type", "tetanus", "-", "diphtheria", "(", "Td", ")", "vaccine", "dose", "plus", "tetanus", "immune", "globulin", "(", "TIG", ")", ".", "Sixty", "and", "59", "healthy", "young", "adults", "previously", "immunized", "against", "tetanus", "(", "T", ")", "and", "diphtheria", "(", "D", ")", "were", "randomized", "to", "receive", "intramuscularly", "either", "Td", "vaccine", "alone", "(", "group", "1", ")", "or", "Td", "vaccine", "plus", "500", "IU", "of", "TIG", "(", "group", "2", ")", "simultaneously", ".", "Antitoxin", "response", "was", "assessed", "after", "4", "weeks", "and", "4", "months", ".", "Circulating", "antibodies", "were", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "The", "cutoff", "of", "these", "tests", "was", "0.1", "IU", "/", "mL", ".", "Titers", "of", "0.1", "IU", "/", "mL", "or", "greater", "were", "considered", "protective", ".", "For", "geometric", "mean", "titers", "(", "GMT", ")", ",", "antibody", "titers", "below", "the", "cutoff", "of", "the", "assay", "were", "given", ",", "arbitrarily", ",", "0.05", "IU", "/", "mL", ".", "At", "4", "weeks", ",", "98", "%", "or", "more", "of", "the", "subjects", "in", "group", "1", "had", "circulating", "T", "and", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ";", "in", "group", "2", ",", "95", "%", "and", "90", "%", "of", "the", "subjects", "had", "titers", "above", "this", "limit", "for", "T", "and", "D", ",", "respectively", ".", "At", "4", "months", ",", "these", "percentages", "were", "98", "%", "and", "95", "%", "for", "T", "antitoxin", "levels", "in", "groups", "1", "and", "2", ",", "respectively", ";", "whereas", "96", "%", "and", "88", "%", "of", "the", "subjects", "in", "groups", "1", "and", "2", "had", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ",", "respectively", ".", "Significantly", "(", "P", "<", ".05", ")", "higher", "GMTs", "were", "seen", "at", "the", "4-week", "assessment", "(", "but", "not", "at", "4", "months", ")", "in", "group", "1", ",", "as", "compared", "with", "group", "2", ",", "in", "both", "T", "and", "D", "antitoxin", "levels", "(", "9.91", "IU", "/", "mL", "versus", "5.60", "IU", "/", "mL", "for", "T", "antitoxin", ",", "and", "2.86", "IU", "/", "mL", "versus", "1.45", "IU", "/", "mL", "for", "D", "antitoxin", ")", ".", "This", "finding", "resulted", "from", "those", "participants", "with", "low", "(", "<", "0.1", "IU", "/", "mL", ")", "prevaccination", "antibody", "titers", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age" ]
tetanus immune globulin, immune response, tetanus - diphtheria vaccine, adults, tetanus - diphtheria ( Td ) vaccine, tetanus immune globulin ( TIG ), Sixty and 59, healthy, young adults, previously immunized against tetanus ( T ) and diphtheria ( D ), Td vaccine alone, ( group 1 ), Td vaccine plus 500 IU of TIG, Antitoxin response, antibody titers, circulating T and D antitoxin levels, T antitoxin levels	81674_task2	Sentence: Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entity words from the input sentence	[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Condition", "B-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "Does", "tetanus", "immune", "globulin", "interfere", "with", "the", "immune", "response", "to", "simultaneous", "administration", "of", "tetanus", "-", "diphtheria", "vaccine", "?", "A", "comparative", "clinical", "trial", "in", "adults", ".", "In", "the", "management", "of", "wounds", ",", "sometimes", "it", "is", "recommended", "to", "give", "an", "adult", "-", "type", "tetanus", "-", "diphtheria", "(", "Td", ")", "vaccine", "dose", "plus", "tetanus", "immune", "globulin", "(", "TIG", ")", ".", "Sixty", "and", "59", "healthy", "young", "adults", "previously", "immunized", "against", "tetanus", "(", "T", ")", "and", "diphtheria", "(", "D", ")", "were", "randomized", "to", "receive", "intramuscularly", "either", "Td", "vaccine", "alone", "(", "group", "1", ")", "or", "Td", "vaccine", "plus", "500", "IU", "of", "TIG", "(", "group", "2", ")", "simultaneously", ".", "Antitoxin", "response", "was", "assessed", "after", "4", "weeks", "and", "4", "months", ".", "Circulating", "antibodies", "were", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "The", "cutoff", "of", "these", "tests", "was", "0.1", "IU", "/", "mL", ".", "Titers", "of", "0.1", "IU", "/", "mL", "or", "greater", "were", "considered", "protective", ".", "For", "geometric", "mean", "titers", "(", "GMT", ")", ",", "antibody", "titers", "below", "the", "cutoff", "of", "the", "assay", "were", "given", ",", "arbitrarily", ",", "0.05", "IU", "/", "mL", ".", "At", "4", "weeks", ",", "98", "%", "or", "more", "of", "the", "subjects", "in", "group", "1", "had", "circulating", "T", "and", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ";", "in", "group", "2", ",", "95", "%", "and", "90", "%", "of", "the", "subjects", "had", "titers", "above", "this", "limit", "for", "T", "and", "D", ",", "respectively", ".", "At", "4", "months", ",", "these", "percentages", "were", "98", "%", "and", "95", "%", "for", "T", "antitoxin", "levels", "in", "groups", "1", "and", "2", ",", "respectively", ";", "whereas", "96", "%", "and", "88", "%", "of", "the", "subjects", "in", "groups", "1", "and", "2", "had", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ",", "respectively", ".", "Significantly", "(", "P", "<", ".05", ")", "higher", "GMTs", "were", "seen", "at", "the", "4-week", "assessment", "(", "but", "not", "at", "4", "months", ")", "in", "group", "1", ",", "as", "compared", "with", "group", "2", ",", "in", "both", "T", "and", "D", "antitoxin", "levels", "(", "9.91", "IU", "/", "mL", "versus", "5.60", "IU", "/", "mL", "for", "T", "antitoxin", ",", "and", "2.86", "IU", "/", "mL", "versus", "1.45", "IU", "/", "mL", "for", "D", "antitoxin", ")", ".", "This", "finding", "resulted", "from", "those", "participants", "with", "low", "(", "<", "0.1", "IU", "/", "mL", ")", "prevaccination", "antibody", "titers", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age" ]
etiology is an umlsterm, patients is an umlsterm, University is an umlsterm, Histopathological is an umlsterm, patients is an umlsterm, patient is an umlsterm	HNO.00480665.eng.abstr_task0	Sentence: Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated .	[ "Orbital", "pseudotumor", "is", "a", "nonspecific", "inflammatory", "process", "of", "unknown", "etiology", "that", "can", "be", "divided", "histopathologically", "into", "three", "basic", "types", ":", "granulomatous", ",", "lymphoid", ",", "and", "sclerosing", ".", "Between", "1995", "and", "1998", ",", "12", "patients", "with", "pseudotumor", "orbitae", "were", "treated", "in", "the", "ENT", "Department", "of", "the", "University", "of", "Saarland", ".", "Histopathological", "examination", "showed", "granulomatous", "type", "of", "pseudotumor", "in", "six", ",", "lymphoid", "in", "three", ",", "and", "sclerosing", "in", "three", "patients", ".", "In", "seven", "cases", "the", "pseudotumor", "orbitae", "were", "medially", "located", "and", "in", "four", "cases", "laterally", ".", "In", "one", "patient", "nearly", "all", "orbital", "structures", "were", "infiltrated", "." ]	[ "umlsterm" ]
etiology is an umlsterm, patients is an umlsterm, University is an umlsterm, Histopathological is an umlsterm, patients is an umlsterm, patient is an umlsterm	HNO.00480665.eng.abstr_task1	Sentence: Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated . Instructions: please typing these entity words according to sentence: etiology, patients, University, Histopathological, patients, patient Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated .	[ "Orbital", "pseudotumor", "is", "a", "nonspecific", "inflammatory", "process", "of", "unknown", "etiology", "that", "can", "be", "divided", "histopathologically", "into", "three", "basic", "types", ":", "granulomatous", ",", "lymphoid", ",", "and", "sclerosing", ".", "Between", "1995", "and", "1998", ",", "12", "patients", "with", "pseudotumor", "orbitae", "were", "treated", "in", "the", "ENT", "Department", "of", "the", "University", "of", "Saarland", ".", "Histopathological", "examination", "showed", "granulomatous", "type", "of", "pseudotumor", "in", "six", ",", "lymphoid", "in", "three", ",", "and", "sclerosing", "in", "three", "patients", ".", "In", "seven", "cases", "the", "pseudotumor", "orbitae", "were", "medially", "located", "and", "in", "four", "cases", "laterally", ".", "In", "one", "patient", "nearly", "all", "orbital", "structures", "were", "infiltrated", "." ]	[ "umlsterm" ]
etiology, patients, University, Histopathological, patients, patient	HNO.00480665.eng.abstr_task2	Sentence: Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated .	[ "Orbital", "pseudotumor", "is", "a", "nonspecific", "inflammatory", "process", "of", "unknown", "etiology", "that", "can", "be", "divided", "histopathologically", "into", "three", "basic", "types", ":", "granulomatous", ",", "lymphoid", ",", "and", "sclerosing", ".", "Between", "1995", "and", "1998", ",", "12", "patients", "with", "pseudotumor", "orbitae", "were", "treated", "in", "the", "ENT", "Department", "of", "the", "University", "of", "Saarland", ".", "Histopathological", "examination", "showed", "granulomatous", "type", "of", "pseudotumor", "in", "six", ",", "lymphoid", "in", "three", ",", "and", "sclerosing", "in", "three", "patients", ".", "In", "seven", "cases", "the", "pseudotumor", "orbitae", "were", "medially", "located", "and", "in", "four", "cases", "laterally", ".", "In", "one", "patient", "nearly", "all", "orbital", "structures", "were", "infiltrated", "." ]	[ "umlsterm" ]
natural beta - carotene is a Intervention_Pharmacological, humans is a Participant_Condition, beta - carotene preparation is a Intervention_Pharmacological, beta - carotene - rich algae is a Intervention_Pharmacological, 60 mg of the beta - carotene preparation is a Intervention_Pharmacological, plasma is a Outcome_Physical, red blood cells ( RBC ) is a Outcome_Physical, platelets ( PLT ) , is a Outcome_Physical, mononuclear cells ( MN ) is a Outcome_Physical, all - trans beta - carotene level is a Outcome_Physical, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN is a Outcome_Physical, Plasma and RBC alpha - tocopherol levels is a Outcome_Physical, No side effects or toxicities is a Outcome_Adverse-effects	82856_task0	Sentence: Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Outcome_Adverse-effects	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells .	[ "Changes", "in", "beta", "-", "carotene", "levels", "by", "long", "-", "term", "administration", "of", "natural", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "in", "humans", ".", "Long", "-", "term", "administration", "of", "a", "beta", "-", "carotene", "preparation", "derived", "from", "Dunaliella", "bardawil", ",", "a", "beta", "-", "carotene", "-", "rich", "algae", ",", "was", "studied", "in", "healthy", "young", "male", "volunteers", ".", "The", "daily", "administration", "of", "60", "mg", "of", "the", "beta", "-", "carotene", "preparation", "(", "30", "mg", "of", "all", "-", "trans", "beta", "-", "carotene", "and", "30", "mg", "of", "9-cis", "beta", "-", "carotene", ")", "was", "performed", "and", "beta", "-", "carotene", "concentrations", "were", "determined", "in", "the", "plasma", ",", "red", "blood", "cells", "(", "RBC", ")", ",", "platelets", "(", "PLT", ")", ",", "and", "mononuclear", "cells", "(", "MN", ")", ".", "The", "all", "-", "trans", "beta", "-", "carotene", "level", "increased", "four-", ",", "two-", ",", "and", "threefold", "the", "baseline", "in", "plasma", ",", "PLT", ",", "and", "MN", ",", "respectively", ".", "Basal", "levels", "of", "9-cis", "beta", "-", "carotene", "in", "plasma", ",", "PLT", ",", "and", "MN", "were", "low", "and", "found", "as", "one", "-", "tenth", ",", "one", "-", "fifth", ",", "and", "one", "-", "fifth", "of", "all", "-", "trans", "beta", "-", "carotene", ",", "which", "increased", "three-", ",", "two-", ",", "and", "1.5-fold", "the", "baseline", ",", "respectively", ".", "Plasma", "and", "RBC", "alpha", "-", "tocopherol", "levels", "were", "not", "changed", "by", "the", "intake", "of", "beta", "-", "carotene", ".", "No", "side", "effects", "or", "toxicities", "were", "documented", "in", "any", "of", "the", "subjects", "during", "the", "administration", "period", ".", "In", "conclusion", ",", "the", "bioavailability", "of", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "was", "preferential", "for", "all", "-", "trans", "beta", "-", "carotene", ",", "although", "a", "small", "amount", "of", "the", "9-cis", "form", "was", "detected", "in", "the", "plasma", "and", "blood", "cells", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Participant_Condition" ]
natural beta - carotene is a Intervention_Pharmacological, humans is a Participant_Condition, beta - carotene preparation is a Intervention_Pharmacological, beta - carotene - rich algae is a Intervention_Pharmacological, 60 mg of the beta - carotene preparation is a Intervention_Pharmacological, plasma is a Outcome_Physical, red blood cells ( RBC ) is a Outcome_Physical, platelets ( PLT ) , is a Outcome_Physical, mononuclear cells ( MN ) is a Outcome_Physical, all - trans beta - carotene level is a Outcome_Physical, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN is a Outcome_Physical, Plasma and RBC alpha - tocopherol levels is a Outcome_Physical, No side effects or toxicities is a Outcome_Adverse-effects	82856_task1	Sentence: Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells . Instructions: please typing these entity words according to sentence: natural beta - carotene, humans, beta - carotene preparation, beta - carotene - rich algae, 60 mg of the beta - carotene preparation, plasma, red blood cells ( RBC ), platelets ( PLT ) ,, mononuclear cells ( MN ), all - trans beta - carotene level, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN, Plasma and RBC alpha - tocopherol levels, No side effects or toxicities Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Outcome_Adverse-effects	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells .	[ "Changes", "in", "beta", "-", "carotene", "levels", "by", "long", "-", "term", "administration", "of", "natural", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "in", "humans", ".", "Long", "-", "term", "administration", "of", "a", "beta", "-", "carotene", "preparation", "derived", "from", "Dunaliella", "bardawil", ",", "a", "beta", "-", "carotene", "-", "rich", "algae", ",", "was", "studied", "in", "healthy", "young", "male", "volunteers", ".", "The", "daily", "administration", "of", "60", "mg", "of", "the", "beta", "-", "carotene", "preparation", "(", "30", "mg", "of", "all", "-", "trans", "beta", "-", "carotene", "and", "30", "mg", "of", "9-cis", "beta", "-", "carotene", ")", "was", "performed", "and", "beta", "-", "carotene", "concentrations", "were", "determined", "in", "the", "plasma", ",", "red", "blood", "cells", "(", "RBC", ")", ",", "platelets", "(", "PLT", ")", ",", "and", "mononuclear", "cells", "(", "MN", ")", ".", "The", "all", "-", "trans", "beta", "-", "carotene", "level", "increased", "four-", ",", "two-", ",", "and", "threefold", "the", "baseline", "in", "plasma", ",", "PLT", ",", "and", "MN", ",", "respectively", ".", "Basal", "levels", "of", "9-cis", "beta", "-", "carotene", "in", "plasma", ",", "PLT", ",", "and", "MN", "were", "low", "and", "found", "as", "one", "-", "tenth", ",", "one", "-", "fifth", ",", "and", "one", "-", "fifth", "of", "all", "-", "trans", "beta", "-", "carotene", ",", "which", "increased", "three-", ",", "two-", ",", "and", "1.5-fold", "the", "baseline", ",", "respectively", ".", "Plasma", "and", "RBC", "alpha", "-", "tocopherol", "levels", "were", "not", "changed", "by", "the", "intake", "of", "beta", "-", "carotene", ".", "No", "side", "effects", "or", "toxicities", "were", "documented", "in", "any", "of", "the", "subjects", "during", "the", "administration", "period", ".", "In", "conclusion", ",", "the", "bioavailability", "of", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "was", "preferential", "for", "all", "-", "trans", "beta", "-", "carotene", ",", "although", "a", "small", "amount", "of", "the", "9-cis", "form", "was", "detected", "in", "the", "plasma", "and", "blood", "cells", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Participant_Condition" ]
natural beta - carotene, humans, beta - carotene preparation, beta - carotene - rich algae, 60 mg of the beta - carotene preparation, plasma, red blood cells ( RBC ), platelets ( PLT ) ,, mononuclear cells ( MN ), all - trans beta - carotene level, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN, Plasma and RBC alpha - tocopherol levels, No side effects or toxicities	82856_task2	Sentence: Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells .	[ "Changes", "in", "beta", "-", "carotene", "levels", "by", "long", "-", "term", "administration", "of", "natural", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "in", "humans", ".", "Long", "-", "term", "administration", "of", "a", "beta", "-", "carotene", "preparation", "derived", "from", "Dunaliella", "bardawil", ",", "a", "beta", "-", "carotene", "-", "rich", "algae", ",", "was", "studied", "in", "healthy", "young", "male", "volunteers", ".", "The", "daily", "administration", "of", "60", "mg", "of", "the", "beta", "-", "carotene", "preparation", "(", "30", "mg", "of", "all", "-", "trans", "beta", "-", "carotene", "and", "30", "mg", "of", "9-cis", "beta", "-", "carotene", ")", "was", "performed", "and", "beta", "-", "carotene", "concentrations", "were", "determined", "in", "the", "plasma", ",", "red", "blood", "cells", "(", "RBC", ")", ",", "platelets", "(", "PLT", ")", ",", "and", "mononuclear", "cells", "(", "MN", ")", ".", "The", "all", "-", "trans", "beta", "-", "carotene", "level", "increased", "four-", ",", "two-", ",", "and", "threefold", "the", "baseline", "in", "plasma", ",", "PLT", ",", "and", "MN", ",", "respectively", ".", "Basal", "levels", "of", "9-cis", "beta", "-", "carotene", "in", "plasma", ",", "PLT", ",", "and", "MN", "were", "low", "and", "found", "as", "one", "-", "tenth", ",", "one", "-", "fifth", ",", "and", "one", "-", "fifth", "of", "all", "-", "trans", "beta", "-", "carotene", ",", "which", "increased", "three-", ",", "two-", ",", "and", "1.5-fold", "the", "baseline", ",", "respectively", ".", "Plasma", "and", "RBC", "alpha", "-", "tocopherol", "levels", "were", "not", "changed", "by", "the", "intake", "of", "beta", "-", "carotene", ".", "No", "side", "effects", "or", "toxicities", "were", "documented", "in", "any", "of", "the", "subjects", "during", "the", "administration", "period", ".", "In", "conclusion", ",", "the", "bioavailability", "of", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "was", "preferential", "for", "all", "-", "trans", "beta", "-", "carotene", ",", "although", "a", "small", "amount", "of", "the", "9-cis", "form", "was", "detected", "in", "the", "plasma", "and", "blood", "cells", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Participant_Condition" ]
Apolipoprotein E is a Gene, apolipoprotein ( apo ) E is a Gene, triglyceride - rich lipoprotein ( TGRL)-triglyceride is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene	238_task0	Sentence: Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene	[ "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD.	[ "Apolipoprotein", "E", "polymorphism", "influences", "postprandial", "retinyl", "palmitate", "but", "not", "triglyceride", "concentrations", ".", "To", "quantify", "the", "effect", "of", "the", "apolipoprotein", "(", "apo", ")", "E", "polymorphism", "on", "the", "magnitude", "of", "postprandial", "lipemia", ",", "we", "have", "defined", "its", "role", "in", "determining", "the", "response", "to", "a", "single", "high", "-", "fat", "meal", "in", "a", "large", "sample", "of", "(", "N", "=", "474", ")", "individuals", "taking", "part", "in", "the", "biethnic", "Atherosclerosis", "Risk", "in", "Communities", "Study", ".", "The", "profile", "of", "postprandial", "response", "in", "plasma", "was", "monitored", "over", "8", "h", "by", "triglyceride", ",", "triglyceride", "-", "rich", "lipoprotein", "(", "TGRL)-triglyceride", ",", "apo", "B-48", "/", "apo", "B-100", "ratio", ",", "and", "retinyl", "palmitate", "concentrations", ",", "and", "the", "apo", "E", "polymorphism", "was", "determined", "by", "DNA", "amplification", "and", "digestion", ".", "The", "frequency", "of", "the", "apo", "E", "alleles", "and", "their", "effects", "on", "fasting", "lipid", "levels", "in", "this", "sample", "were", "similar", "to", "those", "reported", "elsewhere", ".", "Postprandial", "plasma", "retinyl", "palmitate", "response", "to", "a", "high", "-", "fat", "meal", "with", "vitamin", "A", "was", "significantly", "different", "among", "apo", "E", "genotypes", ",", "with", "delayed", "clearance", "in", "individuals", "with", "an", "epsilon", "2", "allele", ",", "compared", "with", "epsilon", "3/3", "and", "epsilon", "3/4", "individuals", ".", "In", "the", "sample", "of", "397", "Caucasians", ",", "average", "retinyl", "palmitate", "response", "was", "1,489", "micrograms", "/", "dl", "in", "epsilon", "2/3", "individuals", ",", "compared", "with", "1,037", "micrograms", "/", "dl", "in", "epsilon", "3/3", "individuals", "and", "1,108", "micrograms", "/", "dl", "in", "epsilon", "3/4", "individuals", ".", "The", "apo", "E", "polymorphism", "accounted", "for", "7.1", "%", "of", "the", "interindividual", "variation", "in", "postprandial", "retinyl", "palmitate", "response", ",", "a", "contribution", "proportionally", "greater", "than", "its", "well", "-", "known", "effect", "on", "fasting", "LDL", "-", "cholesterol", ".", "However", ",", "despite", "this", "effect", "on", "postprandial", "retinyl", "palmitate", ",", "the", "profile", "of", "postprandial", "triglyceride", "response", "was", "not", "significantly", "different", "among", "apo", "E", "genotypes", ".", "The", "profile", "of", "postprandial", "response", "was", "consistent", "between", "the", "sample", "of", "Caucasians", "and", "a", "smaller", "sample", "of", "black", "subjects", ".", "While", "these", "data", "indicate", "that", "the", "removal", "of", "remnant", "particles", "from", "circulation", "is", "delayed", "in", "subjects", "with", "the", "epsilon", "2/3", "genotype", ",", "there", "is", "no", "reported", "evidence", "that", "the", "epsilon", "2", "allele", "predisposes", "to", "coronary", "artery", "disease", "(", "CAD", ")", ".", "The", "results", "of", "this", "study", "provide", "not", "only", "a", "reliable", "estimate", "of", "the", "magnitude", "of", "the", "effect", "of", "the", "apo", "E", "polymorphism", "on", "various", "measurements", "commonly", "used", "to", "characterize", "postprandial", "lipemia", ",", "but", "also", "provide", "mechanistic", "insight", "into", "the", "effects", "of", "the", "apo", "E", "gene", "polymorphism", "on", "postprandial", "lipemia", "and", "CAD", ".", "\n" ]	[ "Gene" ]
Apolipoprotein E is a Gene, apolipoprotein ( apo ) E is a Gene, triglyceride - rich lipoprotein ( TGRL)-triglyceride is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene	238_task1	Sentence: Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD. Instructions: please typing these entity words according to sentence: Apolipoprotein E, apolipoprotein ( apo ) E, triglyceride - rich lipoprotein ( TGRL)-triglyceride, apo E, apo E, apo E, apo E, apo E, apo E, apo E Options: Gene	[ "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD.	[ "Apolipoprotein", "E", "polymorphism", "influences", "postprandial", "retinyl", "palmitate", "but", "not", "triglyceride", "concentrations", ".", "To", "quantify", "the", "effect", "of", "the", "apolipoprotein", "(", "apo", ")", "E", "polymorphism", "on", "the", "magnitude", "of", "postprandial", "lipemia", ",", "we", "have", "defined", "its", "role", "in", "determining", "the", "response", "to", "a", "single", "high", "-", "fat", "meal", "in", "a", "large", "sample", "of", "(", "N", "=", "474", ")", "individuals", "taking", "part", "in", "the", "biethnic", "Atherosclerosis", "Risk", "in", "Communities", "Study", ".", "The", "profile", "of", "postprandial", "response", "in", "plasma", "was", "monitored", "over", "8", "h", "by", "triglyceride", ",", "triglyceride", "-", "rich", "lipoprotein", "(", "TGRL)-triglyceride", ",", "apo", "B-48", "/", "apo", "B-100", "ratio", ",", "and", "retinyl", "palmitate", "concentrations", ",", "and", "the", "apo", "E", "polymorphism", "was", "determined", "by", "DNA", "amplification", "and", "digestion", ".", "The", "frequency", "of", "the", "apo", "E", "alleles", "and", "their", "effects", "on", "fasting", "lipid", "levels", "in", "this", "sample", "were", "similar", "to", "those", "reported", "elsewhere", ".", "Postprandial", "plasma", "retinyl", "palmitate", "response", "to", "a", "high", "-", "fat", "meal", "with", "vitamin", "A", "was", "significantly", "different", "among", "apo", "E", "genotypes", ",", "with", "delayed", "clearance", "in", "individuals", "with", "an", "epsilon", "2", "allele", ",", "compared", "with", "epsilon", "3/3", "and", "epsilon", "3/4", "individuals", ".", "In", "the", "sample", "of", "397", "Caucasians", ",", "average", "retinyl", "palmitate", "response", "was", "1,489", "micrograms", "/", "dl", "in", "epsilon", "2/3", "individuals", ",", "compared", "with", "1,037", "micrograms", "/", "dl", "in", "epsilon", "3/3", "individuals", "and", "1,108", "micrograms", "/", "dl", "in", "epsilon", "3/4", "individuals", ".", "The", "apo", "E", "polymorphism", "accounted", "for", "7.1", "%", "of", "the", "interindividual", "variation", "in", "postprandial", "retinyl", "palmitate", "response", ",", "a", "contribution", "proportionally", "greater", "than", "its", "well", "-", "known", "effect", "on", "fasting", "LDL", "-", "cholesterol", ".", "However", ",", "despite", "this", "effect", "on", "postprandial", "retinyl", "palmitate", ",", "the", "profile", "of", "postprandial", "triglyceride", "response", "was", "not", "significantly", "different", "among", "apo", "E", "genotypes", ".", "The", "profile", "of", "postprandial", "response", "was", "consistent", "between", "the", "sample", "of", "Caucasians", "and", "a", "smaller", "sample", "of", "black", "subjects", ".", "While", "these", "data", "indicate", "that", "the", "removal", "of", "remnant", "particles", "from", "circulation", "is", "delayed", "in", "subjects", "with", "the", "epsilon", "2/3", "genotype", ",", "there", "is", "no", "reported", "evidence", "that", "the", "epsilon", "2", "allele", "predisposes", "to", "coronary", "artery", "disease", "(", "CAD", ")", ".", "The", "results", "of", "this", "study", "provide", "not", "only", "a", "reliable", "estimate", "of", "the", "magnitude", "of", "the", "effect", "of", "the", "apo", "E", "polymorphism", "on", "various", "measurements", "commonly", "used", "to", "characterize", "postprandial", "lipemia", ",", "but", "also", "provide", "mechanistic", "insight", "into", "the", "effects", "of", "the", "apo", "E", "gene", "polymorphism", "on", "postprandial", "lipemia", "and", "CAD", ".", "\n" ]	[ "Gene" ]
Apolipoprotein E, apolipoprotein ( apo ) E, triglyceride - rich lipoprotein ( TGRL)-triglyceride, apo E, apo E, apo E, apo E, apo E, apo E, apo E	238_task2	Sentence: Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD. Instructions: please extract entity words from the input sentence	[ "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD.	[ "Apolipoprotein", "E", "polymorphism", "influences", "postprandial", "retinyl", "palmitate", "but", "not", "triglyceride", "concentrations", ".", "To", "quantify", "the", "effect", "of", "the", "apolipoprotein", "(", "apo", ")", "E", "polymorphism", "on", "the", "magnitude", "of", "postprandial", "lipemia", ",", "we", "have", "defined", "its", "role", "in", "determining", "the", "response", "to", "a", "single", "high", "-", "fat", "meal", "in", "a", "large", "sample", "of", "(", "N", "=", "474", ")", "individuals", "taking", "part", "in", "the", "biethnic", "Atherosclerosis", "Risk", "in", "Communities", "Study", ".", "The", "profile", "of", "postprandial", "response", "in", "plasma", "was", "monitored", "over", "8", "h", "by", "triglyceride", ",", "triglyceride", "-", "rich", "lipoprotein", "(", "TGRL)-triglyceride", ",", "apo", "B-48", "/", "apo", "B-100", "ratio", ",", "and", "retinyl", "palmitate", "concentrations", ",", "and", "the", "apo", "E", "polymorphism", "was", "determined", "by", "DNA", "amplification", "and", "digestion", ".", "The", "frequency", "of", "the", "apo", "E", "alleles", "and", "their", "effects", "on", "fasting", "lipid", "levels", "in", "this", "sample", "were", "similar", "to", "those", "reported", "elsewhere", ".", "Postprandial", "plasma", "retinyl", "palmitate", "response", "to", "a", "high", "-", "fat", "meal", "with", "vitamin", "A", "was", "significantly", "different", "among", "apo", "E", "genotypes", ",", "with", "delayed", "clearance", "in", "individuals", "with", "an", "epsilon", "2", "allele", ",", "compared", "with", "epsilon", "3/3", "and", "epsilon", "3/4", "individuals", ".", "In", "the", "sample", "of", "397", "Caucasians", ",", "average", "retinyl", "palmitate", "response", "was", "1,489", "micrograms", "/", "dl", "in", "epsilon", "2/3", "individuals", ",", "compared", "with", "1,037", "micrograms", "/", "dl", "in", "epsilon", "3/3", "individuals", "and", "1,108", "micrograms", "/", "dl", "in", "epsilon", "3/4", "individuals", ".", "The", "apo", "E", "polymorphism", "accounted", "for", "7.1", "%", "of", "the", "interindividual", "variation", "in", "postprandial", "retinyl", "palmitate", "response", ",", "a", "contribution", "proportionally", "greater", "than", "its", "well", "-", "known", "effect", "on", "fasting", "LDL", "-", "cholesterol", ".", "However", ",", "despite", "this", "effect", "on", "postprandial", "retinyl", "palmitate", ",", "the", "profile", "of", "postprandial", "triglyceride", "response", "was", "not", "significantly", "different", "among", "apo", "E", "genotypes", ".", "The", "profile", "of", "postprandial", "response", "was", "consistent", "between", "the", "sample", "of", "Caucasians", "and", "a", "smaller", "sample", "of", "black", "subjects", ".", "While", "these", "data", "indicate", "that", "the", "removal", "of", "remnant", "particles", "from", "circulation", "is", "delayed", "in", "subjects", "with", "the", "epsilon", "2/3", "genotype", ",", "there", "is", "no", "reported", "evidence", "that", "the", "epsilon", "2", "allele", "predisposes", "to", "coronary", "artery", "disease", "(", "CAD", ")", ".", "The", "results", "of", "this", "study", "provide", "not", "only", "a", "reliable", "estimate", "of", "the", "magnitude", "of", "the", "effect", "of", "the", "apo", "E", "polymorphism", "on", "various", "measurements", "commonly", "used", "to", "characterize", "postprandial", "lipemia", ",", "but", "also", "provide", "mechanistic", "insight", "into", "the", "effects", "of", "the", "apo", "E", "gene", "polymorphism", "on", "postprandial", "lipemia", "and", "CAD", ".", "\n" ]	[ "Gene" ]
Coronary artery disease is an umlsterm, developed countries is an umlsterm, stage is an umlsterm, coronary artery disease is an umlsterm, patients is an umlsterm, need is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, change of life is an umlsterm, treatment is an umlsterm, risk factors is an umlsterm	Herz.00250623.eng.abstr_task0	Sentence: Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory .	[ "Coronary", "artery", "disease", "is", "stoll", "the", "no", ".", "1", "killer", "in", "the", "developed", "countries", "and", "must", "thus", "be", "detected", "and", "treated", "at", "an", "earlier", "stage", ".", "If", "coronary", "artery", "disease", "is", "advanced", ",", "patients", "have", "to", "be", "examined", "regarding", "the", "need", "for", "revascularization", ".", "For", "secondary", "prevention", ",", "of", "course", ",", "an", "optimal", "change", "of", "life", "style", "and", "optimal", "medical", "treatment", "of", "risk", "factors", "is", "mandatory", "." ]	[ "umlsterm" ]
Coronary artery disease is an umlsterm, developed countries is an umlsterm, stage is an umlsterm, coronary artery disease is an umlsterm, patients is an umlsterm, need is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, change of life is an umlsterm, treatment is an umlsterm, risk factors is an umlsterm	Herz.00250623.eng.abstr_task1	Sentence: Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory . Instructions: please typing these entity words according to sentence: Coronary artery disease, developed countries, stage, coronary artery disease, patients, need, secondary, prevention, change of life, treatment, risk factors Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory .	[ "Coronary", "artery", "disease", "is", "stoll", "the", "no", ".", "1", "killer", "in", "the", "developed", "countries", "and", "must", "thus", "be", "detected", "and", "treated", "at", "an", "earlier", "stage", ".", "If", "coronary", "artery", "disease", "is", "advanced", ",", "patients", "have", "to", "be", "examined", "regarding", "the", "need", "for", "revascularization", ".", "For", "secondary", "prevention", ",", "of", "course", ",", "an", "optimal", "change", "of", "life", "style", "and", "optimal", "medical", "treatment", "of", "risk", "factors", "is", "mandatory", "." ]	[ "umlsterm" ]
Coronary artery disease, developed countries, stage, coronary artery disease, patients, need, secondary, prevention, change of life, treatment, risk factors	Herz.00250623.eng.abstr_task2	Sentence: Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory .	[ "Coronary", "artery", "disease", "is", "stoll", "the", "no", ".", "1", "killer", "in", "the", "developed", "countries", "and", "must", "thus", "be", "detected", "and", "treated", "at", "an", "earlier", "stage", ".", "If", "coronary", "artery", "disease", "is", "advanced", ",", "patients", "have", "to", "be", "examined", "regarding", "the", "need", "for", "revascularization", ".", "For", "secondary", "prevention", ",", "of", "course", ",", "an", "optimal", "change", "of", "life", "style", "and", "optimal", "medical", "treatment", "of", "risk", "factors", "is", "mandatory", "." ]	[ "umlsterm" ]
kidney transplant is a Procedure	NCT02707809_inc_task0	Sentence: kidney transplant recipient Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Procedure	[ "B-Procedure", "I-Procedure", "O", "O" ]	kidney transplant recipient	[ "kidney", "transplant", "recipient", "\n" ]	[ "Procedure" ]
kidney transplant is a Procedure	NCT02707809_inc_task1	Sentence: kidney transplant recipient Instructions: please typing these entity words according to sentence: kidney transplant Options: Procedure	[ "B-Procedure", "I-Procedure", "O", "O" ]	kidney transplant recipient	[ "kidney", "transplant", "recipient", "\n" ]	[ "Procedure" ]
kidney transplant	NCT02707809_inc_task2	Sentence: kidney transplant recipient Instructions: please extract entity words from the input sentence	[ "B-Procedure", "I-Procedure", "O", "O" ]	kidney transplant recipient	[ "kidney", "transplant", "recipient", "\n" ]	[ "Procedure" ]
tóxicos is a UNCLEAR, sertralina is a NORMALIZABLES, ácido fólico is a NORMALIZABLES, vitamina B12 is a NORMALIZABLES, tóxicos is a UNCLEAR, aciclovir is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, venlafaxina is a NORMALIZABLES, tiapride is a NORMALIZABLES, tiapride is a NORMALIZABLES, haloperidol is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, levetirazepam is a NORMALIZABLES, corticoides is a NORMALIZABLES, hemina is a NORMALIZABLES, uroporfirinas is a NORMALIZABLES, coproporfirinas is a NORMALIZABLES, zinc is a NORMALIZABLES, hemina is a NORMALIZABLES, polimerasas is a PROTEINAS, priones is a PROTEINAS, proteína is a PROTEINAS, ceruloplasmina is a PROTEINAS, cobre is a NORMALIZABLES, anti - Hu is a PROTEINAS, anti - Yo is a PROTEINAS, anti - Ri is a PROTEINAS, anti - CV2 is a PROTEINAS, antifisina is a PROTEINAS, anti - Tr is a PROTEINAS, anti - canales de calcio is a PROTEINAS, anticuerpos anti - NMDA is a PROTEINAS, ziprasidona is a NORMALIZABLES, receptores N - metil - D - aspartato is a PROTEINAS, ECR - NMDA is a PROTEINAS, ECR - NMDA is a PROTEINAS	481_task0	Sentence: Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: UNCLEAR, NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O" ]	Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA).	[ "Mujer", "de", "29", "años", ",", "soltera", ",", "vive", "con", "sus", "padres", ",", "sin", "antecedentes", "de", "patología", "orgánica", ",", "psiquiátrica", "o", "abuso", "de", "tóxicos", ",", "ingresada", "en", "neurología", "por", "alteraciones", "de", "conducta", ",", "desorientación", "y", "falta", "de", "conexión", "con", "el", "medio", ".", "La", "familia", "refería", "que", "era", "el", "primer", "episodio", "de", "estas", "características", ",", "que", "desde", "hacía", "2", "semanas", "veían", "a", "la", "paciente", "desanimada", ",", "poco", "comunicativa", "(", "no", "identificaban", "ningún", "desencadenante", "ni", "factor", "descompensatorio", ",", "la", "relación", "con", "la", "paciente", "era", "buena", ",", "tenía", "buena", "red", "social", "de", "apoyo", ",", "buen", "desempeño", "laboral", ",", "etc", ".", ")", ",", "a", "veces", "se", "quedaba", "con", "la", "mirada", "perdida", ",", "llegando", "a", "hablar", "incoherencias", "(", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ")", ",", "no", "había", "alteración", "de", "los", "ritmos", "biológicos", ".", "Todo", "ello", "era", "motivo", "de", "gran", "agobio", "familiar", ",", "por", "lo", "que", "acudieron", "al", "médico", "de", "familia", ",", "siendo", "tratada", "como", "un", "cuadro", "depresivo", "y", "pautándosele", "sertralina", "50", "mg", "/", "día", "(", "1", "semana", "antes", "del", "ingreso", ")", ".", "La", "evolución", "fue", "tórpida", ",", "presentado", "episodios", "de", "agitación", "psicomotriz", "y", "desorientación", ",", "motivo", "por", "el", "que", "la", "familia", "decide", "llevar", "a", "la", "paciente", "a", "las", "urgencias", "de", "medicina", ".", "No", "había", "antecedentes", "familiares", "de", "enfermedad", "psiquiátrica", "u", "orgánica", "importante", ".", "En", "el", "examen", ",", "aparte", "de", "la", "desorientación", "espacio", "-", "temporal", "y", "la", "agitación", ",", "no", "se", "encontró", "nada", "llamativo", ",", "no", "presentando", "focalidad", "neurológica", ".", "\n", "Las", "analíticas", "(", "hemograma", ",", "coagulación", ",", "pruebas", "de", "función", "hepática", ",", "renal", ",", "tiroidea", ",", "orina", ",", "ácido", "fólico", "y", "vitamina", "B12", ")", "y", "tomografía", "cerebral", "fueron", "normales", ".", "Los", "tóxicos", "en", "orina", "fueron", "negativos", ".", "La", "punción", "lumbar", "(", "PL", ")", "mostró", "26", "leucocitos", "/", "mm3", ".", "En", "urgencias", "presentó", "una", "convulsión", "tónico", "-", "clónica", "generalizada", ",", "siendo", "ingresada", "con", "el", "diagnóstico", "presuntivo", "de", "encefalitis", "vírica", ",", "iniciándose", "tratamiento", "con", "aciclovir", "y", "ácido", "valproico", ".", "\n", "Durante", "su", "ingreso", "fue", "evaluada", "por", "Psiquiatría", ".", "La", "familia", "nuevamente", "refirió", "que", "la", "paciente", "se", "encontraba", "apática", "desde", "hacía", "2", "semanas", ",", "repitiendo", "que", "tenía", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ".", "Se", "la", "catalogó", "como", "una", "depresión", "psicótica", "y", "se", "pautó", "venlafaxina", "75", "mg", "/", "día", ".", "La", "serología", "para", "VIH", ",", "Brucella", ",", "Citomegalovirus", ",", "Herpes", "Simple", ",", "Sífilis", ",", "Toxoplasmosis", "y", "Epstein", "Barr", "fueron", "negativas", ".", "\n", "Durante", "la", "primera", "semana", "de", "hospitalización", "la", "paciente", "estaba", "confusa", ",", "presentaba", "soliloquios", "y", "risas", "inmotivadas", ".", "Se", "repitió", "la", "PL", "(", "34", "leucocitos", "/", "mm3", ",", "linfocitos", "100", "%", ",", "la", "serología", "y", "cultivo", "del", "líquido", "cefalorraquídeo", "(", "LCR", ")", "para", "Brucella", ",", "Lúes", "y", "Borrellia", "fueron", "negativos", ")", ".", "La", "resonancia", "magnética", "(", "RM", ")", "cerebral", "fue", "normal", ".", "Se", "suspendió", "el", "antidepresivo", "y", "se", "pautó", "tiapride", ".", "\n", "Durante", "la", "segunda", "semana", ",", "el", "electroencefalograma", "(", "EEG", ")", "mostró", "signos", "de", "encefalopatía", "lenta", "difusa", "de", "grado", "moderado", ".", "La", "paciente", "no", "respondía", "a", "órdenes", "simples", ",", "estaba", "mutista", ",", "estuporosa", ",", "por", "lo", "que", "se", "suspendió", "el", "tiapride", ",", "dejándola", "con", "haloperidol", "intramuscular", "en", "caso", "de", "agitación", ".", "Debido", "a", "la", "evolución", "tórpida", "se", "la", "ingresó", "en", "UCI", "suspendiéndose", "el", "ácido", "valproico", "e", "iniciando", "levetirazepam", ".", "La", "paciente", "comenzó", "a", "presentar", "movimientos", "involuntarios", "y", "distonías", ".", "La", "ecocardiografía", "transtorácica", "fue", "normal", ".", "Se", "añadieron", "megadosis", "de", "corticoides", "y", "hemina", "(", "por", "sospecha", "de", "porfiria", "aguda", "intermitente", ")", ".", "Debido", "a", "las", "crisis", "tónicas", "complejas", "más", "frecuentes", "se", "decide", "sedación", "e", "intubación", "endotraqueal", ".", "No", "se", "detectaron", "uroporfirinas", ",", "las", "coproporfirinas", "y", "el", "zinc", "estaban", "en", "límites", "normales", "(", "por", "lo", "que", "se", "suspendió", "la", "hemina", ")", ".", "Se", "repitió", "PL", ",", "siendo", "la", "reacción", "en", "cadena", "de", "polimerasas", "para", "micoplasma", "y", "micobacterias", "normales", ".", "\n", "Durante", "la", "cuarta", "semana", ",", "se", "retiró", "la", "sedación", ":", "respondía", "a", "órdenes", "sencillas", ",", "presentaba", "mioclonías", "faciales", "y", "movimientos", "bucolinguales", ",", "procediéndose", "a", "la", "extubación", ".", "El", "EEG", "siguió", "mostrando", "signos", "de", "encefalopatía", "difusa", ".", "Se", "descartó", "enfermedad", "por", "priones", "(", "negativo", "a", "proteína", "en", "LCR", ")", ".", "La", "ecografía", "ginecológica", "mostró", "un", "ovario", "ligeramente", "aumentado", "de", "tamaño", ".", "\n", "Durante", "la", "sexta", "semana", ",", "la", "ceruloplasmina", ",", "cobre", "sérico", "y", "ecografía", "abdominal", "fueron", "normales", ".", "La", "paciente", "estaba", "más", "consciente", "y", "reactiva", ".", "Se", "planteó", "la", "posibilidad", "de", "encefalitis", "con", "relación", "a", "teratoma", "no", "objetivado", ".", "Se", "repitió", "la", "PL", "buscando", "la", "presencia", "de", "anticuerpos", "paraneoplásicos", "(", "anti", "-", "Hu", ",", "anti", "-", "Yo", ",", "anti", "-", "Ri", ",", "anti", "-", "CV2", ",", "antifisina", ",", "anti", "-", "Tr", "y", "anti", "-", "canales", "de", "calcio", ")", ",", "que", "fueron", "negativos", ",", "excepto", "los", "anticuerpos", "anti", "-", "NMDA", ".", "Se", "llamó", "nuevamente", "a", "Psiquiatría", "por", "agitación", "psicomotriz", "e", "ideas", "delirantes", "autorreferenciales", ",", "iniciándose", "ziprasidona", "40", "mg", "/", "día", ",", "llegando", "hasta", "160", "mg", "/", "día", "con", "mejoría", "progresiva", ",", "siendo", "el", "diagnóstico", "final", "el", "de", "encefalitis", "contra", "los", "receptores", "N", "-", "metil", "-", "D", "-", "aspartato", "(", "ECR", "-", "NMDA", ")", "y", "trastorno", "psicótico", "secundario", "a", "patología", "orgánica", "(", "ECR", "-", "NMDA", ")", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR" ]
tóxicos is a UNCLEAR, sertralina is a NORMALIZABLES, ácido fólico is a NORMALIZABLES, vitamina B12 is a NORMALIZABLES, tóxicos is a UNCLEAR, aciclovir is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, venlafaxina is a NORMALIZABLES, tiapride is a NORMALIZABLES, tiapride is a NORMALIZABLES, haloperidol is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, levetirazepam is a NORMALIZABLES, corticoides is a NORMALIZABLES, hemina is a NORMALIZABLES, uroporfirinas is a NORMALIZABLES, coproporfirinas is a NORMALIZABLES, zinc is a NORMALIZABLES, hemina is a NORMALIZABLES, polimerasas is a PROTEINAS, priones is a PROTEINAS, proteína is a PROTEINAS, ceruloplasmina is a PROTEINAS, cobre is a NORMALIZABLES, anti - Hu is a PROTEINAS, anti - Yo is a PROTEINAS, anti - Ri is a PROTEINAS, anti - CV2 is a PROTEINAS, antifisina is a PROTEINAS, anti - Tr is a PROTEINAS, anti - canales de calcio is a PROTEINAS, anticuerpos anti - NMDA is a PROTEINAS, ziprasidona is a NORMALIZABLES, receptores N - metil - D - aspartato is a PROTEINAS, ECR - NMDA is a PROTEINAS, ECR - NMDA is a PROTEINAS	481_task1	Sentence: Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA). Instructions: please typing these entity words according to sentence: tóxicos, sertralina, ácido fólico, vitamina B12, tóxicos, aciclovir, ácido valproico, venlafaxina, tiapride, tiapride, haloperidol, ácido valproico, levetirazepam, corticoides, hemina, uroporfirinas, coproporfirinas, zinc, hemina, polimerasas, priones, proteína, ceruloplasmina, cobre, anti - Hu, anti - Yo, anti - Ri, anti - CV2, antifisina, anti - Tr, anti - canales de calcio, anticuerpos anti - NMDA, ziprasidona, receptores N - metil - D - aspartato, ECR - NMDA, ECR - NMDA Options: UNCLEAR, NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O" ]	Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA).	[ "Mujer", "de", "29", "años", ",", "soltera", ",", "vive", "con", "sus", "padres", ",", "sin", "antecedentes", "de", "patología", "orgánica", ",", "psiquiátrica", "o", "abuso", "de", "tóxicos", ",", "ingresada", "en", "neurología", "por", "alteraciones", "de", "conducta", ",", "desorientación", "y", "falta", "de", "conexión", "con", "el", "medio", ".", "La", "familia", "refería", "que", "era", "el", "primer", "episodio", "de", "estas", "características", ",", "que", "desde", "hacía", "2", "semanas", "veían", "a", "la", "paciente", "desanimada", ",", "poco", "comunicativa", "(", "no", "identificaban", "ningún", "desencadenante", "ni", "factor", "descompensatorio", ",", "la", "relación", "con", "la", "paciente", "era", "buena", ",", "tenía", "buena", "red", "social", "de", "apoyo", ",", "buen", "desempeño", "laboral", ",", "etc", ".", ")", ",", "a", "veces", "se", "quedaba", "con", "la", "mirada", "perdida", ",", "llegando", "a", "hablar", "incoherencias", "(", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ")", ",", "no", "había", "alteración", "de", "los", "ritmos", "biológicos", ".", "Todo", "ello", "era", "motivo", "de", "gran", "agobio", "familiar", ",", "por", "lo", "que", "acudieron", "al", "médico", "de", "familia", ",", "siendo", "tratada", "como", "un", "cuadro", "depresivo", "y", "pautándosele", "sertralina", "50", "mg", "/", "día", "(", "1", "semana", "antes", "del", "ingreso", ")", ".", "La", "evolución", "fue", "tórpida", ",", "presentado", "episodios", "de", "agitación", "psicomotriz", "y", "desorientación", ",", "motivo", "por", "el", "que", "la", "familia", "decide", "llevar", "a", "la", "paciente", "a", "las", "urgencias", "de", "medicina", ".", "No", "había", "antecedentes", "familiares", "de", "enfermedad", "psiquiátrica", "u", "orgánica", "importante", ".", "En", "el", "examen", ",", "aparte", "de", "la", "desorientación", "espacio", "-", "temporal", "y", "la", "agitación", ",", "no", "se", "encontró", "nada", "llamativo", ",", "no", "presentando", "focalidad", "neurológica", ".", "\n", "Las", "analíticas", "(", "hemograma", ",", "coagulación", ",", "pruebas", "de", "función", "hepática", ",", "renal", ",", "tiroidea", ",", "orina", ",", "ácido", "fólico", "y", "vitamina", "B12", ")", "y", "tomografía", "cerebral", "fueron", "normales", ".", "Los", "tóxicos", "en", "orina", "fueron", "negativos", ".", "La", "punción", "lumbar", "(", "PL", ")", "mostró", "26", "leucocitos", "/", "mm3", ".", "En", "urgencias", "presentó", "una", "convulsión", "tónico", "-", "clónica", "generalizada", ",", "siendo", "ingresada", "con", "el", "diagnóstico", "presuntivo", "de", "encefalitis", "vírica", ",", "iniciándose", "tratamiento", "con", "aciclovir", "y", "ácido", "valproico", ".", "\n", "Durante", "su", "ingreso", "fue", "evaluada", "por", "Psiquiatría", ".", "La", "familia", "nuevamente", "refirió", "que", "la", "paciente", "se", "encontraba", "apática", "desde", "hacía", "2", "semanas", ",", "repitiendo", "que", "tenía", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ".", "Se", "la", "catalogó", "como", "una", "depresión", "psicótica", "y", "se", "pautó", "venlafaxina", "75", "mg", "/", "día", ".", "La", "serología", "para", "VIH", ",", "Brucella", ",", "Citomegalovirus", ",", "Herpes", "Simple", ",", "Sífilis", ",", "Toxoplasmosis", "y", "Epstein", "Barr", "fueron", "negativas", ".", "\n", "Durante", "la", "primera", "semana", "de", "hospitalización", "la", "paciente", "estaba", "confusa", ",", "presentaba", "soliloquios", "y", "risas", "inmotivadas", ".", "Se", "repitió", "la", "PL", "(", "34", "leucocitos", "/", "mm3", ",", "linfocitos", "100", "%", ",", "la", "serología", "y", "cultivo", "del", "líquido", "cefalorraquídeo", "(", "LCR", ")", "para", "Brucella", ",", "Lúes", "y", "Borrellia", "fueron", "negativos", ")", ".", "La", "resonancia", "magnética", "(", "RM", ")", "cerebral", "fue", "normal", ".", "Se", "suspendió", "el", "antidepresivo", "y", "se", "pautó", "tiapride", ".", "\n", "Durante", "la", "segunda", "semana", ",", "el", "electroencefalograma", "(", "EEG", ")", "mostró", "signos", "de", "encefalopatía", "lenta", "difusa", "de", "grado", "moderado", ".", "La", "paciente", "no", "respondía", "a", "órdenes", "simples", ",", "estaba", "mutista", ",", "estuporosa", ",", "por", "lo", "que", "se", "suspendió", "el", "tiapride", ",", "dejándola", "con", "haloperidol", "intramuscular", "en", "caso", "de", "agitación", ".", "Debido", "a", "la", "evolución", "tórpida", "se", "la", "ingresó", "en", "UCI", "suspendiéndose", "el", "ácido", "valproico", "e", "iniciando", "levetirazepam", ".", "La", "paciente", "comenzó", "a", "presentar", "movimientos", "involuntarios", "y", "distonías", ".", "La", "ecocardiografía", "transtorácica", "fue", "normal", ".", "Se", "añadieron", "megadosis", "de", "corticoides", "y", "hemina", "(", "por", "sospecha", "de", "porfiria", "aguda", "intermitente", ")", ".", "Debido", "a", "las", "crisis", "tónicas", "complejas", "más", "frecuentes", "se", "decide", "sedación", "e", "intubación", "endotraqueal", ".", "No", "se", "detectaron", "uroporfirinas", ",", "las", "coproporfirinas", "y", "el", "zinc", "estaban", "en", "límites", "normales", "(", "por", "lo", "que", "se", "suspendió", "la", "hemina", ")", ".", "Se", "repitió", "PL", ",", "siendo", "la", "reacción", "en", "cadena", "de", "polimerasas", "para", "micoplasma", "y", "micobacterias", "normales", ".", "\n", "Durante", "la", "cuarta", "semana", ",", "se", "retiró", "la", "sedación", ":", "respondía", "a", "órdenes", "sencillas", ",", "presentaba", "mioclonías", "faciales", "y", "movimientos", "bucolinguales", ",", "procediéndose", "a", "la", "extubación", ".", "El", "EEG", "siguió", "mostrando", "signos", "de", "encefalopatía", "difusa", ".", "Se", "descartó", "enfermedad", "por", "priones", "(", "negativo", "a", "proteína", "en", "LCR", ")", ".", "La", "ecografía", "ginecológica", "mostró", "un", "ovario", "ligeramente", "aumentado", "de", "tamaño", ".", "\n", "Durante", "la", "sexta", "semana", ",", "la", "ceruloplasmina", ",", "cobre", "sérico", "y", "ecografía", "abdominal", "fueron", "normales", ".", "La", "paciente", "estaba", "más", "consciente", "y", "reactiva", ".", "Se", "planteó", "la", "posibilidad", "de", "encefalitis", "con", "relación", "a", "teratoma", "no", "objetivado", ".", "Se", "repitió", "la", "PL", "buscando", "la", "presencia", "de", "anticuerpos", "paraneoplásicos", "(", "anti", "-", "Hu", ",", "anti", "-", "Yo", ",", "anti", "-", "Ri", ",", "anti", "-", "CV2", ",", "antifisina", ",", "anti", "-", "Tr", "y", "anti", "-", "canales", "de", "calcio", ")", ",", "que", "fueron", "negativos", ",", "excepto", "los", "anticuerpos", "anti", "-", "NMDA", ".", "Se", "llamó", "nuevamente", "a", "Psiquiatría", "por", "agitación", "psicomotriz", "e", "ideas", "delirantes", "autorreferenciales", ",", "iniciándose", "ziprasidona", "40", "mg", "/", "día", ",", "llegando", "hasta", "160", "mg", "/", "día", "con", "mejoría", "progresiva", ",", "siendo", "el", "diagnóstico", "final", "el", "de", "encefalitis", "contra", "los", "receptores", "N", "-", "metil", "-", "D", "-", "aspartato", "(", "ECR", "-", "NMDA", ")", "y", "trastorno", "psicótico", "secundario", "a", "patología", "orgánica", "(", "ECR", "-", "NMDA", ")", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR" ]
tóxicos, sertralina, ácido fólico, vitamina B12, tóxicos, aciclovir, ácido valproico, venlafaxina, tiapride, tiapride, haloperidol, ácido valproico, levetirazepam, corticoides, hemina, uroporfirinas, coproporfirinas, zinc, hemina, polimerasas, priones, proteína, ceruloplasmina, cobre, anti - Hu, anti - Yo, anti - Ri, anti - CV2, antifisina, anti - Tr, anti - canales de calcio, anticuerpos anti - NMDA, ziprasidona, receptores N - metil - D - aspartato, ECR - NMDA, ECR - NMDA	481_task2	Sentence: Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O" ]	Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA).	[ "Mujer", "de", "29", "años", ",", "soltera", ",", "vive", "con", "sus", "padres", ",", "sin", "antecedentes", "de", "patología", "orgánica", ",", "psiquiátrica", "o", "abuso", "de", "tóxicos", ",", "ingresada", "en", "neurología", "por", "alteraciones", "de", "conducta", ",", "desorientación", "y", "falta", "de", "conexión", "con", "el", "medio", ".", "La", "familia", "refería", "que", "era", "el", "primer", "episodio", "de", "estas", "características", ",", "que", "desde", "hacía", "2", "semanas", "veían", "a", "la", "paciente", "desanimada", ",", "poco", "comunicativa", "(", "no", "identificaban", "ningún", "desencadenante", "ni", "factor", "descompensatorio", ",", "la", "relación", "con", "la", "paciente", "era", "buena", ",", "tenía", "buena", "red", "social", "de", "apoyo", ",", "buen", "desempeño", "laboral", ",", "etc", ".", ")", ",", "a", "veces", "se", "quedaba", "con", "la", "mirada", "perdida", ",", "llegando", "a", "hablar", "incoherencias", "(", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ")", ",", "no", "había", "alteración", "de", "los", "ritmos", "biológicos", ".", "Todo", "ello", "era", "motivo", "de", "gran", "agobio", "familiar", ",", "por", "lo", "que", "acudieron", "al", "médico", "de", "familia", ",", "siendo", "tratada", "como", "un", "cuadro", "depresivo", "y", "pautándosele", "sertralina", "50", "mg", "/", "día", "(", "1", "semana", "antes", "del", "ingreso", ")", ".", "La", "evolución", "fue", "tórpida", ",", "presentado", "episodios", "de", "agitación", "psicomotriz", "y", "desorientación", ",", "motivo", "por", "el", "que", "la", "familia", "decide", "llevar", "a", "la", "paciente", "a", "las", "urgencias", "de", "medicina", ".", "No", "había", "antecedentes", "familiares", "de", "enfermedad", "psiquiátrica", "u", "orgánica", "importante", ".", "En", "el", "examen", ",", "aparte", "de", "la", "desorientación", "espacio", "-", "temporal", "y", "la", "agitación", ",", "no", "se", "encontró", "nada", "llamativo", ",", "no", "presentando", "focalidad", "neurológica", ".", "\n", "Las", "analíticas", "(", "hemograma", ",", "coagulación", ",", "pruebas", "de", "función", "hepática", ",", "renal", ",", "tiroidea", ",", "orina", ",", "ácido", "fólico", "y", "vitamina", "B12", ")", "y", "tomografía", "cerebral", "fueron", "normales", ".", "Los", "tóxicos", "en", "orina", "fueron", "negativos", ".", "La", "punción", "lumbar", "(", "PL", ")", "mostró", "26", "leucocitos", "/", "mm3", ".", "En", "urgencias", "presentó", "una", "convulsión", "tónico", "-", "clónica", "generalizada", ",", "siendo", "ingresada", "con", "el", "diagnóstico", "presuntivo", "de", "encefalitis", "vírica", ",", "iniciándose", "tratamiento", "con", "aciclovir", "y", "ácido", "valproico", ".", "\n", "Durante", "su", "ingreso", "fue", "evaluada", "por", "Psiquiatría", ".", "La", "familia", "nuevamente", "refirió", "que", "la", "paciente", "se", "encontraba", "apática", "desde", "hacía", "2", "semanas", ",", "repitiendo", "que", "tenía", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ".", "Se", "la", "catalogó", "como", "una", "depresión", "psicótica", "y", "se", "pautó", "venlafaxina", "75", "mg", "/", "día", ".", "La", "serología", "para", "VIH", ",", "Brucella", ",", "Citomegalovirus", ",", "Herpes", "Simple", ",", "Sífilis", ",", "Toxoplasmosis", "y", "Epstein", "Barr", "fueron", "negativas", ".", "\n", "Durante", "la", "primera", "semana", "de", "hospitalización", "la", "paciente", "estaba", "confusa", ",", "presentaba", "soliloquios", "y", "risas", "inmotivadas", ".", "Se", "repitió", "la", "PL", "(", "34", "leucocitos", "/", "mm3", ",", "linfocitos", "100", "%", ",", "la", "serología", "y", "cultivo", "del", "líquido", "cefalorraquídeo", "(", "LCR", ")", "para", "Brucella", ",", "Lúes", "y", "Borrellia", "fueron", "negativos", ")", ".", "La", "resonancia", "magnética", "(", "RM", ")", "cerebral", "fue", "normal", ".", "Se", "suspendió", "el", "antidepresivo", "y", "se", "pautó", "tiapride", ".", "\n", "Durante", "la", "segunda", "semana", ",", "el", "electroencefalograma", "(", "EEG", ")", "mostró", "signos", "de", "encefalopatía", "lenta", "difusa", "de", "grado", "moderado", ".", "La", "paciente", "no", "respondía", "a", "órdenes", "simples", ",", "estaba", "mutista", ",", "estuporosa", ",", "por", "lo", "que", "se", "suspendió", "el", "tiapride", ",", "dejándola", "con", "haloperidol", "intramuscular", "en", "caso", "de", "agitación", ".", "Debido", "a", "la", "evolución", "tórpida", "se", "la", "ingresó", "en", "UCI", "suspendiéndose", "el", "ácido", "valproico", "e", "iniciando", "levetirazepam", ".", "La", "paciente", "comenzó", "a", "presentar", "movimientos", "involuntarios", "y", "distonías", ".", "La", "ecocardiografía", "transtorácica", "fue", "normal", ".", "Se", "añadieron", "megadosis", "de", "corticoides", "y", "hemina", "(", "por", "sospecha", "de", "porfiria", "aguda", "intermitente", ")", ".", "Debido", "a", "las", "crisis", "tónicas", "complejas", "más", "frecuentes", "se", "decide", "sedación", "e", "intubación", "endotraqueal", ".", "No", "se", "detectaron", "uroporfirinas", ",", "las", "coproporfirinas", "y", "el", "zinc", "estaban", "en", "límites", "normales", "(", "por", "lo", "que", "se", "suspendió", "la", "hemina", ")", ".", "Se", "repitió", "PL", ",", "siendo", "la", "reacción", "en", "cadena", "de", "polimerasas", "para", "micoplasma", "y", "micobacterias", "normales", ".", "\n", "Durante", "la", "cuarta", "semana", ",", "se", "retiró", "la", "sedación", ":", "respondía", "a", "órdenes", "sencillas", ",", "presentaba", "mioclonías", "faciales", "y", "movimientos", "bucolinguales", ",", "procediéndose", "a", "la", "extubación", ".", "El", "EEG", "siguió", "mostrando", "signos", "de", "encefalopatía", "difusa", ".", "Se", "descartó", "enfermedad", "por", "priones", "(", "negativo", "a", "proteína", "en", "LCR", ")", ".", "La", "ecografía", "ginecológica", "mostró", "un", "ovario", "ligeramente", "aumentado", "de", "tamaño", ".", "\n", "Durante", "la", "sexta", "semana", ",", "la", "ceruloplasmina", ",", "cobre", "sérico", "y", "ecografía", "abdominal", "fueron", "normales", ".", "La", "paciente", "estaba", "más", "consciente", "y", "reactiva", ".", "Se", "planteó", "la", "posibilidad", "de", "encefalitis", "con", "relación", "a", "teratoma", "no", "objetivado", ".", "Se", "repitió", "la", "PL", "buscando", "la", "presencia", "de", "anticuerpos", "paraneoplásicos", "(", "anti", "-", "Hu", ",", "anti", "-", "Yo", ",", "anti", "-", "Ri", ",", "anti", "-", "CV2", ",", "antifisina", ",", "anti", "-", "Tr", "y", "anti", "-", "canales", "de", "calcio", ")", ",", "que", "fueron", "negativos", ",", "excepto", "los", "anticuerpos", "anti", "-", "NMDA", ".", "Se", "llamó", "nuevamente", "a", "Psiquiatría", "por", "agitación", "psicomotriz", "e", "ideas", "delirantes", "autorreferenciales", ",", "iniciándose", "ziprasidona", "40", "mg", "/", "día", ",", "llegando", "hasta", "160", "mg", "/", "día", "con", "mejoría", "progresiva", ",", "siendo", "el", "diagnóstico", "final", "el", "de", "encefalitis", "contra", "los", "receptores", "N", "-", "metil", "-", "D", "-", "aspartato", "(", "ECR", "-", "NMDA", ")", "y", "trastorno", "psicótico", "secundario", "a", "patología", "orgánica", "(", "ECR", "-", "NMDA", ")", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR" ]
Pembrolizumab is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, previously treated , PD - L1-positive , advanced non - small - cell lung cancer is a Participant_Condition, pembrolizumab is a Intervention_Pharmacological, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells is a Participant_Condition, survival and progression - free survival is a Outcome_Mortality, 1034 patients is a Participant_Sample-size, median overall survival is a Outcome_Mortality, Overall survival is a Outcome_Mortality, Median progression - free survival is a Outcome_Mortality, Grade 3 - 5 treatment - related adverse events is a Outcome_Adverse-effects	73209_task0	Sentence: Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Sample-size	[ "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co .	[ "Pembrolizumab", "versus", "docetaxel", "for", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "KEYNOTE-010", ")", ":", "a", "randomised", "controlled", "trial", ".", "BACKGROUND", "Despite", "recent", "advances", "in", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ",", "there", "remains", "a", "need", "for", "effective", "treatments", "for", "progressive", "disease", ".", "We", "assessed", "the", "efficacy", "of", "pembrolizumab", "for", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "METHODS", "We", "did", "this", "randomised", ",", "open", "-", "label", ",", "phase", "2/3", "study", "at", "202", "academic", "medical", "centres", "in", "24", "countries", ".", "Patients", "with", "previously", "treated", "non", "-", "small", "-", "cell", "lung", "cancer", "with", "PD", "-", "L1", "expression", "on", "at", "least", "1", "%", "of", "tumour", "cells", "were", "randomly", "assigned", "(", "1:1:1", ")", "in", "blocks", "of", "six", "per", "stratum", "with", "an", "interactive", "voice", "-", "response", "system", "to", "receive", "pembrolizumab", "2", "mg", "/", "kg", ",", "pembrolizumab", "10", "mg", "/", "kg", ",", "or", "docetaxel", "75", "mg", "/", "m", "(", "2", ")", "every", "3", "weeks", ".", "The", "primary", "endpoints", "were", "overall", "survival", "and", "progression", "-", "free", "survival", "both", "in", "the", "total", "population", "and", "in", "patients", "with", "PD", "-", "L1", "expression", "on", "at", "least", "50", "%", "of", "tumour", "cells", ".", "We", "used", "a", "threshold", "for", "significance", "of", "p", "<", "0.00825", "(", "one", "-", "sided", ")", "for", "the", "analysis", "of", "overall", "survival", "and", "a", "threshold", "of", "p", "<", "0.001", "for", "progression", "-", "free", "survival", ".", "This", "trial", "is", "registered", "at", "ClinicalTrials.gov", ",", "number", "NCT01905657", ".", "FINDINGS", "Between", "Aug", "28", ",", "2013", ",", "and", "Feb", "27", ",", "2015", ",", "we", "enrolled", "1034", "patients", ":", "345", "allocated", "to", "pembrolizumab", "2", "mg", "/", "kg", ",", "346", "allocated", "to", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "343", "allocated", "to", "docetaxel", ".", "By", "Sept", "30", ",", "2015", ",", "521", "patients", "had", "died", ".", "In", "the", "total", "population", ",", "median", "overall", "survival", "was", "10.4", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "12.7", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "8.5", "months", "with", "docetaxel", ".", "Overall", "survival", "was", "significantly", "longer", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "hazard", "ratio", "[", "HR", "]", "0.71", ",", "95", "%", "CI", "0.58", "-", "0.88", ";", "p=0.0008", ")", "and", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "0.61", ",", "0.49", "-", "0.75", ";", "p", "<", "0.0001", ")", ".", "Median", "progression", "-", "free", "survival", "was", "3.9", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "4.0", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "4.0", "months", "with", "docetaxel", ",", "with", "no", "significant", "difference", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "0.88", ",", "0.74", "-", "1.05", ";", "p=0.07", ")", "or", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "HR", "0.79", ",", "95", "%", "CI", "0.66", "-", "0.94", ";", "p=0.004", ")", ".", "Among", "patients", "with", "at", "least", "50", "%", "of", "tumour", "cells", "expressing", "PD", "-", "L1", ",", "overall", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "14.9", "months", "vs", "8.2", "months", ";", "HR", "0.54", ",", "95", "%", "CI", "0.38", "-", "0.77", ";", "p=0.0002", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "17.3", "months", "vs", "8.2", "months", ";", "0.50", ",", "0.36", "-", "0.70", ";", "p", "<", "0.0001", ")", ".", "Likewise", ",", "for", "this", "patient", "population", ",", "progression", "-", "free", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "5.0", "months", "vs", "4.1", "months", ";", "HR", "0.59", ",", "95", "%", "CI", "0.44", "-", "0.78", ";", "p=0.0001", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "5.2", "months", "vs", "4.1", "months", ";", "0.59", ",", "0.45", "-", "0.78", ";", "p", "<", "0.0001", ")", ".", "Grade", "3", "-", "5", "treatment", "-", "related", "adverse", "events", "were", "less", "common", "with", "pembrolizumab", "than", "with", "docetaxel", "(", "43", "[", "13", "%", "]", "of", "339", "patients", "given", "2", "mg", "/", "kg", ",", "55", "[", "16", "%", "]", "of", "343", "given", "10", "mg", "/", "kg", ",", "and", "109", "[", "35", "%", "]", "of", "309", "given", "docetaxel", ")", ".", "INTERPRETATION", "Pembrolizumab", "prolongs", "overall", "survival", "and", "has", "a", "favourable", "benefit", "-", "to", "-", "risk", "profile", "in", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "These", "data", "establish", "pembrolizumab", "as", "a", "new", "treatment", "option", "for", "this", "population", "and", "validate", "the", "use", "of", "PD", "-", "L1", "selection", ".", "FUNDING", "Merck", "&", "Co", "." ]	[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]
Pembrolizumab is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, previously treated , PD - L1-positive , advanced non - small - cell lung cancer is a Participant_Condition, pembrolizumab is a Intervention_Pharmacological, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells is a Participant_Condition, survival and progression - free survival is a Outcome_Mortality, 1034 patients is a Participant_Sample-size, median overall survival is a Outcome_Mortality, Overall survival is a Outcome_Mortality, Median progression - free survival is a Outcome_Mortality, Grade 3 - 5 treatment - related adverse events is a Outcome_Adverse-effects	73209_task1	Sentence: Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co . Instructions: please typing these entity words according to sentence: Pembrolizumab, docetaxel, previously treated , PD - L1-positive , advanced non - small - cell lung cancer, pembrolizumab, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells, survival and progression - free survival, 1034 patients, median overall survival, Overall survival, Median progression - free survival, Grade 3 - 5 treatment - related adverse events Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Sample-size	[ "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co .	[ "Pembrolizumab", "versus", "docetaxel", "for", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "KEYNOTE-010", ")", ":", "a", "randomised", "controlled", "trial", ".", "BACKGROUND", "Despite", "recent", "advances", "in", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ",", "there", "remains", "a", "need", "for", "effective", "treatments", "for", "progressive", "disease", ".", "We", "assessed", "the", "efficacy", "of", "pembrolizumab", "for", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "METHODS", "We", "did", "this", "randomised", ",", "open", "-", "label", ",", "phase", "2/3", "study", "at", "202", "academic", "medical", "centres", "in", "24", "countries", ".", "Patients", "with", "previously", "treated", "non", "-", "small", "-", "cell", "lung", "cancer", "with", "PD", "-", "L1", "expression", "on", "at", "least", "1", "%", "of", "tumour", "cells", "were", "randomly", "assigned", "(", "1:1:1", ")", "in", "blocks", "of", "six", "per", "stratum", "with", "an", "interactive", "voice", "-", "response", "system", "to", "receive", "pembrolizumab", "2", "mg", "/", "kg", ",", "pembrolizumab", "10", "mg", "/", "kg", ",", "or", "docetaxel", "75", "mg", "/", "m", "(", "2", ")", "every", "3", "weeks", ".", "The", "primary", "endpoints", "were", "overall", "survival", "and", "progression", "-", "free", "survival", "both", "in", "the", "total", "population", "and", "in", "patients", "with", "PD", "-", "L1", "expression", "on", "at", "least", "50", "%", "of", "tumour", "cells", ".", "We", "used", "a", "threshold", "for", "significance", "of", "p", "<", "0.00825", "(", "one", "-", "sided", ")", "for", "the", "analysis", "of", "overall", "survival", "and", "a", "threshold", "of", "p", "<", "0.001", "for", "progression", "-", "free", "survival", ".", "This", "trial", "is", "registered", "at", "ClinicalTrials.gov", ",", "number", "NCT01905657", ".", "FINDINGS", "Between", "Aug", "28", ",", "2013", ",", "and", "Feb", "27", ",", "2015", ",", "we", "enrolled", "1034", "patients", ":", "345", "allocated", "to", "pembrolizumab", "2", "mg", "/", "kg", ",", "346", "allocated", "to", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "343", "allocated", "to", "docetaxel", ".", "By", "Sept", "30", ",", "2015", ",", "521", "patients", "had", "died", ".", "In", "the", "total", "population", ",", "median", "overall", "survival", "was", "10.4", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "12.7", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "8.5", "months", "with", "docetaxel", ".", "Overall", "survival", "was", "significantly", "longer", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "hazard", "ratio", "[", "HR", "]", "0.71", ",", "95", "%", "CI", "0.58", "-", "0.88", ";", "p=0.0008", ")", "and", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "0.61", ",", "0.49", "-", "0.75", ";", "p", "<", "0.0001", ")", ".", "Median", "progression", "-", "free", "survival", "was", "3.9", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "4.0", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "4.0", "months", "with", "docetaxel", ",", "with", "no", "significant", "difference", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "0.88", ",", "0.74", "-", "1.05", ";", "p=0.07", ")", "or", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "HR", "0.79", ",", "95", "%", "CI", "0.66", "-", "0.94", ";", "p=0.004", ")", ".", "Among", "patients", "with", "at", "least", "50", "%", "of", "tumour", "cells", "expressing", "PD", "-", "L1", ",", "overall", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "14.9", "months", "vs", "8.2", "months", ";", "HR", "0.54", ",", "95", "%", "CI", "0.38", "-", "0.77", ";", "p=0.0002", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "17.3", "months", "vs", "8.2", "months", ";", "0.50", ",", "0.36", "-", "0.70", ";", "p", "<", "0.0001", ")", ".", "Likewise", ",", "for", "this", "patient", "population", ",", "progression", "-", "free", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "5.0", "months", "vs", "4.1", "months", ";", "HR", "0.59", ",", "95", "%", "CI", "0.44", "-", "0.78", ";", "p=0.0001", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "5.2", "months", "vs", "4.1", "months", ";", "0.59", ",", "0.45", "-", "0.78", ";", "p", "<", "0.0001", ")", ".", "Grade", "3", "-", "5", "treatment", "-", "related", "adverse", "events", "were", "less", "common", "with", "pembrolizumab", "than", "with", "docetaxel", "(", "43", "[", "13", "%", "]", "of", "339", "patients", "given", "2", "mg", "/", "kg", ",", "55", "[", "16", "%", "]", "of", "343", "given", "10", "mg", "/", "kg", ",", "and", "109", "[", "35", "%", "]", "of", "309", "given", "docetaxel", ")", ".", "INTERPRETATION", "Pembrolizumab", "prolongs", "overall", "survival", "and", "has", "a", "favourable", "benefit", "-", "to", "-", "risk", "profile", "in", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "These", "data", "establish", "pembrolizumab", "as", "a", "new", "treatment", "option", "for", "this", "population", "and", "validate", "the", "use", "of", "PD", "-", "L1", "selection", ".", "FUNDING", "Merck", "&", "Co", "." ]	[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]
Pembrolizumab, docetaxel, previously treated , PD - L1-positive , advanced non - small - cell lung cancer, pembrolizumab, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells, survival and progression - free survival, 1034 patients, median overall survival, Overall survival, Median progression - free survival, Grade 3 - 5 treatment - related adverse events	73209_task2	Sentence: Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co .	[ "Pembrolizumab", "versus", "docetaxel", "for", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "KEYNOTE-010", ")", ":", "a", "randomised", "controlled", "trial", ".", "BACKGROUND", "Despite", "recent", "advances", "in", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ",", "there", "remains", "a", "need", "for", "effective", "treatments", "for", "progressive", "disease", ".", "We", "assessed", "the", "efficacy", "of", "pembrolizumab", "for", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "METHODS", "We", "did", "this", "randomised", ",", "open", "-", "label", ",", "phase", "2/3", "study", "at", "202", "academic", "medical", "centres", "in", "24", "countries", ".", "Patients", "with", "previously", "treated", "non", "-", "small", "-", "cell", "lung", "cancer", "with", "PD", "-", "L1", "expression", "on", "at", "least", "1", "%", "of", "tumour", "cells", "were", "randomly", "assigned", "(", "1:1:1", ")", "in", "blocks", "of", "six", "per", "stratum", "with", "an", "interactive", "voice", "-", "response", "system", "to", "receive", "pembrolizumab", "2", "mg", "/", "kg", ",", "pembrolizumab", "10", "mg", "/", "kg", ",", "or", "docetaxel", "75", "mg", "/", "m", "(", "2", ")", "every", "3", "weeks", ".", "The", "primary", "endpoints", "were", "overall", "survival", "and", "progression", "-", "free", "survival", "both", "in", "the", "total", "population", "and", "in", "patients", "with", "PD", "-", "L1", "expression", "on", "at", "least", "50", "%", "of", "tumour", "cells", ".", "We", "used", "a", "threshold", "for", "significance", "of", "p", "<", "0.00825", "(", "one", "-", "sided", ")", "for", "the", "analysis", "of", "overall", "survival", "and", "a", "threshold", "of", "p", "<", "0.001", "for", "progression", "-", "free", "survival", ".", "This", "trial", "is", "registered", "at", "ClinicalTrials.gov", ",", "number", "NCT01905657", ".", "FINDINGS", "Between", "Aug", "28", ",", "2013", ",", "and", "Feb", "27", ",", "2015", ",", "we", "enrolled", "1034", "patients", ":", "345", "allocated", "to", "pembrolizumab", "2", "mg", "/", "kg", ",", "346", "allocated", "to", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "343", "allocated", "to", "docetaxel", ".", "By", "Sept", "30", ",", "2015", ",", "521", "patients", "had", "died", ".", "In", "the", "total", "population", ",", "median", "overall", "survival", "was", "10.4", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "12.7", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "8.5", "months", "with", "docetaxel", ".", "Overall", "survival", "was", "significantly", "longer", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "hazard", "ratio", "[", "HR", "]", "0.71", ",", "95", "%", "CI", "0.58", "-", "0.88", ";", "p=0.0008", ")", "and", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "0.61", ",", "0.49", "-", "0.75", ";", "p", "<", "0.0001", ")", ".", "Median", "progression", "-", "free", "survival", "was", "3.9", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "4.0", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "4.0", "months", "with", "docetaxel", ",", "with", "no", "significant", "difference", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "0.88", ",", "0.74", "-", "1.05", ";", "p=0.07", ")", "or", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "HR", "0.79", ",", "95", "%", "CI", "0.66", "-", "0.94", ";", "p=0.004", ")", ".", "Among", "patients", "with", "at", "least", "50", "%", "of", "tumour", "cells", "expressing", "PD", "-", "L1", ",", "overall", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "14.9", "months", "vs", "8.2", "months", ";", "HR", "0.54", ",", "95", "%", "CI", "0.38", "-", "0.77", ";", "p=0.0002", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "17.3", "months", "vs", "8.2", "months", ";", "0.50", ",", "0.36", "-", "0.70", ";", "p", "<", "0.0001", ")", ".", "Likewise", ",", "for", "this", "patient", "population", ",", "progression", "-", "free", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "5.0", "months", "vs", "4.1", "months", ";", "HR", "0.59", ",", "95", "%", "CI", "0.44", "-", "0.78", ";", "p=0.0001", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "5.2", "months", "vs", "4.1", "months", ";", "0.59", ",", "0.45", "-", "0.78", ";", "p", "<", "0.0001", ")", ".", "Grade", "3", "-", "5", "treatment", "-", "related", "adverse", "events", "were", "less", "common", "with", "pembrolizumab", "than", "with", "docetaxel", "(", "43", "[", "13", "%", "]", "of", "339", "patients", "given", "2", "mg", "/", "kg", ",", "55", "[", "16", "%", "]", "of", "343", "given", "10", "mg", "/", "kg", ",", "and", "109", "[", "35", "%", "]", "of", "309", "given", "docetaxel", ")", ".", "INTERPRETATION", "Pembrolizumab", "prolongs", "overall", "survival", "and", "has", "a", "favourable", "benefit", "-", "to", "-", "risk", "profile", "in", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "These", "data", "establish", "pembrolizumab", "as", "a", "new", "treatment", "option", "for", "this", "population", "and", "validate", "the", "use", "of", "PD", "-", "L1", "selection", ".", "FUNDING", "Merck", "&", "Co", "." ]	[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]
Inzidenz is an umlsterm, Herzerkrankung is an umlsterm, Koronararterienaneurysma is an umlsterm, Herzkranzarterie is an umlsterm, Koronarstenosen is an umlsterm	IntensiveMedizin.90360375.ger.abstr_task0	Sentence: Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen .	[ "Koronaraneurysmata", "kommen", "mit", "einer", "Inzidenz", "von", "0,2", "bis", "4,9", "%", "selten", "vor", ".", "Sie", "sind", "zu", "90", "%", "mit", "einer", "koronaren", "Herzerkrankung", "vergesellschaftet", ".", "In", "der", "vorliegenden", "Fallbeschreibung", "berichten", "wir", "ueber", "das", "therapeutische", "Vorgehen", "bei", "Koronararterienaneurysma", "der", "rechten", "Herzkranzarterie", "bei", "koexistenten", "signifikanten", "Koronarstenosen", "." ]	[ "umlsterm" ]
Inzidenz is an umlsterm, Herzerkrankung is an umlsterm, Koronararterienaneurysma is an umlsterm, Herzkranzarterie is an umlsterm, Koronarstenosen is an umlsterm	IntensiveMedizin.90360375.ger.abstr_task1	Sentence: Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen . Instructions: please typing these entity words according to sentence: Inzidenz, Herzerkrankung, Koronararterienaneurysma, Herzkranzarterie, Koronarstenosen Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen .	[ "Koronaraneurysmata", "kommen", "mit", "einer", "Inzidenz", "von", "0,2", "bis", "4,9", "%", "selten", "vor", ".", "Sie", "sind", "zu", "90", "%", "mit", "einer", "koronaren", "Herzerkrankung", "vergesellschaftet", ".", "In", "der", "vorliegenden", "Fallbeschreibung", "berichten", "wir", "ueber", "das", "therapeutische", "Vorgehen", "bei", "Koronararterienaneurysma", "der", "rechten", "Herzkranzarterie", "bei", "koexistenten", "signifikanten", "Koronarstenosen", "." ]	[ "umlsterm" ]
Inzidenz, Herzerkrankung, Koronararterienaneurysma, Herzkranzarterie, Koronarstenosen	IntensiveMedizin.90360375.ger.abstr_task2	Sentence: Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]	Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen .	[ "Koronaraneurysmata", "kommen", "mit", "einer", "Inzidenz", "von", "0,2", "bis", "4,9", "%", "selten", "vor", ".", "Sie", "sind", "zu", "90", "%", "mit", "einer", "koronaren", "Herzerkrankung", "vergesellschaftet", ".", "In", "der", "vorliegenden", "Fallbeschreibung", "berichten", "wir", "ueber", "das", "therapeutische", "Vorgehen", "bei", "Koronararterienaneurysma", "der", "rechten", "Herzkranzarterie", "bei", "koexistenten", "signifikanten", "Koronarstenosen", "." ]	[ "umlsterm" ]
Germany is an umlsterm, inpatient is an umlsterm, psychotherapy is an umlsterm, hospitals is an umlsterm, aims is an umlsterm, care is an umlsterm, rehabilitation is an umlsterm, hospitals is an umlsterm, times is an umlsterm, hospitals is an umlsterm, treatment is an umlsterm, rehabilitation is an umlsterm, conflicts is an umlsterm, staff 's is an umlsterm, therapeutic is an umlsterm, work is an umlsterm, rehabilitation is an umlsterm, doctor is an umlsterm, social roles is an umlsterm, role is an umlsterm, physician is an umlsterm, role is an umlsterm, role is an umlsterm, social medicine is an umlsterm, social security is an umlsterm, social roles is an umlsterm, social security- is an umlsterm, hospital- is an umlsterm, doctor is an umlsterm, doctor is an umlsterm, conflicts is an umlsterm, development is an umlsterm, rehabilitation is an umlsterm	Psychotherapeut.80430171.eng.abstr_task0	Sentence: In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation .	[ "In", "Germany", "inpatient", "psychotherapy", "generally", "takes", "place", "in", "special", "psychosomatic", "hospitals", ".", "Their", "aims", "are", "often", "not", "clear", ",", "just", "as", "their", "place", "in", "the", "whole", "system", "of", "medical", "care", ".", "Although", "most", "of", "them", "are", "rehabilitation", "hospitals", "from", "a", "juridical", "point", "of", "view", ",", "they", "are", "many", "times", "defined", "as", "specialised", "hospitals", "which", "do", "not", "differentiate", "between", "treatment", "and", "rehabilitation", ".", "This", "lack", "of", "clear", "definition", "leads", "to", "a", "number", "of", "structural", "conflicts", "which", "largely", "influence", "the", "staff", "'s", "scope", "of", "action", "and", "the", "therapeutic", "work", ".", "In", "psychosomatic", "rehabilitation", "the", "doctor", "is", "taking", "over", "three", "social", "roles", ":", "the", "role", "of", "physician", ",", "the", "role", "of", "psychotherapist", "and", "the", "role", "of", "the", "expert", "in", "social", "medicine", "towards", "the", "social", "security", "institution", ".", "These", "social", "roles", "can", "be", "understood", "as", "a", "complex", "of", "behavioral", "expectations", "arising", "from", "different", "reference", "systems", "(", "social", "security-", ",", "hospital-", ",", "treatment-", ",", "patient", "-", "system", ")", "directed", "towards", "the", "social", "position", "of", "the", "doctor", ".", "Within", "his", "social", "position", "the", "doctor", "is", "thereby", "involved", "into", "certain", "conflicts", ".", "This", "article", "will", "analyze", "the", "described", "structural", "problems", "and", "try", "to", "contribute", "to", "further", "development", "of", "the", "concepts", "in", "psychosomatic", "rehabilitation", "." ]	[ "umlsterm" ]
Germany is an umlsterm, inpatient is an umlsterm, psychotherapy is an umlsterm, hospitals is an umlsterm, aims is an umlsterm, care is an umlsterm, rehabilitation is an umlsterm, hospitals is an umlsterm, times is an umlsterm, hospitals is an umlsterm, treatment is an umlsterm, rehabilitation is an umlsterm, conflicts is an umlsterm, staff 's is an umlsterm, therapeutic is an umlsterm, work is an umlsterm, rehabilitation is an umlsterm, doctor is an umlsterm, social roles is an umlsterm, role is an umlsterm, physician is an umlsterm, role is an umlsterm, role is an umlsterm, social medicine is an umlsterm, social security is an umlsterm, social roles is an umlsterm, social security- is an umlsterm, hospital- is an umlsterm, doctor is an umlsterm, doctor is an umlsterm, conflicts is an umlsterm, development is an umlsterm, rehabilitation is an umlsterm	Psychotherapeut.80430171.eng.abstr_task1	Sentence: In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation . Instructions: please typing these entity words according to sentence: Germany, inpatient, psychotherapy, hospitals, aims, care, rehabilitation, hospitals, times, hospitals, treatment, rehabilitation, conflicts, staff 's, therapeutic, work, rehabilitation, doctor, social roles, role, physician, role, role, social medicine, social security, social roles, social security-, hospital-, doctor, doctor, conflicts, development, rehabilitation Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation .	[ "In", "Germany", "inpatient", "psychotherapy", "generally", "takes", "place", "in", "special", "psychosomatic", "hospitals", ".", "Their", "aims", "are", "often", "not", "clear", ",", "just", "as", "their", "place", "in", "the", "whole", "system", "of", "medical", "care", ".", "Although", "most", "of", "them", "are", "rehabilitation", "hospitals", "from", "a", "juridical", "point", "of", "view", ",", "they", "are", "many", "times", "defined", "as", "specialised", "hospitals", "which", "do", "not", "differentiate", "between", "treatment", "and", "rehabilitation", ".", "This", "lack", "of", "clear", "definition", "leads", "to", "a", "number", "of", "structural", "conflicts", "which", "largely", "influence", "the", "staff", "'s", "scope", "of", "action", "and", "the", "therapeutic", "work", ".", "In", "psychosomatic", "rehabilitation", "the", "doctor", "is", "taking", "over", "three", "social", "roles", ":", "the", "role", "of", "physician", ",", "the", "role", "of", "psychotherapist", "and", "the", "role", "of", "the", "expert", "in", "social", "medicine", "towards", "the", "social", "security", "institution", ".", "These", "social", "roles", "can", "be", "understood", "as", "a", "complex", "of", "behavioral", "expectations", "arising", "from", "different", "reference", "systems", "(", "social", "security-", ",", "hospital-", ",", "treatment-", ",", "patient", "-", "system", ")", "directed", "towards", "the", "social", "position", "of", "the", "doctor", ".", "Within", "his", "social", "position", "the", "doctor", "is", "thereby", "involved", "into", "certain", "conflicts", ".", "This", "article", "will", "analyze", "the", "described", "structural", "problems", "and", "try", "to", "contribute", "to", "further", "development", "of", "the", "concepts", "in", "psychosomatic", "rehabilitation", "." ]	[ "umlsterm" ]
Germany, inpatient, psychotherapy, hospitals, aims, care, rehabilitation, hospitals, times, hospitals, treatment, rehabilitation, conflicts, staff 's, therapeutic, work, rehabilitation, doctor, social roles, role, physician, role, role, social medicine, social security, social roles, social security-, hospital-, doctor, doctor, conflicts, development, rehabilitation	Psychotherapeut.80430171.eng.abstr_task2	Sentence: In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation .	[ "In", "Germany", "inpatient", "psychotherapy", "generally", "takes", "place", "in", "special", "psychosomatic", "hospitals", ".", "Their", "aims", "are", "often", "not", "clear", ",", "just", "as", "their", "place", "in", "the", "whole", "system", "of", "medical", "care", ".", "Although", "most", "of", "them", "are", "rehabilitation", "hospitals", "from", "a", "juridical", "point", "of", "view", ",", "they", "are", "many", "times", "defined", "as", "specialised", "hospitals", "which", "do", "not", "differentiate", "between", "treatment", "and", "rehabilitation", ".", "This", "lack", "of", "clear", "definition", "leads", "to", "a", "number", "of", "structural", "conflicts", "which", "largely", "influence", "the", "staff", "'s", "scope", "of", "action", "and", "the", "therapeutic", "work", ".", "In", "psychosomatic", "rehabilitation", "the", "doctor", "is", "taking", "over", "three", "social", "roles", ":", "the", "role", "of", "physician", ",", "the", "role", "of", "psychotherapist", "and", "the", "role", "of", "the", "expert", "in", "social", "medicine", "towards", "the", "social", "security", "institution", ".", "These", "social", "roles", "can", "be", "understood", "as", "a", "complex", "of", "behavioral", "expectations", "arising", "from", "different", "reference", "systems", "(", "social", "security-", ",", "hospital-", ",", "treatment-", ",", "patient", "-", "system", ")", "directed", "towards", "the", "social", "position", "of", "the", "doctor", ".", "Within", "his", "social", "position", "the", "doctor", "is", "thereby", "involved", "into", "certain", "conflicts", ".", "This", "article", "will", "analyze", "the", "described", "structural", "problems", "and", "try", "to", "contribute", "to", "further", "development", "of", "the", "concepts", "in", "psychosomatic", "rehabilitation", "." ]	[ "umlsterm" ]
anthra[1,2-d]imidazole-6,11-dione is a CHEMICAL, telomerase is a GENE-Y	23279865_task0	Sentence: Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]	Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.	[ "Structure", "-", "based", "design", ",", "synthesis", "and", "evaluation", "of", "novel", "anthra[1,2-d]imidazole-6,11-dione", "derivatives", "as", "telomerase", "inhibitors", "and", "potential", "for", "cancer", "polypharmacology", "." ]	[ "CHEMICAL", "GENE-Y" ]
anthra[1,2-d]imidazole-6,11-dione is a CHEMICAL, telomerase is a GENE-Y	23279865_task1	Sentence: Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology. Instructions: please typing these entity words according to sentence: anthra[1,2-d]imidazole-6,11-dione, telomerase Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]	Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.	[ "Structure", "-", "based", "design", ",", "synthesis", "and", "evaluation", "of", "novel", "anthra[1,2-d]imidazole-6,11-dione", "derivatives", "as", "telomerase", "inhibitors", "and", "potential", "for", "cancer", "polypharmacology", "." ]	[ "CHEMICAL", "GENE-Y" ]
anthra[1,2-d]imidazole-6,11-dione, telomerase	23279865_task2	Sentence: Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]	Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.	[ "Structure", "-", "based", "design", ",", "synthesis", "and", "evaluation", "of", "novel", "anthra[1,2-d]imidazole-6,11-dione", "derivatives", "as", "telomerase", "inhibitors", "and", "potential", "for", "cancer", "polypharmacology", "." ]	[ "CHEMICAL", "GENE-Y" ]
Chirurgie is an umlsterm, Krankenhausbau is an umlsterm, Klinikorganisation is an umlsterm	DerChirurg.80690105.ger.abstr_task0	Sentence: Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus .	[ "Zusammenfassung", ".", "Die", "Zwickauer", "Klinik", "bildete", "seit", "ihrer", "Erbauung", "durch", "Heinrich", "Braun", ",", "den", "Schoepfer", "der", "modernen", "Lokalanaesthesie", ",", "ein", "weithin", "bekanntes", "chirurgisches", "Zentrum", ".", "Seine", "direkten", "Nachfolger", "Kulenkampff", "und", "Mayer", "haben", "Brauns", "Lebenswerk", "bewahrt", ",", "fortgesetzt", "und", "ergaenzt", ".", "Von", "der", "Zwickauer", "Chirurgie", "gingen", "wichtige", "Impulse", "fuer", "die", "Allgemein-", "und", "Lokalanaesthesie", ",", "fuer", "den", "Krankenhausbau", "und", "die", "Klinikorganisation", "sowie", "fuer", "die", "chirurgische", "Lehre", "in", "Wort", "und", "Bild", "aus", "." ]	[ "umlsterm" ]
Chirurgie is an umlsterm, Krankenhausbau is an umlsterm, Klinikorganisation is an umlsterm	DerChirurg.80690105.ger.abstr_task1	Sentence: Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus . Instructions: please typing these entity words according to sentence: Chirurgie, Krankenhausbau, Klinikorganisation Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus .	[ "Zusammenfassung", ".", "Die", "Zwickauer", "Klinik", "bildete", "seit", "ihrer", "Erbauung", "durch", "Heinrich", "Braun", ",", "den", "Schoepfer", "der", "modernen", "Lokalanaesthesie", ",", "ein", "weithin", "bekanntes", "chirurgisches", "Zentrum", ".", "Seine", "direkten", "Nachfolger", "Kulenkampff", "und", "Mayer", "haben", "Brauns", "Lebenswerk", "bewahrt", ",", "fortgesetzt", "und", "ergaenzt", ".", "Von", "der", "Zwickauer", "Chirurgie", "gingen", "wichtige", "Impulse", "fuer", "die", "Allgemein-", "und", "Lokalanaesthesie", ",", "fuer", "den", "Krankenhausbau", "und", "die", "Klinikorganisation", "sowie", "fuer", "die", "chirurgische", "Lehre", "in", "Wort", "und", "Bild", "aus", "." ]	[ "umlsterm" ]
Chirurgie, Krankenhausbau, Klinikorganisation	DerChirurg.80690105.ger.abstr_task2	Sentence: Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus .	[ "Zusammenfassung", ".", "Die", "Zwickauer", "Klinik", "bildete", "seit", "ihrer", "Erbauung", "durch", "Heinrich", "Braun", ",", "den", "Schoepfer", "der", "modernen", "Lokalanaesthesie", ",", "ein", "weithin", "bekanntes", "chirurgisches", "Zentrum", ".", "Seine", "direkten", "Nachfolger", "Kulenkampff", "und", "Mayer", "haben", "Brauns", "Lebenswerk", "bewahrt", ",", "fortgesetzt", "und", "ergaenzt", ".", "Von", "der", "Zwickauer", "Chirurgie", "gingen", "wichtige", "Impulse", "fuer", "die", "Allgemein-", "und", "Lokalanaesthesie", ",", "fuer", "den", "Krankenhausbau", "und", "die", "Klinikorganisation", "sowie", "fuer", "die", "chirurgische", "Lehre", "in", "Wort", "und", "Bild", "aus", "." ]	[ "umlsterm" ]
Isofluran is an umlsterm, Dopplersonographie is an umlsterm, Patienten is an umlsterm, Blutdruck is an umlsterm, Koerpertemperatur is an umlsterm, Isofluran is an umlsterm, Konzentrationsstufe is an umlsterm, Isofluran is an umlsterm, Student is an umlsterm, Varianzanalysen is an umlsterm, ANOVA is an umlsterm	DerAnaesthesist.70460029.ger.abstr_task0	Sentence: Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde .	[ "Die", "Einfluesse", "von", "Sevofluran", "im", "Vergleich", "zu", "Isofluran", "auf", "die", "Messgroessen", "der", "transkraniellen", "Dopplersonographie", "(", "TCD", ")", "wurden", "an", "30", "Patienten", "untersucht", ".", "Neben", "den", "TCD", "-", "Parametern", "wurden", "simultan", "arterieller", "Blutdruck", ",", "Herzfrequenz", "und", "Koerpertemperatur", "registriert", ".", "Messungen", "erfolgten", "vor", "Narkoseeinleitung", ",", "unter", "kontrollierter", "Beatmung", "mit", "0,5", ",", "1,0", "und", "1,5", "MAC", "Sevofluran", "bzw", ".", "Isofluran", "in", "Sauerstoff", "/", "Luft", ",", "anschliessend", "mit", "1,5", ",", "1,0", "und", "0,5", "MAC", "in", "Sauerstoff", "/", "Lachgas", "sowie", "nach", "Extubation", ".", "Waehrend", "jeder", "Konzentrationsstufe", "von", "Sevofluran", "bzw", ".", "Isofluran", "wurde", "zunaechst", "normoventiliert", ",", "anschliessend", "hyperventiliert", ".", "Die", "statistische", "Auswertung", "erfolgte", "mit", "dem", "t", "-", "Test", "nach", "Student", "und", "Varianzanalysen", "(", "ANOVA", ")", ",", "wobei", "p", "0,05", "als", "signifikant", "betrachtet", "wurde", "." ]	[ "umlsterm" ]
Isofluran is an umlsterm, Dopplersonographie is an umlsterm, Patienten is an umlsterm, Blutdruck is an umlsterm, Koerpertemperatur is an umlsterm, Isofluran is an umlsterm, Konzentrationsstufe is an umlsterm, Isofluran is an umlsterm, Student is an umlsterm, Varianzanalysen is an umlsterm, ANOVA is an umlsterm	DerAnaesthesist.70460029.ger.abstr_task1	Sentence: Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde . Instructions: please typing these entity words according to sentence: Isofluran, Dopplersonographie, Patienten, Blutdruck, Koerpertemperatur, Isofluran, Konzentrationsstufe, Isofluran, Student, Varianzanalysen, ANOVA Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde .	[ "Die", "Einfluesse", "von", "Sevofluran", "im", "Vergleich", "zu", "Isofluran", "auf", "die", "Messgroessen", "der", "transkraniellen", "Dopplersonographie", "(", "TCD", ")", "wurden", "an", "30", "Patienten", "untersucht", ".", "Neben", "den", "TCD", "-", "Parametern", "wurden", "simultan", "arterieller", "Blutdruck", ",", "Herzfrequenz", "und", "Koerpertemperatur", "registriert", ".", "Messungen", "erfolgten", "vor", "Narkoseeinleitung", ",", "unter", "kontrollierter", "Beatmung", "mit", "0,5", ",", "1,0", "und", "1,5", "MAC", "Sevofluran", "bzw", ".", "Isofluran", "in", "Sauerstoff", "/", "Luft", ",", "anschliessend", "mit", "1,5", ",", "1,0", "und", "0,5", "MAC", "in", "Sauerstoff", "/", "Lachgas", "sowie", "nach", "Extubation", ".", "Waehrend", "jeder", "Konzentrationsstufe", "von", "Sevofluran", "bzw", ".", "Isofluran", "wurde", "zunaechst", "normoventiliert", ",", "anschliessend", "hyperventiliert", ".", "Die", "statistische", "Auswertung", "erfolgte", "mit", "dem", "t", "-", "Test", "nach", "Student", "und", "Varianzanalysen", "(", "ANOVA", ")", ",", "wobei", "p", "0,05", "als", "signifikant", "betrachtet", "wurde", "." ]	[ "umlsterm" ]
Isofluran, Dopplersonographie, Patienten, Blutdruck, Koerpertemperatur, Isofluran, Konzentrationsstufe, Isofluran, Student, Varianzanalysen, ANOVA	DerAnaesthesist.70460029.ger.abstr_task2	Sentence: Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde .	[ "Die", "Einfluesse", "von", "Sevofluran", "im", "Vergleich", "zu", "Isofluran", "auf", "die", "Messgroessen", "der", "transkraniellen", "Dopplersonographie", "(", "TCD", ")", "wurden", "an", "30", "Patienten", "untersucht", ".", "Neben", "den", "TCD", "-", "Parametern", "wurden", "simultan", "arterieller", "Blutdruck", ",", "Herzfrequenz", "und", "Koerpertemperatur", "registriert", ".", "Messungen", "erfolgten", "vor", "Narkoseeinleitung", ",", "unter", "kontrollierter", "Beatmung", "mit", "0,5", ",", "1,0", "und", "1,5", "MAC", "Sevofluran", "bzw", ".", "Isofluran", "in", "Sauerstoff", "/", "Luft", ",", "anschliessend", "mit", "1,5", ",", "1,0", "und", "0,5", "MAC", "in", "Sauerstoff", "/", "Lachgas", "sowie", "nach", "Extubation", ".", "Waehrend", "jeder", "Konzentrationsstufe", "von", "Sevofluran", "bzw", ".", "Isofluran", "wurde", "zunaechst", "normoventiliert", ",", "anschliessend", "hyperventiliert", ".", "Die", "statistische", "Auswertung", "erfolgte", "mit", "dem", "t", "-", "Test", "nach", "Student", "und", "Varianzanalysen", "(", "ANOVA", ")", ",", "wobei", "p", "0,05", "als", "signifikant", "betrachtet", "wurde", "." ]	[ "umlsterm" ]
Population is an umlsterm, demographic transitions is an umlsterm, world 's is an umlsterm, health is an umlsterm, needs is an umlsterm, Chronic diseases is an umlsterm, population is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, deaths is an umlsterm	ZfuerGerontologie+Geriatrie.9032s080.eng.abstr_task0	Sentence: Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions .	[ "Population", "aging", "is", "a", "global", ".", "These", "demographic", "transitions", "have", "brought", "about", "dramatic", "changes", "in", "the", "world", "'s", "health", "needs", "and", "status", ".", "Chronic", "diseases", "of", "aging", "account", "for", "nearly", "half", "of", "population", "morbidity", "and", "mortality", "in", "the", "developing", "regions", "of", "the", "world", "85", "%", "of", "deaths", "and", "disability", "in", "developed", "regions", "." ]	[ "umlsterm" ]
Population is an umlsterm, demographic transitions is an umlsterm, world 's is an umlsterm, health is an umlsterm, needs is an umlsterm, Chronic diseases is an umlsterm, population is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, deaths is an umlsterm	ZfuerGerontologie+Geriatrie.9032s080.eng.abstr_task1	Sentence: Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions . Instructions: please typing these entity words according to sentence: Population, demographic transitions, world 's, health, needs, Chronic diseases, population, morbidity, mortality, deaths Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions .	[ "Population", "aging", "is", "a", "global", ".", "These", "demographic", "transitions", "have", "brought", "about", "dramatic", "changes", "in", "the", "world", "'s", "health", "needs", "and", "status", ".", "Chronic", "diseases", "of", "aging", "account", "for", "nearly", "half", "of", "population", "morbidity", "and", "mortality", "in", "the", "developing", "regions", "of", "the", "world", "85", "%", "of", "deaths", "and", "disability", "in", "developed", "regions", "." ]	[ "umlsterm" ]
Population, demographic transitions, world 's, health, needs, Chronic diseases, population, morbidity, mortality, deaths	ZfuerGerontologie+Geriatrie.9032s080.eng.abstr_task2	Sentence: Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions .	[ "Population", "aging", "is", "a", "global", ".", "These", "demographic", "transitions", "have", "brought", "about", "dramatic", "changes", "in", "the", "world", "'s", "health", "needs", "and", "status", ".", "Chronic", "diseases", "of", "aging", "account", "for", "nearly", "half", "of", "population", "morbidity", "and", "mortality", "in", "the", "developing", "regions", "of", "the", "world", "85", "%", "of", "deaths", "and", "disability", "in", "developed", "regions", "." ]	[ "umlsterm" ]
Therapie is an umlsterm, Kreuzbandverletzung is an umlsterm, Krankengut is an umlsterm, Rupturen is an umlsterm, Kombinationsverletzungen is an umlsterm, Bandes is an umlsterm, Trevira - Band is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Rupturen is an umlsterm, Verletzungen is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Kombinationsverletzungen is an umlsterm, Trevira - Band is an umlsterm	DerUnfallchirurg.91020763.ger.abstr_task0	Sentence: Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt .	[ "Bei", "der", "Therapie", "der", "hinteren", "Kreuzbandverletzung", "(", "HKB", "-", "Verletzung", ")", "konkurrieren", "konservative", "wiederherstellende", "und", "ersetzende", "Verfahren", ".", ",", "Im", "eigenen", "Krankengut", "von", "1993", "-", "1997", "wurden", "49", "HKB", "-", "Verletzungen", "operativ", "stabilisiert", ",", "21", "Rupturen", "ohne", "weitere", "Begleitverletzungen", "und", "28", "Kombinationsverletzungen", ".", "Die", "Stabilisierung", "erfolgte", "in", "allen", "Faellen", "mit", "ligamentaerer", "Zerreissung", "durch", "Naht", "des", "Bandes", "und", "Augmentation", "mit", "3", "mm", "Trevira", "-", "Band", ",", "knoecherne", "Verletzungen", "wurden", "mittels", "Osteosynthese", "refixiert", ".", "Nachuntersucht", "wurden", "36", "Patienten", ",", "davon", "15", "mit", "isolierten", "ligamentaeren", "Rupturen", ".", "Die", "knoechernen", "Verletzungen", "ergaben", "in", "allen", "Faellen", "gute", "Stabilitaet", ",", "die", "ligamentaeren", "Verletzungen", "zeigten", "in", "7", "von", "15", "Faellen", "gute", "Stabilitaet", ",", "in", "8", "Faellen", "eine", "deutliche", "hintere", "Schublade", ".", "Im", "Lysholm", "-", "Score", "wurde", "eine", "mittlere", "Punktzahl", "von", "76,8", "(", "+", "/-", "21,6", ")", "Punkten", "erzielt", ",", "im", "OAK", "-", "Score", "fanden", "sich", "2", "sehr", "gute", ",", "5", "gute", ",", "3", "maessige", "und", "5", "schlechte", "Ergebnisse", ",", "im", "IKDC", "-", "Score", "3", "sehr", "gute", ",", "4", "gute", ",", "2", "maessige", "und", "6", "schlechte", "Ergebnisse", ".", "In", "der", "subjektiven", "Einschaetzung", "beurteilten", "10", "Patienten", "das", "Ergebnis", "als", "gut", "oder", "sehr", "gut", ",", "2", "als", "maessig", ",", "3", "als", "schlecht", ".", "Die", "Kombinationsverletzungen", "ergaben", "nur", "in", "40", "%", "der", "Faelle", "sehr", "gute", "oder", "gute", "Ergebnisse", ".", "Die", "Augmentationsnaht", "der", "ligamentaeren", "HKB", "-", "Ruptur", "mit", "3", "mm", "Trevira", "-", "Band", "erscheint", "alternativ", "zu", "den", "primaeren", "Ersatzverfahren", "gerechtfertigt", "." ]	[ "umlsterm" ]
Therapie is an umlsterm, Kreuzbandverletzung is an umlsterm, Krankengut is an umlsterm, Rupturen is an umlsterm, Kombinationsverletzungen is an umlsterm, Bandes is an umlsterm, Trevira - Band is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Rupturen is an umlsterm, Verletzungen is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Kombinationsverletzungen is an umlsterm, Trevira - Band is an umlsterm	DerUnfallchirurg.91020763.ger.abstr_task1	Sentence: Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt . Instructions: please typing these entity words according to sentence: Therapie, Kreuzbandverletzung, Krankengut, Rupturen, Kombinationsverletzungen, Bandes, Trevira - Band, Verletzungen, Patienten, Rupturen, Verletzungen, Verletzungen, Patienten, Kombinationsverletzungen, Trevira - Band Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt .	[ "Bei", "der", "Therapie", "der", "hinteren", "Kreuzbandverletzung", "(", "HKB", "-", "Verletzung", ")", "konkurrieren", "konservative", "wiederherstellende", "und", "ersetzende", "Verfahren", ".", ",", "Im", "eigenen", "Krankengut", "von", "1993", "-", "1997", "wurden", "49", "HKB", "-", "Verletzungen", "operativ", "stabilisiert", ",", "21", "Rupturen", "ohne", "weitere", "Begleitverletzungen", "und", "28", "Kombinationsverletzungen", ".", "Die", "Stabilisierung", "erfolgte", "in", "allen", "Faellen", "mit", "ligamentaerer", "Zerreissung", "durch", "Naht", "des", "Bandes", "und", "Augmentation", "mit", "3", "mm", "Trevira", "-", "Band", ",", "knoecherne", "Verletzungen", "wurden", "mittels", "Osteosynthese", "refixiert", ".", "Nachuntersucht", "wurden", "36", "Patienten", ",", "davon", "15", "mit", "isolierten", "ligamentaeren", "Rupturen", ".", "Die", "knoechernen", "Verletzungen", "ergaben", "in", "allen", "Faellen", "gute", "Stabilitaet", ",", "die", "ligamentaeren", "Verletzungen", "zeigten", "in", "7", "von", "15", "Faellen", "gute", "Stabilitaet", ",", "in", "8", "Faellen", "eine", "deutliche", "hintere", "Schublade", ".", "Im", "Lysholm", "-", "Score", "wurde", "eine", "mittlere", "Punktzahl", "von", "76,8", "(", "+", "/-", "21,6", ")", "Punkten", "erzielt", ",", "im", "OAK", "-", "Score", "fanden", "sich", "2", "sehr", "gute", ",", "5", "gute", ",", "3", "maessige", "und", "5", "schlechte", "Ergebnisse", ",", "im", "IKDC", "-", "Score", "3", "sehr", "gute", ",", "4", "gute", ",", "2", "maessige", "und", "6", "schlechte", "Ergebnisse", ".", "In", "der", "subjektiven", "Einschaetzung", "beurteilten", "10", "Patienten", "das", "Ergebnis", "als", "gut", "oder", "sehr", "gut", ",", "2", "als", "maessig", ",", "3", "als", "schlecht", ".", "Die", "Kombinationsverletzungen", "ergaben", "nur", "in", "40", "%", "der", "Faelle", "sehr", "gute", "oder", "gute", "Ergebnisse", ".", "Die", "Augmentationsnaht", "der", "ligamentaeren", "HKB", "-", "Ruptur", "mit", "3", "mm", "Trevira", "-", "Band", "erscheint", "alternativ", "zu", "den", "primaeren", "Ersatzverfahren", "gerechtfertigt", "." ]	[ "umlsterm" ]
Therapie, Kreuzbandverletzung, Krankengut, Rupturen, Kombinationsverletzungen, Bandes, Trevira - Band, Verletzungen, Patienten, Rupturen, Verletzungen, Verletzungen, Patienten, Kombinationsverletzungen, Trevira - Band	DerUnfallchirurg.91020763.ger.abstr_task2	Sentence: Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt .	[ "Bei", "der", "Therapie", "der", "hinteren", "Kreuzbandverletzung", "(", "HKB", "-", "Verletzung", ")", "konkurrieren", "konservative", "wiederherstellende", "und", "ersetzende", "Verfahren", ".", ",", "Im", "eigenen", "Krankengut", "von", "1993", "-", "1997", "wurden", "49", "HKB", "-", "Verletzungen", "operativ", "stabilisiert", ",", "21", "Rupturen", "ohne", "weitere", "Begleitverletzungen", "und", "28", "Kombinationsverletzungen", ".", "Die", "Stabilisierung", "erfolgte", "in", "allen", "Faellen", "mit", "ligamentaerer", "Zerreissung", "durch", "Naht", "des", "Bandes", "und", "Augmentation", "mit", "3", "mm", "Trevira", "-", "Band", ",", "knoecherne", "Verletzungen", "wurden", "mittels", "Osteosynthese", "refixiert", ".", "Nachuntersucht", "wurden", "36", "Patienten", ",", "davon", "15", "mit", "isolierten", "ligamentaeren", "Rupturen", ".", "Die", "knoechernen", "Verletzungen", "ergaben", "in", "allen", "Faellen", "gute", "Stabilitaet", ",", "die", "ligamentaeren", "Verletzungen", "zeigten", "in", "7", "von", "15", "Faellen", "gute", "Stabilitaet", ",", "in", "8", "Faellen", "eine", "deutliche", "hintere", "Schublade", ".", "Im", "Lysholm", "-", "Score", "wurde", "eine", "mittlere", "Punktzahl", "von", "76,8", "(", "+", "/-", "21,6", ")", "Punkten", "erzielt", ",", "im", "OAK", "-", "Score", "fanden", "sich", "2", "sehr", "gute", ",", "5", "gute", ",", "3", "maessige", "und", "5", "schlechte", "Ergebnisse", ",", "im", "IKDC", "-", "Score", "3", "sehr", "gute", ",", "4", "gute", ",", "2", "maessige", "und", "6", "schlechte", "Ergebnisse", ".", "In", "der", "subjektiven", "Einschaetzung", "beurteilten", "10", "Patienten", "das", "Ergebnis", "als", "gut", "oder", "sehr", "gut", ",", "2", "als", "maessig", ",", "3", "als", "schlecht", ".", "Die", "Kombinationsverletzungen", "ergaben", "nur", "in", "40", "%", "der", "Faelle", "sehr", "gute", "oder", "gute", "Ergebnisse", ".", "Die", "Augmentationsnaht", "der", "ligamentaeren", "HKB", "-", "Ruptur", "mit", "3", "mm", "Trevira", "-", "Band", "erscheint", "alternativ", "zu", "den", "primaeren", "Ersatzverfahren", "gerechtfertigt", "." ]	[ "umlsterm" ]
Lipidsenker is an umlsterm, Rolle is an umlsterm, Koronararteriosklerose is an umlsterm, Myopathien is an umlsterm, Pharmaka is an umlsterm	ZfuerHerzThoraxGefaesschirurgie.80120201.ger.abstr_task0	Sentence: Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind .	[ "Lipidsenker", "vom", "Typ", "der", "HMG", "-", "CoA", "-", "Reduktasehemmer", "spielen", "eine", "wesentliche", "Rolle", "in", "der", "Prophylaxe", "der", "Koronararteriosklerose", ".", "Eine", "moegliche", "Nebenwirkung", "besteht", "in", "der", "Ausloesung", "von", "Myopathien", ",", "die", "vorwiegend", "bei", "Interaktion", "mit", "anderen", "Pharmaka", "beschrieben", "sind", "." ]	[ "umlsterm" ]
Lipidsenker is an umlsterm, Rolle is an umlsterm, Koronararteriosklerose is an umlsterm, Myopathien is an umlsterm, Pharmaka is an umlsterm	ZfuerHerzThoraxGefaesschirurgie.80120201.ger.abstr_task1	Sentence: Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind . Instructions: please typing these entity words according to sentence: Lipidsenker, Rolle, Koronararteriosklerose, Myopathien, Pharmaka Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind .	[ "Lipidsenker", "vom", "Typ", "der", "HMG", "-", "CoA", "-", "Reduktasehemmer", "spielen", "eine", "wesentliche", "Rolle", "in", "der", "Prophylaxe", "der", "Koronararteriosklerose", ".", "Eine", "moegliche", "Nebenwirkung", "besteht", "in", "der", "Ausloesung", "von", "Myopathien", ",", "die", "vorwiegend", "bei", "Interaktion", "mit", "anderen", "Pharmaka", "beschrieben", "sind", "." ]	[ "umlsterm" ]
Lipidsenker, Rolle, Koronararteriosklerose, Myopathien, Pharmaka	ZfuerHerzThoraxGefaesschirurgie.80120201.ger.abstr_task2	Sentence: Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind .	[ "Lipidsenker", "vom", "Typ", "der", "HMG", "-", "CoA", "-", "Reduktasehemmer", "spielen", "eine", "wesentliche", "Rolle", "in", "der", "Prophylaxe", "der", "Koronararteriosklerose", ".", "Eine", "moegliche", "Nebenwirkung", "besteht", "in", "der", "Ausloesung", "von", "Myopathien", ",", "die", "vorwiegend", "bei", "Interaktion", "mit", "anderen", "Pharmaka", "beschrieben", "sind", "." ]	[ "umlsterm" ]
Theileria annulata is a mono_cell, matrix metalloproteinase 9 is a protein_molecule, transcription factor is a protein_family_or_group, AP-1 is a protein_molecule, bovine leucocytes is a cell_type	8908_task0	Sentence: Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: mono_cell, cell_type, protein_family_or_group, protein_molecule	[ "O", "O", "B-mono_cell", "I-mono_cell", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]	Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes.	[ "Infection", "with", "Theileria", "annulata", "induces", "expression", "of", "matrix", "metalloproteinase", "9", "and", "transcription", "factor", "AP-1", "in", "bovine", "leucocytes", "." ]	[ "other_name", "cell_type", "protein_molecule", "protein_family_or_group", "mono_cell", "DNA_family_or_group", "multi_cell", "RNA_family_or_group" ]
Theileria annulata is a mono_cell, matrix metalloproteinase 9 is a protein_molecule, transcription factor is a protein_family_or_group, AP-1 is a protein_molecule, bovine leucocytes is a cell_type	8908_task1	Sentence: Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes. Instructions: please typing these entity words according to sentence: Theileria annulata, matrix metalloproteinase 9, transcription factor, AP-1, bovine leucocytes Options: mono_cell, cell_type, protein_family_or_group, protein_molecule	[ "O", "O", "B-mono_cell", "I-mono_cell", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]	Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes.	[ "Infection", "with", "Theileria", "annulata", "induces", "expression", "of", "matrix", "metalloproteinase", "9", "and", "transcription", "factor", "AP-1", "in", "bovine", "leucocytes", "." ]	[ "other_name", "cell_type", "protein_molecule", "protein_family_or_group", "mono_cell", "DNA_family_or_group", "multi_cell", "RNA_family_or_group" ]
Theileria annulata, matrix metalloproteinase 9, transcription factor, AP-1, bovine leucocytes	8908_task2	Sentence: Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-mono_cell", "I-mono_cell", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]	Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes.	[ "Infection", "with", "Theileria", "annulata", "induces", "expression", "of", "matrix", "metalloproteinase", "9", "and", "transcription", "factor", "AP-1", "in", "bovine", "leucocytes", "." ]	[ "other_name", "cell_type", "protein_molecule", "protein_family_or_group", "mono_cell", "DNA_family_or_group", "multi_cell", "RNA_family_or_group" ]
Gastric ulcer is a Participant_Condition, human epidermal growth factor is a Intervention_Pharmacological, intravenous human epidermal growth factor ( hEGF ) is a Intervention_Pharmacological, cetraxate hydrochloride ( CH ) is a Intervention_Pharmacological, gastric ulcers is a Outcome_Physical, rate of ulcer healing is a Outcome_Physical, 67/86 is a Participant_Sample-size, healing rate is a Outcome_Physical, pain relief is a Outcome_Pain, blood examination is a Outcome_Physical, adverse reactions is a Outcome_Adverse-effects, hydroxypropyl cellulose is a Intervention_Pharmacological, residual mEGF levels is a Outcome_Physical, healing of rat gastric ulcers is a Outcome_Physical	82758_task0	Sentence: Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Pain, Outcome_Physical, Participant_Sample-size	[ "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial .	[ "Gastric", "ulcer", "treatment", "with", "intravenous", "human", "epidermal", "growth", "factor", ":", "a", "double", "-", "blind", "controlled", "clinical", "study", ".", "We", "introduced", "a", "double", "-", "blind", "controlled", "clinical", "study", "to", "compare", "intravenous", "human", "epidermal", "growth", "factor", "(", "hEGF", ")", "to", "cetraxate", "hydrochloride", "(", "CH", ")", ",", "an", "antiulcer", "drug", ",", "for", "their", "healing", "effect", "on", "gastric", "ulcers", ".", "We", "also", "prospected", "an", "oral", "use", "of", "EGF", "on", "the", "basis", "of", "our", "experimental", "evidence", ".", "In", "the", "clinical", "trial", ",", "the", "rate", "of", "ulcer", "healing", "within", "8", "weeks", "was", "77.9", "%", "(", "67/86", ")", "in", "patients", "receiving", "6", "micrograms", "EGF", "intravenously", "twice", "a", "week", ",", "being", "significantly", "greater", "than", "51.7", "%", "(", "45/87", ")", "in", "those", "given", "CH", ".", "Taking", "together", "all", "aspects", "assessed", "including", "the", "healing", "rate", ",", "pain", "relief", ",", "blood", "examination", "and", "adverse", "reactions", ",", "we", "judged", "the", "hEGF", "to", "be", "a", "useful", "and", "safe", "anticuler", "drug", ".", "In", "rats", ",", "50", "micrograms", "/", "kg", "mouse", "EGF", "(", "mEGF", ")", "and", "2", "%", "hydroxypropyl", "cellulose", "(", "HPC", ")", "or", "1.0", "g", "/", "kg", "sucralfate", "given", "by", "gastric", "intubation", "significantly", "raised", "the", "residual", "mEGF", "levels", "in", "both", "gastric", "luminal", "content", "(", "HPC", ":", "x", "30", ";", "sucralfate", ":", "x", "300", "as", "high", "as", "those", "in", "EGF", "alone", ")", "and", "tissue", "(", "HPC", ":", "x", "60", ";", "sucralfate", ":", "x", "100", ")", ".", "In", "addition", ",", "the", "combined", "treatments", "significantly", "promoted", "healing", "of", "rat", "gastric", "ulcers", "whereas", "each", "agent", "alone", "had", "no", "significant", "effect", "as", "compared", "with", "control", "(", "saline", ")", ".", "This", "indicated", "the", "beneficial", "effect", "on", "ulcers", "of", "oral", "administration", "of", "EGF", "with", "agents", "allowing", "it", "to", "remain", "at", "high", "levels", "in", "the", "stomach", ",", "whereas", "most", "reports", "suggested", "less", "effect", "of", "oral", "EGF", "on", "healing", "of", "gastroduodenal", "ulcers", ".", "Subsequent", "to", "the", "clinical", "study", ",", "evaluation", "of", "oral", "use", "of", "EGF", "may", "be", "expected", "as", "the", "next", "step", "in", "the", "treatment", "of", "ulcers", ".", "The", "experimental", "evidence", "above", "would", "possibly", "be", "a", "guide", "for", "such", "trial", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Pain", "Participant_Sample-size" ]
Gastric ulcer is a Participant_Condition, human epidermal growth factor is a Intervention_Pharmacological, intravenous human epidermal growth factor ( hEGF ) is a Intervention_Pharmacological, cetraxate hydrochloride ( CH ) is a Intervention_Pharmacological, gastric ulcers is a Outcome_Physical, rate of ulcer healing is a Outcome_Physical, 67/86 is a Participant_Sample-size, healing rate is a Outcome_Physical, pain relief is a Outcome_Pain, blood examination is a Outcome_Physical, adverse reactions is a Outcome_Adverse-effects, hydroxypropyl cellulose is a Intervention_Pharmacological, residual mEGF levels is a Outcome_Physical, healing of rat gastric ulcers is a Outcome_Physical	82758_task1	Sentence: Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial . Instructions: please typing these entity words according to sentence: Gastric ulcer, human epidermal growth factor, intravenous human epidermal growth factor ( hEGF ), cetraxate hydrochloride ( CH ), gastric ulcers, rate of ulcer healing, 67/86, healing rate, pain relief, blood examination, adverse reactions, hydroxypropyl cellulose, residual mEGF levels, healing of rat gastric ulcers Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Pain, Outcome_Physical, Participant_Sample-size	[ "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial .	[ "Gastric", "ulcer", "treatment", "with", "intravenous", "human", "epidermal", "growth", "factor", ":", "a", "double", "-", "blind", "controlled", "clinical", "study", ".", "We", "introduced", "a", "double", "-", "blind", "controlled", "clinical", "study", "to", "compare", "intravenous", "human", "epidermal", "growth", "factor", "(", "hEGF", ")", "to", "cetraxate", "hydrochloride", "(", "CH", ")", ",", "an", "antiulcer", "drug", ",", "for", "their", "healing", "effect", "on", "gastric", "ulcers", ".", "We", "also", "prospected", "an", "oral", "use", "of", "EGF", "on", "the", "basis", "of", "our", "experimental", "evidence", ".", "In", "the", "clinical", "trial", ",", "the", "rate", "of", "ulcer", "healing", "within", "8", "weeks", "was", "77.9", "%", "(", "67/86", ")", "in", "patients", "receiving", "6", "micrograms", "EGF", "intravenously", "twice", "a", "week", ",", "being", "significantly", "greater", "than", "51.7", "%", "(", "45/87", ")", "in", "those", "given", "CH", ".", "Taking", "together", "all", "aspects", "assessed", "including", "the", "healing", "rate", ",", "pain", "relief", ",", "blood", "examination", "and", "adverse", "reactions", ",", "we", "judged", "the", "hEGF", "to", "be", "a", "useful", "and", "safe", "anticuler", "drug", ".", "In", "rats", ",", "50", "micrograms", "/", "kg", "mouse", "EGF", "(", "mEGF", ")", "and", "2", "%", "hydroxypropyl", "cellulose", "(", "HPC", ")", "or", "1.0", "g", "/", "kg", "sucralfate", "given", "by", "gastric", "intubation", "significantly", "raised", "the", "residual", "mEGF", "levels", "in", "both", "gastric", "luminal", "content", "(", "HPC", ":", "x", "30", ";", "sucralfate", ":", "x", "300", "as", "high", "as", "those", "in", "EGF", "alone", ")", "and", "tissue", "(", "HPC", ":", "x", "60", ";", "sucralfate", ":", "x", "100", ")", ".", "In", "addition", ",", "the", "combined", "treatments", "significantly", "promoted", "healing", "of", "rat", "gastric", "ulcers", "whereas", "each", "agent", "alone", "had", "no", "significant", "effect", "as", "compared", "with", "control", "(", "saline", ")", ".", "This", "indicated", "the", "beneficial", "effect", "on", "ulcers", "of", "oral", "administration", "of", "EGF", "with", "agents", "allowing", "it", "to", "remain", "at", "high", "levels", "in", "the", "stomach", ",", "whereas", "most", "reports", "suggested", "less", "effect", "of", "oral", "EGF", "on", "healing", "of", "gastroduodenal", "ulcers", ".", "Subsequent", "to", "the", "clinical", "study", ",", "evaluation", "of", "oral", "use", "of", "EGF", "may", "be", "expected", "as", "the", "next", "step", "in", "the", "treatment", "of", "ulcers", ".", "The", "experimental", "evidence", "above", "would", "possibly", "be", "a", "guide", "for", "such", "trial", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Pain", "Participant_Sample-size" ]
Gastric ulcer, human epidermal growth factor, intravenous human epidermal growth factor ( hEGF ), cetraxate hydrochloride ( CH ), gastric ulcers, rate of ulcer healing, 67/86, healing rate, pain relief, blood examination, adverse reactions, hydroxypropyl cellulose, residual mEGF levels, healing of rat gastric ulcers	82758_task2	Sentence: Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial . Instructions: please extract entity words from the input sentence	[ "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial .	[ "Gastric", "ulcer", "treatment", "with", "intravenous", "human", "epidermal", "growth", "factor", ":", "a", "double", "-", "blind", "controlled", "clinical", "study", ".", "We", "introduced", "a", "double", "-", "blind", "controlled", "clinical", "study", "to", "compare", "intravenous", "human", "epidermal", "growth", "factor", "(", "hEGF", ")", "to", "cetraxate", "hydrochloride", "(", "CH", ")", ",", "an", "antiulcer", "drug", ",", "for", "their", "healing", "effect", "on", "gastric", "ulcers", ".", "We", "also", "prospected", "an", "oral", "use", "of", "EGF", "on", "the", "basis", "of", "our", "experimental", "evidence", ".", "In", "the", "clinical", "trial", ",", "the", "rate", "of", "ulcer", "healing", "within", "8", "weeks", "was", "77.9", "%", "(", "67/86", ")", "in", "patients", "receiving", "6", "micrograms", "EGF", "intravenously", "twice", "a", "week", ",", "being", "significantly", "greater", "than", "51.7", "%", "(", "45/87", ")", "in", "those", "given", "CH", ".", "Taking", "together", "all", "aspects", "assessed", "including", "the", "healing", "rate", ",", "pain", "relief", ",", "blood", "examination", "and", "adverse", "reactions", ",", "we", "judged", "the", "hEGF", "to", "be", "a", "useful", "and", "safe", "anticuler", "drug", ".", "In", "rats", ",", "50", "micrograms", "/", "kg", "mouse", "EGF", "(", "mEGF", ")", "and", "2", "%", "hydroxypropyl", "cellulose", "(", "HPC", ")", "or", "1.0", "g", "/", "kg", "sucralfate", "given", "by", "gastric", "intubation", "significantly", "raised", "the", "residual", "mEGF", "levels", "in", "both", "gastric", "luminal", "content", "(", "HPC", ":", "x", "30", ";", "sucralfate", ":", "x", "300", "as", "high", "as", "those", "in", "EGF", "alone", ")", "and", "tissue", "(", "HPC", ":", "x", "60", ";", "sucralfate", ":", "x", "100", ")", ".", "In", "addition", ",", "the", "combined", "treatments", "significantly", "promoted", "healing", "of", "rat", "gastric", "ulcers", "whereas", "each", "agent", "alone", "had", "no", "significant", "effect", "as", "compared", "with", "control", "(", "saline", ")", ".", "This", "indicated", "the", "beneficial", "effect", "on", "ulcers", "of", "oral", "administration", "of", "EGF", "with", "agents", "allowing", "it", "to", "remain", "at", "high", "levels", "in", "the", "stomach", ",", "whereas", "most", "reports", "suggested", "less", "effect", "of", "oral", "EGF", "on", "healing", "of", "gastroduodenal", "ulcers", ".", "Subsequent", "to", "the", "clinical", "study", ",", "evaluation", "of", "oral", "use", "of", "EGF", "may", "be", "expected", "as", "the", "next", "step", "in", "the", "treatment", "of", "ulcers", ".", "The", "experimental", "evidence", "above", "would", "possibly", "be", "a", "guide", "for", "such", "trial", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Pain", "Participant_Sample-size" ]
Kinderwunsches is an umlsterm, Techniken is an umlsterm, Techniken is an umlsterm, Behandlung is an umlsterm	DerGynaekologe.00330782.ger.abstr_task0	Sentence: Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind .	[ "Die", "ungewollt", "kinderlosen", "Paare", "hoffen", "auf", "die", "Erfuellung", "des", "Kinderwunsches", "fast", "ausschliesslich", "unter", "Anwendung", "reproduktionsmedizinischer", "Techniken", ".", "Im", "Diskurs", "um", "die", "Anwendung", "und", "die", "Entwicklungen", "reproduktiver", "Techniken", "treten", "die", "Erlebensaspekte", "der", "Betroffenen", "in", "den", "Hintergrund", ".", "Hilfe", "ausserhalb", "der", "medizinischen", "Behandlung", "wird", "von", "vielen", "erst", "zu", "einem", "Zeitpunkt", "angefragt", ",", "an", "dem", "sie", "von", "den", "erfolglosen", "Behandlungsversuchen", "erschoepft", "oder", "sehr", "enttaeuscht", "sind", "." ]	[ "umlsterm" ]
Kinderwunsches is an umlsterm, Techniken is an umlsterm, Techniken is an umlsterm, Behandlung is an umlsterm	DerGynaekologe.00330782.ger.abstr_task1	Sentence: Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind . Instructions: please typing these entity words according to sentence: Kinderwunsches, Techniken, Techniken, Behandlung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind .	[ "Die", "ungewollt", "kinderlosen", "Paare", "hoffen", "auf", "die", "Erfuellung", "des", "Kinderwunsches", "fast", "ausschliesslich", "unter", "Anwendung", "reproduktionsmedizinischer", "Techniken", ".", "Im", "Diskurs", "um", "die", "Anwendung", "und", "die", "Entwicklungen", "reproduktiver", "Techniken", "treten", "die", "Erlebensaspekte", "der", "Betroffenen", "in", "den", "Hintergrund", ".", "Hilfe", "ausserhalb", "der", "medizinischen", "Behandlung", "wird", "von", "vielen", "erst", "zu", "einem", "Zeitpunkt", "angefragt", ",", "an", "dem", "sie", "von", "den", "erfolglosen", "Behandlungsversuchen", "erschoepft", "oder", "sehr", "enttaeuscht", "sind", "." ]	[ "umlsterm" ]
Kinderwunsches, Techniken, Techniken, Behandlung	DerGynaekologe.00330782.ger.abstr_task2	Sentence: Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind .	[ "Die", "ungewollt", "kinderlosen", "Paare", "hoffen", "auf", "die", "Erfuellung", "des", "Kinderwunsches", "fast", "ausschliesslich", "unter", "Anwendung", "reproduktionsmedizinischer", "Techniken", ".", "Im", "Diskurs", "um", "die", "Anwendung", "und", "die", "Entwicklungen", "reproduktiver", "Techniken", "treten", "die", "Erlebensaspekte", "der", "Betroffenen", "in", "den", "Hintergrund", ".", "Hilfe", "ausserhalb", "der", "medizinischen", "Behandlung", "wird", "von", "vielen", "erst", "zu", "einem", "Zeitpunkt", "angefragt", ",", "an", "dem", "sie", "von", "den", "erfolglosen", "Behandlungsversuchen", "erschoepft", "oder", "sehr", "enttaeuscht", "sind", "." ]	[ "umlsterm" ]
precipitinas is a PROTEINAS, IgG is a PROTEINAS, antígeno galactomanano is a PROTEINAS, voriconazol is a NORMALIZABLES, precipitinas is a PROTEINAS	414_task0	Sentence: Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O" ]	Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas.	[ "Varón", "de", "45", "años", ",", "trabajador", "en", "canteras", "durante", "15", "años", ".", "Diagnosticado", "de", "silicosis", "complicada", "en", "FMP", ".", "Exfumador", "desde", "hace", "dos", "años", ",", "de", "25", "paquetes", "/", "año", ".", "Tuberculosis", "pulmonar", "en", "2007", ".", "Acudió", "al", "Servicio", "de", "Urgencias", "en", "marzo", "2009", "con", "hemoptisis", "amenazante", ",", "precedida", "de", "tos", "y", "expectoración", "marronácea", "de", "4", "semanas", "de", "evolución", ".", "En", "la", "exploración", "física", "destacar", "constantes", "vitales", "dentro", "de", "la", "normalidad", "y", "roncus", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sérica", "destacar", "leucocitosis", "(", "11.280", "células", "/", "μl", "con", "80", "%", "de", "neutrófilos", ")", "sin", "otras", "alteraciones", ".", "La", "fibrobroncoscopia", "permitió", "ver", "un", "gran", "coágulo", "en", "bronquio", "de", "lóbulo", "superior", "derecho", ".", "La", "TAC", "mostraba", "afectación", "intersticial", "micronodular", "bilateral", "y", "difusa", ",", "algunos", "nódulos", "calcificados", ",", "de", "predominio", "en", "lóbulos", "superiores", "y", "conglomerados", "que", "habían", "aumentado", "respecto", "a", "estudios", "previos", ",", "con", "aparición", "de", "material", "en", "su", "interior", ",", "así", "como", "engrosamiento", "pleural", "nodular", "y", "difuso", ".", "El", "cultivo", "fue", "positivo", "para", "Aspergillus", "fumigatus", "en", "esputo", "y", "en", "aspirado", "bronquial", ".", "En", "sangre", "las", "precipitinas", "IgG", "resultaron", "positivas", "y", "el", "antígeno", "galactomanano", "negativo", ".", "Se", "realizó", "embolización", "de", "arterias", "bronquiales", "del", "LSI", "con", "control", "de", "la", "hemoptisis", "y", "se", "instauró", "tratamiento", "con", "voriconazol", "con", "buena", "evolución", "al", "año", "de", "tratamiento", "con", "negativización", "de", "las", "precipitinas", "séricas", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES" ]
precipitinas is a PROTEINAS, IgG is a PROTEINAS, antígeno galactomanano is a PROTEINAS, voriconazol is a NORMALIZABLES, precipitinas is a PROTEINAS	414_task1	Sentence: Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas. Instructions: please typing these entity words according to sentence: precipitinas, IgG, antígeno galactomanano, voriconazol, precipitinas Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O" ]	Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas.	[ "Varón", "de", "45", "años", ",", "trabajador", "en", "canteras", "durante", "15", "años", ".", "Diagnosticado", "de", "silicosis", "complicada", "en", "FMP", ".", "Exfumador", "desde", "hace", "dos", "años", ",", "de", "25", "paquetes", "/", "año", ".", "Tuberculosis", "pulmonar", "en", "2007", ".", "Acudió", "al", "Servicio", "de", "Urgencias", "en", "marzo", "2009", "con", "hemoptisis", "amenazante", ",", "precedida", "de", "tos", "y", "expectoración", "marronácea", "de", "4", "semanas", "de", "evolución", ".", "En", "la", "exploración", "física", "destacar", "constantes", "vitales", "dentro", "de", "la", "normalidad", "y", "roncus", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sérica", "destacar", "leucocitosis", "(", "11.280", "células", "/", "μl", "con", "80", "%", "de", "neutrófilos", ")", "sin", "otras", "alteraciones", ".", "La", "fibrobroncoscopia", "permitió", "ver", "un", "gran", "coágulo", "en", "bronquio", "de", "lóbulo", "superior", "derecho", ".", "La", "TAC", "mostraba", "afectación", "intersticial", "micronodular", "bilateral", "y", "difusa", ",", "algunos", "nódulos", "calcificados", ",", "de", "predominio", "en", "lóbulos", "superiores", "y", "conglomerados", "que", "habían", "aumentado", "respecto", "a", "estudios", "previos", ",", "con", "aparición", "de", "material", "en", "su", "interior", ",", "así", "como", "engrosamiento", "pleural", "nodular", "y", "difuso", ".", "El", "cultivo", "fue", "positivo", "para", "Aspergillus", "fumigatus", "en", "esputo", "y", "en", "aspirado", "bronquial", ".", "En", "sangre", "las", "precipitinas", "IgG", "resultaron", "positivas", "y", "el", "antígeno", "galactomanano", "negativo", ".", "Se", "realizó", "embolización", "de", "arterias", "bronquiales", "del", "LSI", "con", "control", "de", "la", "hemoptisis", "y", "se", "instauró", "tratamiento", "con", "voriconazol", "con", "buena", "evolución", "al", "año", "de", "tratamiento", "con", "negativización", "de", "las", "precipitinas", "séricas", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES" ]
precipitinas, IgG, antígeno galactomanano, voriconazol, precipitinas	414_task2	Sentence: Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O" ]	Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas.	[ "Varón", "de", "45", "años", ",", "trabajador", "en", "canteras", "durante", "15", "años", ".", "Diagnosticado", "de", "silicosis", "complicada", "en", "FMP", ".", "Exfumador", "desde", "hace", "dos", "años", ",", "de", "25", "paquetes", "/", "año", ".", "Tuberculosis", "pulmonar", "en", "2007", ".", "Acudió", "al", "Servicio", "de", "Urgencias", "en", "marzo", "2009", "con", "hemoptisis", "amenazante", ",", "precedida", "de", "tos", "y", "expectoración", "marronácea", "de", "4", "semanas", "de", "evolución", ".", "En", "la", "exploración", "física", "destacar", "constantes", "vitales", "dentro", "de", "la", "normalidad", "y", "roncus", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sérica", "destacar", "leucocitosis", "(", "11.280", "células", "/", "μl", "con", "80", "%", "de", "neutrófilos", ")", "sin", "otras", "alteraciones", ".", "La", "fibrobroncoscopia", "permitió", "ver", "un", "gran", "coágulo", "en", "bronquio", "de", "lóbulo", "superior", "derecho", ".", "La", "TAC", "mostraba", "afectación", "intersticial", "micronodular", "bilateral", "y", "difusa", ",", "algunos", "nódulos", "calcificados", ",", "de", "predominio", "en", "lóbulos", "superiores", "y", "conglomerados", "que", "habían", "aumentado", "respecto", "a", "estudios", "previos", ",", "con", "aparición", "de", "material", "en", "su", "interior", ",", "así", "como", "engrosamiento", "pleural", "nodular", "y", "difuso", ".", "El", "cultivo", "fue", "positivo", "para", "Aspergillus", "fumigatus", "en", "esputo", "y", "en", "aspirado", "bronquial", ".", "En", "sangre", "las", "precipitinas", "IgG", "resultaron", "positivas", "y", "el", "antígeno", "galactomanano", "negativo", ".", "Se", "realizó", "embolización", "de", "arterias", "bronquiales", "del", "LSI", "con", "control", "de", "la", "hemoptisis", "y", "se", "instauró", "tratamiento", "con", "voriconazol", "con", "buena", "evolución", "al", "año", "de", "tratamiento", "con", "negativización", "de", "las", "precipitinas", "séricas", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES" ]
brain damage is a ADVERSE	example-399_task0	Sentence: Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful.	[ "Iatrogenic", "intravenous", "medication", "errors", "reported", "to", "the", "PIC", "Erfurt", ".", " ", "BACKGROUND", ":", "We", "investigated", "the", "iatrogenic", "intravenous", "medication", "errors", "(", "IIME", ")", "reported", "to", "the", "Poisons", "Information", "Center", "(", "PIC", ")", "Erfurt", ".", "METHODS", ":", "All", "IIME", "over", "a", "ten", "year", "period", "were", "analyzed", "retrospectively", "and", "categorized", "into", "error", "types", ",", "age", "groups", ",", "drugs", "involved", ",", "and", "estimated", "risk", "of", "toxicity", ".", "RESULTS", ":", "From", "1997", "to", "2006", "the", "PIC", "Erfurt", "registered", "132", "cases", "of", "IIME", ".", "They", "increased", "from", "7", "in", "1997", "to", "31", "in", "2006", ".", "Children", "accounted", "for", "31.1", "%", "of", "the", "patients", "affected", "and", "adults", "for", "68.9", "%", ".", "The", "drug", "classes", "(", "ATC", "classification", ")", "involved", "most", "frequently", "were", "antipsychotics", "(", "9.8", "%", ")", "and", "antihistamines", "for", "systemic", "use", "(", "7.5", "%", ")", ".", "The", "main", "types", "of", "IIME", "were", "overdose", "(", "53.1", "%", ")", "and", "incorrect", "route", "of", "administration", "(", "29.7", "%", ")", ".", "The", "estimated", "risk", "of", "toxicity", "was", ":", "14.4", "%", "none", ",", "71.2", "%", "risk", "of", "toxicity", ",", "and", "14.4", "%", "unpredictable", "risk", ".", "Medical", "treatment", "was", "recommended", "in", "82", "%", ".", "The", "outcome", "of", "104", "of", "the", "132", "(", "78.8", "%", ")", "courses", "was", "unknown", ".", "In", "the", "28", "cases", "followed", "to", "a", "known", "outcome", ",", "9", "(", "32", "%", ")", "were", "asymptomatic", "and", "19", "(", "68", "%", ")", "symptomatic", "with", "minor", "(", "9", "cases", ")", ",", "moderate", "(", "1", "case", ")", ",", "and", "severe", "features", "(", "6", "cases", ")", "but", "mostly", "complete", "recovery", ".", "Two", "IIME", "resulted", "in", "hypoxia", "-", "induced", "brain", "damage", "and", "one", "in", "death", "despite", "of", "resuscitation", ".", "CONCLUSION", ":", "Approximately", "0.1", "%", "of", "all", "calls", "registered", "by", "the", "PIC", "Erfurt", "from", "1997", "to", "2006", "concerned", "IIME", ".", "Thirty", "-", "two", "percent", "of", "IIME", "followed", "to", "a", "known", "outcome", "resulted", "in", "severe", "symptoms", ".", "These", "data", "show", "that", "IIME", "can", "be", "harmful", "." ]	[ "ADVERSE" ]
brain damage is a ADVERSE	example-399_task1	Sentence: Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful. Instructions: please typing these entity words according to sentence: brain damage Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful.	[ "Iatrogenic", "intravenous", "medication", "errors", "reported", "to", "the", "PIC", "Erfurt", ".", " ", "BACKGROUND", ":", "We", "investigated", "the", "iatrogenic", "intravenous", "medication", "errors", "(", "IIME", ")", "reported", "to", "the", "Poisons", "Information", "Center", "(", "PIC", ")", "Erfurt", ".", "METHODS", ":", "All", "IIME", "over", "a", "ten", "year", "period", "were", "analyzed", "retrospectively", "and", "categorized", "into", "error", "types", ",", "age", "groups", ",", "drugs", "involved", ",", "and", "estimated", "risk", "of", "toxicity", ".", "RESULTS", ":", "From", "1997", "to", "2006", "the", "PIC", "Erfurt", "registered", "132", "cases", "of", "IIME", ".", "They", "increased", "from", "7", "in", "1997", "to", "31", "in", "2006", ".", "Children", "accounted", "for", "31.1", "%", "of", "the", "patients", "affected", "and", "adults", "for", "68.9", "%", ".", "The", "drug", "classes", "(", "ATC", "classification", ")", "involved", "most", "frequently", "were", "antipsychotics", "(", "9.8", "%", ")", "and", "antihistamines", "for", "systemic", "use", "(", "7.5", "%", ")", ".", "The", "main", "types", "of", "IIME", "were", "overdose", "(", "53.1", "%", ")", "and", "incorrect", "route", "of", "administration", "(", "29.7", "%", ")", ".", "The", "estimated", "risk", "of", "toxicity", "was", ":", "14.4", "%", "none", ",", "71.2", "%", "risk", "of", "toxicity", ",", "and", "14.4", "%", "unpredictable", "risk", ".", "Medical", "treatment", "was", "recommended", "in", "82", "%", ".", "The", "outcome", "of", "104", "of", "the", "132", "(", "78.8", "%", ")", "courses", "was", "unknown", ".", "In", "the", "28", "cases", "followed", "to", "a", "known", "outcome", ",", "9", "(", "32", "%", ")", "were", "asymptomatic", "and", "19", "(", "68", "%", ")", "symptomatic", "with", "minor", "(", "9", "cases", ")", ",", "moderate", "(", "1", "case", ")", ",", "and", "severe", "features", "(", "6", "cases", ")", "but", "mostly", "complete", "recovery", ".", "Two", "IIME", "resulted", "in", "hypoxia", "-", "induced", "brain", "damage", "and", "one", "in", "death", "despite", "of", "resuscitation", ".", "CONCLUSION", ":", "Approximately", "0.1", "%", "of", "all", "calls", "registered", "by", "the", "PIC", "Erfurt", "from", "1997", "to", "2006", "concerned", "IIME", ".", "Thirty", "-", "two", "percent", "of", "IIME", "followed", "to", "a", "known", "outcome", "resulted", "in", "severe", "symptoms", ".", "These", "data", "show", "that", "IIME", "can", "be", "harmful", "." ]	[ "ADVERSE" ]
brain damage	example-399_task2	Sentence: Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful.	[ "Iatrogenic", "intravenous", "medication", "errors", "reported", "to", "the", "PIC", "Erfurt", ".", " ", "BACKGROUND", ":", "We", "investigated", "the", "iatrogenic", "intravenous", "medication", "errors", "(", "IIME", ")", "reported", "to", "the", "Poisons", "Information", "Center", "(", "PIC", ")", "Erfurt", ".", "METHODS", ":", "All", "IIME", "over", "a", "ten", "year", "period", "were", "analyzed", "retrospectively", "and", "categorized", "into", "error", "types", ",", "age", "groups", ",", "drugs", "involved", ",", "and", "estimated", "risk", "of", "toxicity", ".", "RESULTS", ":", "From", "1997", "to", "2006", "the", "PIC", "Erfurt", "registered", "132", "cases", "of", "IIME", ".", "They", "increased", "from", "7", "in", "1997", "to", "31", "in", "2006", ".", "Children", "accounted", "for", "31.1", "%", "of", "the", "patients", "affected", "and", "adults", "for", "68.9", "%", ".", "The", "drug", "classes", "(", "ATC", "classification", ")", "involved", "most", "frequently", "were", "antipsychotics", "(", "9.8", "%", ")", "and", "antihistamines", "for", "systemic", "use", "(", "7.5", "%", ")", ".", "The", "main", "types", "of", "IIME", "were", "overdose", "(", "53.1", "%", ")", "and", "incorrect", "route", "of", "administration", "(", "29.7", "%", ")", ".", "The", "estimated", "risk", "of", "toxicity", "was", ":", "14.4", "%", "none", ",", "71.2", "%", "risk", "of", "toxicity", ",", "and", "14.4", "%", "unpredictable", "risk", ".", "Medical", "treatment", "was", "recommended", "in", "82", "%", ".", "The", "outcome", "of", "104", "of", "the", "132", "(", "78.8", "%", ")", "courses", "was", "unknown", ".", "In", "the", "28", "cases", "followed", "to", "a", "known", "outcome", ",", "9", "(", "32", "%", ")", "were", "asymptomatic", "and", "19", "(", "68", "%", ")", "symptomatic", "with", "minor", "(", "9", "cases", ")", ",", "moderate", "(", "1", "case", ")", ",", "and", "severe", "features", "(", "6", "cases", ")", "but", "mostly", "complete", "recovery", ".", "Two", "IIME", "resulted", "in", "hypoxia", "-", "induced", "brain", "damage", "and", "one", "in", "death", "despite", "of", "resuscitation", ".", "CONCLUSION", ":", "Approximately", "0.1", "%", "of", "all", "calls", "registered", "by", "the", "PIC", "Erfurt", "from", "1997", "to", "2006", "concerned", "IIME", ".", "Thirty", "-", "two", "percent", "of", "IIME", "followed", "to", "a", "known", "outcome", "resulted", "in", "severe", "symptoms", ".", "These", "data", "show", "that", "IIME", "can", "be", "harmful", "." ]	[ "ADVERSE" ]
prostaglandin D synthase is a GENE-Y	8415655_task0	Sentence: Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.	[ "Dominant", "expression", "of", "mRNA", "for", "prostaglandin", "D", "synthase", "in", "leptomeninges", ",", "choroid", "plexus", ",", "and", "oligodendrocytes", "of", "the", "adult", "rat", "brain", "." ]	[ "GENE-Y", "CHEMICAL" ]
prostaglandin D synthase is a GENE-Y	8415655_task1	Sentence: Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Instructions: please typing these entity words according to sentence: prostaglandin D synthase Options: GENE-Y	[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.	[ "Dominant", "expression", "of", "mRNA", "for", "prostaglandin", "D", "synthase", "in", "leptomeninges", ",", "choroid", "plexus", ",", "and", "oligodendrocytes", "of", "the", "adult", "rat", "brain", "." ]	[ "GENE-Y", "CHEMICAL" ]
prostaglandin D synthase	8415655_task2	Sentence: Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.	[ "Dominant", "expression", "of", "mRNA", "for", "prostaglandin", "D", "synthase", "in", "leptomeninges", ",", "choroid", "plexus", ",", "and", "oligodendrocytes", "of", "the", "adult", "rat", "brain", "." ]	[ "GENE-Y", "CHEMICAL" ]
Jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, Jacalin is a DRUG_N	3871459_task0	Sentence: Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG_N	[ "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.	[ "Jacalin", ":", "an", "IgA", "-", "binding", "lectin", ".", "We", "previously", "reported", "that", "seeds", "of", "Artocarpus", "integrifolia", "(", "jackfruit", ")", "contain", "a", "lectin", ",", "which", "we", "call", "jacalin", ",", "that", "is", "both", "a", "potent", "T", "cell", "mitogen", "and", "an", "apparently", "T", "cell", "-", "independent", "activator", "of", "human", "B", "cells", "for", "the", "secretion", "of", "immunoglobulins", ".", "During", "the", "above", "experiments", "we", "noted", "a", "massive", "precipitation", "in", "cell", "cultures", "stimulated", "with", "greater", "than", "or", "equal", "to", "100", "micrograms", "of", "lectin", ".", "In", "this", "paper", ",", "we", "show", "that", "the", "precipitate", "is", "formed", "after", "the", "interaction", "of", "jacalin", "and", "the", "serum", "protein", "added", "to", "the", "culture", "medium", ".", "More", "importantly", ",", "we", "demonstrate", "that", "IgA", "is", "probably", "the", "major", "serum", "constituent", "precipitated", "by", "the", "lectin", "and", "that", "no", "IgG", "or", "IgM", "can", "be", "detected", "in", "the", "precipitates", ".", "In", "secretions", "such", "as", "colostrum", ",", "IgA", "is", "the", "only", "protein", "precipitated", "by", "jacalin", ".", "On", "the", "basis", "of", "this", "specificity", "we", "describe", "a", "simple", "and", "reliable", "affinity", "chromatography", "procedure", "for", "the", "purification", "of", "both", "human", "serum", "and", "colostrum", "IgA.", "Jacalin", "is", "a", "D", "-", "Gal", "binding", "lectin", "and", "should", "be", "a", "useful", "tool", "for", "studying", "of", "serum", "and", "secretory", "IgA." ]	[ "DRUG_N" ]
Jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, Jacalin is a DRUG_N	3871459_task1	Sentence: Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA. Instructions: please typing these entity words according to sentence: Jacalin, jacalin, jacalin, jacalin, Jacalin Options: DRUG_N	[ "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.	[ "Jacalin", ":", "an", "IgA", "-", "binding", "lectin", ".", "We", "previously", "reported", "that", "seeds", "of", "Artocarpus", "integrifolia", "(", "jackfruit", ")", "contain", "a", "lectin", ",", "which", "we", "call", "jacalin", ",", "that", "is", "both", "a", "potent", "T", "cell", "mitogen", "and", "an", "apparently", "T", "cell", "-", "independent", "activator", "of", "human", "B", "cells", "for", "the", "secretion", "of", "immunoglobulins", ".", "During", "the", "above", "experiments", "we", "noted", "a", "massive", "precipitation", "in", "cell", "cultures", "stimulated", "with", "greater", "than", "or", "equal", "to", "100", "micrograms", "of", "lectin", ".", "In", "this", "paper", ",", "we", "show", "that", "the", "precipitate", "is", "formed", "after", "the", "interaction", "of", "jacalin", "and", "the", "serum", "protein", "added", "to", "the", "culture", "medium", ".", "More", "importantly", ",", "we", "demonstrate", "that", "IgA", "is", "probably", "the", "major", "serum", "constituent", "precipitated", "by", "the", "lectin", "and", "that", "no", "IgG", "or", "IgM", "can", "be", "detected", "in", "the", "precipitates", ".", "In", "secretions", "such", "as", "colostrum", ",", "IgA", "is", "the", "only", "protein", "precipitated", "by", "jacalin", ".", "On", "the", "basis", "of", "this", "specificity", "we", "describe", "a", "simple", "and", "reliable", "affinity", "chromatography", "procedure", "for", "the", "purification", "of", "both", "human", "serum", "and", "colostrum", "IgA.", "Jacalin", "is", "a", "D", "-", "Gal", "binding", "lectin", "and", "should", "be", "a", "useful", "tool", "for", "studying", "of", "serum", "and", "secretory", "IgA." ]	[ "DRUG_N" ]
Jacalin, jacalin, jacalin, jacalin, Jacalin	3871459_task2	Sentence: Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA. Instructions: please extract entity words from the input sentence	[ "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.	[ "Jacalin", ":", "an", "IgA", "-", "binding", "lectin", ".", "We", "previously", "reported", "that", "seeds", "of", "Artocarpus", "integrifolia", "(", "jackfruit", ")", "contain", "a", "lectin", ",", "which", "we", "call", "jacalin", ",", "that", "is", "both", "a", "potent", "T", "cell", "mitogen", "and", "an", "apparently", "T", "cell", "-", "independent", "activator", "of", "human", "B", "cells", "for", "the", "secretion", "of", "immunoglobulins", ".", "During", "the", "above", "experiments", "we", "noted", "a", "massive", "precipitation", "in", "cell", "cultures", "stimulated", "with", "greater", "than", "or", "equal", "to", "100", "micrograms", "of", "lectin", ".", "In", "this", "paper", ",", "we", "show", "that", "the", "precipitate", "is", "formed", "after", "the", "interaction", "of", "jacalin", "and", "the", "serum", "protein", "added", "to", "the", "culture", "medium", ".", "More", "importantly", ",", "we", "demonstrate", "that", "IgA", "is", "probably", "the", "major", "serum", "constituent", "precipitated", "by", "the", "lectin", "and", "that", "no", "IgG", "or", "IgM", "can", "be", "detected", "in", "the", "precipitates", ".", "In", "secretions", "such", "as", "colostrum", ",", "IgA", "is", "the", "only", "protein", "precipitated", "by", "jacalin", ".", "On", "the", "basis", "of", "this", "specificity", "we", "describe", "a", "simple", "and", "reliable", "affinity", "chromatography", "procedure", "for", "the", "purification", "of", "both", "human", "serum", "and", "colostrum", "IgA.", "Jacalin", "is", "a", "D", "-", "Gal", "binding", "lectin", "and", "should", "be", "a", "useful", "tool", "for", "studying", "of", "serum", "and", "secretory", "IgA." ]	[ "DRUG_N" ]
Intraokularlinsen is an umlsterm, Lichtaufteilung is an umlsterm, Lichtmenge is an umlsterm, Lichtmenge is an umlsterm	DerOpthalmologe.90960578.ger.abstr_task0	Sentence: Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung .	[ "Hintergrund", ":", "Multifokale", "Intraokularlinsen", "(", "MIOL", ")", "werden", "seit", "Jahren", "mit", "gutem", "Erfolg", "implantiert", ".", "Bedingt", "durch", "die", "Lichtaufteilung", "auf", "mehrere", "Brennpunkte", "steht", "fuer", "jedes", "Bild", "eine", "geringere", "Lichtmenge", "zur", "Verfuegung", ".", "Eine", "zusaetzliche", "Reduktion", "der", "Lichtmenge", "oder", "Streulichteffekte", "durch", "eine", "Kapselfibrose", "fuehren", "moeglicherweise", "fruehzeitig", "zu", "einer", "Sehverschlechterung", "." ]	[ "umlsterm" ]
Intraokularlinsen is an umlsterm, Lichtaufteilung is an umlsterm, Lichtmenge is an umlsterm, Lichtmenge is an umlsterm	DerOpthalmologe.90960578.ger.abstr_task1	Sentence: Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung . Instructions: please typing these entity words according to sentence: Intraokularlinsen, Lichtaufteilung, Lichtmenge, Lichtmenge Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung .	[ "Hintergrund", ":", "Multifokale", "Intraokularlinsen", "(", "MIOL", ")", "werden", "seit", "Jahren", "mit", "gutem", "Erfolg", "implantiert", ".", "Bedingt", "durch", "die", "Lichtaufteilung", "auf", "mehrere", "Brennpunkte", "steht", "fuer", "jedes", "Bild", "eine", "geringere", "Lichtmenge", "zur", "Verfuegung", ".", "Eine", "zusaetzliche", "Reduktion", "der", "Lichtmenge", "oder", "Streulichteffekte", "durch", "eine", "Kapselfibrose", "fuehren", "moeglicherweise", "fruehzeitig", "zu", "einer", "Sehverschlechterung", "." ]	[ "umlsterm" ]
Intraokularlinsen, Lichtaufteilung, Lichtmenge, Lichtmenge	DerOpthalmologe.90960578.ger.abstr_task2	Sentence: Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung .	[ "Hintergrund", ":", "Multifokale", "Intraokularlinsen", "(", "MIOL", ")", "werden", "seit", "Jahren", "mit", "gutem", "Erfolg", "implantiert", ".", "Bedingt", "durch", "die", "Lichtaufteilung", "auf", "mehrere", "Brennpunkte", "steht", "fuer", "jedes", "Bild", "eine", "geringere", "Lichtmenge", "zur", "Verfuegung", ".", "Eine", "zusaetzliche", "Reduktion", "der", "Lichtmenge", "oder", "Streulichteffekte", "durch", "eine", "Kapselfibrose", "fuehren", "moeglicherweise", "fruehzeitig", "zu", "einer", "Sehverschlechterung", "." ]	[ "umlsterm" ]
lymph node dissection is an umlsterm, patients scheduled is an umlsterm, prostatectomy is an umlsterm, radiation therapy is an umlsterm, lymph nodes is an umlsterm, patient is an umlsterm, patients is an umlsterm, metastatic disease is an umlsterm, lymph nodes is an umlsterm, time is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, one - stage is an umlsterm, procedure is an umlsterm, overall is an umlsterm, complication is an umlsterm, open is an umlsterm, patients is an umlsterm, Postoperative is an umlsterm, hospital is an umlsterm, patients is an umlsterm, lymph node dissection is an umlsterm, invasive procedure is an umlsterm, patients is an umlsterm, lymph node is an umlsterm, metastases is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, radiation therapy is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, hospital is an umlsterm, period is an umlsterm, convalescence is an umlsterm	DerUrologeA.60350413.eng.abstr_task0	Sentence: Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence .	[ "Laparoscopic", "pelvic", "lymph", "node", "dissection", "was", "performed", "in", "120", "patients", "scheduled", "to", "undergo", "either", "radical", "perineal", "prostatectomy", "or", "radiation", "therapy", ".", "On", "average", "13", "lymph", "nodes", "were", "resected", "in", "each", "patient", ",", "and", "21", "patients", "were", "found", "to", "have", "metastatic", "disease", "in", "1", "-", "9", "lymph", "nodes", ".", "After", "an", "initial", "learning", "curve", ",", "mean", "operative", "time", "was", "reduced", "significantly", ",", "allowing", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "prostatectomy", "to", "be", "performed", "as", "a", "one", "-", "stage", "procedure", ".", "The", "overall", "complication", "rate", "was", "10", "%", ";", "open", "revisions", "were", "necessary", "in", "only", "2", "of", "120", "patients", ".", "Postoperative", "hospital", "stay", "was", "2", "days", "in", "patients", "undergoing", "laparoscopic", "lymph", "node", "dissection", "only", ".", "This", "minimally", "invasive", "procedure", "is", "particularly", "beneficial", "to", "patients", "with", "lymph", "node", "metastases", "not", "undergoing", "radical", "prostatectomy", ",", "as", "well", "as", "to", "patients", "planned", "to", "be", "treated", "by", "radiation", "therapy", ".", "The", "combination", "of", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "perineal", "prostatectomy", "avoids", "an", "abdominal", "incision", "and", "thus", "shortens", "both", "the", "hospital", "stay", "and", "the", "period", "of", "convalescence", "." ]	[ "umlsterm" ]
lymph node dissection is an umlsterm, patients scheduled is an umlsterm, prostatectomy is an umlsterm, radiation therapy is an umlsterm, lymph nodes is an umlsterm, patient is an umlsterm, patients is an umlsterm, metastatic disease is an umlsterm, lymph nodes is an umlsterm, time is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, one - stage is an umlsterm, procedure is an umlsterm, overall is an umlsterm, complication is an umlsterm, open is an umlsterm, patients is an umlsterm, Postoperative is an umlsterm, hospital is an umlsterm, patients is an umlsterm, lymph node dissection is an umlsterm, invasive procedure is an umlsterm, patients is an umlsterm, lymph node is an umlsterm, metastases is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, radiation therapy is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, hospital is an umlsterm, period is an umlsterm, convalescence is an umlsterm	DerUrologeA.60350413.eng.abstr_task1	Sentence: Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence . Instructions: please typing these entity words according to sentence: lymph node dissection, patients scheduled, prostatectomy, radiation therapy, lymph nodes, patient, patients, metastatic disease, lymph nodes, time, lymph node dissection, prostatectomy, one - stage, procedure, overall, complication, open, patients, Postoperative, hospital, patients, lymph node dissection, invasive procedure, patients, lymph node, metastases, prostatectomy, patients, radiation therapy, lymph node dissection, prostatectomy, hospital, period, convalescence Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence .	[ "Laparoscopic", "pelvic", "lymph", "node", "dissection", "was", "performed", "in", "120", "patients", "scheduled", "to", "undergo", "either", "radical", "perineal", "prostatectomy", "or", "radiation", "therapy", ".", "On", "average", "13", "lymph", "nodes", "were", "resected", "in", "each", "patient", ",", "and", "21", "patients", "were", "found", "to", "have", "metastatic", "disease", "in", "1", "-", "9", "lymph", "nodes", ".", "After", "an", "initial", "learning", "curve", ",", "mean", "operative", "time", "was", "reduced", "significantly", ",", "allowing", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "prostatectomy", "to", "be", "performed", "as", "a", "one", "-", "stage", "procedure", ".", "The", "overall", "complication", "rate", "was", "10", "%", ";", "open", "revisions", "were", "necessary", "in", "only", "2", "of", "120", "patients", ".", "Postoperative", "hospital", "stay", "was", "2", "days", "in", "patients", "undergoing", "laparoscopic", "lymph", "node", "dissection", "only", ".", "This", "minimally", "invasive", "procedure", "is", "particularly", "beneficial", "to", "patients", "with", "lymph", "node", "metastases", "not", "undergoing", "radical", "prostatectomy", ",", "as", "well", "as", "to", "patients", "planned", "to", "be", "treated", "by", "radiation", "therapy", ".", "The", "combination", "of", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "perineal", "prostatectomy", "avoids", "an", "abdominal", "incision", "and", "thus", "shortens", "both", "the", "hospital", "stay", "and", "the", "period", "of", "convalescence", "." ]	[ "umlsterm" ]
lymph node dissection, patients scheduled, prostatectomy, radiation therapy, lymph nodes, patient, patients, metastatic disease, lymph nodes, time, lymph node dissection, prostatectomy, one - stage, procedure, overall, complication, open, patients, Postoperative, hospital, patients, lymph node dissection, invasive procedure, patients, lymph node, metastases, prostatectomy, patients, radiation therapy, lymph node dissection, prostatectomy, hospital, period, convalescence	DerUrologeA.60350413.eng.abstr_task2	Sentence: Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence .	[ "Laparoscopic", "pelvic", "lymph", "node", "dissection", "was", "performed", "in", "120", "patients", "scheduled", "to", "undergo", "either", "radical", "perineal", "prostatectomy", "or", "radiation", "therapy", ".", "On", "average", "13", "lymph", "nodes", "were", "resected", "in", "each", "patient", ",", "and", "21", "patients", "were", "found", "to", "have", "metastatic", "disease", "in", "1", "-", "9", "lymph", "nodes", ".", "After", "an", "initial", "learning", "curve", ",", "mean", "operative", "time", "was", "reduced", "significantly", ",", "allowing", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "prostatectomy", "to", "be", "performed", "as", "a", "one", "-", "stage", "procedure", ".", "The", "overall", "complication", "rate", "was", "10", "%", ";", "open", "revisions", "were", "necessary", "in", "only", "2", "of", "120", "patients", ".", "Postoperative", "hospital", "stay", "was", "2", "days", "in", "patients", "undergoing", "laparoscopic", "lymph", "node", "dissection", "only", ".", "This", "minimally", "invasive", "procedure", "is", "particularly", "beneficial", "to", "patients", "with", "lymph", "node", "metastases", "not", "undergoing", "radical", "prostatectomy", ",", "as", "well", "as", "to", "patients", "planned", "to", "be", "treated", "by", "radiation", "therapy", ".", "The", "combination", "of", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "perineal", "prostatectomy", "avoids", "an", "abdominal", "incision", "and", "thus", "shortens", "both", "the", "hospital", "stay", "and", "the", "period", "of", "convalescence", "." ]	[ "umlsterm" ]
tolerance is a Outcome_Other, bronchoprotective effect is a Outcome_Physical, salmeterol / fluticasone is a Intervention_Pharmacological, salmeterol / fluticasone propionate is a Intervention_Pharmacological, early airway response ( EAR ) is a Outcome_Physical, placebo is a Intervention_Control, allergen challenge ( T1 ) is a Intervention_Pharmacological, single dose of salmeterol / fluticasone is a Intervention_Pharmacological, allergen challenge ( T2 ) is a Intervention_Pharmacological, allergen challenge ( T3 ) is a Intervention_Pharmacological, FEV1 is a Outcome_Physical, MaxDeltaFEV1 % is a Outcome_Physical, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge is a Outcome_Physical, significantly greater is a Outcome_Other, No difference is a Outcome_Other, area under the curve is a Outcome_Physical, protected against EAR is a Outcome_Physical, protected against EAR . is a Outcome_Physical, tolerance to the protective effect is a Outcome_Physical	24706_task0	Sentence: Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control	[ "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma .	[ "Minimal", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "inhaled", "salmeterol", "/", "fluticasone", "combination", "on", "allergene", "challenge", ".", "In", "order", "to", "assess", "whether", "the", "administration", "of", "salmeterol", "/", "fluticasone", "propionate", "combination", "(", "50/250", "mcg", "by", "Diskus", ")", "for", "1", "week", "induces", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ",", "a", "single", "-", "blind", ",", "cross", "-", "over", "study", "was", "carried", "out", ".", "We", "studied", "nine", "subjects", "(", "eight", "men", "and", "one", "woman", ";", "mean", "age+/-SD", ":", "31.3+/-11.0", "yr", ")", "with", "mild", "intermittent", "allergic", "asthma", ",", "never", "treated", "with", "regular", "beta2-agonists", "or", "inhaled", "corticosteroids", ".", "In", "a", "previous", "allergen", "challenge", "all", "subjects", "had", "shown", "a", "positive", "early", "airway", "response", "(", "EAR", ")", "to", "allergen", ".", "They", "underwent", "allergen", "challenge", "after", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "placebo", "immediately", "before", "allergen", "challenge", "(", "T1", ")", ",", "or", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T2", ")", ",", "or", "1-week", "treatment", "with", "salmeterol", "/", "fluticasone", "combination", "bid", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T3", ")", ".", "EAR", "was", "evaluated", "both", "as", "maximum", "decrease", "in", "FEV1", "(", "MaxDeltaFEV1", "%", ")", "after", "allergen", "challenge", "and", "as", "area", "under", "FEV1", "-time", "curve", ".", "MaxDeltaFEV1", "%", "during", "allergen", "challenge", "protected", "by", "placebo", "(", "T1", ")", "was", "significantly", "greater", "than", "MaxDeltaFEV1", "%", "during", "allergen", "challenges", "protected", "by", "single", "dose", "of", "salmeterol", "/", "fluticasone", "(", "T2", ")", "and", "by", "salmeterol", "/", "fluticasone", "1-week", "treatment", "(", "T3", ")", ".", "No", "difference", "was", "found", "in", "MaxDeltaFEV1", "%", "between", "T2", "and", "T3", ".", "The", "same", "results", "were", "observed", "also", "after", "computing", "the", "area", "under", "the", "curve", "for", "each", "challenge", ".", "When", "individually", "considered", ",", "all", "subjects", "were", "protected", "against", "EAR", "(", "protection", "index", ">", "or", "=", "80", "%", ")", "at", "T2", ",", "while", "at", "3", "seven", "out", "of", "nine", "subjects", "were", "still", "protected", "against", "EAR", ".", "In", "conclusion", ",", "the", "simultaneous", "administration", "of", "salmeterol", "and", "fluticasone", "in", "the", "same", "device", "prevents", "in", "almost", "80", "%", "of", "examined", "subjects", "the", "development", "of", "tolerance", "to", "the", "protective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ".", "This", "observation", "may", "contribute", "to", "explain", "the", "positive", "interaction", "between", "inhaled", "beta2-agonists", "and", "corticosteroids", "in", "the", "long", "-", "term", "treatment", "of", "asthma", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Intervention_Control" ]

Arbeit is an umlsterm, Stickstoffmonoxid is an umlsterm, ischaemiebedingten is an umlsterm, Zelltod is an umlsterm, Feten is an umlsterm, Herz - Kreislauf - System is an umlsterm, Gewebeschnittmodell is an umlsterm, Marker is an umlsterm, Energiestoffwechsels is an umlsterm, Proteinbiosynthese is an umlsterm, Methode is an umlsterm, Meerschweinchenfeten is an umlsterm, Halothan is an umlsterm, Gehirns is an umlsterm, Gewebescheiben is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, glukosefreien is an umlsterm, Gewebeschnitte is an umlsterm, NO - Synthase is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gewebekonzentration is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, Konzentration is an umlsterm, HPLC is an umlsterm, Proteinbiosynthese is an umlsterm, Leucin is an umlsterm, Gewebeproteine is an umlsterm, Varianzanalyse is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Konzentration is an umlsterm, Gewebescheiben is an umlsterm, Protein is an umlsterm, Protein is an umlsterm, Ischaemie is an umlsterm, Energiestoffwechsel is an umlsterm, Proteinbiosynthese is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm, Stickstoffmonoxid is an umlsterm, Herz - Kreislauf - System is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm

PerinatalMedizin.80100016.ger.abstr_task0

Sentence: In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben .

[ "In", "der", "vorliegenden", "Arbeit", "sollte", "die", "Bedeutung", "von", "Stickstoffmonoxid", "(", "NO", ")", "fuer", "den", "ischaemiebedingten", "neuronalen", "Zelltod", "beim", "Feten", "unabhaengig", "vom", "Herz", "-", "Kreislauf", "-", "System", "untersucht", "werden", ".", "Hierzu", "verwendeten", "wir", "ein", "hippokampales", "Gewebeschnittmodell", ".", "Als", "Marker", "fuer", "den", "neuronalen", "Zellschaden", "waehlten", "wir", "die", "postischaemische", "Beeintraechtigung", "des", "Energiestoffwechsels", "und", "der", "Proteinbiosynthese", ".", "Methode", ":", "Reife", "Meerschweinchenfeten", "wurden", "mit", "Halothan", "narkotisiert", ".", "Das", "Hippokampusareal", "des", "Gehirns", "wurde", "entnommen", "und", "in", "500", "µm", "dicke", "Scheiben", "geschnitten", ".", "Die", "Gewebescheiben", "wurden", "in", "artifizielle", "Liquorfluessigkeit", "(", "aCSF", ")", "transferiert", "und", "mit", "O2", "/", "CO2", "(", "95%/5", "%", ")", "in", "einer", "Inkubationskammer", "begast", ".", "Zur", "Induktion", "der", "Ischaemie", "in", "vitro", "wurden", "die", "Gewebescheiben", "in", "einen", "glukosefreien", "aCSF", "transferiert", "und", "fuer", "10", "-", "40", "min", "mit", "N2", "/", "CO2", "(", "95%/5", "%", ")", "begast", ".", "Bei", "einem", "Teil", "der", "Gewebeschnitte", "wurde", "die", "NO", "-", "Synthase", "mit", "100", "µM", "N", "-", "Nitro", "-", "L", "-", "Arginin", "(", "NNLA", ")", "geblockt", ".", "Die", "Aktivierung", "der", "NO", "-", "Synthase", "waehrend", "der", "Ischaemie", "wurde", "ueber", "die", "Gewebekonzentration", "von", "cGMP", "bestimmt", ".", "cGMP", "wurde", "mit", "einem", "Radioimmunoassay", "gemessen", "12", ";", "h", "nach", "Ischaemie", "in", "vitro", "wurden", "die", "Adenylate", "und", "die", "Proteinbiosyntheses", "in", "den", "Gewebescheiben", "bestimmt", ".", "Die", "Konzentration", "der", "Adenylate", "wurde", "mit", "HPLC", "nach", "Extraktion", "mit", "Perchloressigsaeure", "gemessen", ".", "Die", "Proteinbiosynthese", "wurde", "als", "Inkorporationsrate", "von", "L-", "[", "1", "-", "14C", "]", "Leucin", "in", "Gewebeproteine", "ermittelt", ".", "Unterschiede", "innerhalb", "und", "zwischen", "den", "Gruppen", "wurden", "mit", "einer", "zweifaktoriellen", "Varianzanalyse", "und", "Scheffé", "-", "post", "-", "hoc", "-", "Test", "auf", "Signifikanz", "(", "p", "0.05", ")", "geprueft", ".", "Ergebnisse", ":", "Waehrend", "einer", "40minuetigen", "Ischaemie", "in", "vitro", "stieg", "die", "Konzentration", "von", "cGMP", "in", "den", "Gewebescheiben", "signifikant", "an", "(", "Kontrolle", ";", "1,35", "+", "/-", "0,38", "pmol", "/", "mg", "Protein", "vs", ".", "I", "40", ":", "18,6", "+", "/-", "1,04", "pmol", "/", "mg", "Protein", ":", "p", "0.05", ")", ".", "Der", "cGMP", "-", "Anstieg", "waehrend", "der", "Ischaemie", "konnte", "durch", "NNLA", "nahezu", "vollstaendig", "inhibiert", "werden", ".", "Allerdings", "gelang", "es", "nicht", "durch", "NNLA", "den", "Energiestoffwechsel", "oder", "die", "Proteinbiosynthese", "12", "h", "nach", "40minue", "-", "tiger", "Ischaemie", "in", "vitro", "zu", "verbessern", ".", "Schlussfolgerung", ":", "Die", "NO", "-", "Synthase", "wird", "waehrend", "einer", "Ischaemie", "im", "fetalen", "Gehirn", "erheblich", "aktiviert", ".", "Stickstoffmonoxid", "scheint", "dabei", "unabhaengig", "von", "seinen", "Wirkungen", "auf", "das", "Herz", "-", "Kreislauf", "-", "System", "fuer", "die", "Genese", "des", "neuronalen", "Zelltodes", "nach", "einer", "transienten", "Ischaemie", "im", "unreifen", "Gehirn", "keine", "groessere", "Bedeutung", "zu", "haben", "." ]

[ "umlsterm" ]

Arbeit is an umlsterm, Stickstoffmonoxid is an umlsterm, ischaemiebedingten is an umlsterm, Zelltod is an umlsterm, Feten is an umlsterm, Herz - Kreislauf - System is an umlsterm, Gewebeschnittmodell is an umlsterm, Marker is an umlsterm, Energiestoffwechsels is an umlsterm, Proteinbiosynthese is an umlsterm, Methode is an umlsterm, Meerschweinchenfeten is an umlsterm, Halothan is an umlsterm, Gehirns is an umlsterm, Gewebescheiben is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, glukosefreien is an umlsterm, Gewebeschnitte is an umlsterm, NO - Synthase is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gewebekonzentration is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Gewebescheiben is an umlsterm, Konzentration is an umlsterm, HPLC is an umlsterm, Proteinbiosynthese is an umlsterm, Leucin is an umlsterm, Gewebeproteine is an umlsterm, Varianzanalyse is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, Konzentration is an umlsterm, Gewebescheiben is an umlsterm, Protein is an umlsterm, Protein is an umlsterm, Ischaemie is an umlsterm, Energiestoffwechsel is an umlsterm, Proteinbiosynthese is an umlsterm, Ischaemie is an umlsterm, in vitro is an umlsterm, NO - Synthase is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm, Stickstoffmonoxid is an umlsterm, Herz - Kreislauf - System is an umlsterm, Ischaemie is an umlsterm, Gehirn is an umlsterm

PerinatalMedizin.80100016.ger.abstr_task1

Sentence: In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben . Instructions: please typing these entity words according to sentence: Arbeit, Stickstoffmonoxid, ischaemiebedingten, Zelltod, Feten, Herz - Kreislauf - System, Gewebeschnittmodell, Marker, Energiestoffwechsels, Proteinbiosynthese, Methode, Meerschweinchenfeten, Halothan, Gehirns, Gewebescheiben, Ischaemie, in vitro, Gewebescheiben, glukosefreien, Gewebeschnitte, NO - Synthase, NO - Synthase, Ischaemie, Gewebekonzentration, Ischaemie, in vitro, Gewebescheiben, Konzentration, HPLC, Proteinbiosynthese, Leucin, Gewebeproteine, Varianzanalyse, Ischaemie, in vitro, Konzentration, Gewebescheiben, Protein, Protein, Ischaemie, Energiestoffwechsel, Proteinbiosynthese, Ischaemie, in vitro, NO - Synthase, Ischaemie, Gehirn, Stickstoffmonoxid, Herz - Kreislauf - System, Ischaemie, Gehirn Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben .

[ "In", "der", "vorliegenden", "Arbeit", "sollte", "die", "Bedeutung", "von", "Stickstoffmonoxid", "(", "NO", ")", "fuer", "den", "ischaemiebedingten", "neuronalen", "Zelltod", "beim", "Feten", "unabhaengig", "vom", "Herz", "-", "Kreislauf", "-", "System", "untersucht", "werden", ".", "Hierzu", "verwendeten", "wir", "ein", "hippokampales", "Gewebeschnittmodell", ".", "Als", "Marker", "fuer", "den", "neuronalen", "Zellschaden", "waehlten", "wir", "die", "postischaemische", "Beeintraechtigung", "des", "Energiestoffwechsels", "und", "der", "Proteinbiosynthese", ".", "Methode", ":", "Reife", "Meerschweinchenfeten", "wurden", "mit", "Halothan", "narkotisiert", ".", "Das", "Hippokampusareal", "des", "Gehirns", "wurde", "entnommen", "und", "in", "500", "µm", "dicke", "Scheiben", "geschnitten", ".", "Die", "Gewebescheiben", "wurden", "in", "artifizielle", "Liquorfluessigkeit", "(", "aCSF", ")", "transferiert", "und", "mit", "O2", "/", "CO2", "(", "95%/5", "%", ")", "in", "einer", "Inkubationskammer", "begast", ".", "Zur", "Induktion", "der", "Ischaemie", "in", "vitro", "wurden", "die", "Gewebescheiben", "in", "einen", "glukosefreien", "aCSF", "transferiert", "und", "fuer", "10", "-", "40", "min", "mit", "N2", "/", "CO2", "(", "95%/5", "%", ")", "begast", ".", "Bei", "einem", "Teil", "der", "Gewebeschnitte", "wurde", "die", "NO", "-", "Synthase", "mit", "100", "µM", "N", "-", "Nitro", "-", "L", "-", "Arginin", "(", "NNLA", ")", "geblockt", ".", "Die", "Aktivierung", "der", "NO", "-", "Synthase", "waehrend", "der", "Ischaemie", "wurde", "ueber", "die", "Gewebekonzentration", "von", "cGMP", "bestimmt", ".", "cGMP", "wurde", "mit", "einem", "Radioimmunoassay", "gemessen", "12", ";", "h", "nach", "Ischaemie", "in", "vitro", "wurden", "die", "Adenylate", "und", "die", "Proteinbiosyntheses", "in", "den", "Gewebescheiben", "bestimmt", ".", "Die", "Konzentration", "der", "Adenylate", "wurde", "mit", "HPLC", "nach", "Extraktion", "mit", "Perchloressigsaeure", "gemessen", ".", "Die", "Proteinbiosynthese", "wurde", "als", "Inkorporationsrate", "von", "L-", "[", "1", "-", "14C", "]", "Leucin", "in", "Gewebeproteine", "ermittelt", ".", "Unterschiede", "innerhalb", "und", "zwischen", "den", "Gruppen", "wurden", "mit", "einer", "zweifaktoriellen", "Varianzanalyse", "und", "Scheffé", "-", "post", "-", "hoc", "-", "Test", "auf", "Signifikanz", "(", "p", "0.05", ")", "geprueft", ".", "Ergebnisse", ":", "Waehrend", "einer", "40minuetigen", "Ischaemie", "in", "vitro", "stieg", "die", "Konzentration", "von", "cGMP", "in", "den", "Gewebescheiben", "signifikant", "an", "(", "Kontrolle", ";", "1,35", "+", "/-", "0,38", "pmol", "/", "mg", "Protein", "vs", ".", "I", "40", ":", "18,6", "+", "/-", "1,04", "pmol", "/", "mg", "Protein", ":", "p", "0.05", ")", ".", "Der", "cGMP", "-", "Anstieg", "waehrend", "der", "Ischaemie", "konnte", "durch", "NNLA", "nahezu", "vollstaendig", "inhibiert", "werden", ".", "Allerdings", "gelang", "es", "nicht", "durch", "NNLA", "den", "Energiestoffwechsel", "oder", "die", "Proteinbiosynthese", "12", "h", "nach", "40minue", "-", "tiger", "Ischaemie", "in", "vitro", "zu", "verbessern", ".", "Schlussfolgerung", ":", "Die", "NO", "-", "Synthase", "wird", "waehrend", "einer", "Ischaemie", "im", "fetalen", "Gehirn", "erheblich", "aktiviert", ".", "Stickstoffmonoxid", "scheint", "dabei", "unabhaengig", "von", "seinen", "Wirkungen", "auf", "das", "Herz", "-", "Kreislauf", "-", "System", "fuer", "die", "Genese", "des", "neuronalen", "Zelltodes", "nach", "einer", "transienten", "Ischaemie", "im", "unreifen", "Gehirn", "keine", "groessere", "Bedeutung", "zu", "haben", "." ]

[ "umlsterm" ]

Arbeit, Stickstoffmonoxid, ischaemiebedingten, Zelltod, Feten, Herz - Kreislauf - System, Gewebeschnittmodell, Marker, Energiestoffwechsels, Proteinbiosynthese, Methode, Meerschweinchenfeten, Halothan, Gehirns, Gewebescheiben, Ischaemie, in vitro, Gewebescheiben, glukosefreien, Gewebeschnitte, NO - Synthase, NO - Synthase, Ischaemie, Gewebekonzentration, Ischaemie, in vitro, Gewebescheiben, Konzentration, HPLC, Proteinbiosynthese, Leucin, Gewebeproteine, Varianzanalyse, Ischaemie, in vitro, Konzentration, Gewebescheiben, Protein, Protein, Ischaemie, Energiestoffwechsel, Proteinbiosynthese, Ischaemie, in vitro, NO - Synthase, Ischaemie, Gehirn, Stickstoffmonoxid, Herz - Kreislauf - System, Ischaemie, Gehirn

PerinatalMedizin.80100016.ger.abstr_task2

Sentence: In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In der vorliegenden Arbeit sollte die Bedeutung von Stickstoffmonoxid ( NO ) fuer den ischaemiebedingten neuronalen Zelltod beim Feten unabhaengig vom Herz-Kreislauf-System untersucht werden . Hierzu verwendeten wir ein hippokampales Gewebeschnittmodell . Als Marker fuer den neuronalen Zellschaden waehlten wir die postischaemische Beeintraechtigung des Energiestoffwechsels und der Proteinbiosynthese . Methode : Reife Meerschweinchenfeten wurden mit Halothan narkotisiert . Das Hippokampusareal des Gehirns wurde entnommen und in 500 µm dicke Scheiben geschnitten . Die Gewebescheiben wurden in artifizielle Liquorfluessigkeit ( aCSF ) transferiert und mit O2/CO2 ( 95%/5% ) in einer Inkubationskammer begast . Zur Induktion der Ischaemie in vitro wurden die Gewebescheiben in einen glukosefreien aCSF transferiert und fuer 10 - 40 min mit N2/CO2 ( 95%/5% ) begast . Bei einem Teil der Gewebeschnitte wurde die NO-Synthase mit 100 µM N-Nitro-L-Arginin ( NNLA ) geblockt . Die Aktivierung der NO-Synthase waehrend der Ischaemie wurde ueber die Gewebekonzentration von cGMP bestimmt . cGMP wurde mit einem Radioimmunoassay gemessen 12 ; h nach Ischaemie in vitro wurden die Adenylate und die Proteinbiosyntheses in den Gewebescheiben bestimmt . Die Konzentration der Adenylate wurde mit HPLC nach Extraktion mit Perchloressigsaeure gemessen . Die Proteinbiosynthese wurde als Inkorporationsrate von L- [ 1-14C] Leucin in Gewebeproteine ermittelt . Unterschiede innerhalb und zwischen den Gruppen wurden mit einer zweifaktoriellen Varianzanalyse und Scheffé-post-hoc-Test auf Signifikanz ( p 0.05 ) geprueft . Ergebnisse : Waehrend einer 40minuetigen Ischaemie in vitro stieg die Konzentration von cGMP in den Gewebescheiben signifikant an ( Kontrolle ; 1,35 +/- 0,38 pmol/mg Protein vs. I 40 : 18,6 +/- 1,04 pmol/mg Protein : p 0.05 ) . Der cGMP-Anstieg waehrend der Ischaemie konnte durch NNLA nahezu vollstaendig inhibiert werden . Allerdings gelang es nicht durch NNLA den Energiestoffwechsel oder die Proteinbiosynthese 12 h nach 40minue-tiger Ischaemie in vitro zu verbessern . Schlussfolgerung : Die NO-Synthase wird waehrend einer Ischaemie im fetalen Gehirn erheblich aktiviert . Stickstoffmonoxid scheint dabei unabhaengig von seinen Wirkungen auf das Herz-Kreislauf-System fuer die Genese des neuronalen Zelltodes nach einer transienten Ischaemie im unreifen Gehirn keine groessere Bedeutung zu haben .

[ "In", "der", "vorliegenden", "Arbeit", "sollte", "die", "Bedeutung", "von", "Stickstoffmonoxid", "(", "NO", ")", "fuer", "den", "ischaemiebedingten", "neuronalen", "Zelltod", "beim", "Feten", "unabhaengig", "vom", "Herz", "-", "Kreislauf", "-", "System", "untersucht", "werden", ".", "Hierzu", "verwendeten", "wir", "ein", "hippokampales", "Gewebeschnittmodell", ".", "Als", "Marker", "fuer", "den", "neuronalen", "Zellschaden", "waehlten", "wir", "die", "postischaemische", "Beeintraechtigung", "des", "Energiestoffwechsels", "und", "der", "Proteinbiosynthese", ".", "Methode", ":", "Reife", "Meerschweinchenfeten", "wurden", "mit", "Halothan", "narkotisiert", ".", "Das", "Hippokampusareal", "des", "Gehirns", "wurde", "entnommen", "und", "in", "500", "µm", "dicke", "Scheiben", "geschnitten", ".", "Die", "Gewebescheiben", "wurden", "in", "artifizielle", "Liquorfluessigkeit", "(", "aCSF", ")", "transferiert", "und", "mit", "O2", "/", "CO2", "(", "95%/5", "%", ")", "in", "einer", "Inkubationskammer", "begast", ".", "Zur", "Induktion", "der", "Ischaemie", "in", "vitro", "wurden", "die", "Gewebescheiben", "in", "einen", "glukosefreien", "aCSF", "transferiert", "und", "fuer", "10", "-", "40", "min", "mit", "N2", "/", "CO2", "(", "95%/5", "%", ")", "begast", ".", "Bei", "einem", "Teil", "der", "Gewebeschnitte", "wurde", "die", "NO", "-", "Synthase", "mit", "100", "µM", "N", "-", "Nitro", "-", "L", "-", "Arginin", "(", "NNLA", ")", "geblockt", ".", "Die", "Aktivierung", "der", "NO", "-", "Synthase", "waehrend", "der", "Ischaemie", "wurde", "ueber", "die", "Gewebekonzentration", "von", "cGMP", "bestimmt", ".", "cGMP", "wurde", "mit", "einem", "Radioimmunoassay", "gemessen", "12", ";", "h", "nach", "Ischaemie", "in", "vitro", "wurden", "die", "Adenylate", "und", "die", "Proteinbiosyntheses", "in", "den", "Gewebescheiben", "bestimmt", ".", "Die", "Konzentration", "der", "Adenylate", "wurde", "mit", "HPLC", "nach", "Extraktion", "mit", "Perchloressigsaeure", "gemessen", ".", "Die", "Proteinbiosynthese", "wurde", "als", "Inkorporationsrate", "von", "L-", "[", "1", "-", "14C", "]", "Leucin", "in", "Gewebeproteine", "ermittelt", ".", "Unterschiede", "innerhalb", "und", "zwischen", "den", "Gruppen", "wurden", "mit", "einer", "zweifaktoriellen", "Varianzanalyse", "und", "Scheffé", "-", "post", "-", "hoc", "-", "Test", "auf", "Signifikanz", "(", "p", "0.05", ")", "geprueft", ".", "Ergebnisse", ":", "Waehrend", "einer", "40minuetigen", "Ischaemie", "in", "vitro", "stieg", "die", "Konzentration", "von", "cGMP", "in", "den", "Gewebescheiben", "signifikant", "an", "(", "Kontrolle", ";", "1,35", "+", "/-", "0,38", "pmol", "/", "mg", "Protein", "vs", ".", "I", "40", ":", "18,6", "+", "/-", "1,04", "pmol", "/", "mg", "Protein", ":", "p", "0.05", ")", ".", "Der", "cGMP", "-", "Anstieg", "waehrend", "der", "Ischaemie", "konnte", "durch", "NNLA", "nahezu", "vollstaendig", "inhibiert", "werden", ".", "Allerdings", "gelang", "es", "nicht", "durch", "NNLA", "den", "Energiestoffwechsel", "oder", "die", "Proteinbiosynthese", "12", "h", "nach", "40minue", "-", "tiger", "Ischaemie", "in", "vitro", "zu", "verbessern", ".", "Schlussfolgerung", ":", "Die", "NO", "-", "Synthase", "wird", "waehrend", "einer", "Ischaemie", "im", "fetalen", "Gehirn", "erheblich", "aktiviert", ".", "Stickstoffmonoxid", "scheint", "dabei", "unabhaengig", "von", "seinen", "Wirkungen", "auf", "das", "Herz", "-", "Kreislauf", "-", "System", "fuer", "die", "Genese", "des", "neuronalen", "Zelltodes", "nach", "einer", "transienten", "Ischaemie", "im", "unreifen", "Gehirn", "keine", "groessere", "Bedeutung", "zu", "haben", "." ]

[ "umlsterm" ]

Empyemhoehlenrevision is an umlsterm, Drainagetherapie is an umlsterm, Empyeme is an umlsterm, Therapieverfahren is an umlsterm, Thoraxdrainage is an umlsterm, Geschlechtsverteilung is an umlsterm, Drainagegruppe is an umlsterm, Drainagedauer is an umlsterm, Drainage is an umlsterm, Rezidivrate is an umlsterm, Therapieversagern is an umlsterm, Drainagebehandlungen is an umlsterm

DerChirurg.90700464.ger.abstr_task0

Sentence: Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern .

[ "Zusammenfassung", ".", "Im", "fibropurulenten", "Stadium", "des", "Pleuraempyems", "gewinnt", "die", "videoassistierte", "thoracoskopische", "(", "VAT", ")", "Empyemhoehlenrevision", "im", "Sinne", "der", "Fruehdecortication", "an", "Bedeutung", ".", "Dieser", "Zugang", "ist", "bisher", "im", "Vergleich", "zur", "Drainagetherapie", "oder", "Thoracotomie", "nicht", "befriedigend", "evaluiert", ".", "356", "parapneumonische", "Empyeme", "aus", "den", "Jahren", "1986", "bis", "1997", "wurden", "retrospektiv", "im", "Hinblick", "auf", "die", "Ergebnisse", "nach", "den", "verschiedenen", "primaeren", "Therapieverfahren", "(", "225", "Thoraxdrainage", ",", "80", "Thoracotomie", ",", "51", "VAT", ")", "ausgewertet", ".", "Bezueglich", "Geschlechtsverteilung", "und", "Begleiterkrankungen", "waren", "die", "3", "Gruppen", "vergleichbar", ".", "Das", "mediane", "Alter", "der", "Drainagegruppe", "(", "54", "Jahre", ")", "lag", "aber", "hoeher", "als", "bei", "Thoracotomie", "(", "43,5", ")", "oder", "VAT", "(", "39", ")", ".", "Die", "mediane", "Drainagedauer", "nach", "Thoracotomie", "(", "7", "Tage", ")", "war", "kuerzer", "als", "nach", "VAT", "(", "13Tage", "oder", "Drainage", "(", ")", "20", "Tage", ")", "(", "p", "0,0001", ")", ".", "Auch", "bzgl", ".", "Liegedauer", ",", "Rezidivrate", "und", "Therapieversagern", "waren", "die", "jeweils", "invasiveren", "den", "weniger", "invasiven", "Verfahren", "ueberlegen", ".", "Trotz", "der", "besseren", "Ergebnisse", "wird", "die", "Thoracotomie", "beim", "Pleuraempyem", "durch", "die", "VAT", "zurueckgedraengt", "werden", ".", "Die", "Akzeptanz", "der", "VAT", "spiegelt", "sich", "in", "steigenden", "Zuweisungszahlen", "und", "kann", "protrahierte", "Drainagebehandlungen", "vermeiden", ".", "Auf", "der", "Basis", "dieser", "retrospektiven", "Daten", "planen", "wir", "eine", "prospektive", "multizentrische", "Studie", ",", "um", "die", "Indikation", "zur", "VAT", "beim", "Pleuraempyem", "abzusichern", "." ]

[ "umlsterm" ]

Empyemhoehlenrevision is an umlsterm, Drainagetherapie is an umlsterm, Empyeme is an umlsterm, Therapieverfahren is an umlsterm, Thoraxdrainage is an umlsterm, Geschlechtsverteilung is an umlsterm, Drainagegruppe is an umlsterm, Drainagedauer is an umlsterm, Drainage is an umlsterm, Rezidivrate is an umlsterm, Therapieversagern is an umlsterm, Drainagebehandlungen is an umlsterm

DerChirurg.90700464.ger.abstr_task1

Sentence: Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern . Instructions: please typing these entity words according to sentence: Empyemhoehlenrevision, Drainagetherapie, Empyeme, Therapieverfahren, Thoraxdrainage, Geschlechtsverteilung, Drainagegruppe, Drainagedauer, Drainage, Rezidivrate, Therapieversagern, Drainagebehandlungen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern .

[ "Zusammenfassung", ".", "Im", "fibropurulenten", "Stadium", "des", "Pleuraempyems", "gewinnt", "die", "videoassistierte", "thoracoskopische", "(", "VAT", ")", "Empyemhoehlenrevision", "im", "Sinne", "der", "Fruehdecortication", "an", "Bedeutung", ".", "Dieser", "Zugang", "ist", "bisher", "im", "Vergleich", "zur", "Drainagetherapie", "oder", "Thoracotomie", "nicht", "befriedigend", "evaluiert", ".", "356", "parapneumonische", "Empyeme", "aus", "den", "Jahren", "1986", "bis", "1997", "wurden", "retrospektiv", "im", "Hinblick", "auf", "die", "Ergebnisse", "nach", "den", "verschiedenen", "primaeren", "Therapieverfahren", "(", "225", "Thoraxdrainage", ",", "80", "Thoracotomie", ",", "51", "VAT", ")", "ausgewertet", ".", "Bezueglich", "Geschlechtsverteilung", "und", "Begleiterkrankungen", "waren", "die", "3", "Gruppen", "vergleichbar", ".", "Das", "mediane", "Alter", "der", "Drainagegruppe", "(", "54", "Jahre", ")", "lag", "aber", "hoeher", "als", "bei", "Thoracotomie", "(", "43,5", ")", "oder", "VAT", "(", "39", ")", ".", "Die", "mediane", "Drainagedauer", "nach", "Thoracotomie", "(", "7", "Tage", ")", "war", "kuerzer", "als", "nach", "VAT", "(", "13Tage", "oder", "Drainage", "(", ")", "20", "Tage", ")", "(", "p", "0,0001", ")", ".", "Auch", "bzgl", ".", "Liegedauer", ",", "Rezidivrate", "und", "Therapieversagern", "waren", "die", "jeweils", "invasiveren", "den", "weniger", "invasiven", "Verfahren", "ueberlegen", ".", "Trotz", "der", "besseren", "Ergebnisse", "wird", "die", "Thoracotomie", "beim", "Pleuraempyem", "durch", "die", "VAT", "zurueckgedraengt", "werden", ".", "Die", "Akzeptanz", "der", "VAT", "spiegelt", "sich", "in", "steigenden", "Zuweisungszahlen", "und", "kann", "protrahierte", "Drainagebehandlungen", "vermeiden", ".", "Auf", "der", "Basis", "dieser", "retrospektiven", "Daten", "planen", "wir", "eine", "prospektive", "multizentrische", "Studie", ",", "um", "die", "Indikation", "zur", "VAT", "beim", "Pleuraempyem", "abzusichern", "." ]

[ "umlsterm" ]

Empyemhoehlenrevision, Drainagetherapie, Empyeme, Therapieverfahren, Thoraxdrainage, Geschlechtsverteilung, Drainagegruppe, Drainagedauer, Drainage, Rezidivrate, Therapieversagern, Drainagebehandlungen

DerChirurg.90700464.ger.abstr_task2

Sentence: Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Im fibropurulenten Stadium des Pleuraempyems gewinnt die videoassistierte thoracoskopische ( VAT ) Empyemhoehlenrevision im Sinne der Fruehdecortication an Bedeutung . Dieser Zugang ist bisher im Vergleich zur Drainagetherapie oder Thoracotomie nicht befriedigend evaluiert . 356 parapneumonische Empyeme aus den Jahren 1986 bis 1997 wurden retrospektiv im Hinblick auf die Ergebnisse nach den verschiedenen primaeren Therapieverfahren ( 225 Thoraxdrainage , 80 Thoracotomie , 51 VAT ) ausgewertet . Bezueglich Geschlechtsverteilung und Begleiterkrankungen waren die 3 Gruppen vergleichbar . Das mediane Alter der Drainagegruppe ( 54 Jahre ) lag aber hoeher als bei Thoracotomie ( 43,5 ) oder VAT ( 39 ) . Die mediane Drainagedauer nach Thoracotomie ( 7 Tage ) war kuerzer als nach VAT ( 13Tage oder Drainage ( ) 20 Tage ) ( p 0,0001 ) . Auch bzgl. Liegedauer , Rezidivrate und Therapieversagern waren die jeweils invasiveren den weniger invasiven Verfahren ueberlegen . Trotz der besseren Ergebnisse wird die Thoracotomie beim Pleuraempyem durch die VAT zurueckgedraengt werden . Die Akzeptanz der VAT spiegelt sich in steigenden Zuweisungszahlen und kann protrahierte Drainagebehandlungen vermeiden . Auf der Basis dieser retrospektiven Daten planen wir eine prospektive multizentrische Studie , um die Indikation zur VAT beim Pleuraempyem abzusichern .

[ "Zusammenfassung", ".", "Im", "fibropurulenten", "Stadium", "des", "Pleuraempyems", "gewinnt", "die", "videoassistierte", "thoracoskopische", "(", "VAT", ")", "Empyemhoehlenrevision", "im", "Sinne", "der", "Fruehdecortication", "an", "Bedeutung", ".", "Dieser", "Zugang", "ist", "bisher", "im", "Vergleich", "zur", "Drainagetherapie", "oder", "Thoracotomie", "nicht", "befriedigend", "evaluiert", ".", "356", "parapneumonische", "Empyeme", "aus", "den", "Jahren", "1986", "bis", "1997", "wurden", "retrospektiv", "im", "Hinblick", "auf", "die", "Ergebnisse", "nach", "den", "verschiedenen", "primaeren", "Therapieverfahren", "(", "225", "Thoraxdrainage", ",", "80", "Thoracotomie", ",", "51", "VAT", ")", "ausgewertet", ".", "Bezueglich", "Geschlechtsverteilung", "und", "Begleiterkrankungen", "waren", "die", "3", "Gruppen", "vergleichbar", ".", "Das", "mediane", "Alter", "der", "Drainagegruppe", "(", "54", "Jahre", ")", "lag", "aber", "hoeher", "als", "bei", "Thoracotomie", "(", "43,5", ")", "oder", "VAT", "(", "39", ")", ".", "Die", "mediane", "Drainagedauer", "nach", "Thoracotomie", "(", "7", "Tage", ")", "war", "kuerzer", "als", "nach", "VAT", "(", "13Tage", "oder", "Drainage", "(", ")", "20", "Tage", ")", "(", "p", "0,0001", ")", ".", "Auch", "bzgl", ".", "Liegedauer", ",", "Rezidivrate", "und", "Therapieversagern", "waren", "die", "jeweils", "invasiveren", "den", "weniger", "invasiven", "Verfahren", "ueberlegen", ".", "Trotz", "der", "besseren", "Ergebnisse", "wird", "die", "Thoracotomie", "beim", "Pleuraempyem", "durch", "die", "VAT", "zurueckgedraengt", "werden", ".", "Die", "Akzeptanz", "der", "VAT", "spiegelt", "sich", "in", "steigenden", "Zuweisungszahlen", "und", "kann", "protrahierte", "Drainagebehandlungen", "vermeiden", ".", "Auf", "der", "Basis", "dieser", "retrospektiven", "Daten", "planen", "wir", "eine", "prospektive", "multizentrische", "Studie", ",", "um", "die", "Indikation", "zur", "VAT", "beim", "Pleuraempyem", "abzusichern", "." ]

[ "umlsterm" ]

heparin - binding EGF - like growth factor is a GENE-Y, EGF receptor is a GENE-Y, imatinib mesylate is a CHEMICAL

15887238_task0

Sentence: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.

[ "Induction", "of", "heparin", "-", "binding", "EGF", "-", "like", "growth", "factor", "and", "activation", "of", "EGF", "receptor", "in", "imatinib", "mesylate", "-", "treated", "squamous", "carcinoma", "cells", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

heparin - binding EGF - like growth factor is a GENE-Y, EGF receptor is a GENE-Y, imatinib mesylate is a CHEMICAL

15887238_task1

Sentence: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Instructions: please typing these entity words according to sentence: heparin - binding EGF - like growth factor, EGF receptor, imatinib mesylate Options: GENE-Y, CHEMICAL

[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.

[ "Induction", "of", "heparin", "-", "binding", "EGF", "-", "like", "growth", "factor", "and", "activation", "of", "EGF", "receptor", "in", "imatinib", "mesylate", "-", "treated", "squamous", "carcinoma", "cells", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

heparin - binding EGF - like growth factor, EGF receptor, imatinib mesylate

15887238_task2

Sentence: Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.

[ "Induction", "of", "heparin", "-", "binding", "EGF", "-", "like", "growth", "factor", "and", "activation", "of", "EGF", "receptor", "in", "imatinib", "mesylate", "-", "treated", "squamous", "carcinoma", "cells", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Gehirns is an umlsterm, Zeit is an umlsterm, Methoden is an umlsterm, SPECT is an umlsterm, Kontrastmittelapplikationen is an umlsterm, Magnetresonanztomographie is an umlsterm, kontrastmittelunterstuetzten is an umlsterm, Gewebeperfusion is an umlsterm, Mikrozirkulation is an umlsterm, Permeabilitaet is an umlsterm, Blut - Hirn - Schranke is an umlsterm, Nuklearmedizin is an umlsterm, Eigendiffusion is an umlsterm, Wassermolekuelen is an umlsterm, Gewebe is an umlsterm, Techniken is an umlsterm, Natur is an umlsterm, Gewebe is an umlsterm, Stoffwechselvorgaenge is an umlsterm, Strahlenbelastung is an umlsterm, Methoden is an umlsterm, Methoden is an umlsterm, zerebralen Ischaemie is an umlsterm, Schlaganfall is an umlsterm, Gefaessmissbildungen is an umlsterm, Tumordiagnostik is an umlsterm, Therapiefindung is an umlsterm, Therapieplanung is an umlsterm, Methoden is an umlsterm, Demenzen is an umlsterm, Psychosen is an umlsterm

DerRadiologe.00400849.ger.abstr_task0

Sentence: Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen .

[ "Funktionelle", "Untersuchungen", "des", "Gehirns", "waren", "lange", "Zeit", "lediglich", "mit", "nuklearmedizinischen", "Methoden", "wie", "der", "Positronenemissionstomographie", "(", "PET", ")", "und", "der", "Single", "-", "Photonen", "-", "Emission", "-", "Computed", "-", "Tomography", "(", "SPECT", ")", "moeglich", ".", "Durch", "den", "Einsatz", "schneller", "Bildgebungssequenzen", ",", "optimierter", "Kontrastmittelapplikationen", "und", "spezieller", "Nachverarbeitungsmethoden", "wurde", "es", "moeglich", "physiologische", "und", "pathophysiologische", "Prozesse", ",", "mittels", "der", "Magnetresonanztomographie", "(", "MRT", ")", "zu", "beobachten", ".", "Mit", "T1-", "und", "T2", "*", "-gewichteten", "kontrastmittelunterstuetzten", "Bildgebungssequenzen", "koennen", "Informationen", "ueber", "die", "Gewebeperfusion", ",", "Mikrozirkulation", "und", "die", "Permeabilitaet", "der", "Blut", "-", "Hirn", "-", "Schranke", "unter", "Anwendung", "spezieller", "z", ".", ",", "T.", "aus", "der", "Nuklearmedizin", "stammender", "Modelle", "erfasst", "werden", ".", "Die", "Eigendiffusion", "von", "Wassermolekuelen", "im", "Gewebe", "ist", "mit", "diffusionsgewichteter", "MRT", ",", "die", "Markrovaskulatur", ",", "zeitlich", "aufgeloest", ",", "mit", "MR", "-", "angiographischen", "Techniken", "darstellbar", ".", "Auch", "eine", "neuronale", "Aktivitaet", "einfacher", "oder", "komplexer", "Natur", "kann", "mit", "funktionellen", "MR", "-", "Techniken", "visualisiert", "werden", ".", "Mit", "MR", "-", "spektroskopischen", "Untersuchungen", "koennen", "metabolische", "Verteilungen", "in", "normalem", "und", "pathologischem", "Gewebe", "mehrdimensional", "erfasst", "und", "Stoffwechselvorgaenge", "im", "Verlauf", "beobachtet", "werden", ".", "Vorteile", "der", "MRT", "ist", "die", "geringe", "Invasivitaet", ",", "die", "Moeglichkeit", "einer", "dreidimensionalen", "Darstellung", "der", "Daten", "und", "eine", "beliebige", "Wiederholbarkeit", "der", "Untersuchung", "bei", "fehlender", "Strahlenbelastung", ".", "Die", "bereits", "klinisch", "einsetzbaren", "funktionellen", "Methoden", "werden", "beschrieben", "und", "ihr", "Einsatz", "in", "der", "Neuroradiologie", "auch", "in", "Bezug", "auf", "die", "Wertigkeit", "im", "Vergleich", "zu", "nuklearmedizinischen", "Methoden", "diskutiert", ".", "Perfusions-", "und", "Diffusions", "-", "MRT", "liefern", "wichtige", "Zusatzinformationen", "im", "akuten", "und", "chronischen", "Stadium", "der", "zerebralen", "Ischaemie", "und", "werden", "bereits", "routinemaessig", "bei", "akutem", "Schlaganfall", "eingesetzt", ".", "Dynamische", "MR", "-", "Angiographien", "erlauben", "eine", "haemodynamische", "Einstufung", "von", "Gefaessmissbildungen", ".", "In", "der", "Tumordiagnostik", "liefern", "die", "funktionellen", "MR", "-", "Techniken", "wichtige", "Zusatzinformationen", "fuer", "die", "Therapiefindung", ",", "Therapieplanung", "und", "das", "Therapiemonitoring", ".", "Die", "Untersuchung", "psychiatrischen", "Erkrankungen", "wurde", "durch", "die", "funktionelle", "MRT", "revolutioniert", ",", "obwohl", "der", "klinische", "Einsatz", "noch", "limitiert", "ist", ".", "Erste", "Untersuchungen", "konnten", "zeigen", ",", "dass", "die", "Methoden", "in", "der", "Lage", "sind", ",", "pathophysiologische", "Veraenderungen", "bei", "Demenzen", "und", "Psychosen", "sensitiv", "zu", "erfassen", "." ]

[ "umlsterm" ]

Gehirns is an umlsterm, Zeit is an umlsterm, Methoden is an umlsterm, SPECT is an umlsterm, Kontrastmittelapplikationen is an umlsterm, Magnetresonanztomographie is an umlsterm, kontrastmittelunterstuetzten is an umlsterm, Gewebeperfusion is an umlsterm, Mikrozirkulation is an umlsterm, Permeabilitaet is an umlsterm, Blut - Hirn - Schranke is an umlsterm, Nuklearmedizin is an umlsterm, Eigendiffusion is an umlsterm, Wassermolekuelen is an umlsterm, Gewebe is an umlsterm, Techniken is an umlsterm, Natur is an umlsterm, Gewebe is an umlsterm, Stoffwechselvorgaenge is an umlsterm, Strahlenbelastung is an umlsterm, Methoden is an umlsterm, Methoden is an umlsterm, zerebralen Ischaemie is an umlsterm, Schlaganfall is an umlsterm, Gefaessmissbildungen is an umlsterm, Tumordiagnostik is an umlsterm, Therapiefindung is an umlsterm, Therapieplanung is an umlsterm, Methoden is an umlsterm, Demenzen is an umlsterm, Psychosen is an umlsterm

DerRadiologe.00400849.ger.abstr_task1

Sentence: Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen . Instructions: please typing these entity words according to sentence: Gehirns, Zeit, Methoden, SPECT, Kontrastmittelapplikationen, Magnetresonanztomographie, kontrastmittelunterstuetzten, Gewebeperfusion, Mikrozirkulation, Permeabilitaet, Blut - Hirn - Schranke, Nuklearmedizin, Eigendiffusion, Wassermolekuelen, Gewebe, Techniken, Natur, Gewebe, Stoffwechselvorgaenge, Strahlenbelastung, Methoden, Methoden, zerebralen Ischaemie, Schlaganfall, Gefaessmissbildungen, Tumordiagnostik, Therapiefindung, Therapieplanung, Methoden, Demenzen, Psychosen Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen .

[ "Funktionelle", "Untersuchungen", "des", "Gehirns", "waren", "lange", "Zeit", "lediglich", "mit", "nuklearmedizinischen", "Methoden", "wie", "der", "Positronenemissionstomographie", "(", "PET", ")", "und", "der", "Single", "-", "Photonen", "-", "Emission", "-", "Computed", "-", "Tomography", "(", "SPECT", ")", "moeglich", ".", "Durch", "den", "Einsatz", "schneller", "Bildgebungssequenzen", ",", "optimierter", "Kontrastmittelapplikationen", "und", "spezieller", "Nachverarbeitungsmethoden", "wurde", "es", "moeglich", "physiologische", "und", "pathophysiologische", "Prozesse", ",", "mittels", "der", "Magnetresonanztomographie", "(", "MRT", ")", "zu", "beobachten", ".", "Mit", "T1-", "und", "T2", "*", "-gewichteten", "kontrastmittelunterstuetzten", "Bildgebungssequenzen", "koennen", "Informationen", "ueber", "die", "Gewebeperfusion", ",", "Mikrozirkulation", "und", "die", "Permeabilitaet", "der", "Blut", "-", "Hirn", "-", "Schranke", "unter", "Anwendung", "spezieller", "z", ".", ",", "T.", "aus", "der", "Nuklearmedizin", "stammender", "Modelle", "erfasst", "werden", ".", "Die", "Eigendiffusion", "von", "Wassermolekuelen", "im", "Gewebe", "ist", "mit", "diffusionsgewichteter", "MRT", ",", "die", "Markrovaskulatur", ",", "zeitlich", "aufgeloest", ",", "mit", "MR", "-", "angiographischen", "Techniken", "darstellbar", ".", "Auch", "eine", "neuronale", "Aktivitaet", "einfacher", "oder", "komplexer", "Natur", "kann", "mit", "funktionellen", "MR", "-", "Techniken", "visualisiert", "werden", ".", "Mit", "MR", "-", "spektroskopischen", "Untersuchungen", "koennen", "metabolische", "Verteilungen", "in", "normalem", "und", "pathologischem", "Gewebe", "mehrdimensional", "erfasst", "und", "Stoffwechselvorgaenge", "im", "Verlauf", "beobachtet", "werden", ".", "Vorteile", "der", "MRT", "ist", "die", "geringe", "Invasivitaet", ",", "die", "Moeglichkeit", "einer", "dreidimensionalen", "Darstellung", "der", "Daten", "und", "eine", "beliebige", "Wiederholbarkeit", "der", "Untersuchung", "bei", "fehlender", "Strahlenbelastung", ".", "Die", "bereits", "klinisch", "einsetzbaren", "funktionellen", "Methoden", "werden", "beschrieben", "und", "ihr", "Einsatz", "in", "der", "Neuroradiologie", "auch", "in", "Bezug", "auf", "die", "Wertigkeit", "im", "Vergleich", "zu", "nuklearmedizinischen", "Methoden", "diskutiert", ".", "Perfusions-", "und", "Diffusions", "-", "MRT", "liefern", "wichtige", "Zusatzinformationen", "im", "akuten", "und", "chronischen", "Stadium", "der", "zerebralen", "Ischaemie", "und", "werden", "bereits", "routinemaessig", "bei", "akutem", "Schlaganfall", "eingesetzt", ".", "Dynamische", "MR", "-", "Angiographien", "erlauben", "eine", "haemodynamische", "Einstufung", "von", "Gefaessmissbildungen", ".", "In", "der", "Tumordiagnostik", "liefern", "die", "funktionellen", "MR", "-", "Techniken", "wichtige", "Zusatzinformationen", "fuer", "die", "Therapiefindung", ",", "Therapieplanung", "und", "das", "Therapiemonitoring", ".", "Die", "Untersuchung", "psychiatrischen", "Erkrankungen", "wurde", "durch", "die", "funktionelle", "MRT", "revolutioniert", ",", "obwohl", "der", "klinische", "Einsatz", "noch", "limitiert", "ist", ".", "Erste", "Untersuchungen", "konnten", "zeigen", ",", "dass", "die", "Methoden", "in", "der", "Lage", "sind", ",", "pathophysiologische", "Veraenderungen", "bei", "Demenzen", "und", "Psychosen", "sensitiv", "zu", "erfassen", "." ]

[ "umlsterm" ]

Gehirns, Zeit, Methoden, SPECT, Kontrastmittelapplikationen, Magnetresonanztomographie, kontrastmittelunterstuetzten, Gewebeperfusion, Mikrozirkulation, Permeabilitaet, Blut - Hirn - Schranke, Nuklearmedizin, Eigendiffusion, Wassermolekuelen, Gewebe, Techniken, Natur, Gewebe, Stoffwechselvorgaenge, Strahlenbelastung, Methoden, Methoden, zerebralen Ischaemie, Schlaganfall, Gefaessmissbildungen, Tumordiagnostik, Therapiefindung, Therapieplanung, Methoden, Demenzen, Psychosen

DerRadiologe.00400849.ger.abstr_task2

Sentence: Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Funktionelle Untersuchungen des Gehirns waren lange Zeit lediglich mit nuklearmedizinischen Methoden wie der Positronenemissionstomographie ( PET ) und der Single-Photonen-Emission-Computed-Tomography ( SPECT ) moeglich . Durch den Einsatz schneller Bildgebungssequenzen , optimierter Kontrastmittelapplikationen und spezieller Nachverarbeitungsmethoden wurde es moeglich physiologische und pathophysiologische Prozesse , mittels der Magnetresonanztomographie ( MRT ) zu beobachten . Mit T1- und T2*-gewichteten kontrastmittelunterstuetzten Bildgebungssequenzen koennen Informationen ueber die Gewebeperfusion , Mikrozirkulation und die Permeabilitaet der Blut-Hirn-Schranke unter Anwendung spezieller z . , T. aus der Nuklearmedizin stammender Modelle erfasst werden . Die Eigendiffusion von Wassermolekuelen im Gewebe ist mit diffusionsgewichteter MRT , die Markrovaskulatur , zeitlich aufgeloest , mit MR-angiographischen Techniken darstellbar . Auch eine neuronale Aktivitaet einfacher oder komplexer Natur kann mit funktionellen MR-Techniken visualisiert werden . Mit MR-spektroskopischen Untersuchungen koennen metabolische Verteilungen in normalem und pathologischem Gewebe mehrdimensional erfasst und Stoffwechselvorgaenge im Verlauf beobachtet werden . Vorteile der MRT ist die geringe Invasivitaet , die Moeglichkeit einer dreidimensionalen Darstellung der Daten und eine beliebige Wiederholbarkeit der Untersuchung bei fehlender Strahlenbelastung . Die bereits klinisch einsetzbaren funktionellen Methoden werden beschrieben und ihr Einsatz in der Neuroradiologie auch in Bezug auf die Wertigkeit im Vergleich zu nuklearmedizinischen Methoden diskutiert . Perfusions- und Diffusions-MRT liefern wichtige Zusatzinformationen im akuten und chronischen Stadium der zerebralen Ischaemie und werden bereits routinemaessig bei akutem Schlaganfall eingesetzt . Dynamische MR-Angiographien erlauben eine haemodynamische Einstufung von Gefaessmissbildungen . In der Tumordiagnostik liefern die funktionellen MR-Techniken wichtige Zusatzinformationen fuer die Therapiefindung , Therapieplanung und das Therapiemonitoring . Die Untersuchung psychiatrischen Erkrankungen wurde durch die funktionelle MRT revolutioniert , obwohl der klinische Einsatz noch limitiert ist . Erste Untersuchungen konnten zeigen , dass die Methoden in der Lage sind , pathophysiologische Veraenderungen bei Demenzen und Psychosen sensitiv zu erfassen .

[ "Funktionelle", "Untersuchungen", "des", "Gehirns", "waren", "lange", "Zeit", "lediglich", "mit", "nuklearmedizinischen", "Methoden", "wie", "der", "Positronenemissionstomographie", "(", "PET", ")", "und", "der", "Single", "-", "Photonen", "-", "Emission", "-", "Computed", "-", "Tomography", "(", "SPECT", ")", "moeglich", ".", "Durch", "den", "Einsatz", "schneller", "Bildgebungssequenzen", ",", "optimierter", "Kontrastmittelapplikationen", "und", "spezieller", "Nachverarbeitungsmethoden", "wurde", "es", "moeglich", "physiologische", "und", "pathophysiologische", "Prozesse", ",", "mittels", "der", "Magnetresonanztomographie", "(", "MRT", ")", "zu", "beobachten", ".", "Mit", "T1-", "und", "T2", "*", "-gewichteten", "kontrastmittelunterstuetzten", "Bildgebungssequenzen", "koennen", "Informationen", "ueber", "die", "Gewebeperfusion", ",", "Mikrozirkulation", "und", "die", "Permeabilitaet", "der", "Blut", "-", "Hirn", "-", "Schranke", "unter", "Anwendung", "spezieller", "z", ".", ",", "T.", "aus", "der", "Nuklearmedizin", "stammender", "Modelle", "erfasst", "werden", ".", "Die", "Eigendiffusion", "von", "Wassermolekuelen", "im", "Gewebe", "ist", "mit", "diffusionsgewichteter", "MRT", ",", "die", "Markrovaskulatur", ",", "zeitlich", "aufgeloest", ",", "mit", "MR", "-", "angiographischen", "Techniken", "darstellbar", ".", "Auch", "eine", "neuronale", "Aktivitaet", "einfacher", "oder", "komplexer", "Natur", "kann", "mit", "funktionellen", "MR", "-", "Techniken", "visualisiert", "werden", ".", "Mit", "MR", "-", "spektroskopischen", "Untersuchungen", "koennen", "metabolische", "Verteilungen", "in", "normalem", "und", "pathologischem", "Gewebe", "mehrdimensional", "erfasst", "und", "Stoffwechselvorgaenge", "im", "Verlauf", "beobachtet", "werden", ".", "Vorteile", "der", "MRT", "ist", "die", "geringe", "Invasivitaet", ",", "die", "Moeglichkeit", "einer", "dreidimensionalen", "Darstellung", "der", "Daten", "und", "eine", "beliebige", "Wiederholbarkeit", "der", "Untersuchung", "bei", "fehlender", "Strahlenbelastung", ".", "Die", "bereits", "klinisch", "einsetzbaren", "funktionellen", "Methoden", "werden", "beschrieben", "und", "ihr", "Einsatz", "in", "der", "Neuroradiologie", "auch", "in", "Bezug", "auf", "die", "Wertigkeit", "im", "Vergleich", "zu", "nuklearmedizinischen", "Methoden", "diskutiert", ".", "Perfusions-", "und", "Diffusions", "-", "MRT", "liefern", "wichtige", "Zusatzinformationen", "im", "akuten", "und", "chronischen", "Stadium", "der", "zerebralen", "Ischaemie", "und", "werden", "bereits", "routinemaessig", "bei", "akutem", "Schlaganfall", "eingesetzt", ".", "Dynamische", "MR", "-", "Angiographien", "erlauben", "eine", "haemodynamische", "Einstufung", "von", "Gefaessmissbildungen", ".", "In", "der", "Tumordiagnostik", "liefern", "die", "funktionellen", "MR", "-", "Techniken", "wichtige", "Zusatzinformationen", "fuer", "die", "Therapiefindung", ",", "Therapieplanung", "und", "das", "Therapiemonitoring", ".", "Die", "Untersuchung", "psychiatrischen", "Erkrankungen", "wurde", "durch", "die", "funktionelle", "MRT", "revolutioniert", ",", "obwohl", "der", "klinische", "Einsatz", "noch", "limitiert", "ist", ".", "Erste", "Untersuchungen", "konnten", "zeigen", ",", "dass", "die", "Methoden", "in", "der", "Lage", "sind", ",", "pathophysiologische", "Veraenderungen", "bei", "Demenzen", "und", "Psychosen", "sensitiv", "zu", "erfassen", "." ]

[ "umlsterm" ]

ProTon is an umlsterm, Tiermodell is an umlsterm

DerOpthalmologe.00970788.ger.abstr_task0

Sentence: Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell .

[ "Fragestellung", ".", "Untersuchung", "des", "lageunabhaengigen", "Applanationstonometers", "ProTon", "im", "Tiermodell", "." ]

[ "umlsterm" ]

ProTon is an umlsterm, Tiermodell is an umlsterm

DerOpthalmologe.00970788.ger.abstr_task1

Sentence: Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell . Instructions: please typing these entity words according to sentence: ProTon, Tiermodell Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell .

[ "Fragestellung", ".", "Untersuchung", "des", "lageunabhaengigen", "Applanationstonometers", "ProTon", "im", "Tiermodell", "." ]

[ "umlsterm" ]

ProTon, Tiermodell

DerOpthalmologe.00970788.ger.abstr_task2

Sentence: Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Fragestellung . Untersuchung des lageunabhaengigen Applanationstonometers ProTon im Tiermodell .

[ "Fragestellung", ".", "Untersuchung", "des", "lageunabhaengigen", "Applanationstonometers", "ProTon", "im", "Tiermodell", "." ]

[ "umlsterm" ]

18 55 years is a Value, age is a Person, History is a Observation, good health is a Condition, Medical Assessment is a Procedure, Medical History is a Observation, Physical Examination is a Procedure, Vital Signs is a Measurement, EKG is a Procedure, oral HIV test is a Procedure, height is a Measurement, urinalysis is a Procedure, blood sample is a Procedure, CBC is a Procedure, complete metabolic profile is a Procedure, TSH is a Procedure, ESR is a Procedure, STS is a Procedure, HIV is a Procedure, positive is a Value, salivary test for HIV is a Measurement, disqualify is a Negation, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 + is a Scope, Serum glucose over 140 mg / dl is a Scope, fasting serum glucose assessment is a Procedure, Right - handed is a Condition, Edinburgh Handedness Inventory is a Procedure, Estimated IQ is a Measurement, greater than or equal to 85 is a Value, Wechsler Abbreviated Scale of Intelligence is a Procedure

NCT02231892_inc_task0

Sentence: Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Observation, Procedure, Negation, Scope, Measurement

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Measurement", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O" ]

Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence.

[ "Subjects", "must", ":", "\n", "1", ".", "Be", "able", "to", "give", "valid", "informed", "consent", "\n", "2", ".", "Be", "18", "55", "years", "of", "age", ".", "\n", "1", ".", "Justification", ":", "Many", "neural", "processes", "change", "with", "age", ",", "and", "these", "changes", "could", "introduce", "unwanted", "variability", "in", "both", "behavioral", "and", "MRI", "signals", ".", "In", "addition", ",", "the", "risk", "of", "difficult", "-", "to", "-", "detect", "medical", "abnormalities", "such", "as", "silent", "cerebral", "infarcts", "increases", "with", "age", ".", "\n", "2", ".", "Screening", "tool", ":", "History", ".", "Government", "-", "issued", "forms", "of", "identification", "(", "e.g", ".", "driver", "s", "license", ",", "birth", "certificate", ")", "will", "be", "required", "when", "participant", "appears", "to", "be", "out", "of", "age", "range", ".", "\n", "3", ".", "Be", "in", "good", "health", ".", "\n", "1", ".", "Justification", ":", "Many", "illnesses", "may", "alter", "neural", "functioning", "as", "well", "as", "fMRI", "signals", ".", "\n", "2", ".", "Screening", "tools", ":", "Medical", "Assessment", ",", "Medical", "History", "and", "Physical", "Examination", ".", "Medical", "assessments", "include", ":", "Vital", "Signs", ",", "EKG", ",", "oral", "HIV", "test", ",", "height", "/", "weight", "measurements", ",", "urinalysis", "and", "blood", "sample", ".", "Tests", "on", "the", "blood", "sample", "include", "CBC", ",", "complete", "metabolic", "profile", ",", "TSH", ",", "ESR", ",", "STS", "and", "HIV", "(", "if", "needed", "to", "confirm", "a", "positive", "salivary", "test", "for", "HIV", ")", ".", "The", "following", "individual", "laboratory", "results", "will", "independently", "disqualify", "individuals", ":", "Cholesterol", ">", "250", "mg", "/", "dl", ",", "Hemoglobin", "<", "10.5", "g", "/", "dl", ",", "WBC", "<", "2400", "/", "microl", ",", "LFTs", ">", "3Xnormal", ",", "HCG", "positive", ",", "Casual", "serum", "glucose", ">", "200", "mg", "/", "dl", ",", "Urine", "protein", ">", "1", "+", ".", "The", "MAI", "will", "retain", "discretion", "to", "exclude", "at", "less", "extreme", "values", ",", "depending", "on", "the", "clinical", "presentation", ".", "(", "Serum", "glucose", "over", "140", "mg", "/", "dl", "will", "be", "followed", "up", "with", "a", "fasting", "serum", "glucose", "assessment", ".", "Those", "with", "fasting", "glucose", "below", "100", "mg", "/", "dl", "may", "be", "considered", "for", "the", "protocol", ".", "Others", "will", "be", "rejected", "and", "referred", "for", "work", "-", "up", ".", ")", "MAI", "will", "make", "the", "final", "judgment", "on", "any", "questionable", "lab", "results", ".", "\n", "4", ".", "Right", "-", "handed", ".", "\n", "1", ".", "Justification", ":", "Using", "right", "-", "handed", "individuals", "will", "reduce", "variability", "in", "BOLD", "MRI", "data", ".", "\n", "2", ".", "Screening", "tool", ":", "Edinburgh", "Handedness", "Inventory", ".", "\n", "5", ".", "Estimated", "IQ", "greater", "than", "or", "equal", "to", "85", "\n", "1", ".", "Justification", ":", "Subjects", "must", "be", "able", "to", "perform", "a", "cognitively", "challenging", "task", "to", "a", "high", "standard", ".", "\n", "2", ".", "Screening", "tool", ":", "Wechsler", "Abbreviated", "Scale", "of", "Intelligence", ".", "\n" ]

[ "Scope", "Procedure", "Value", "Measurement", "Observation", "Condition", "Negation", "Person" ]

18 55 years is a Value, age is a Person, History is a Observation, good health is a Condition, Medical Assessment is a Procedure, Medical History is a Observation, Physical Examination is a Procedure, Vital Signs is a Measurement, EKG is a Procedure, oral HIV test is a Procedure, height is a Measurement, urinalysis is a Procedure, blood sample is a Procedure, CBC is a Procedure, complete metabolic profile is a Procedure, TSH is a Procedure, ESR is a Procedure, STS is a Procedure, HIV is a Procedure, positive is a Value, salivary test for HIV is a Measurement, disqualify is a Negation, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 + is a Scope, Serum glucose over 140 mg / dl is a Scope, fasting serum glucose assessment is a Procedure, Right - handed is a Condition, Edinburgh Handedness Inventory is a Procedure, Estimated IQ is a Measurement, greater than or equal to 85 is a Value, Wechsler Abbreviated Scale of Intelligence is a Procedure

NCT02231892_inc_task1

Sentence: Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence. Instructions: please typing these entity words according to sentence: 18 55 years, age, History, good health, Medical Assessment, Medical History, Physical Examination, Vital Signs, EKG, oral HIV test, height, urinalysis, blood sample, CBC, complete metabolic profile, TSH, ESR, STS, HIV, positive, salivary test for HIV, disqualify, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 +, Serum glucose over 140 mg / dl, fasting serum glucose assessment, Right - handed, Edinburgh Handedness Inventory, Estimated IQ, greater than or equal to 85, Wechsler Abbreviated Scale of Intelligence Options: Condition, Value, Person, Observation, Procedure, Negation, Scope, Measurement

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Measurement", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O" ]

Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence.

[ "Subjects", "must", ":", "\n", "1", ".", "Be", "able", "to", "give", "valid", "informed", "consent", "\n", "2", ".", "Be", "18", "55", "years", "of", "age", ".", "\n", "1", ".", "Justification", ":", "Many", "neural", "processes", "change", "with", "age", ",", "and", "these", "changes", "could", "introduce", "unwanted", "variability", "in", "both", "behavioral", "and", "MRI", "signals", ".", "In", "addition", ",", "the", "risk", "of", "difficult", "-", "to", "-", "detect", "medical", "abnormalities", "such", "as", "silent", "cerebral", "infarcts", "increases", "with", "age", ".", "\n", "2", ".", "Screening", "tool", ":", "History", ".", "Government", "-", "issued", "forms", "of", "identification", "(", "e.g", ".", "driver", "s", "license", ",", "birth", "certificate", ")", "will", "be", "required", "when", "participant", "appears", "to", "be", "out", "of", "age", "range", ".", "\n", "3", ".", "Be", "in", "good", "health", ".", "\n", "1", ".", "Justification", ":", "Many", "illnesses", "may", "alter", "neural", "functioning", "as", "well", "as", "fMRI", "signals", ".", "\n", "2", ".", "Screening", "tools", ":", "Medical", "Assessment", ",", "Medical", "History", "and", "Physical", "Examination", ".", "Medical", "assessments", "include", ":", "Vital", "Signs", ",", "EKG", ",", "oral", "HIV", "test", ",", "height", "/", "weight", "measurements", ",", "urinalysis", "and", "blood", "sample", ".", "Tests", "on", "the", "blood", "sample", "include", "CBC", ",", "complete", "metabolic", "profile", ",", "TSH", ",", "ESR", ",", "STS", "and", "HIV", "(", "if", "needed", "to", "confirm", "a", "positive", "salivary", "test", "for", "HIV", ")", ".", "The", "following", "individual", "laboratory", "results", "will", "independently", "disqualify", "individuals", ":", "Cholesterol", ">", "250", "mg", "/", "dl", ",", "Hemoglobin", "<", "10.5", "g", "/", "dl", ",", "WBC", "<", "2400", "/", "microl", ",", "LFTs", ">", "3Xnormal", ",", "HCG", "positive", ",", "Casual", "serum", "glucose", ">", "200", "mg", "/", "dl", ",", "Urine", "protein", ">", "1", "+", ".", "The", "MAI", "will", "retain", "discretion", "to", "exclude", "at", "less", "extreme", "values", ",", "depending", "on", "the", "clinical", "presentation", ".", "(", "Serum", "glucose", "over", "140", "mg", "/", "dl", "will", "be", "followed", "up", "with", "a", "fasting", "serum", "glucose", "assessment", ".", "Those", "with", "fasting", "glucose", "below", "100", "mg", "/", "dl", "may", "be", "considered", "for", "the", "protocol", ".", "Others", "will", "be", "rejected", "and", "referred", "for", "work", "-", "up", ".", ")", "MAI", "will", "make", "the", "final", "judgment", "on", "any", "questionable", "lab", "results", ".", "\n", "4", ".", "Right", "-", "handed", ".", "\n", "1", ".", "Justification", ":", "Using", "right", "-", "handed", "individuals", "will", "reduce", "variability", "in", "BOLD", "MRI", "data", ".", "\n", "2", ".", "Screening", "tool", ":", "Edinburgh", "Handedness", "Inventory", ".", "\n", "5", ".", "Estimated", "IQ", "greater", "than", "or", "equal", "to", "85", "\n", "1", ".", "Justification", ":", "Subjects", "must", "be", "able", "to", "perform", "a", "cognitively", "challenging", "task", "to", "a", "high", "standard", ".", "\n", "2", ".", "Screening", "tool", ":", "Wechsler", "Abbreviated", "Scale", "of", "Intelligence", ".", "\n" ]

[ "Scope", "Procedure", "Value", "Measurement", "Observation", "Condition", "Negation", "Person" ]

18 55 years, age, History, good health, Medical Assessment, Medical History, Physical Examination, Vital Signs, EKG, oral HIV test, height, urinalysis, blood sample, CBC, complete metabolic profile, TSH, ESR, STS, HIV, positive, salivary test for HIV, disqualify, Cholesterol > 250 mg / dl , Hemoglobin < 10.5 g / dl , WBC < 2400 / microl , LFTs > 3Xnormal , HCG positive , Casual serum glucose > 200 mg / dl , Urine protein > 1 +, Serum glucose over 140 mg / dl, fasting serum glucose assessment, Right - handed, Edinburgh Handedness Inventory, Estimated IQ, greater than or equal to 85, Wechsler Abbreviated Scale of Intelligence

NCT02231892_inc_task2

Sentence: Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Observation", "I-Observation", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Measurement", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "B-Procedure", "O", "O", "O", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O" ]

Subjects must: 1. Be able to give valid informed consent 2. Be 18 55 years of age. 1. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals. In addition, the risk of difficult-to-detect medical abnormalities such as silent cerebral infarcts increases with age. 2. Screening tool: History. Government-issued forms of identification (e.g. driver s license, birth certificate) will be required when participant appears to be out of age range. 3. Be in good health. 1. Justification: Many illnesses may alter neural functioning as well as fMRI signals. 2. Screening tools: Medical Assessment, Medical History and Physical Examination. Medical assessments include: Vital Signs, EKG, oral HIV test, height/weight measurements, urinalysis and blood sample. Tests on the blood sample include CBC, complete metabolic profile, TSH, ESR, STS and HIV (if needed to confirm a positive salivary test for HIV). The following individual laboratory results will independently disqualify individuals: Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl, WBC < 2400/microl, LFTs > 3Xnormal, HCG positive, Casual serum glucose > 200 mg/dl, Urine protein > 1+. The MAI will retain discretion to exclude at less extreme values, depending on the clinical presentation. (Serum glucose over 140 mg/dl will be followed up with a fasting serum glucose assessment. Those with fasting glucose below 100 mg/dl may be considered for the protocol. Others will be rejected and referred for work-up.) MAI will make the final judgment on any questionable lab results. 4. Right-handed. 1. Justification: Using right-handed individuals will reduce variability in BOLD MRI data. 2. Screening tool: Edinburgh Handedness Inventory. 5. Estimated IQ greater than or equal to 85 1. Justification: Subjects must be able to perform a cognitively challenging task to a high standard. 2. Screening tool: Wechsler Abbreviated Scale of Intelligence.

[ "Subjects", "must", ":", "\n", "1", ".", "Be", "able", "to", "give", "valid", "informed", "consent", "\n", "2", ".", "Be", "18", "55", "years", "of", "age", ".", "\n", "1", ".", "Justification", ":", "Many", "neural", "processes", "change", "with", "age", ",", "and", "these", "changes", "could", "introduce", "unwanted", "variability", "in", "both", "behavioral", "and", "MRI", "signals", ".", "In", "addition", ",", "the", "risk", "of", "difficult", "-", "to", "-", "detect", "medical", "abnormalities", "such", "as", "silent", "cerebral", "infarcts", "increases", "with", "age", ".", "\n", "2", ".", "Screening", "tool", ":", "History", ".", "Government", "-", "issued", "forms", "of", "identification", "(", "e.g", ".", "driver", "s", "license", ",", "birth", "certificate", ")", "will", "be", "required", "when", "participant", "appears", "to", "be", "out", "of", "age", "range", ".", "\n", "3", ".", "Be", "in", "good", "health", ".", "\n", "1", ".", "Justification", ":", "Many", "illnesses", "may", "alter", "neural", "functioning", "as", "well", "as", "fMRI", "signals", ".", "\n", "2", ".", "Screening", "tools", ":", "Medical", "Assessment", ",", "Medical", "History", "and", "Physical", "Examination", ".", "Medical", "assessments", "include", ":", "Vital", "Signs", ",", "EKG", ",", "oral", "HIV", "test", ",", "height", "/", "weight", "measurements", ",", "urinalysis", "and", "blood", "sample", ".", "Tests", "on", "the", "blood", "sample", "include", "CBC", ",", "complete", "metabolic", "profile", ",", "TSH", ",", "ESR", ",", "STS", "and", "HIV", "(", "if", "needed", "to", "confirm", "a", "positive", "salivary", "test", "for", "HIV", ")", ".", "The", "following", "individual", "laboratory", "results", "will", "independently", "disqualify", "individuals", ":", "Cholesterol", ">", "250", "mg", "/", "dl", ",", "Hemoglobin", "<", "10.5", "g", "/", "dl", ",", "WBC", "<", "2400", "/", "microl", ",", "LFTs", ">", "3Xnormal", ",", "HCG", "positive", ",", "Casual", "serum", "glucose", ">", "200", "mg", "/", "dl", ",", "Urine", "protein", ">", "1", "+", ".", "The", "MAI", "will", "retain", "discretion", "to", "exclude", "at", "less", "extreme", "values", ",", "depending", "on", "the", "clinical", "presentation", ".", "(", "Serum", "glucose", "over", "140", "mg", "/", "dl", "will", "be", "followed", "up", "with", "a", "fasting", "serum", "glucose", "assessment", ".", "Those", "with", "fasting", "glucose", "below", "100", "mg", "/", "dl", "may", "be", "considered", "for", "the", "protocol", ".", "Others", "will", "be", "rejected", "and", "referred", "for", "work", "-", "up", ".", ")", "MAI", "will", "make", "the", "final", "judgment", "on", "any", "questionable", "lab", "results", ".", "\n", "4", ".", "Right", "-", "handed", ".", "\n", "1", ".", "Justification", ":", "Using", "right", "-", "handed", "individuals", "will", "reduce", "variability", "in", "BOLD", "MRI", "data", ".", "\n", "2", ".", "Screening", "tool", ":", "Edinburgh", "Handedness", "Inventory", ".", "\n", "5", ".", "Estimated", "IQ", "greater", "than", "or", "equal", "to", "85", "\n", "1", ".", "Justification", ":", "Subjects", "must", "be", "able", "to", "perform", "a", "cognitively", "challenging", "task", "to", "a", "high", "standard", ".", "\n", "2", ".", "Screening", "tool", ":", "Wechsler", "Abbreviated", "Scale", "of", "Intelligence", ".", "\n" ]

[ "Scope", "Procedure", "Value", "Measurement", "Observation", "Condition", "Negation", "Person" ]

survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, Survivin is a Gene_or_gene_product, p53 is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, pRB is a Gene_or_gene_product, p130 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, E2F3 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product

128_task0

Sentence: Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene_or_gene_product

[ "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O" ]

Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.

[ "Aberrant", "regulation", "of", "survivin", "by", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "\n", "Survivin", "is", "a", "putative", "oncogene", "that", "is", "aberrantly", "expressed", "in", "cancer", "cells", ".", "It", "has", "been", "hypothesized", "to", "play", "a", "central", "role", "in", "cancer", "progression", "and", "resistance", "to", "therapy", "in", "diverse", "tumor", "types", ".", "Although", "some", "of", "the", "transcriptional", "processes", "regulating", "its", "expression", "have", "been", "established", ",", "the", "diversity", "of", "genes", "that", "may", "be", "controlling", "the", "levels", "of", "its", "expression", "in", "both", "normal", "cells", "as", "well", "as", "in", "cancer", "cells", "has", "not", "been", "fully", "explored", ".", "The", "most", "common", "genetically", "mutated", "pathways", "in", "human", "malignancies", "are", "the", "p53", "tumor", "suppressor", "pathway", "and", "the", "RB", "/", "E2F", "pathway", ".", "Both", "of", "these", "pathways", ",", "when", "intact", ",", "provide", "essential", "checkpoints", "in", "the", "maintenance", "of", "normal", "cell", "growth", "and", "protect", "the", "cell", "from", "DNA", "damage", ".", "Using", "non", "-", "transformed", "embryonic", "fibroblasts", ",", "we", "provide", "evidence", "of", "a", "molecular", "link", "between", "the", "regulation", "of", "survivin", "transcription", "and", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "We", "demonstrate", "that", "both", "pRB", "and", "p130", "can", "interact", "with", "the", "survivin", "promoter", "and", "can", "repress", "survivin", "transcription", ".", "We", "also", "show", "that", "the", "E2F", "activators", "(", "E2F1", ",", "E2F2", ",", "and", "E2F3", ")", "can", "bind", "to", "the", "survivin", "promoter", "and", "induce", "survivin", "transcription", ".", "Genetically", "modified", "cells", "that", "harbor", "deletions", "in", "various", "members", "of", "the", "RB", "/", "E2F", "family", "confirm", "our", "data", "from", "the", "wild", "-", "type", "cells", ".", "Our", "findings", "implicate", "several", "members", "of", "the", "RB", "/", "E2F", "pathway", "in", "an", "intricate", "mechanism", "of", "survivin", "gene", "regulation", "that", ",", "when", "genetically", "altered", "during", "the", "process", "of", "tumorigenesis", ",", "may", "function", "within", "cancer", "cells", "to", "aberrantly", "alter", "survivin", "levels", "and", "enhance", "tumor", "progression", ".", "\n" ]

[ "Gene_or_gene_product" ]

survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, Survivin is a Gene_or_gene_product, p53 is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, pRB is a Gene_or_gene_product, p130 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, E2F3 is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, RB is a Gene_or_gene_product, E2F is a Gene_or_gene_product, survivin is a Gene_or_gene_product, survivin is a Gene_or_gene_product

128_task1

Sentence: Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression. Instructions: please typing these entity words according to sentence: survivin, RB, E2F, Survivin, p53, RB, E2F, survivin, RB, E2F, pRB, p130, survivin, survivin, E2F, E2F1, E2F2, E2F3, survivin, survivin, RB, E2F, RB, E2F, survivin, survivin Options: Gene_or_gene_product

[ "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O" ]

Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.

[ "Aberrant", "regulation", "of", "survivin", "by", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "\n", "Survivin", "is", "a", "putative", "oncogene", "that", "is", "aberrantly", "expressed", "in", "cancer", "cells", ".", "It", "has", "been", "hypothesized", "to", "play", "a", "central", "role", "in", "cancer", "progression", "and", "resistance", "to", "therapy", "in", "diverse", "tumor", "types", ".", "Although", "some", "of", "the", "transcriptional", "processes", "regulating", "its", "expression", "have", "been", "established", ",", "the", "diversity", "of", "genes", "that", "may", "be", "controlling", "the", "levels", "of", "its", "expression", "in", "both", "normal", "cells", "as", "well", "as", "in", "cancer", "cells", "has", "not", "been", "fully", "explored", ".", "The", "most", "common", "genetically", "mutated", "pathways", "in", "human", "malignancies", "are", "the", "p53", "tumor", "suppressor", "pathway", "and", "the", "RB", "/", "E2F", "pathway", ".", "Both", "of", "these", "pathways", ",", "when", "intact", ",", "provide", "essential", "checkpoints", "in", "the", "maintenance", "of", "normal", "cell", "growth", "and", "protect", "the", "cell", "from", "DNA", "damage", ".", "Using", "non", "-", "transformed", "embryonic", "fibroblasts", ",", "we", "provide", "evidence", "of", "a", "molecular", "link", "between", "the", "regulation", "of", "survivin", "transcription", "and", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "We", "demonstrate", "that", "both", "pRB", "and", "p130", "can", "interact", "with", "the", "survivin", "promoter", "and", "can", "repress", "survivin", "transcription", ".", "We", "also", "show", "that", "the", "E2F", "activators", "(", "E2F1", ",", "E2F2", ",", "and", "E2F3", ")", "can", "bind", "to", "the", "survivin", "promoter", "and", "induce", "survivin", "transcription", ".", "Genetically", "modified", "cells", "that", "harbor", "deletions", "in", "various", "members", "of", "the", "RB", "/", "E2F", "family", "confirm", "our", "data", "from", "the", "wild", "-", "type", "cells", ".", "Our", "findings", "implicate", "several", "members", "of", "the", "RB", "/", "E2F", "pathway", "in", "an", "intricate", "mechanism", "of", "survivin", "gene", "regulation", "that", ",", "when", "genetically", "altered", "during", "the", "process", "of", "tumorigenesis", ",", "may", "function", "within", "cancer", "cells", "to", "aberrantly", "alter", "survivin", "levels", "and", "enhance", "tumor", "progression", ".", "\n" ]

[ "Gene_or_gene_product" ]

survivin, RB, E2F, Survivin, p53, RB, E2F, survivin, RB, E2F, pRB, p130, survivin, survivin, E2F, E2F1, E2F2, E2F3, survivin, survivin, RB, E2F, RB, E2F, survivin, survivin

128_task2

Sentence: Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O" ]

Aberrant regulation of survivin by the RB/E2F family of proteins. Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.

[ "Aberrant", "regulation", "of", "survivin", "by", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "\n", "Survivin", "is", "a", "putative", "oncogene", "that", "is", "aberrantly", "expressed", "in", "cancer", "cells", ".", "It", "has", "been", "hypothesized", "to", "play", "a", "central", "role", "in", "cancer", "progression", "and", "resistance", "to", "therapy", "in", "diverse", "tumor", "types", ".", "Although", "some", "of", "the", "transcriptional", "processes", "regulating", "its", "expression", "have", "been", "established", ",", "the", "diversity", "of", "genes", "that", "may", "be", "controlling", "the", "levels", "of", "its", "expression", "in", "both", "normal", "cells", "as", "well", "as", "in", "cancer", "cells", "has", "not", "been", "fully", "explored", ".", "The", "most", "common", "genetically", "mutated", "pathways", "in", "human", "malignancies", "are", "the", "p53", "tumor", "suppressor", "pathway", "and", "the", "RB", "/", "E2F", "pathway", ".", "Both", "of", "these", "pathways", ",", "when", "intact", ",", "provide", "essential", "checkpoints", "in", "the", "maintenance", "of", "normal", "cell", "growth", "and", "protect", "the", "cell", "from", "DNA", "damage", ".", "Using", "non", "-", "transformed", "embryonic", "fibroblasts", ",", "we", "provide", "evidence", "of", "a", "molecular", "link", "between", "the", "regulation", "of", "survivin", "transcription", "and", "the", "RB", "/", "E2F", "family", "of", "proteins", ".", "We", "demonstrate", "that", "both", "pRB", "and", "p130", "can", "interact", "with", "the", "survivin", "promoter", "and", "can", "repress", "survivin", "transcription", ".", "We", "also", "show", "that", "the", "E2F", "activators", "(", "E2F1", ",", "E2F2", ",", "and", "E2F3", ")", "can", "bind", "to", "the", "survivin", "promoter", "and", "induce", "survivin", "transcription", ".", "Genetically", "modified", "cells", "that", "harbor", "deletions", "in", "various", "members", "of", "the", "RB", "/", "E2F", "family", "confirm", "our", "data", "from", "the", "wild", "-", "type", "cells", ".", "Our", "findings", "implicate", "several", "members", "of", "the", "RB", "/", "E2F", "pathway", "in", "an", "intricate", "mechanism", "of", "survivin", "gene", "regulation", "that", ",", "when", "genetically", "altered", "during", "the", "process", "of", "tumorigenesis", ",", "may", "function", "within", "cancer", "cells", "to", "aberrantly", "alter", "survivin", "levels", "and", "enhance", "tumor", "progression", ".", "\n" ]

[ "Gene_or_gene_product" ]

IL-2 is a protein_molecule, IL-7 is a protein_molecule, heterodimerization is an other_name, STAT5 isoforms is a protein_family_or_group, human peripheral blood T lymphoblasts is a cell_type

56266_task0

Sentence: IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name, protein_family_or_group, protein_molecule

[ "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts.

[ "IL-2", "and", "IL-7", "induce", "heterodimerization", "of", "STAT5", "isoforms", "in", "human", "peripheral", "blood", "T", "lymphoblasts", "." ]

[ "protein_family_or_group", "cell_type", "DNA_domain_or_region", "(AND other_name other_name)", "other_name", "(OR cell_line cell_line)", "protein_molecule", "", "cell_line", "protein_complex", "amino_acid_monomer" ]

IL-2 is a protein_molecule, IL-7 is a protein_molecule, heterodimerization is an other_name, STAT5 isoforms is a protein_family_or_group, human peripheral blood T lymphoblasts is a cell_type

56266_task1

Sentence: IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Instructions: please typing these entity words according to sentence: IL-2, IL-7, heterodimerization, STAT5 isoforms, human peripheral blood T lymphoblasts Options: cell_type, other_name, protein_family_or_group, protein_molecule

[ "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts.

[ "IL-2", "and", "IL-7", "induce", "heterodimerization", "of", "STAT5", "isoforms", "in", "human", "peripheral", "blood", "T", "lymphoblasts", "." ]

[ "protein_family_or_group", "cell_type", "DNA_domain_or_region", "(AND other_name other_name)", "other_name", "(OR cell_line cell_line)", "protein_molecule", "", "cell_line", "protein_complex", "amino_acid_monomer" ]

IL-2, IL-7, heterodimerization, STAT5 isoforms, human peripheral blood T lymphoblasts

56266_task2

Sentence: IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Instructions: please extract entity words from the input sentence

[ "B-protein_molecule", "O", "B-protein_molecule", "O", "B-other_name", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O" ]

IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts.

[ "IL-2", "and", "IL-7", "induce", "heterodimerization", "of", "STAT5", "isoforms", "in", "human", "peripheral", "blood", "T", "lymphoblasts", "." ]

[ "protein_family_or_group", "cell_type", "DNA_domain_or_region", "(AND other_name other_name)", "other_name", "(OR cell_line cell_line)", "protein_molecule", "", "cell_line", "protein_complex", "amino_acid_monomer" ]

tetanus immune globulin is a Intervention_Pharmacological, immune response is a Outcome_Physical, tetanus - diphtheria vaccine is a Intervention_Pharmacological, adults is a Participant_Age, tetanus - diphtheria ( Td ) vaccine is a Intervention_Pharmacological, tetanus immune globulin ( TIG ) is a Intervention_Pharmacological, Sixty and 59 is a Participant_Sample-size, healthy is a Participant_Condition, young adults is a Participant_Age, previously immunized against tetanus ( T ) and diphtheria ( D ) is a Participant_Condition, Td vaccine alone is a Intervention_Control, ( group 1 ) is a Intervention_Pharmacological, Td vaccine plus 500 IU of TIG is a Intervention_Pharmacological, Antitoxin response is a Outcome_Physical, antibody titers is a Outcome_Physical, circulating T and D antitoxin levels is a Outcome_Physical, T antitoxin levels is a Outcome_Physical

81674_task0

Sentence: Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size

[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Condition", "B-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "Does", "tetanus", "immune", "globulin", "interfere", "with", "the", "immune", "response", "to", "simultaneous", "administration", "of", "tetanus", "-", "diphtheria", "vaccine", "?", "A", "comparative", "clinical", "trial", "in", "adults", ".", "In", "the", "management", "of", "wounds", ",", "sometimes", "it", "is", "recommended", "to", "give", "an", "adult", "-", "type", "tetanus", "-", "diphtheria", "(", "Td", ")", "vaccine", "dose", "plus", "tetanus", "immune", "globulin", "(", "TIG", ")", ".", "Sixty", "and", "59", "healthy", "young", "adults", "previously", "immunized", "against", "tetanus", "(", "T", ")", "and", "diphtheria", "(", "D", ")", "were", "randomized", "to", "receive", "intramuscularly", "either", "Td", "vaccine", "alone", "(", "group", "1", ")", "or", "Td", "vaccine", "plus", "500", "IU", "of", "TIG", "(", "group", "2", ")", "simultaneously", ".", "Antitoxin", "response", "was", "assessed", "after", "4", "weeks", "and", "4", "months", ".", "Circulating", "antibodies", "were", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "The", "cutoff", "of", "these", "tests", "was", "0.1", "IU", "/", "mL", ".", "Titers", "of", "0.1", "IU", "/", "mL", "or", "greater", "were", "considered", "protective", ".", "For", "geometric", "mean", "titers", "(", "GMT", ")", ",", "antibody", "titers", "below", "the", "cutoff", "of", "the", "assay", "were", "given", ",", "arbitrarily", ",", "0.05", "IU", "/", "mL", ".", "At", "4", "weeks", ",", "98", "%", "or", "more", "of", "the", "subjects", "in", "group", "1", "had", "circulating", "T", "and", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ";", "in", "group", "2", ",", "95", "%", "and", "90", "%", "of", "the", "subjects", "had", "titers", "above", "this", "limit", "for", "T", "and", "D", ",", "respectively", ".", "At", "4", "months", ",", "these", "percentages", "were", "98", "%", "and", "95", "%", "for", "T", "antitoxin", "levels", "in", "groups", "1", "and", "2", ",", "respectively", ";", "whereas", "96", "%", "and", "88", "%", "of", "the", "subjects", "in", "groups", "1", "and", "2", "had", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ",", "respectively", ".", "Significantly", "(", "P", "<", ".05", ")", "higher", "GMTs", "were", "seen", "at", "the", "4-week", "assessment", "(", "but", "not", "at", "4", "months", ")", "in", "group", "1", ",", "as", "compared", "with", "group", "2", ",", "in", "both", "T", "and", "D", "antitoxin", "levels", "(", "9.91", "IU", "/", "mL", "versus", "5.60", "IU", "/", "mL", "for", "T", "antitoxin", ",", "and", "2.86", "IU", "/", "mL", "versus", "1.45", "IU", "/", "mL", "for", "D", "antitoxin", ")", ".", "This", "finding", "resulted", "from", "those", "participants", "with", "low", "(", "<", "0.1", "IU", "/", "mL", ")", "prevaccination", "antibody", "titers", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age" ]

tetanus immune globulin is a Intervention_Pharmacological, immune response is a Outcome_Physical, tetanus - diphtheria vaccine is a Intervention_Pharmacological, adults is a Participant_Age, tetanus - diphtheria ( Td ) vaccine is a Intervention_Pharmacological, tetanus immune globulin ( TIG ) is a Intervention_Pharmacological, Sixty and 59 is a Participant_Sample-size, healthy is a Participant_Condition, young adults is a Participant_Age, previously immunized against tetanus ( T ) and diphtheria ( D ) is a Participant_Condition, Td vaccine alone is a Intervention_Control, ( group 1 ) is a Intervention_Pharmacological, Td vaccine plus 500 IU of TIG is a Intervention_Pharmacological, Antitoxin response is a Outcome_Physical, antibody titers is a Outcome_Physical, circulating T and D antitoxin levels is a Outcome_Physical, T antitoxin levels is a Outcome_Physical

81674_task1

Sentence: Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please typing these entity words according to sentence: tetanus immune globulin, immune response, tetanus - diphtheria vaccine, adults, tetanus - diphtheria ( Td ) vaccine, tetanus immune globulin ( TIG ), Sixty and 59, healthy, young adults, previously immunized against tetanus ( T ) and diphtheria ( D ), Td vaccine alone, ( group 1 ), Td vaccine plus 500 IU of TIG, Antitoxin response, antibody titers, circulating T and D antitoxin levels, T antitoxin levels Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size

[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Condition", "B-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "Does", "tetanus", "immune", "globulin", "interfere", "with", "the", "immune", "response", "to", "simultaneous", "administration", "of", "tetanus", "-", "diphtheria", "vaccine", "?", "A", "comparative", "clinical", "trial", "in", "adults", ".", "In", "the", "management", "of", "wounds", ",", "sometimes", "it", "is", "recommended", "to", "give", "an", "adult", "-", "type", "tetanus", "-", "diphtheria", "(", "Td", ")", "vaccine", "dose", "plus", "tetanus", "immune", "globulin", "(", "TIG", ")", ".", "Sixty", "and", "59", "healthy", "young", "adults", "previously", "immunized", "against", "tetanus", "(", "T", ")", "and", "diphtheria", "(", "D", ")", "were", "randomized", "to", "receive", "intramuscularly", "either", "Td", "vaccine", "alone", "(", "group", "1", ")", "or", "Td", "vaccine", "plus", "500", "IU", "of", "TIG", "(", "group", "2", ")", "simultaneously", ".", "Antitoxin", "response", "was", "assessed", "after", "4", "weeks", "and", "4", "months", ".", "Circulating", "antibodies", "were", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "The", "cutoff", "of", "these", "tests", "was", "0.1", "IU", "/", "mL", ".", "Titers", "of", "0.1", "IU", "/", "mL", "or", "greater", "were", "considered", "protective", ".", "For", "geometric", "mean", "titers", "(", "GMT", ")", ",", "antibody", "titers", "below", "the", "cutoff", "of", "the", "assay", "were", "given", ",", "arbitrarily", ",", "0.05", "IU", "/", "mL", ".", "At", "4", "weeks", ",", "98", "%", "or", "more", "of", "the", "subjects", "in", "group", "1", "had", "circulating", "T", "and", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ";", "in", "group", "2", ",", "95", "%", "and", "90", "%", "of", "the", "subjects", "had", "titers", "above", "this", "limit", "for", "T", "and", "D", ",", "respectively", ".", "At", "4", "months", ",", "these", "percentages", "were", "98", "%", "and", "95", "%", "for", "T", "antitoxin", "levels", "in", "groups", "1", "and", "2", ",", "respectively", ";", "whereas", "96", "%", "and", "88", "%", "of", "the", "subjects", "in", "groups", "1", "and", "2", "had", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ",", "respectively", ".", "Significantly", "(", "P", "<", ".05", ")", "higher", "GMTs", "were", "seen", "at", "the", "4-week", "assessment", "(", "but", "not", "at", "4", "months", ")", "in", "group", "1", ",", "as", "compared", "with", "group", "2", ",", "in", "both", "T", "and", "D", "antitoxin", "levels", "(", "9.91", "IU", "/", "mL", "versus", "5.60", "IU", "/", "mL", "for", "T", "antitoxin", ",", "and", "2.86", "IU", "/", "mL", "versus", "1.45", "IU", "/", "mL", "for", "D", "antitoxin", ")", ".", "This", "finding", "resulted", "from", "those", "participants", "with", "low", "(", "<", "0.1", "IU", "/", "mL", ")", "prevaccination", "antibody", "titers", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age" ]

tetanus immune globulin, immune response, tetanus - diphtheria vaccine, adults, tetanus - diphtheria ( Td ) vaccine, tetanus immune globulin ( TIG ), Sixty and 59, healthy, young adults, previously immunized against tetanus ( T ) and diphtheria ( D ), Td vaccine alone, ( group 1 ), Td vaccine plus 500 IU of TIG, Antitoxin response, antibody titers, circulating T and D antitoxin levels, T antitoxin levels

81674_task2

Sentence: Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entity words from the input sentence

[ "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "B-Participant_Condition", "B-Participant_Age", "I-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine ? A comparative clinical trial in adults . In the management of wounds , sometimes it is recommended to give an adult-type tetanus-diphtheria ( Td ) vaccine dose plus tetanus immune globulin ( TIG ) . Sixty and 59 healthy young adults previously immunized against tetanus ( T ) and diphtheria ( D ) were randomized to receive intramuscularly either Td vaccine alone ( group 1 ) or Td vaccine plus 500 IU of TIG ( group 2 ) simultaneously . Antitoxin response was assessed after 4 weeks and 4 months . Circulating antibodies were measured by enzyme-linked immunosorbent assay ( ELISA ) . The cutoff of these tests was 0.1 IU/mL . Titers of 0.1 IU/mL or greater were considered protective . For geometric mean titers ( GMT ) , antibody titers below the cutoff of the assay were given , arbitrarily , 0.05 IU/mL . At 4 weeks , 98 % or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher ; in group 2 , 95 % and 90 % of the subjects had titers above this limit for T and D , respectively . At 4 months , these percentages were 98 % and 95 % for T antitoxin levels in groups 1 and 2 , respectively ; whereas 96 % and 88 % of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher , respectively . Significantly ( P < .05 ) higher GMTs were seen at the 4-week assessment ( but not at 4 months ) in group 1 , as compared with group 2 , in both T and D antitoxin levels ( 9.91 IU/mL versus 5.60 IU/mL for T antitoxin , and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin ) . This finding resulted from those participants with low ( < 0.1 IU/mL ) prevaccination antibody titers . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "Does", "tetanus", "immune", "globulin", "interfere", "with", "the", "immune", "response", "to", "simultaneous", "administration", "of", "tetanus", "-", "diphtheria", "vaccine", "?", "A", "comparative", "clinical", "trial", "in", "adults", ".", "In", "the", "management", "of", "wounds", ",", "sometimes", "it", "is", "recommended", "to", "give", "an", "adult", "-", "type", "tetanus", "-", "diphtheria", "(", "Td", ")", "vaccine", "dose", "plus", "tetanus", "immune", "globulin", "(", "TIG", ")", ".", "Sixty", "and", "59", "healthy", "young", "adults", "previously", "immunized", "against", "tetanus", "(", "T", ")", "and", "diphtheria", "(", "D", ")", "were", "randomized", "to", "receive", "intramuscularly", "either", "Td", "vaccine", "alone", "(", "group", "1", ")", "or", "Td", "vaccine", "plus", "500", "IU", "of", "TIG", "(", "group", "2", ")", "simultaneously", ".", "Antitoxin", "response", "was", "assessed", "after", "4", "weeks", "and", "4", "months", ".", "Circulating", "antibodies", "were", "measured", "by", "enzyme", "-", "linked", "immunosorbent", "assay", "(", "ELISA", ")", ".", "The", "cutoff", "of", "these", "tests", "was", "0.1", "IU", "/", "mL", ".", "Titers", "of", "0.1", "IU", "/", "mL", "or", "greater", "were", "considered", "protective", ".", "For", "geometric", "mean", "titers", "(", "GMT", ")", ",", "antibody", "titers", "below", "the", "cutoff", "of", "the", "assay", "were", "given", ",", "arbitrarily", ",", "0.05", "IU", "/", "mL", ".", "At", "4", "weeks", ",", "98", "%", "or", "more", "of", "the", "subjects", "in", "group", "1", "had", "circulating", "T", "and", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ";", "in", "group", "2", ",", "95", "%", "and", "90", "%", "of", "the", "subjects", "had", "titers", "above", "this", "limit", "for", "T", "and", "D", ",", "respectively", ".", "At", "4", "months", ",", "these", "percentages", "were", "98", "%", "and", "95", "%", "for", "T", "antitoxin", "levels", "in", "groups", "1", "and", "2", ",", "respectively", ";", "whereas", "96", "%", "and", "88", "%", "of", "the", "subjects", "in", "groups", "1", "and", "2", "had", "D", "antitoxin", "levels", "of", "0.1", "IU", "/", "mL", "or", "higher", ",", "respectively", ".", "Significantly", "(", "P", "<", ".05", ")", "higher", "GMTs", "were", "seen", "at", "the", "4-week", "assessment", "(", "but", "not", "at", "4", "months", ")", "in", "group", "1", ",", "as", "compared", "with", "group", "2", ",", "in", "both", "T", "and", "D", "antitoxin", "levels", "(", "9.91", "IU", "/", "mL", "versus", "5.60", "IU", "/", "mL", "for", "T", "antitoxin", ",", "and", "2.86", "IU", "/", "mL", "versus", "1.45", "IU", "/", "mL", "for", "D", "antitoxin", ")", ".", "This", "finding", "resulted", "from", "those", "participants", "with", "low", "(", "<", "0.1", "IU", "/", "mL", ")", "prevaccination", "antibody", "titers", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age" ]

etiology is an umlsterm, patients is an umlsterm, University is an umlsterm, Histopathological is an umlsterm, patients is an umlsterm, patient is an umlsterm

HNO.00480665.eng.abstr_task0

Sentence: Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated .

[ "Orbital", "pseudotumor", "is", "a", "nonspecific", "inflammatory", "process", "of", "unknown", "etiology", "that", "can", "be", "divided", "histopathologically", "into", "three", "basic", "types", ":", "granulomatous", ",", "lymphoid", ",", "and", "sclerosing", ".", "Between", "1995", "and", "1998", ",", "12", "patients", "with", "pseudotumor", "orbitae", "were", "treated", "in", "the", "ENT", "Department", "of", "the", "University", "of", "Saarland", ".", "Histopathological", "examination", "showed", "granulomatous", "type", "of", "pseudotumor", "in", "six", ",", "lymphoid", "in", "three", ",", "and", "sclerosing", "in", "three", "patients", ".", "In", "seven", "cases", "the", "pseudotumor", "orbitae", "were", "medially", "located", "and", "in", "four", "cases", "laterally", ".", "In", "one", "patient", "nearly", "all", "orbital", "structures", "were", "infiltrated", "." ]

[ "umlsterm" ]

etiology is an umlsterm, patients is an umlsterm, University is an umlsterm, Histopathological is an umlsterm, patients is an umlsterm, patient is an umlsterm

HNO.00480665.eng.abstr_task1

Sentence: Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated . Instructions: please typing these entity words according to sentence: etiology, patients, University, Histopathological, patients, patient Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated .

[ "Orbital", "pseudotumor", "is", "a", "nonspecific", "inflammatory", "process", "of", "unknown", "etiology", "that", "can", "be", "divided", "histopathologically", "into", "three", "basic", "types", ":", "granulomatous", ",", "lymphoid", ",", "and", "sclerosing", ".", "Between", "1995", "and", "1998", ",", "12", "patients", "with", "pseudotumor", "orbitae", "were", "treated", "in", "the", "ENT", "Department", "of", "the", "University", "of", "Saarland", ".", "Histopathological", "examination", "showed", "granulomatous", "type", "of", "pseudotumor", "in", "six", ",", "lymphoid", "in", "three", ",", "and", "sclerosing", "in", "three", "patients", ".", "In", "seven", "cases", "the", "pseudotumor", "orbitae", "were", "medially", "located", "and", "in", "four", "cases", "laterally", ".", "In", "one", "patient", "nearly", "all", "orbital", "structures", "were", "infiltrated", "." ]

[ "umlsterm" ]

etiology, patients, University, Histopathological, patients, patient

HNO.00480665.eng.abstr_task2

Sentence: Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Orbital pseudotumor is a nonspecific inflammatory process of unknown etiology that can be divided histopathologically into three basic types : granulomatous , lymphoid , and sclerosing . Between 1995 and 1998 , 12 patients with pseudotumor orbitae were treated in the ENT Department of the University of Saarland . Histopathological examination showed granulomatous type of pseudotumor in six , lymphoid in three , and sclerosing in three patients . In seven cases the pseudotumor orbitae were medially located and in four cases laterally . In one patient nearly all orbital structures were infiltrated .

[ "Orbital", "pseudotumor", "is", "a", "nonspecific", "inflammatory", "process", "of", "unknown", "etiology", "that", "can", "be", "divided", "histopathologically", "into", "three", "basic", "types", ":", "granulomatous", ",", "lymphoid", ",", "and", "sclerosing", ".", "Between", "1995", "and", "1998", ",", "12", "patients", "with", "pseudotumor", "orbitae", "were", "treated", "in", "the", "ENT", "Department", "of", "the", "University", "of", "Saarland", ".", "Histopathological", "examination", "showed", "granulomatous", "type", "of", "pseudotumor", "in", "six", ",", "lymphoid", "in", "three", ",", "and", "sclerosing", "in", "three", "patients", ".", "In", "seven", "cases", "the", "pseudotumor", "orbitae", "were", "medially", "located", "and", "in", "four", "cases", "laterally", ".", "In", "one", "patient", "nearly", "all", "orbital", "structures", "were", "infiltrated", "." ]

[ "umlsterm" ]

natural beta - carotene is a Intervention_Pharmacological, humans is a Participant_Condition, beta - carotene preparation is a Intervention_Pharmacological, beta - carotene - rich algae is a Intervention_Pharmacological, 60 mg of the beta - carotene preparation is a Intervention_Pharmacological, plasma is a Outcome_Physical, red blood cells ( RBC ) is a Outcome_Physical, platelets ( PLT ) , is a Outcome_Physical, mononuclear cells ( MN ) is a Outcome_Physical, all - trans beta - carotene level is a Outcome_Physical, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN is a Outcome_Physical, Plasma and RBC alpha - tocopherol levels is a Outcome_Physical, No side effects or toxicities is a Outcome_Adverse-effects

82856_task0

Sentence: Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Outcome_Adverse-effects

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells .

[ "Changes", "in", "beta", "-", "carotene", "levels", "by", "long", "-", "term", "administration", "of", "natural", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "in", "humans", ".", "Long", "-", "term", "administration", "of", "a", "beta", "-", "carotene", "preparation", "derived", "from", "Dunaliella", "bardawil", ",", "a", "beta", "-", "carotene", "-", "rich", "algae", ",", "was", "studied", "in", "healthy", "young", "male", "volunteers", ".", "The", "daily", "administration", "of", "60", "mg", "of", "the", "beta", "-", "carotene", "preparation", "(", "30", "mg", "of", "all", "-", "trans", "beta", "-", "carotene", "and", "30", "mg", "of", "9-cis", "beta", "-", "carotene", ")", "was", "performed", "and", "beta", "-", "carotene", "concentrations", "were", "determined", "in", "the", "plasma", ",", "red", "blood", "cells", "(", "RBC", ")", ",", "platelets", "(", "PLT", ")", ",", "and", "mononuclear", "cells", "(", "MN", ")", ".", "The", "all", "-", "trans", "beta", "-", "carotene", "level", "increased", "four-", ",", "two-", ",", "and", "threefold", "the", "baseline", "in", "plasma", ",", "PLT", ",", "and", "MN", ",", "respectively", ".", "Basal", "levels", "of", "9-cis", "beta", "-", "carotene", "in", "plasma", ",", "PLT", ",", "and", "MN", "were", "low", "and", "found", "as", "one", "-", "tenth", ",", "one", "-", "fifth", ",", "and", "one", "-", "fifth", "of", "all", "-", "trans", "beta", "-", "carotene", ",", "which", "increased", "three-", ",", "two-", ",", "and", "1.5-fold", "the", "baseline", ",", "respectively", ".", "Plasma", "and", "RBC", "alpha", "-", "tocopherol", "levels", "were", "not", "changed", "by", "the", "intake", "of", "beta", "-", "carotene", ".", "No", "side", "effects", "or", "toxicities", "were", "documented", "in", "any", "of", "the", "subjects", "during", "the", "administration", "period", ".", "In", "conclusion", ",", "the", "bioavailability", "of", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "was", "preferential", "for", "all", "-", "trans", "beta", "-", "carotene", ",", "although", "a", "small", "amount", "of", "the", "9-cis", "form", "was", "detected", "in", "the", "plasma", "and", "blood", "cells", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Participant_Condition" ]

natural beta - carotene is a Intervention_Pharmacological, humans is a Participant_Condition, beta - carotene preparation is a Intervention_Pharmacological, beta - carotene - rich algae is a Intervention_Pharmacological, 60 mg of the beta - carotene preparation is a Intervention_Pharmacological, plasma is a Outcome_Physical, red blood cells ( RBC ) is a Outcome_Physical, platelets ( PLT ) , is a Outcome_Physical, mononuclear cells ( MN ) is a Outcome_Physical, all - trans beta - carotene level is a Outcome_Physical, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN is a Outcome_Physical, Plasma and RBC alpha - tocopherol levels is a Outcome_Physical, No side effects or toxicities is a Outcome_Adverse-effects

82856_task1

Sentence: Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells . Instructions: please typing these entity words according to sentence: natural beta - carotene, humans, beta - carotene preparation, beta - carotene - rich algae, 60 mg of the beta - carotene preparation, plasma, red blood cells ( RBC ), platelets ( PLT ) ,, mononuclear cells ( MN ), all - trans beta - carotene level, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN, Plasma and RBC alpha - tocopherol levels, No side effects or toxicities Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Outcome_Adverse-effects

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells .

[ "Changes", "in", "beta", "-", "carotene", "levels", "by", "long", "-", "term", "administration", "of", "natural", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "in", "humans", ".", "Long", "-", "term", "administration", "of", "a", "beta", "-", "carotene", "preparation", "derived", "from", "Dunaliella", "bardawil", ",", "a", "beta", "-", "carotene", "-", "rich", "algae", ",", "was", "studied", "in", "healthy", "young", "male", "volunteers", ".", "The", "daily", "administration", "of", "60", "mg", "of", "the", "beta", "-", "carotene", "preparation", "(", "30", "mg", "of", "all", "-", "trans", "beta", "-", "carotene", "and", "30", "mg", "of", "9-cis", "beta", "-", "carotene", ")", "was", "performed", "and", "beta", "-", "carotene", "concentrations", "were", "determined", "in", "the", "plasma", ",", "red", "blood", "cells", "(", "RBC", ")", ",", "platelets", "(", "PLT", ")", ",", "and", "mononuclear", "cells", "(", "MN", ")", ".", "The", "all", "-", "trans", "beta", "-", "carotene", "level", "increased", "four-", ",", "two-", ",", "and", "threefold", "the", "baseline", "in", "plasma", ",", "PLT", ",", "and", "MN", ",", "respectively", ".", "Basal", "levels", "of", "9-cis", "beta", "-", "carotene", "in", "plasma", ",", "PLT", ",", "and", "MN", "were", "low", "and", "found", "as", "one", "-", "tenth", ",", "one", "-", "fifth", ",", "and", "one", "-", "fifth", "of", "all", "-", "trans", "beta", "-", "carotene", ",", "which", "increased", "three-", ",", "two-", ",", "and", "1.5-fold", "the", "baseline", ",", "respectively", ".", "Plasma", "and", "RBC", "alpha", "-", "tocopherol", "levels", "were", "not", "changed", "by", "the", "intake", "of", "beta", "-", "carotene", ".", "No", "side", "effects", "or", "toxicities", "were", "documented", "in", "any", "of", "the", "subjects", "during", "the", "administration", "period", ".", "In", "conclusion", ",", "the", "bioavailability", "of", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "was", "preferential", "for", "all", "-", "trans", "beta", "-", "carotene", ",", "although", "a", "small", "amount", "of", "the", "9-cis", "form", "was", "detected", "in", "the", "plasma", "and", "blood", "cells", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Participant_Condition" ]

natural beta - carotene, humans, beta - carotene preparation, beta - carotene - rich algae, 60 mg of the beta - carotene preparation, plasma, red blood cells ( RBC ), platelets ( PLT ) ,, mononuclear cells ( MN ), all - trans beta - carotene level, Basal levels of 9-cis beta - carotene in plasma , PLT , and MN, Plasma and RBC alpha - tocopherol levels, No side effects or toxicities

82856_task2

Sentence: Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Changes in beta-carotene levels by long-term administration of natural beta-carotene derived from Dunaliella bardawil in humans . Long-term administration of a beta-carotene preparation derived from Dunaliella bardawil , a beta-carotene-rich algae , was studied in healthy young male volunteers . The daily administration of 60 mg of the beta-carotene preparation ( 30 mg of all-trans beta-carotene and 30 mg of 9-cis beta-carotene ) was performed and beta-carotene concentrations were determined in the plasma , red blood cells ( RBC ) , platelets ( PLT ) , and mononuclear cells ( MN ) . The all-trans beta-carotene level increased four- , two- , and threefold the baseline in plasma , PLT , and MN , respectively . Basal levels of 9-cis beta-carotene in plasma , PLT , and MN were low and found as one-tenth , one-fifth , and one-fifth of all-trans beta-carotene , which increased three- , two- , and 1.5-fold the baseline , respectively . Plasma and RBC alpha-tocopherol levels were not changed by the intake of beta-carotene . No side effects or toxicities were documented in any of the subjects during the administration period . In conclusion , the bioavailability of beta-carotene derived from Dunaliella bardawil was preferential for all-trans beta-carotene , although a small amount of the 9-cis form was detected in the plasma and blood cells .

[ "Changes", "in", "beta", "-", "carotene", "levels", "by", "long", "-", "term", "administration", "of", "natural", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "in", "humans", ".", "Long", "-", "term", "administration", "of", "a", "beta", "-", "carotene", "preparation", "derived", "from", "Dunaliella", "bardawil", ",", "a", "beta", "-", "carotene", "-", "rich", "algae", ",", "was", "studied", "in", "healthy", "young", "male", "volunteers", ".", "The", "daily", "administration", "of", "60", "mg", "of", "the", "beta", "-", "carotene", "preparation", "(", "30", "mg", "of", "all", "-", "trans", "beta", "-", "carotene", "and", "30", "mg", "of", "9-cis", "beta", "-", "carotene", ")", "was", "performed", "and", "beta", "-", "carotene", "concentrations", "were", "determined", "in", "the", "plasma", ",", "red", "blood", "cells", "(", "RBC", ")", ",", "platelets", "(", "PLT", ")", ",", "and", "mononuclear", "cells", "(", "MN", ")", ".", "The", "all", "-", "trans", "beta", "-", "carotene", "level", "increased", "four-", ",", "two-", ",", "and", "threefold", "the", "baseline", "in", "plasma", ",", "PLT", ",", "and", "MN", ",", "respectively", ".", "Basal", "levels", "of", "9-cis", "beta", "-", "carotene", "in", "plasma", ",", "PLT", ",", "and", "MN", "were", "low", "and", "found", "as", "one", "-", "tenth", ",", "one", "-", "fifth", ",", "and", "one", "-", "fifth", "of", "all", "-", "trans", "beta", "-", "carotene", ",", "which", "increased", "three-", ",", "two-", ",", "and", "1.5-fold", "the", "baseline", ",", "respectively", ".", "Plasma", "and", "RBC", "alpha", "-", "tocopherol", "levels", "were", "not", "changed", "by", "the", "intake", "of", "beta", "-", "carotene", ".", "No", "side", "effects", "or", "toxicities", "were", "documented", "in", "any", "of", "the", "subjects", "during", "the", "administration", "period", ".", "In", "conclusion", ",", "the", "bioavailability", "of", "beta", "-", "carotene", "derived", "from", "Dunaliella", "bardawil", "was", "preferential", "for", "all", "-", "trans", "beta", "-", "carotene", ",", "although", "a", "small", "amount", "of", "the", "9-cis", "form", "was", "detected", "in", "the", "plasma", "and", "blood", "cells", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Adverse-effects", "Participant_Condition" ]

Apolipoprotein E is a Gene, apolipoprotein ( apo ) E is a Gene, triglyceride - rich lipoprotein ( TGRL)-triglyceride is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene

238_task0

Sentence: Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene

[ "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD.

[ "Apolipoprotein", "E", "polymorphism", "influences", "postprandial", "retinyl", "palmitate", "but", "not", "triglyceride", "concentrations", ".", "To", "quantify", "the", "effect", "of", "the", "apolipoprotein", "(", "apo", ")", "E", "polymorphism", "on", "the", "magnitude", "of", "postprandial", "lipemia", ",", "we", "have", "defined", "its", "role", "in", "determining", "the", "response", "to", "a", "single", "high", "-", "fat", "meal", "in", "a", "large", "sample", "of", "(", "N", "=", "474", ")", "individuals", "taking", "part", "in", "the", "biethnic", "Atherosclerosis", "Risk", "in", "Communities", "Study", ".", "The", "profile", "of", "postprandial", "response", "in", "plasma", "was", "monitored", "over", "8", "h", "by", "triglyceride", ",", "triglyceride", "-", "rich", "lipoprotein", "(", "TGRL)-triglyceride", ",", "apo", "B-48", "/", "apo", "B-100", "ratio", ",", "and", "retinyl", "palmitate", "concentrations", ",", "and", "the", "apo", "E", "polymorphism", "was", "determined", "by", "DNA", "amplification", "and", "digestion", ".", "The", "frequency", "of", "the", "apo", "E", "alleles", "and", "their", "effects", "on", "fasting", "lipid", "levels", "in", "this", "sample", "were", "similar", "to", "those", "reported", "elsewhere", ".", "Postprandial", "plasma", "retinyl", "palmitate", "response", "to", "a", "high", "-", "fat", "meal", "with", "vitamin", "A", "was", "significantly", "different", "among", "apo", "E", "genotypes", ",", "with", "delayed", "clearance", "in", "individuals", "with", "an", "epsilon", "2", "allele", ",", "compared", "with", "epsilon", "3/3", "and", "epsilon", "3/4", "individuals", ".", "In", "the", "sample", "of", "397", "Caucasians", ",", "average", "retinyl", "palmitate", "response", "was", "1,489", "micrograms", "/", "dl", "in", "epsilon", "2/3", "individuals", ",", "compared", "with", "1,037", "micrograms", "/", "dl", "in", "epsilon", "3/3", "individuals", "and", "1,108", "micrograms", "/", "dl", "in", "epsilon", "3/4", "individuals", ".", "The", "apo", "E", "polymorphism", "accounted", "for", "7.1", "%", "of", "the", "interindividual", "variation", "in", "postprandial", "retinyl", "palmitate", "response", ",", "a", "contribution", "proportionally", "greater", "than", "its", "well", "-", "known", "effect", "on", "fasting", "LDL", "-", "cholesterol", ".", "However", ",", "despite", "this", "effect", "on", "postprandial", "retinyl", "palmitate", ",", "the", "profile", "of", "postprandial", "triglyceride", "response", "was", "not", "significantly", "different", "among", "apo", "E", "genotypes", ".", "The", "profile", "of", "postprandial", "response", "was", "consistent", "between", "the", "sample", "of", "Caucasians", "and", "a", "smaller", "sample", "of", "black", "subjects", ".", "While", "these", "data", "indicate", "that", "the", "removal", "of", "remnant", "particles", "from", "circulation", "is", "delayed", "in", "subjects", "with", "the", "epsilon", "2/3", "genotype", ",", "there", "is", "no", "reported", "evidence", "that", "the", "epsilon", "2", "allele", "predisposes", "to", "coronary", "artery", "disease", "(", "CAD", ")", ".", "The", "results", "of", "this", "study", "provide", "not", "only", "a", "reliable", "estimate", "of", "the", "magnitude", "of", "the", "effect", "of", "the", "apo", "E", "polymorphism", "on", "various", "measurements", "commonly", "used", "to", "characterize", "postprandial", "lipemia", ",", "but", "also", "provide", "mechanistic", "insight", "into", "the", "effects", "of", "the", "apo", "E", "gene", "polymorphism", "on", "postprandial", "lipemia", "and", "CAD", ".", "\n" ]

[ "Gene" ]

Apolipoprotein E is a Gene, apolipoprotein ( apo ) E is a Gene, triglyceride - rich lipoprotein ( TGRL)-triglyceride is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene, apo E is a Gene

238_task1

Sentence: Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD. Instructions: please typing these entity words according to sentence: Apolipoprotein E, apolipoprotein ( apo ) E, triglyceride - rich lipoprotein ( TGRL)-triglyceride, apo E, apo E, apo E, apo E, apo E, apo E, apo E Options: Gene

[ "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD.

[ "Apolipoprotein", "E", "polymorphism", "influences", "postprandial", "retinyl", "palmitate", "but", "not", "triglyceride", "concentrations", ".", "To", "quantify", "the", "effect", "of", "the", "apolipoprotein", "(", "apo", ")", "E", "polymorphism", "on", "the", "magnitude", "of", "postprandial", "lipemia", ",", "we", "have", "defined", "its", "role", "in", "determining", "the", "response", "to", "a", "single", "high", "-", "fat", "meal", "in", "a", "large", "sample", "of", "(", "N", "=", "474", ")", "individuals", "taking", "part", "in", "the", "biethnic", "Atherosclerosis", "Risk", "in", "Communities", "Study", ".", "The", "profile", "of", "postprandial", "response", "in", "plasma", "was", "monitored", "over", "8", "h", "by", "triglyceride", ",", "triglyceride", "-", "rich", "lipoprotein", "(", "TGRL)-triglyceride", ",", "apo", "B-48", "/", "apo", "B-100", "ratio", ",", "and", "retinyl", "palmitate", "concentrations", ",", "and", "the", "apo", "E", "polymorphism", "was", "determined", "by", "DNA", "amplification", "and", "digestion", ".", "The", "frequency", "of", "the", "apo", "E", "alleles", "and", "their", "effects", "on", "fasting", "lipid", "levels", "in", "this", "sample", "were", "similar", "to", "those", "reported", "elsewhere", ".", "Postprandial", "plasma", "retinyl", "palmitate", "response", "to", "a", "high", "-", "fat", "meal", "with", "vitamin", "A", "was", "significantly", "different", "among", "apo", "E", "genotypes", ",", "with", "delayed", "clearance", "in", "individuals", "with", "an", "epsilon", "2", "allele", ",", "compared", "with", "epsilon", "3/3", "and", "epsilon", "3/4", "individuals", ".", "In", "the", "sample", "of", "397", "Caucasians", ",", "average", "retinyl", "palmitate", "response", "was", "1,489", "micrograms", "/", "dl", "in", "epsilon", "2/3", "individuals", ",", "compared", "with", "1,037", "micrograms", "/", "dl", "in", "epsilon", "3/3", "individuals", "and", "1,108", "micrograms", "/", "dl", "in", "epsilon", "3/4", "individuals", ".", "The", "apo", "E", "polymorphism", "accounted", "for", "7.1", "%", "of", "the", "interindividual", "variation", "in", "postprandial", "retinyl", "palmitate", "response", ",", "a", "contribution", "proportionally", "greater", "than", "its", "well", "-", "known", "effect", "on", "fasting", "LDL", "-", "cholesterol", ".", "However", ",", "despite", "this", "effect", "on", "postprandial", "retinyl", "palmitate", ",", "the", "profile", "of", "postprandial", "triglyceride", "response", "was", "not", "significantly", "different", "among", "apo", "E", "genotypes", ".", "The", "profile", "of", "postprandial", "response", "was", "consistent", "between", "the", "sample", "of", "Caucasians", "and", "a", "smaller", "sample", "of", "black", "subjects", ".", "While", "these", "data", "indicate", "that", "the", "removal", "of", "remnant", "particles", "from", "circulation", "is", "delayed", "in", "subjects", "with", "the", "epsilon", "2/3", "genotype", ",", "there", "is", "no", "reported", "evidence", "that", "the", "epsilon", "2", "allele", "predisposes", "to", "coronary", "artery", "disease", "(", "CAD", ")", ".", "The", "results", "of", "this", "study", "provide", "not", "only", "a", "reliable", "estimate", "of", "the", "magnitude", "of", "the", "effect", "of", "the", "apo", "E", "polymorphism", "on", "various", "measurements", "commonly", "used", "to", "characterize", "postprandial", "lipemia", ",", "but", "also", "provide", "mechanistic", "insight", "into", "the", "effects", "of", "the", "apo", "E", "gene", "polymorphism", "on", "postprandial", "lipemia", "and", "CAD", ".", "\n" ]

[ "Gene" ]

Apolipoprotein E, apolipoprotein ( apo ) E, triglyceride - rich lipoprotein ( TGRL)-triglyceride, apo E, apo E, apo E, apo E, apo E, apo E, apo E

238_task2

Sentence: Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD. Instructions: please extract entity words from the input sentence

[ "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. To quantify the effect of the apolipoprotein (apo) E polymorphism on the magnitude of postprandial lipemia, we have defined its role in determining the response to a single high-fat meal in a large sample of (N = 474) individuals taking part in the biethnic Atherosclerosis Risk in Communities Study. The profile of postprandial response in plasma was monitored over 8 h by triglyceride, triglyceride-rich lipoprotein (TGRL)-triglyceride, apo B-48/apo B-100 ratio, and retinyl palmitate concentrations, and the apo E polymorphism was determined by DNA amplification and digestion. The frequency of the apo E alleles and their effects on fasting lipid levels in this sample were similar to those reported elsewhere. Postprandial plasma retinyl palmitate response to a high-fat meal with vitamin A was significantly different among apo E genotypes, with delayed clearance in individuals with an epsilon 2 allele, compared with epsilon 3/3 and epsilon 3/4 individuals. In the sample of 397 Caucasians, average retinyl palmitate response was 1,489 micrograms/dl in epsilon 2/3 individuals, compared with 1,037 micrograms/dl in epsilon 3/3 individuals and 1,108 micrograms/dl in epsilon 3/4 individuals. The apo E polymorphism accounted for 7.1% of the interindividual variation in postprandial retinyl palmitate response, a contribution proportionally greater than its well-known effect on fasting LDL-cholesterol. However, despite this effect on postprandial retinyl palmitate, the profile of postprandial triglyceride response was not significantly different among apo E genotypes. The profile of postprandial response was consistent between the sample of Caucasians and a smaller sample of black subjects. While these data indicate that the removal of remnant particles from circulation is delayed in subjects with the epsilon 2/3 genotype, there is no reported evidence that the epsilon 2 allele predisposes to coronary artery disease (CAD). The results of this study provide not only a reliable estimate of the magnitude of the effect of the apo E polymorphism on various measurements commonly used to characterize postprandial lipemia, but also provide mechanistic insight into the effects of the apo E gene polymorphism on postprandial lipemia and CAD.

[ "Apolipoprotein", "E", "polymorphism", "influences", "postprandial", "retinyl", "palmitate", "but", "not", "triglyceride", "concentrations", ".", "To", "quantify", "the", "effect", "of", "the", "apolipoprotein", "(", "apo", ")", "E", "polymorphism", "on", "the", "magnitude", "of", "postprandial", "lipemia", ",", "we", "have", "defined", "its", "role", "in", "determining", "the", "response", "to", "a", "single", "high", "-", "fat", "meal", "in", "a", "large", "sample", "of", "(", "N", "=", "474", ")", "individuals", "taking", "part", "in", "the", "biethnic", "Atherosclerosis", "Risk", "in", "Communities", "Study", ".", "The", "profile", "of", "postprandial", "response", "in", "plasma", "was", "monitored", "over", "8", "h", "by", "triglyceride", ",", "triglyceride", "-", "rich", "lipoprotein", "(", "TGRL)-triglyceride", ",", "apo", "B-48", "/", "apo", "B-100", "ratio", ",", "and", "retinyl", "palmitate", "concentrations", ",", "and", "the", "apo", "E", "polymorphism", "was", "determined", "by", "DNA", "amplification", "and", "digestion", ".", "The", "frequency", "of", "the", "apo", "E", "alleles", "and", "their", "effects", "on", "fasting", "lipid", "levels", "in", "this", "sample", "were", "similar", "to", "those", "reported", "elsewhere", ".", "Postprandial", "plasma", "retinyl", "palmitate", "response", "to", "a", "high", "-", "fat", "meal", "with", "vitamin", "A", "was", "significantly", "different", "among", "apo", "E", "genotypes", ",", "with", "delayed", "clearance", "in", "individuals", "with", "an", "epsilon", "2", "allele", ",", "compared", "with", "epsilon", "3/3", "and", "epsilon", "3/4", "individuals", ".", "In", "the", "sample", "of", "397", "Caucasians", ",", "average", "retinyl", "palmitate", "response", "was", "1,489", "micrograms", "/", "dl", "in", "epsilon", "2/3", "individuals", ",", "compared", "with", "1,037", "micrograms", "/", "dl", "in", "epsilon", "3/3", "individuals", "and", "1,108", "micrograms", "/", "dl", "in", "epsilon", "3/4", "individuals", ".", "The", "apo", "E", "polymorphism", "accounted", "for", "7.1", "%", "of", "the", "interindividual", "variation", "in", "postprandial", "retinyl", "palmitate", "response", ",", "a", "contribution", "proportionally", "greater", "than", "its", "well", "-", "known", "effect", "on", "fasting", "LDL", "-", "cholesterol", ".", "However", ",", "despite", "this", "effect", "on", "postprandial", "retinyl", "palmitate", ",", "the", "profile", "of", "postprandial", "triglyceride", "response", "was", "not", "significantly", "different", "among", "apo", "E", "genotypes", ".", "The", "profile", "of", "postprandial", "response", "was", "consistent", "between", "the", "sample", "of", "Caucasians", "and", "a", "smaller", "sample", "of", "black", "subjects", ".", "While", "these", "data", "indicate", "that", "the", "removal", "of", "remnant", "particles", "from", "circulation", "is", "delayed", "in", "subjects", "with", "the", "epsilon", "2/3", "genotype", ",", "there", "is", "no", "reported", "evidence", "that", "the", "epsilon", "2", "allele", "predisposes", "to", "coronary", "artery", "disease", "(", "CAD", ")", ".", "The", "results", "of", "this", "study", "provide", "not", "only", "a", "reliable", "estimate", "of", "the", "magnitude", "of", "the", "effect", "of", "the", "apo", "E", "polymorphism", "on", "various", "measurements", "commonly", "used", "to", "characterize", "postprandial", "lipemia", ",", "but", "also", "provide", "mechanistic", "insight", "into", "the", "effects", "of", "the", "apo", "E", "gene", "polymorphism", "on", "postprandial", "lipemia", "and", "CAD", ".", "\n" ]

[ "Gene" ]

Coronary artery disease is an umlsterm, developed countries is an umlsterm, stage is an umlsterm, coronary artery disease is an umlsterm, patients is an umlsterm, need is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, change of life is an umlsterm, treatment is an umlsterm, risk factors is an umlsterm

Herz.00250623.eng.abstr_task0

Sentence: Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory .

[ "Coronary", "artery", "disease", "is", "stoll", "the", "no", ".", "1", "killer", "in", "the", "developed", "countries", "and", "must", "thus", "be", "detected", "and", "treated", "at", "an", "earlier", "stage", ".", "If", "coronary", "artery", "disease", "is", "advanced", ",", "patients", "have", "to", "be", "examined", "regarding", "the", "need", "for", "revascularization", ".", "For", "secondary", "prevention", ",", "of", "course", ",", "an", "optimal", "change", "of", "life", "style", "and", "optimal", "medical", "treatment", "of", "risk", "factors", "is", "mandatory", "." ]

[ "umlsterm" ]

Coronary artery disease is an umlsterm, developed countries is an umlsterm, stage is an umlsterm, coronary artery disease is an umlsterm, patients is an umlsterm, need is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, change of life is an umlsterm, treatment is an umlsterm, risk factors is an umlsterm

Herz.00250623.eng.abstr_task1

Sentence: Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory . Instructions: please typing these entity words according to sentence: Coronary artery disease, developed countries, stage, coronary artery disease, patients, need, secondary, prevention, change of life, treatment, risk factors Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory .

[ "Coronary", "artery", "disease", "is", "stoll", "the", "no", ".", "1", "killer", "in", "the", "developed", "countries", "and", "must", "thus", "be", "detected", "and", "treated", "at", "an", "earlier", "stage", ".", "If", "coronary", "artery", "disease", "is", "advanced", ",", "patients", "have", "to", "be", "examined", "regarding", "the", "need", "for", "revascularization", ".", "For", "secondary", "prevention", ",", "of", "course", ",", "an", "optimal", "change", "of", "life", "style", "and", "optimal", "medical", "treatment", "of", "risk", "factors", "is", "mandatory", "." ]

[ "umlsterm" ]

Coronary artery disease, developed countries, stage, coronary artery disease, patients, need, secondary, prevention, change of life, treatment, risk factors

Herz.00250623.eng.abstr_task2

Sentence: Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

Coronary artery disease is stoll the no . 1 killer in the developed countries and must thus be detected and treated at an earlier stage . If coronary artery disease is advanced , patients have to be examined regarding the need for revascularization . For secondary prevention , of course , an optimal change of life style and optimal medical treatment of risk factors is mandatory .

[ "Coronary", "artery", "disease", "is", "stoll", "the", "no", ".", "1", "killer", "in", "the", "developed", "countries", "and", "must", "thus", "be", "detected", "and", "treated", "at", "an", "earlier", "stage", ".", "If", "coronary", "artery", "disease", "is", "advanced", ",", "patients", "have", "to", "be", "examined", "regarding", "the", "need", "for", "revascularization", ".", "For", "secondary", "prevention", ",", "of", "course", ",", "an", "optimal", "change", "of", "life", "style", "and", "optimal", "medical", "treatment", "of", "risk", "factors", "is", "mandatory", "." ]

[ "umlsterm" ]

kidney transplant is a Procedure

NCT02707809_inc_task0

Sentence: kidney transplant recipient Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Procedure

[ "B-Procedure", "I-Procedure", "O", "O" ]

kidney transplant recipient

[ "kidney", "transplant", "recipient", "\n" ]

[ "Procedure" ]

kidney transplant is a Procedure

NCT02707809_inc_task1

Sentence: kidney transplant recipient Instructions: please typing these entity words according to sentence: kidney transplant Options: Procedure

[ "B-Procedure", "I-Procedure", "O", "O" ]

kidney transplant recipient

[ "kidney", "transplant", "recipient", "\n" ]

[ "Procedure" ]

kidney transplant

NCT02707809_inc_task2

Sentence: kidney transplant recipient Instructions: please extract entity words from the input sentence

[ "B-Procedure", "I-Procedure", "O", "O" ]

kidney transplant recipient

[ "kidney", "transplant", "recipient", "\n" ]

[ "Procedure" ]

tóxicos is a UNCLEAR, sertralina is a NORMALIZABLES, ácido fólico is a NORMALIZABLES, vitamina B12 is a NORMALIZABLES, tóxicos is a UNCLEAR, aciclovir is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, venlafaxina is a NORMALIZABLES, tiapride is a NORMALIZABLES, tiapride is a NORMALIZABLES, haloperidol is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, levetirazepam is a NORMALIZABLES, corticoides is a NORMALIZABLES, hemina is a NORMALIZABLES, uroporfirinas is a NORMALIZABLES, coproporfirinas is a NORMALIZABLES, zinc is a NORMALIZABLES, hemina is a NORMALIZABLES, polimerasas is a PROTEINAS, priones is a PROTEINAS, proteína is a PROTEINAS, ceruloplasmina is a PROTEINAS, cobre is a NORMALIZABLES, anti - Hu is a PROTEINAS, anti - Yo is a PROTEINAS, anti - Ri is a PROTEINAS, anti - CV2 is a PROTEINAS, antifisina is a PROTEINAS, anti - Tr is a PROTEINAS, anti - canales de calcio is a PROTEINAS, anticuerpos anti - NMDA is a PROTEINAS, ziprasidona is a NORMALIZABLES, receptores N - metil - D - aspartato is a PROTEINAS, ECR - NMDA is a PROTEINAS, ECR - NMDA is a PROTEINAS

481_task0

Sentence: Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: UNCLEAR, NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O" ]

Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA).

[ "Mujer", "de", "29", "años", ",", "soltera", ",", "vive", "con", "sus", "padres", ",", "sin", "antecedentes", "de", "patología", "orgánica", ",", "psiquiátrica", "o", "abuso", "de", "tóxicos", ",", "ingresada", "en", "neurología", "por", "alteraciones", "de", "conducta", ",", "desorientación", "y", "falta", "de", "conexión", "con", "el", "medio", ".", "La", "familia", "refería", "que", "era", "el", "primer", "episodio", "de", "estas", "características", ",", "que", "desde", "hacía", "2", "semanas", "veían", "a", "la", "paciente", "desanimada", ",", "poco", "comunicativa", "(", "no", "identificaban", "ningún", "desencadenante", "ni", "factor", "descompensatorio", ",", "la", "relación", "con", "la", "paciente", "era", "buena", ",", "tenía", "buena", "red", "social", "de", "apoyo", ",", "buen", "desempeño", "laboral", ",", "etc", ".", ")", ",", "a", "veces", "se", "quedaba", "con", "la", "mirada", "perdida", ",", "llegando", "a", "hablar", "incoherencias", "(", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ")", ",", "no", "había", "alteración", "de", "los", "ritmos", "biológicos", ".", "Todo", "ello", "era", "motivo", "de", "gran", "agobio", "familiar", ",", "por", "lo", "que", "acudieron", "al", "médico", "de", "familia", ",", "siendo", "tratada", "como", "un", "cuadro", "depresivo", "y", "pautándosele", "sertralina", "50", "mg", "/", "día", "(", "1", "semana", "antes", "del", "ingreso", ")", ".", "La", "evolución", "fue", "tórpida", ",", "presentado", "episodios", "de", "agitación", "psicomotriz", "y", "desorientación", ",", "motivo", "por", "el", "que", "la", "familia", "decide", "llevar", "a", "la", "paciente", "a", "las", "urgencias", "de", "medicina", ".", "No", "había", "antecedentes", "familiares", "de", "enfermedad", "psiquiátrica", "u", "orgánica", "importante", ".", "En", "el", "examen", ",", "aparte", "de", "la", "desorientación", "espacio", "-", "temporal", "y", "la", "agitación", ",", "no", "se", "encontró", "nada", "llamativo", ",", "no", "presentando", "focalidad", "neurológica", ".", "\n", "Las", "analíticas", "(", "hemograma", ",", "coagulación", ",", "pruebas", "de", "función", "hepática", ",", "renal", ",", "tiroidea", ",", "orina", ",", "ácido", "fólico", "y", "vitamina", "B12", ")", "y", "tomografía", "cerebral", "fueron", "normales", ".", "Los", "tóxicos", "en", "orina", "fueron", "negativos", ".", "La", "punción", "lumbar", "(", "PL", ")", "mostró", "26", "leucocitos", "/", "mm3", ".", "En", "urgencias", "presentó", "una", "convulsión", "tónico", "-", "clónica", "generalizada", ",", "siendo", "ingresada", "con", "el", "diagnóstico", "presuntivo", "de", "encefalitis", "vírica", ",", "iniciándose", "tratamiento", "con", "aciclovir", "y", "ácido", "valproico", ".", "\n", "Durante", "su", "ingreso", "fue", "evaluada", "por", "Psiquiatría", ".", "La", "familia", "nuevamente", "refirió", "que", "la", "paciente", "se", "encontraba", "apática", "desde", "hacía", "2", "semanas", ",", "repitiendo", "que", "tenía", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ".", "Se", "la", "catalogó", "como", "una", "depresión", "psicótica", "y", "se", "pautó", "venlafaxina", "75", "mg", "/", "día", ".", "La", "serología", "para", "VIH", ",", "Brucella", ",", "Citomegalovirus", ",", "Herpes", "Simple", ",", "Sífilis", ",", "Toxoplasmosis", "y", "Epstein", "Barr", "fueron", "negativas", ".", "\n", "Durante", "la", "primera", "semana", "de", "hospitalización", "la", "paciente", "estaba", "confusa", ",", "presentaba", "soliloquios", "y", "risas", "inmotivadas", ".", "Se", "repitió", "la", "PL", "(", "34", "leucocitos", "/", "mm3", ",", "linfocitos", "100", "%", ",", "la", "serología", "y", "cultivo", "del", "líquido", "cefalorraquídeo", "(", "LCR", ")", "para", "Brucella", ",", "Lúes", "y", "Borrellia", "fueron", "negativos", ")", ".", "La", "resonancia", "magnética", "(", "RM", ")", "cerebral", "fue", "normal", ".", "Se", "suspendió", "el", "antidepresivo", "y", "se", "pautó", "tiapride", ".", "\n", "Durante", "la", "segunda", "semana", ",", "el", "electroencefalograma", "(", "EEG", ")", "mostró", "signos", "de", "encefalopatía", "lenta", "difusa", "de", "grado", "moderado", ".", "La", "paciente", "no", "respondía", "a", "órdenes", "simples", ",", "estaba", "mutista", ",", "estuporosa", ",", "por", "lo", "que", "se", "suspendió", "el", "tiapride", ",", "dejándola", "con", "haloperidol", "intramuscular", "en", "caso", "de", "agitación", ".", "Debido", "a", "la", "evolución", "tórpida", "se", "la", "ingresó", "en", "UCI", "suspendiéndose", "el", "ácido", "valproico", "e", "iniciando", "levetirazepam", ".", "La", "paciente", "comenzó", "a", "presentar", "movimientos", "involuntarios", "y", "distonías", ".", "La", "ecocardiografía", "transtorácica", "fue", "normal", ".", "Se", "añadieron", "megadosis", "de", "corticoides", "y", "hemina", "(", "por", "sospecha", "de", "porfiria", "aguda", "intermitente", ")", ".", "Debido", "a", "las", "crisis", "tónicas", "complejas", "más", "frecuentes", "se", "decide", "sedación", "e", "intubación", "endotraqueal", ".", "No", "se", "detectaron", "uroporfirinas", ",", "las", "coproporfirinas", "y", "el", "zinc", "estaban", "en", "límites", "normales", "(", "por", "lo", "que", "se", "suspendió", "la", "hemina", ")", ".", "Se", "repitió", "PL", ",", "siendo", "la", "reacción", "en", "cadena", "de", "polimerasas", "para", "micoplasma", "y", "micobacterias", "normales", ".", "\n", "Durante", "la", "cuarta", "semana", ",", "se", "retiró", "la", "sedación", ":", "respondía", "a", "órdenes", "sencillas", ",", "presentaba", "mioclonías", "faciales", "y", "movimientos", "bucolinguales", ",", "procediéndose", "a", "la", "extubación", ".", "El", "EEG", "siguió", "mostrando", "signos", "de", "encefalopatía", "difusa", ".", "Se", "descartó", "enfermedad", "por", "priones", "(", "negativo", "a", "proteína", "en", "LCR", ")", ".", "La", "ecografía", "ginecológica", "mostró", "un", "ovario", "ligeramente", "aumentado", "de", "tamaño", ".", "\n", "Durante", "la", "sexta", "semana", ",", "la", "ceruloplasmina", ",", "cobre", "sérico", "y", "ecografía", "abdominal", "fueron", "normales", ".", "La", "paciente", "estaba", "más", "consciente", "y", "reactiva", ".", "Se", "planteó", "la", "posibilidad", "de", "encefalitis", "con", "relación", "a", "teratoma", "no", "objetivado", ".", "Se", "repitió", "la", "PL", "buscando", "la", "presencia", "de", "anticuerpos", "paraneoplásicos", "(", "anti", "-", "Hu", ",", "anti", "-", "Yo", ",", "anti", "-", "Ri", ",", "anti", "-", "CV2", ",", "antifisina", ",", "anti", "-", "Tr", "y", "anti", "-", "canales", "de", "calcio", ")", ",", "que", "fueron", "negativos", ",", "excepto", "los", "anticuerpos", "anti", "-", "NMDA", ".", "Se", "llamó", "nuevamente", "a", "Psiquiatría", "por", "agitación", "psicomotriz", "e", "ideas", "delirantes", "autorreferenciales", ",", "iniciándose", "ziprasidona", "40", "mg", "/", "día", ",", "llegando", "hasta", "160", "mg", "/", "día", "con", "mejoría", "progresiva", ",", "siendo", "el", "diagnóstico", "final", "el", "de", "encefalitis", "contra", "los", "receptores", "N", "-", "metil", "-", "D", "-", "aspartato", "(", "ECR", "-", "NMDA", ")", "y", "trastorno", "psicótico", "secundario", "a", "patología", "orgánica", "(", "ECR", "-", "NMDA", ")", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR" ]

tóxicos is a UNCLEAR, sertralina is a NORMALIZABLES, ácido fólico is a NORMALIZABLES, vitamina B12 is a NORMALIZABLES, tóxicos is a UNCLEAR, aciclovir is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, venlafaxina is a NORMALIZABLES, tiapride is a NORMALIZABLES, tiapride is a NORMALIZABLES, haloperidol is a NORMALIZABLES, ácido valproico is a NORMALIZABLES, levetirazepam is a NORMALIZABLES, corticoides is a NORMALIZABLES, hemina is a NORMALIZABLES, uroporfirinas is a NORMALIZABLES, coproporfirinas is a NORMALIZABLES, zinc is a NORMALIZABLES, hemina is a NORMALIZABLES, polimerasas is a PROTEINAS, priones is a PROTEINAS, proteína is a PROTEINAS, ceruloplasmina is a PROTEINAS, cobre is a NORMALIZABLES, anti - Hu is a PROTEINAS, anti - Yo is a PROTEINAS, anti - Ri is a PROTEINAS, anti - CV2 is a PROTEINAS, antifisina is a PROTEINAS, anti - Tr is a PROTEINAS, anti - canales de calcio is a PROTEINAS, anticuerpos anti - NMDA is a PROTEINAS, ziprasidona is a NORMALIZABLES, receptores N - metil - D - aspartato is a PROTEINAS, ECR - NMDA is a PROTEINAS, ECR - NMDA is a PROTEINAS

481_task1

Sentence: Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA). Instructions: please typing these entity words according to sentence: tóxicos, sertralina, ácido fólico, vitamina B12, tóxicos, aciclovir, ácido valproico, venlafaxina, tiapride, tiapride, haloperidol, ácido valproico, levetirazepam, corticoides, hemina, uroporfirinas, coproporfirinas, zinc, hemina, polimerasas, priones, proteína, ceruloplasmina, cobre, anti - Hu, anti - Yo, anti - Ri, anti - CV2, antifisina, anti - Tr, anti - canales de calcio, anticuerpos anti - NMDA, ziprasidona, receptores N - metil - D - aspartato, ECR - NMDA, ECR - NMDA Options: UNCLEAR, NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O" ]

Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA).

[ "Mujer", "de", "29", "años", ",", "soltera", ",", "vive", "con", "sus", "padres", ",", "sin", "antecedentes", "de", "patología", "orgánica", ",", "psiquiátrica", "o", "abuso", "de", "tóxicos", ",", "ingresada", "en", "neurología", "por", "alteraciones", "de", "conducta", ",", "desorientación", "y", "falta", "de", "conexión", "con", "el", "medio", ".", "La", "familia", "refería", "que", "era", "el", "primer", "episodio", "de", "estas", "características", ",", "que", "desde", "hacía", "2", "semanas", "veían", "a", "la", "paciente", "desanimada", ",", "poco", "comunicativa", "(", "no", "identificaban", "ningún", "desencadenante", "ni", "factor", "descompensatorio", ",", "la", "relación", "con", "la", "paciente", "era", "buena", ",", "tenía", "buena", "red", "social", "de", "apoyo", ",", "buen", "desempeño", "laboral", ",", "etc", ".", ")", ",", "a", "veces", "se", "quedaba", "con", "la", "mirada", "perdida", ",", "llegando", "a", "hablar", "incoherencias", "(", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ")", ",", "no", "había", "alteración", "de", "los", "ritmos", "biológicos", ".", "Todo", "ello", "era", "motivo", "de", "gran", "agobio", "familiar", ",", "por", "lo", "que", "acudieron", "al", "médico", "de", "familia", ",", "siendo", "tratada", "como", "un", "cuadro", "depresivo", "y", "pautándosele", "sertralina", "50", "mg", "/", "día", "(", "1", "semana", "antes", "del", "ingreso", ")", ".", "La", "evolución", "fue", "tórpida", ",", "presentado", "episodios", "de", "agitación", "psicomotriz", "y", "desorientación", ",", "motivo", "por", "el", "que", "la", "familia", "decide", "llevar", "a", "la", "paciente", "a", "las", "urgencias", "de", "medicina", ".", "No", "había", "antecedentes", "familiares", "de", "enfermedad", "psiquiátrica", "u", "orgánica", "importante", ".", "En", "el", "examen", ",", "aparte", "de", "la", "desorientación", "espacio", "-", "temporal", "y", "la", "agitación", ",", "no", "se", "encontró", "nada", "llamativo", ",", "no", "presentando", "focalidad", "neurológica", ".", "\n", "Las", "analíticas", "(", "hemograma", ",", "coagulación", ",", "pruebas", "de", "función", "hepática", ",", "renal", ",", "tiroidea", ",", "orina", ",", "ácido", "fólico", "y", "vitamina", "B12", ")", "y", "tomografía", "cerebral", "fueron", "normales", ".", "Los", "tóxicos", "en", "orina", "fueron", "negativos", ".", "La", "punción", "lumbar", "(", "PL", ")", "mostró", "26", "leucocitos", "/", "mm3", ".", "En", "urgencias", "presentó", "una", "convulsión", "tónico", "-", "clónica", "generalizada", ",", "siendo", "ingresada", "con", "el", "diagnóstico", "presuntivo", "de", "encefalitis", "vírica", ",", "iniciándose", "tratamiento", "con", "aciclovir", "y", "ácido", "valproico", ".", "\n", "Durante", "su", "ingreso", "fue", "evaluada", "por", "Psiquiatría", ".", "La", "familia", "nuevamente", "refirió", "que", "la", "paciente", "se", "encontraba", "apática", "desde", "hacía", "2", "semanas", ",", "repitiendo", "que", "tenía", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ".", "Se", "la", "catalogó", "como", "una", "depresión", "psicótica", "y", "se", "pautó", "venlafaxina", "75", "mg", "/", "día", ".", "La", "serología", "para", "VIH", ",", "Brucella", ",", "Citomegalovirus", ",", "Herpes", "Simple", ",", "Sífilis", ",", "Toxoplasmosis", "y", "Epstein", "Barr", "fueron", "negativas", ".", "\n", "Durante", "la", "primera", "semana", "de", "hospitalización", "la", "paciente", "estaba", "confusa", ",", "presentaba", "soliloquios", "y", "risas", "inmotivadas", ".", "Se", "repitió", "la", "PL", "(", "34", "leucocitos", "/", "mm3", ",", "linfocitos", "100", "%", ",", "la", "serología", "y", "cultivo", "del", "líquido", "cefalorraquídeo", "(", "LCR", ")", "para", "Brucella", ",", "Lúes", "y", "Borrellia", "fueron", "negativos", ")", ".", "La", "resonancia", "magnética", "(", "RM", ")", "cerebral", "fue", "normal", ".", "Se", "suspendió", "el", "antidepresivo", "y", "se", "pautó", "tiapride", ".", "\n", "Durante", "la", "segunda", "semana", ",", "el", "electroencefalograma", "(", "EEG", ")", "mostró", "signos", "de", "encefalopatía", "lenta", "difusa", "de", "grado", "moderado", ".", "La", "paciente", "no", "respondía", "a", "órdenes", "simples", ",", "estaba", "mutista", ",", "estuporosa", ",", "por", "lo", "que", "se", "suspendió", "el", "tiapride", ",", "dejándola", "con", "haloperidol", "intramuscular", "en", "caso", "de", "agitación", ".", "Debido", "a", "la", "evolución", "tórpida", "se", "la", "ingresó", "en", "UCI", "suspendiéndose", "el", "ácido", "valproico", "e", "iniciando", "levetirazepam", ".", "La", "paciente", "comenzó", "a", "presentar", "movimientos", "involuntarios", "y", "distonías", ".", "La", "ecocardiografía", "transtorácica", "fue", "normal", ".", "Se", "añadieron", "megadosis", "de", "corticoides", "y", "hemina", "(", "por", "sospecha", "de", "porfiria", "aguda", "intermitente", ")", ".", "Debido", "a", "las", "crisis", "tónicas", "complejas", "más", "frecuentes", "se", "decide", "sedación", "e", "intubación", "endotraqueal", ".", "No", "se", "detectaron", "uroporfirinas", ",", "las", "coproporfirinas", "y", "el", "zinc", "estaban", "en", "límites", "normales", "(", "por", "lo", "que", "se", "suspendió", "la", "hemina", ")", ".", "Se", "repitió", "PL", ",", "siendo", "la", "reacción", "en", "cadena", "de", "polimerasas", "para", "micoplasma", "y", "micobacterias", "normales", ".", "\n", "Durante", "la", "cuarta", "semana", ",", "se", "retiró", "la", "sedación", ":", "respondía", "a", "órdenes", "sencillas", ",", "presentaba", "mioclonías", "faciales", "y", "movimientos", "bucolinguales", ",", "procediéndose", "a", "la", "extubación", ".", "El", "EEG", "siguió", "mostrando", "signos", "de", "encefalopatía", "difusa", ".", "Se", "descartó", "enfermedad", "por", "priones", "(", "negativo", "a", "proteína", "en", "LCR", ")", ".", "La", "ecografía", "ginecológica", "mostró", "un", "ovario", "ligeramente", "aumentado", "de", "tamaño", ".", "\n", "Durante", "la", "sexta", "semana", ",", "la", "ceruloplasmina", ",", "cobre", "sérico", "y", "ecografía", "abdominal", "fueron", "normales", ".", "La", "paciente", "estaba", "más", "consciente", "y", "reactiva", ".", "Se", "planteó", "la", "posibilidad", "de", "encefalitis", "con", "relación", "a", "teratoma", "no", "objetivado", ".", "Se", "repitió", "la", "PL", "buscando", "la", "presencia", "de", "anticuerpos", "paraneoplásicos", "(", "anti", "-", "Hu", ",", "anti", "-", "Yo", ",", "anti", "-", "Ri", ",", "anti", "-", "CV2", ",", "antifisina", ",", "anti", "-", "Tr", "y", "anti", "-", "canales", "de", "calcio", ")", ",", "que", "fueron", "negativos", ",", "excepto", "los", "anticuerpos", "anti", "-", "NMDA", ".", "Se", "llamó", "nuevamente", "a", "Psiquiatría", "por", "agitación", "psicomotriz", "e", "ideas", "delirantes", "autorreferenciales", ",", "iniciándose", "ziprasidona", "40", "mg", "/", "día", ",", "llegando", "hasta", "160", "mg", "/", "día", "con", "mejoría", "progresiva", ",", "siendo", "el", "diagnóstico", "final", "el", "de", "encefalitis", "contra", "los", "receptores", "N", "-", "metil", "-", "D", "-", "aspartato", "(", "ECR", "-", "NMDA", ")", "y", "trastorno", "psicótico", "secundario", "a", "patología", "orgánica", "(", "ECR", "-", "NMDA", ")", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR" ]

tóxicos, sertralina, ácido fólico, vitamina B12, tóxicos, aciclovir, ácido valproico, venlafaxina, tiapride, tiapride, haloperidol, ácido valproico, levetirazepam, corticoides, hemina, uroporfirinas, coproporfirinas, zinc, hemina, polimerasas, priones, proteína, ceruloplasmina, cobre, anti - Hu, anti - Yo, anti - Ri, anti - CV2, antifisina, anti - Tr, anti - canales de calcio, anticuerpos anti - NMDA, ziprasidona, receptores N - metil - D - aspartato, ECR - NMDA, ECR - NMDA

481_task2

Sentence: Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O" ]

Mujer de 29 años, soltera, vive con sus padres, sin antecedentes de patología orgánica, psiquiátrica o abuso de tóxicos, ingresada en neurología por alteraciones de conducta, desorientación y falta de conexión con el medio. La familia refería que era el primer episodio de estas características, que desde hacía 2 semanas veían a la paciente desanimada, poco comunicativa (no identificaban ningún desencadenante ni factor descompensatorio, la relación con la paciente era buena, tenía buena red social de apoyo, buen desempeño laboral, etc.), a veces se quedaba con la mirada perdida, llegando a hablar incoherencias ("las venas de la cabeza secas"), no había alteración de los ritmos biológicos. Todo ello era motivo de gran agobio familiar, por lo que acudieron al médico de familia, siendo tratada como un cuadro depresivo y pautándosele sertralina 50 mg/día (1 semana antes del ingreso). La evolución fue tórpida, presentado episodios de agitación psicomotriz y desorientación, motivo por el que la familia decide llevar a la paciente a las urgencias de medicina. No había antecedentes familiares de enfermedad psiquiátrica u orgánica importante. En el examen, aparte de la desorientación espacio-temporal y la agitación, no se encontró nada llamativo, no presentando focalidad neurológica. Las analíticas (hemograma, coagulación, pruebas de función hepática, renal, tiroidea, orina, ácido fólico y vitamina B12) y tomografía cerebral fueron normales. Los tóxicos en orina fueron negativos. La punción lumbar (PL) mostró 26 leucocitos/mm3. En urgencias presentó una convulsión tónico-clónica generalizada, siendo ingresada con el diagnóstico presuntivo de encefalitis vírica, iniciándose tratamiento con aciclovir y ácido valproico. Durante su ingreso fue evaluada por Psiquiatría. La familia nuevamente refirió que la paciente se encontraba apática desde hacía 2 semanas, repitiendo que tenía "las venas de la cabeza secas". Se la catalogó como una depresión psicótica y se pautó venlafaxina 75 mg/día. La serología para VIH, Brucella, Citomegalovirus, Herpes Simple, Sífilis, Toxoplasmosis y Epstein Barr fueron negativas. Durante la primera semana de hospitalización la paciente estaba confusa, presentaba soliloquios y risas inmotivadas. Se repitió la PL (34 leucocitos/mm3, linfocitos 100 %, la serología y cultivo del líquido cefalorraquídeo (LCR) para Brucella, Lúes y Borrellia fueron negativos). La resonancia magnética (RM) cerebral fue normal. Se suspendió el antidepresivo y se pautó tiapride. Durante la segunda semana, el electroencefalograma (EEG) mostró signos de encefalopatía lenta difusa de grado moderado. La paciente no respondía a órdenes simples, estaba mutista, estuporosa, por lo que se suspendió el tiapride, dejándola con haloperidol intramuscular en caso de agitación. Debido a la evolución tórpida se la ingresó en UCI suspendiéndose el ácido valproico e iniciando levetirazepam. La paciente comenzó a presentar movimientos involuntarios y distonías. La ecocardiografía transtorácica fue normal. Se añadieron megadosis de corticoides y hemina (por sospecha de porfiria aguda intermitente). Debido a las crisis tónicas complejas más frecuentes se decide sedación e intubación endotraqueal. No se detectaron uroporfirinas, las coproporfirinas y el zinc estaban en límites normales (por lo que se suspendió la hemina). Se repitió PL, siendo la reacción en cadena de polimerasas para micoplasma y micobacterias normales. Durante la cuarta semana, se retiró la sedación: respondía a órdenes sencillas, presentaba mioclonías faciales y movimientos bucolinguales, procediéndose a la extubación. El EEG siguió mostrando signos de encefalopatía difusa. Se descartó enfermedad por priones (negativo a proteína en LCR). La ecografía ginecológica mostró un ovario ligeramente aumentado de tamaño. Durante la sexta semana, la ceruloplasmina, cobre sérico y ecografía abdominal fueron normales. La paciente estaba más consciente y reactiva. Se planteó la posibilidad de encefalitis con relación a teratoma no objetivado. Se repitió la PL buscando la presencia de anticuerpos paraneoplásicos (anti-Hu, anti-Yo, anti-Ri, anti-CV2, antifisina, anti-Tr y anti-canales de calcio), que fueron negativos, excepto los anticuerpos anti-NMDA. Se llamó nuevamente a Psiquiatría por agitación psicomotriz e ideas delirantes autorreferenciales, iniciándose ziprasidona 40 mg/día, llegando hasta 160 mg/día con mejoría progresiva, siendo el diagnóstico final el de encefalitis contra los receptores N-metil-D-aspartato (ECR-NMDA) y trastorno psicótico secundario a patología orgánica (ECR-NMDA).

[ "Mujer", "de", "29", "años", ",", "soltera", ",", "vive", "con", "sus", "padres", ",", "sin", "antecedentes", "de", "patología", "orgánica", ",", "psiquiátrica", "o", "abuso", "de", "tóxicos", ",", "ingresada", "en", "neurología", "por", "alteraciones", "de", "conducta", ",", "desorientación", "y", "falta", "de", "conexión", "con", "el", "medio", ".", "La", "familia", "refería", "que", "era", "el", "primer", "episodio", "de", "estas", "características", ",", "que", "desde", "hacía", "2", "semanas", "veían", "a", "la", "paciente", "desanimada", ",", "poco", "comunicativa", "(", "no", "identificaban", "ningún", "desencadenante", "ni", "factor", "descompensatorio", ",", "la", "relación", "con", "la", "paciente", "era", "buena", ",", "tenía", "buena", "red", "social", "de", "apoyo", ",", "buen", "desempeño", "laboral", ",", "etc", ".", ")", ",", "a", "veces", "se", "quedaba", "con", "la", "mirada", "perdida", ",", "llegando", "a", "hablar", "incoherencias", "(", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ")", ",", "no", "había", "alteración", "de", "los", "ritmos", "biológicos", ".", "Todo", "ello", "era", "motivo", "de", "gran", "agobio", "familiar", ",", "por", "lo", "que", "acudieron", "al", "médico", "de", "familia", ",", "siendo", "tratada", "como", "un", "cuadro", "depresivo", "y", "pautándosele", "sertralina", "50", "mg", "/", "día", "(", "1", "semana", "antes", "del", "ingreso", ")", ".", "La", "evolución", "fue", "tórpida", ",", "presentado", "episodios", "de", "agitación", "psicomotriz", "y", "desorientación", ",", "motivo", "por", "el", "que", "la", "familia", "decide", "llevar", "a", "la", "paciente", "a", "las", "urgencias", "de", "medicina", ".", "No", "había", "antecedentes", "familiares", "de", "enfermedad", "psiquiátrica", "u", "orgánica", "importante", ".", "En", "el", "examen", ",", "aparte", "de", "la", "desorientación", "espacio", "-", "temporal", "y", "la", "agitación", ",", "no", "se", "encontró", "nada", "llamativo", ",", "no", "presentando", "focalidad", "neurológica", ".", "\n", "Las", "analíticas", "(", "hemograma", ",", "coagulación", ",", "pruebas", "de", "función", "hepática", ",", "renal", ",", "tiroidea", ",", "orina", ",", "ácido", "fólico", "y", "vitamina", "B12", ")", "y", "tomografía", "cerebral", "fueron", "normales", ".", "Los", "tóxicos", "en", "orina", "fueron", "negativos", ".", "La", "punción", "lumbar", "(", "PL", ")", "mostró", "26", "leucocitos", "/", "mm3", ".", "En", "urgencias", "presentó", "una", "convulsión", "tónico", "-", "clónica", "generalizada", ",", "siendo", "ingresada", "con", "el", "diagnóstico", "presuntivo", "de", "encefalitis", "vírica", ",", "iniciándose", "tratamiento", "con", "aciclovir", "y", "ácido", "valproico", ".", "\n", "Durante", "su", "ingreso", "fue", "evaluada", "por", "Psiquiatría", ".", "La", "familia", "nuevamente", "refirió", "que", "la", "paciente", "se", "encontraba", "apática", "desde", "hacía", "2", "semanas", ",", "repitiendo", "que", "tenía", "\"", "las", "venas", "de", "la", "cabeza", "secas", "\"", ".", "Se", "la", "catalogó", "como", "una", "depresión", "psicótica", "y", "se", "pautó", "venlafaxina", "75", "mg", "/", "día", ".", "La", "serología", "para", "VIH", ",", "Brucella", ",", "Citomegalovirus", ",", "Herpes", "Simple", ",", "Sífilis", ",", "Toxoplasmosis", "y", "Epstein", "Barr", "fueron", "negativas", ".", "\n", "Durante", "la", "primera", "semana", "de", "hospitalización", "la", "paciente", "estaba", "confusa", ",", "presentaba", "soliloquios", "y", "risas", "inmotivadas", ".", "Se", "repitió", "la", "PL", "(", "34", "leucocitos", "/", "mm3", ",", "linfocitos", "100", "%", ",", "la", "serología", "y", "cultivo", "del", "líquido", "cefalorraquídeo", "(", "LCR", ")", "para", "Brucella", ",", "Lúes", "y", "Borrellia", "fueron", "negativos", ")", ".", "La", "resonancia", "magnética", "(", "RM", ")", "cerebral", "fue", "normal", ".", "Se", "suspendió", "el", "antidepresivo", "y", "se", "pautó", "tiapride", ".", "\n", "Durante", "la", "segunda", "semana", ",", "el", "electroencefalograma", "(", "EEG", ")", "mostró", "signos", "de", "encefalopatía", "lenta", "difusa", "de", "grado", "moderado", ".", "La", "paciente", "no", "respondía", "a", "órdenes", "simples", ",", "estaba", "mutista", ",", "estuporosa", ",", "por", "lo", "que", "se", "suspendió", "el", "tiapride", ",", "dejándola", "con", "haloperidol", "intramuscular", "en", "caso", "de", "agitación", ".", "Debido", "a", "la", "evolución", "tórpida", "se", "la", "ingresó", "en", "UCI", "suspendiéndose", "el", "ácido", "valproico", "e", "iniciando", "levetirazepam", ".", "La", "paciente", "comenzó", "a", "presentar", "movimientos", "involuntarios", "y", "distonías", ".", "La", "ecocardiografía", "transtorácica", "fue", "normal", ".", "Se", "añadieron", "megadosis", "de", "corticoides", "y", "hemina", "(", "por", "sospecha", "de", "porfiria", "aguda", "intermitente", ")", ".", "Debido", "a", "las", "crisis", "tónicas", "complejas", "más", "frecuentes", "se", "decide", "sedación", "e", "intubación", "endotraqueal", ".", "No", "se", "detectaron", "uroporfirinas", ",", "las", "coproporfirinas", "y", "el", "zinc", "estaban", "en", "límites", "normales", "(", "por", "lo", "que", "se", "suspendió", "la", "hemina", ")", ".", "Se", "repitió", "PL", ",", "siendo", "la", "reacción", "en", "cadena", "de", "polimerasas", "para", "micoplasma", "y", "micobacterias", "normales", ".", "\n", "Durante", "la", "cuarta", "semana", ",", "se", "retiró", "la", "sedación", ":", "respondía", "a", "órdenes", "sencillas", ",", "presentaba", "mioclonías", "faciales", "y", "movimientos", "bucolinguales", ",", "procediéndose", "a", "la", "extubación", ".", "El", "EEG", "siguió", "mostrando", "signos", "de", "encefalopatía", "difusa", ".", "Se", "descartó", "enfermedad", "por", "priones", "(", "negativo", "a", "proteína", "en", "LCR", ")", ".", "La", "ecografía", "ginecológica", "mostró", "un", "ovario", "ligeramente", "aumentado", "de", "tamaño", ".", "\n", "Durante", "la", "sexta", "semana", ",", "la", "ceruloplasmina", ",", "cobre", "sérico", "y", "ecografía", "abdominal", "fueron", "normales", ".", "La", "paciente", "estaba", "más", "consciente", "y", "reactiva", ".", "Se", "planteó", "la", "posibilidad", "de", "encefalitis", "con", "relación", "a", "teratoma", "no", "objetivado", ".", "Se", "repitió", "la", "PL", "buscando", "la", "presencia", "de", "anticuerpos", "paraneoplásicos", "(", "anti", "-", "Hu", ",", "anti", "-", "Yo", ",", "anti", "-", "Ri", ",", "anti", "-", "CV2", ",", "antifisina", ",", "anti", "-", "Tr", "y", "anti", "-", "canales", "de", "calcio", ")", ",", "que", "fueron", "negativos", ",", "excepto", "los", "anticuerpos", "anti", "-", "NMDA", ".", "Se", "llamó", "nuevamente", "a", "Psiquiatría", "por", "agitación", "psicomotriz", "e", "ideas", "delirantes", "autorreferenciales", ",", "iniciándose", "ziprasidona", "40", "mg", "/", "día", ",", "llegando", "hasta", "160", "mg", "/", "día", "con", "mejoría", "progresiva", ",", "siendo", "el", "diagnóstico", "final", "el", "de", "encefalitis", "contra", "los", "receptores", "N", "-", "metil", "-", "D", "-", "aspartato", "(", "ECR", "-", "NMDA", ")", "y", "trastorno", "psicótico", "secundario", "a", "patología", "orgánica", "(", "ECR", "-", "NMDA", ")", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR" ]

Pembrolizumab is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, previously treated , PD - L1-positive , advanced non - small - cell lung cancer is a Participant_Condition, pembrolizumab is a Intervention_Pharmacological, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells is a Participant_Condition, survival and progression - free survival is a Outcome_Mortality, 1034 patients is a Participant_Sample-size, median overall survival is a Outcome_Mortality, Overall survival is a Outcome_Mortality, Median progression - free survival is a Outcome_Mortality, Grade 3 - 5 treatment - related adverse events is a Outcome_Adverse-effects

73209_task0

Sentence: Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Sample-size

[ "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co .

[ "Pembrolizumab", "versus", "docetaxel", "for", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "KEYNOTE-010", ")", ":", "a", "randomised", "controlled", "trial", ".", "BACKGROUND", "Despite", "recent", "advances", "in", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ",", "there", "remains", "a", "need", "for", "effective", "treatments", "for", "progressive", "disease", ".", "We", "assessed", "the", "efficacy", "of", "pembrolizumab", "for", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "METHODS", "We", "did", "this", "randomised", ",", "open", "-", "label", ",", "phase", "2/3", "study", "at", "202", "academic", "medical", "centres", "in", "24", "countries", ".", "Patients", "with", "previously", "treated", "non", "-", "small", "-", "cell", "lung", "cancer", "with", "PD", "-", "L1", "expression", "on", "at", "least", "1", "%", "of", "tumour", "cells", "were", "randomly", "assigned", "(", "1:1:1", ")", "in", "blocks", "of", "six", "per", "stratum", "with", "an", "interactive", "voice", "-", "response", "system", "to", "receive", "pembrolizumab", "2", "mg", "/", "kg", ",", "pembrolizumab", "10", "mg", "/", "kg", ",", "or", "docetaxel", "75", "mg", "/", "m", "(", "2", ")", "every", "3", "weeks", ".", "The", "primary", "endpoints", "were", "overall", "survival", "and", "progression", "-", "free", "survival", "both", "in", "the", "total", "population", "and", "in", "patients", "with", "PD", "-", "L1", "expression", "on", "at", "least", "50", "%", "of", "tumour", "cells", ".", "We", "used", "a", "threshold", "for", "significance", "of", "p", "<", "0.00825", "(", "one", "-", "sided", ")", "for", "the", "analysis", "of", "overall", "survival", "and", "a", "threshold", "of", "p", "<", "0.001", "for", "progression", "-", "free", "survival", ".", "This", "trial", "is", "registered", "at", "ClinicalTrials.gov", ",", "number", "NCT01905657", ".", "FINDINGS", "Between", "Aug", "28", ",", "2013", ",", "and", "Feb", "27", ",", "2015", ",", "we", "enrolled", "1034", "patients", ":", "345", "allocated", "to", "pembrolizumab", "2", "mg", "/", "kg", ",", "346", "allocated", "to", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "343", "allocated", "to", "docetaxel", ".", "By", "Sept", "30", ",", "2015", ",", "521", "patients", "had", "died", ".", "In", "the", "total", "population", ",", "median", "overall", "survival", "was", "10.4", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "12.7", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "8.5", "months", "with", "docetaxel", ".", "Overall", "survival", "was", "significantly", "longer", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "hazard", "ratio", "[", "HR", "]", "0.71", ",", "95", "%", "CI", "0.58", "-", "0.88", ";", "p=0.0008", ")", "and", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "0.61", ",", "0.49", "-", "0.75", ";", "p", "<", "0.0001", ")", ".", "Median", "progression", "-", "free", "survival", "was", "3.9", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "4.0", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "4.0", "months", "with", "docetaxel", ",", "with", "no", "significant", "difference", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "0.88", ",", "0.74", "-", "1.05", ";", "p=0.07", ")", "or", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "HR", "0.79", ",", "95", "%", "CI", "0.66", "-", "0.94", ";", "p=0.004", ")", ".", "Among", "patients", "with", "at", "least", "50", "%", "of", "tumour", "cells", "expressing", "PD", "-", "L1", ",", "overall", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "14.9", "months", "vs", "8.2", "months", ";", "HR", "0.54", ",", "95", "%", "CI", "0.38", "-", "0.77", ";", "p=0.0002", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "17.3", "months", "vs", "8.2", "months", ";", "0.50", ",", "0.36", "-", "0.70", ";", "p", "<", "0.0001", ")", ".", "Likewise", ",", "for", "this", "patient", "population", ",", "progression", "-", "free", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "5.0", "months", "vs", "4.1", "months", ";", "HR", "0.59", ",", "95", "%", "CI", "0.44", "-", "0.78", ";", "p=0.0001", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "5.2", "months", "vs", "4.1", "months", ";", "0.59", ",", "0.45", "-", "0.78", ";", "p", "<", "0.0001", ")", ".", "Grade", "3", "-", "5", "treatment", "-", "related", "adverse", "events", "were", "less", "common", "with", "pembrolizumab", "than", "with", "docetaxel", "(", "43", "[", "13", "%", "]", "of", "339", "patients", "given", "2", "mg", "/", "kg", ",", "55", "[", "16", "%", "]", "of", "343", "given", "10", "mg", "/", "kg", ",", "and", "109", "[", "35", "%", "]", "of", "309", "given", "docetaxel", ")", ".", "INTERPRETATION", "Pembrolizumab", "prolongs", "overall", "survival", "and", "has", "a", "favourable", "benefit", "-", "to", "-", "risk", "profile", "in", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "These", "data", "establish", "pembrolizumab", "as", "a", "new", "treatment", "option", "for", "this", "population", "and", "validate", "the", "use", "of", "PD", "-", "L1", "selection", ".", "FUNDING", "Merck", "&", "Co", "." ]

[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]

Pembrolizumab is a Intervention_Pharmacological, docetaxel is a Intervention_Pharmacological, previously treated , PD - L1-positive , advanced non - small - cell lung cancer is a Participant_Condition, pembrolizumab is a Intervention_Pharmacological, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells is a Participant_Condition, survival and progression - free survival is a Outcome_Mortality, 1034 patients is a Participant_Sample-size, median overall survival is a Outcome_Mortality, Overall survival is a Outcome_Mortality, Median progression - free survival is a Outcome_Mortality, Grade 3 - 5 treatment - related adverse events is a Outcome_Adverse-effects

73209_task1

Sentence: Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co . Instructions: please typing these entity words according to sentence: Pembrolizumab, docetaxel, previously treated , PD - L1-positive , advanced non - small - cell lung cancer, pembrolizumab, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells, survival and progression - free survival, 1034 patients, median overall survival, Overall survival, Median progression - free survival, Grade 3 - 5 treatment - related adverse events Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Participant_Sample-size

[ "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co .

[ "Pembrolizumab", "versus", "docetaxel", "for", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "KEYNOTE-010", ")", ":", "a", "randomised", "controlled", "trial", ".", "BACKGROUND", "Despite", "recent", "advances", "in", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ",", "there", "remains", "a", "need", "for", "effective", "treatments", "for", "progressive", "disease", ".", "We", "assessed", "the", "efficacy", "of", "pembrolizumab", "for", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "METHODS", "We", "did", "this", "randomised", ",", "open", "-", "label", ",", "phase", "2/3", "study", "at", "202", "academic", "medical", "centres", "in", "24", "countries", ".", "Patients", "with", "previously", "treated", "non", "-", "small", "-", "cell", "lung", "cancer", "with", "PD", "-", "L1", "expression", "on", "at", "least", "1", "%", "of", "tumour", "cells", "were", "randomly", "assigned", "(", "1:1:1", ")", "in", "blocks", "of", "six", "per", "stratum", "with", "an", "interactive", "voice", "-", "response", "system", "to", "receive", "pembrolizumab", "2", "mg", "/", "kg", ",", "pembrolizumab", "10", "mg", "/", "kg", ",", "or", "docetaxel", "75", "mg", "/", "m", "(", "2", ")", "every", "3", "weeks", ".", "The", "primary", "endpoints", "were", "overall", "survival", "and", "progression", "-", "free", "survival", "both", "in", "the", "total", "population", "and", "in", "patients", "with", "PD", "-", "L1", "expression", "on", "at", "least", "50", "%", "of", "tumour", "cells", ".", "We", "used", "a", "threshold", "for", "significance", "of", "p", "<", "0.00825", "(", "one", "-", "sided", ")", "for", "the", "analysis", "of", "overall", "survival", "and", "a", "threshold", "of", "p", "<", "0.001", "for", "progression", "-", "free", "survival", ".", "This", "trial", "is", "registered", "at", "ClinicalTrials.gov", ",", "number", "NCT01905657", ".", "FINDINGS", "Between", "Aug", "28", ",", "2013", ",", "and", "Feb", "27", ",", "2015", ",", "we", "enrolled", "1034", "patients", ":", "345", "allocated", "to", "pembrolizumab", "2", "mg", "/", "kg", ",", "346", "allocated", "to", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "343", "allocated", "to", "docetaxel", ".", "By", "Sept", "30", ",", "2015", ",", "521", "patients", "had", "died", ".", "In", "the", "total", "population", ",", "median", "overall", "survival", "was", "10.4", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "12.7", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "8.5", "months", "with", "docetaxel", ".", "Overall", "survival", "was", "significantly", "longer", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "hazard", "ratio", "[", "HR", "]", "0.71", ",", "95", "%", "CI", "0.58", "-", "0.88", ";", "p=0.0008", ")", "and", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "0.61", ",", "0.49", "-", "0.75", ";", "p", "<", "0.0001", ")", ".", "Median", "progression", "-", "free", "survival", "was", "3.9", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "4.0", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "4.0", "months", "with", "docetaxel", ",", "with", "no", "significant", "difference", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "0.88", ",", "0.74", "-", "1.05", ";", "p=0.07", ")", "or", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "HR", "0.79", ",", "95", "%", "CI", "0.66", "-", "0.94", ";", "p=0.004", ")", ".", "Among", "patients", "with", "at", "least", "50", "%", "of", "tumour", "cells", "expressing", "PD", "-", "L1", ",", "overall", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "14.9", "months", "vs", "8.2", "months", ";", "HR", "0.54", ",", "95", "%", "CI", "0.38", "-", "0.77", ";", "p=0.0002", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "17.3", "months", "vs", "8.2", "months", ";", "0.50", ",", "0.36", "-", "0.70", ";", "p", "<", "0.0001", ")", ".", "Likewise", ",", "for", "this", "patient", "population", ",", "progression", "-", "free", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "5.0", "months", "vs", "4.1", "months", ";", "HR", "0.59", ",", "95", "%", "CI", "0.44", "-", "0.78", ";", "p=0.0001", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "5.2", "months", "vs", "4.1", "months", ";", "0.59", ",", "0.45", "-", "0.78", ";", "p", "<", "0.0001", ")", ".", "Grade", "3", "-", "5", "treatment", "-", "related", "adverse", "events", "were", "less", "common", "with", "pembrolizumab", "than", "with", "docetaxel", "(", "43", "[", "13", "%", "]", "of", "339", "patients", "given", "2", "mg", "/", "kg", ",", "55", "[", "16", "%", "]", "of", "343", "given", "10", "mg", "/", "kg", ",", "and", "109", "[", "35", "%", "]", "of", "309", "given", "docetaxel", ")", ".", "INTERPRETATION", "Pembrolizumab", "prolongs", "overall", "survival", "and", "has", "a", "favourable", "benefit", "-", "to", "-", "risk", "profile", "in", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "These", "data", "establish", "pembrolizumab", "as", "a", "new", "treatment", "option", "for", "this", "population", "and", "validate", "the", "use", "of", "PD", "-", "L1", "selection", ".", "FUNDING", "Merck", "&", "Co", "." ]

[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]

Pembrolizumab, docetaxel, previously treated , PD - L1-positive , advanced non - small - cell lung cancer, pembrolizumab, Patients with previously treated non - small - cell lung cancer with PD - L1 expression on at least 1 % of tumour cells, survival and progression - free survival, 1034 patients, median overall survival, Overall survival, Median progression - free survival, Grade 3 - 5 treatment - related adverse events

73209_task2

Sentence: Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co .

[ "Pembrolizumab", "versus", "docetaxel", "for", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "KEYNOTE-010", ")", ":", "a", "randomised", "controlled", "trial", ".", "BACKGROUND", "Despite", "recent", "advances", "in", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ",", "there", "remains", "a", "need", "for", "effective", "treatments", "for", "progressive", "disease", ".", "We", "assessed", "the", "efficacy", "of", "pembrolizumab", "for", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "METHODS", "We", "did", "this", "randomised", ",", "open", "-", "label", ",", "phase", "2/3", "study", "at", "202", "academic", "medical", "centres", "in", "24", "countries", ".", "Patients", "with", "previously", "treated", "non", "-", "small", "-", "cell", "lung", "cancer", "with", "PD", "-", "L1", "expression", "on", "at", "least", "1", "%", "of", "tumour", "cells", "were", "randomly", "assigned", "(", "1:1:1", ")", "in", "blocks", "of", "six", "per", "stratum", "with", "an", "interactive", "voice", "-", "response", "system", "to", "receive", "pembrolizumab", "2", "mg", "/", "kg", ",", "pembrolizumab", "10", "mg", "/", "kg", ",", "or", "docetaxel", "75", "mg", "/", "m", "(", "2", ")", "every", "3", "weeks", ".", "The", "primary", "endpoints", "were", "overall", "survival", "and", "progression", "-", "free", "survival", "both", "in", "the", "total", "population", "and", "in", "patients", "with", "PD", "-", "L1", "expression", "on", "at", "least", "50", "%", "of", "tumour", "cells", ".", "We", "used", "a", "threshold", "for", "significance", "of", "p", "<", "0.00825", "(", "one", "-", "sided", ")", "for", "the", "analysis", "of", "overall", "survival", "and", "a", "threshold", "of", "p", "<", "0.001", "for", "progression", "-", "free", "survival", ".", "This", "trial", "is", "registered", "at", "ClinicalTrials.gov", ",", "number", "NCT01905657", ".", "FINDINGS", "Between", "Aug", "28", ",", "2013", ",", "and", "Feb", "27", ",", "2015", ",", "we", "enrolled", "1034", "patients", ":", "345", "allocated", "to", "pembrolizumab", "2", "mg", "/", "kg", ",", "346", "allocated", "to", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "343", "allocated", "to", "docetaxel", ".", "By", "Sept", "30", ",", "2015", ",", "521", "patients", "had", "died", ".", "In", "the", "total", "population", ",", "median", "overall", "survival", "was", "10.4", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "12.7", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "8.5", "months", "with", "docetaxel", ".", "Overall", "survival", "was", "significantly", "longer", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "hazard", "ratio", "[", "HR", "]", "0.71", ",", "95", "%", "CI", "0.58", "-", "0.88", ";", "p=0.0008", ")", "and", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "0.61", ",", "0.49", "-", "0.75", ";", "p", "<", "0.0001", ")", ".", "Median", "progression", "-", "free", "survival", "was", "3.9", "months", "with", "pembrolizumab", "2", "mg", "/", "kg", ",", "4.0", "months", "with", "pembrolizumab", "10", "mg", "/", "kg", ",", "and", "4.0", "months", "with", "docetaxel", ",", "with", "no", "significant", "difference", "for", "pembrolizumab", "2", "mg", "/", "kg", "versus", "docetaxel", "(", "0.88", ",", "0.74", "-", "1.05", ";", "p=0.07", ")", "or", "for", "pembrolizumab", "10", "mg", "/", "kg", "versus", "docetaxel", "(", "HR", "0.79", ",", "95", "%", "CI", "0.66", "-", "0.94", ";", "p=0.004", ")", ".", "Among", "patients", "with", "at", "least", "50", "%", "of", "tumour", "cells", "expressing", "PD", "-", "L1", ",", "overall", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "14.9", "months", "vs", "8.2", "months", ";", "HR", "0.54", ",", "95", "%", "CI", "0.38", "-", "0.77", ";", "p=0.0002", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "17.3", "months", "vs", "8.2", "months", ";", "0.50", ",", "0.36", "-", "0.70", ";", "p", "<", "0.0001", ")", ".", "Likewise", ",", "for", "this", "patient", "population", ",", "progression", "-", "free", "survival", "was", "significantly", "longer", "with", "pembrolizumab", "2", "mg", "/", "kg", "than", "with", "docetaxel", "(", "median", "5.0", "months", "vs", "4.1", "months", ";", "HR", "0.59", ",", "95", "%", "CI", "0.44", "-", "0.78", ";", "p=0.0001", ")", "and", "with", "pembrolizumab", "10", "mg", "/", "kg", "than", "with", "docetaxel", "(", "5.2", "months", "vs", "4.1", "months", ";", "0.59", ",", "0.45", "-", "0.78", ";", "p", "<", "0.0001", ")", ".", "Grade", "3", "-", "5", "treatment", "-", "related", "adverse", "events", "were", "less", "common", "with", "pembrolizumab", "than", "with", "docetaxel", "(", "43", "[", "13", "%", "]", "of", "339", "patients", "given", "2", "mg", "/", "kg", ",", "55", "[", "16", "%", "]", "of", "343", "given", "10", "mg", "/", "kg", ",", "and", "109", "[", "35", "%", "]", "of", "309", "given", "docetaxel", ")", ".", "INTERPRETATION", "Pembrolizumab", "prolongs", "overall", "survival", "and", "has", "a", "favourable", "benefit", "-", "to", "-", "risk", "profile", "in", "patients", "with", "previously", "treated", ",", "PD", "-", "L1-positive", ",", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ".", "These", "data", "establish", "pembrolizumab", "as", "a", "new", "treatment", "option", "for", "this", "population", "and", "validate", "the", "use", "of", "PD", "-", "L1", "selection", ".", "FUNDING", "Merck", "&", "Co", "." ]

[ "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Mortality", "Intervention_Pharmacological", "Participant_Sample-size" ]

Inzidenz is an umlsterm, Herzerkrankung is an umlsterm, Koronararterienaneurysma is an umlsterm, Herzkranzarterie is an umlsterm, Koronarstenosen is an umlsterm

IntensiveMedizin.90360375.ger.abstr_task0

Sentence: Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen .

[ "Koronaraneurysmata", "kommen", "mit", "einer", "Inzidenz", "von", "0,2", "bis", "4,9", "%", "selten", "vor", ".", "Sie", "sind", "zu", "90", "%", "mit", "einer", "koronaren", "Herzerkrankung", "vergesellschaftet", ".", "In", "der", "vorliegenden", "Fallbeschreibung", "berichten", "wir", "ueber", "das", "therapeutische", "Vorgehen", "bei", "Koronararterienaneurysma", "der", "rechten", "Herzkranzarterie", "bei", "koexistenten", "signifikanten", "Koronarstenosen", "." ]

[ "umlsterm" ]

Inzidenz is an umlsterm, Herzerkrankung is an umlsterm, Koronararterienaneurysma is an umlsterm, Herzkranzarterie is an umlsterm, Koronarstenosen is an umlsterm

IntensiveMedizin.90360375.ger.abstr_task1

Sentence: Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen . Instructions: please typing these entity words according to sentence: Inzidenz, Herzerkrankung, Koronararterienaneurysma, Herzkranzarterie, Koronarstenosen Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen .

[ "Koronaraneurysmata", "kommen", "mit", "einer", "Inzidenz", "von", "0,2", "bis", "4,9", "%", "selten", "vor", ".", "Sie", "sind", "zu", "90", "%", "mit", "einer", "koronaren", "Herzerkrankung", "vergesellschaftet", ".", "In", "der", "vorliegenden", "Fallbeschreibung", "berichten", "wir", "ueber", "das", "therapeutische", "Vorgehen", "bei", "Koronararterienaneurysma", "der", "rechten", "Herzkranzarterie", "bei", "koexistenten", "signifikanten", "Koronarstenosen", "." ]

[ "umlsterm" ]

Inzidenz, Herzerkrankung, Koronararterienaneurysma, Herzkranzarterie, Koronarstenosen

IntensiveMedizin.90360375.ger.abstr_task2

Sentence: Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]

Koronaraneurysmata kommen mit einer Inzidenz von 0,2 bis 4,9% selten vor . Sie sind zu 90% mit einer koronaren Herzerkrankung vergesellschaftet . In der vorliegenden Fallbeschreibung berichten wir ueber das therapeutische Vorgehen bei Koronararterienaneurysma der rechten Herzkranzarterie bei koexistenten signifikanten Koronarstenosen .

[ "Koronaraneurysmata", "kommen", "mit", "einer", "Inzidenz", "von", "0,2", "bis", "4,9", "%", "selten", "vor", ".", "Sie", "sind", "zu", "90", "%", "mit", "einer", "koronaren", "Herzerkrankung", "vergesellschaftet", ".", "In", "der", "vorliegenden", "Fallbeschreibung", "berichten", "wir", "ueber", "das", "therapeutische", "Vorgehen", "bei", "Koronararterienaneurysma", "der", "rechten", "Herzkranzarterie", "bei", "koexistenten", "signifikanten", "Koronarstenosen", "." ]

[ "umlsterm" ]

Germany is an umlsterm, inpatient is an umlsterm, psychotherapy is an umlsterm, hospitals is an umlsterm, aims is an umlsterm, care is an umlsterm, rehabilitation is an umlsterm, hospitals is an umlsterm, times is an umlsterm, hospitals is an umlsterm, treatment is an umlsterm, rehabilitation is an umlsterm, conflicts is an umlsterm, staff 's is an umlsterm, therapeutic is an umlsterm, work is an umlsterm, rehabilitation is an umlsterm, doctor is an umlsterm, social roles is an umlsterm, role is an umlsterm, physician is an umlsterm, role is an umlsterm, role is an umlsterm, social medicine is an umlsterm, social security is an umlsterm, social roles is an umlsterm, social security- is an umlsterm, hospital- is an umlsterm, doctor is an umlsterm, doctor is an umlsterm, conflicts is an umlsterm, development is an umlsterm, rehabilitation is an umlsterm

Psychotherapeut.80430171.eng.abstr_task0

Sentence: In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation .

[ "In", "Germany", "inpatient", "psychotherapy", "generally", "takes", "place", "in", "special", "psychosomatic", "hospitals", ".", "Their", "aims", "are", "often", "not", "clear", ",", "just", "as", "their", "place", "in", "the", "whole", "system", "of", "medical", "care", ".", "Although", "most", "of", "them", "are", "rehabilitation", "hospitals", "from", "a", "juridical", "point", "of", "view", ",", "they", "are", "many", "times", "defined", "as", "specialised", "hospitals", "which", "do", "not", "differentiate", "between", "treatment", "and", "rehabilitation", ".", "This", "lack", "of", "clear", "definition", "leads", "to", "a", "number", "of", "structural", "conflicts", "which", "largely", "influence", "the", "staff", "'s", "scope", "of", "action", "and", "the", "therapeutic", "work", ".", "In", "psychosomatic", "rehabilitation", "the", "doctor", "is", "taking", "over", "three", "social", "roles", ":", "the", "role", "of", "physician", ",", "the", "role", "of", "psychotherapist", "and", "the", "role", "of", "the", "expert", "in", "social", "medicine", "towards", "the", "social", "security", "institution", ".", "These", "social", "roles", "can", "be", "understood", "as", "a", "complex", "of", "behavioral", "expectations", "arising", "from", "different", "reference", "systems", "(", "social", "security-", ",", "hospital-", ",", "treatment-", ",", "patient", "-", "system", ")", "directed", "towards", "the", "social", "position", "of", "the", "doctor", ".", "Within", "his", "social", "position", "the", "doctor", "is", "thereby", "involved", "into", "certain", "conflicts", ".", "This", "article", "will", "analyze", "the", "described", "structural", "problems", "and", "try", "to", "contribute", "to", "further", "development", "of", "the", "concepts", "in", "psychosomatic", "rehabilitation", "." ]

[ "umlsterm" ]

Germany is an umlsterm, inpatient is an umlsterm, psychotherapy is an umlsterm, hospitals is an umlsterm, aims is an umlsterm, care is an umlsterm, rehabilitation is an umlsterm, hospitals is an umlsterm, times is an umlsterm, hospitals is an umlsterm, treatment is an umlsterm, rehabilitation is an umlsterm, conflicts is an umlsterm, staff 's is an umlsterm, therapeutic is an umlsterm, work is an umlsterm, rehabilitation is an umlsterm, doctor is an umlsterm, social roles is an umlsterm, role is an umlsterm, physician is an umlsterm, role is an umlsterm, role is an umlsterm, social medicine is an umlsterm, social security is an umlsterm, social roles is an umlsterm, social security- is an umlsterm, hospital- is an umlsterm, doctor is an umlsterm, doctor is an umlsterm, conflicts is an umlsterm, development is an umlsterm, rehabilitation is an umlsterm

Psychotherapeut.80430171.eng.abstr_task1

Sentence: In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation . Instructions: please typing these entity words according to sentence: Germany, inpatient, psychotherapy, hospitals, aims, care, rehabilitation, hospitals, times, hospitals, treatment, rehabilitation, conflicts, staff 's, therapeutic, work, rehabilitation, doctor, social roles, role, physician, role, role, social medicine, social security, social roles, social security-, hospital-, doctor, doctor, conflicts, development, rehabilitation Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation .

[ "In", "Germany", "inpatient", "psychotherapy", "generally", "takes", "place", "in", "special", "psychosomatic", "hospitals", ".", "Their", "aims", "are", "often", "not", "clear", ",", "just", "as", "their", "place", "in", "the", "whole", "system", "of", "medical", "care", ".", "Although", "most", "of", "them", "are", "rehabilitation", "hospitals", "from", "a", "juridical", "point", "of", "view", ",", "they", "are", "many", "times", "defined", "as", "specialised", "hospitals", "which", "do", "not", "differentiate", "between", "treatment", "and", "rehabilitation", ".", "This", "lack", "of", "clear", "definition", "leads", "to", "a", "number", "of", "structural", "conflicts", "which", "largely", "influence", "the", "staff", "'s", "scope", "of", "action", "and", "the", "therapeutic", "work", ".", "In", "psychosomatic", "rehabilitation", "the", "doctor", "is", "taking", "over", "three", "social", "roles", ":", "the", "role", "of", "physician", ",", "the", "role", "of", "psychotherapist", "and", "the", "role", "of", "the", "expert", "in", "social", "medicine", "towards", "the", "social", "security", "institution", ".", "These", "social", "roles", "can", "be", "understood", "as", "a", "complex", "of", "behavioral", "expectations", "arising", "from", "different", "reference", "systems", "(", "social", "security-", ",", "hospital-", ",", "treatment-", ",", "patient", "-", "system", ")", "directed", "towards", "the", "social", "position", "of", "the", "doctor", ".", "Within", "his", "social", "position", "the", "doctor", "is", "thereby", "involved", "into", "certain", "conflicts", ".", "This", "article", "will", "analyze", "the", "described", "structural", "problems", "and", "try", "to", "contribute", "to", "further", "development", "of", "the", "concepts", "in", "psychosomatic", "rehabilitation", "." ]

[ "umlsterm" ]

Germany, inpatient, psychotherapy, hospitals, aims, care, rehabilitation, hospitals, times, hospitals, treatment, rehabilitation, conflicts, staff 's, therapeutic, work, rehabilitation, doctor, social roles, role, physician, role, role, social medicine, social security, social roles, social security-, hospital-, doctor, doctor, conflicts, development, rehabilitation

Psychotherapeut.80430171.eng.abstr_task2

Sentence: In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In Germany inpatient psychotherapy generally takes place in special psychosomatic hospitals . Their aims are often not clear , just as their place in the whole system of medical care . Although most of them are rehabilitation hospitals from a juridical point of view , they are many times defined as specialised hospitals which do not differentiate between treatment and rehabilitation . This lack of clear definition leads to a number of structural conflicts which largely influence the staff's scope of action and the therapeutic work . In psychosomatic rehabilitation the doctor is taking over three social roles : the role of physician , the role of psychotherapist and the role of the expert in social medicine towards the social security institution . These social roles can be understood as a complex of behavioral expectations arising from different reference systems ( social security- , hospital- , treatment- , patient-system ) directed towards the social position of the doctor . Within his social position the doctor is thereby involved into certain conflicts . This article will analyze the described structural problems and try to contribute to further development of the concepts in psychosomatic rehabilitation .

[ "In", "Germany", "inpatient", "psychotherapy", "generally", "takes", "place", "in", "special", "psychosomatic", "hospitals", ".", "Their", "aims", "are", "often", "not", "clear", ",", "just", "as", "their", "place", "in", "the", "whole", "system", "of", "medical", "care", ".", "Although", "most", "of", "them", "are", "rehabilitation", "hospitals", "from", "a", "juridical", "point", "of", "view", ",", "they", "are", "many", "times", "defined", "as", "specialised", "hospitals", "which", "do", "not", "differentiate", "between", "treatment", "and", "rehabilitation", ".", "This", "lack", "of", "clear", "definition", "leads", "to", "a", "number", "of", "structural", "conflicts", "which", "largely", "influence", "the", "staff", "'s", "scope", "of", "action", "and", "the", "therapeutic", "work", ".", "In", "psychosomatic", "rehabilitation", "the", "doctor", "is", "taking", "over", "three", "social", "roles", ":", "the", "role", "of", "physician", ",", "the", "role", "of", "psychotherapist", "and", "the", "role", "of", "the", "expert", "in", "social", "medicine", "towards", "the", "social", "security", "institution", ".", "These", "social", "roles", "can", "be", "understood", "as", "a", "complex", "of", "behavioral", "expectations", "arising", "from", "different", "reference", "systems", "(", "social", "security-", ",", "hospital-", ",", "treatment-", ",", "patient", "-", "system", ")", "directed", "towards", "the", "social", "position", "of", "the", "doctor", ".", "Within", "his", "social", "position", "the", "doctor", "is", "thereby", "involved", "into", "certain", "conflicts", ".", "This", "article", "will", "analyze", "the", "described", "structural", "problems", "and", "try", "to", "contribute", "to", "further", "development", "of", "the", "concepts", "in", "psychosomatic", "rehabilitation", "." ]

[ "umlsterm" ]

anthra[1,2-d]imidazole-6,11-dione is a CHEMICAL, telomerase is a GENE-Y

23279865_task0

Sentence: Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]

Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.

[ "Structure", "-", "based", "design", ",", "synthesis", "and", "evaluation", "of", "novel", "anthra[1,2-d]imidazole-6,11-dione", "derivatives", "as", "telomerase", "inhibitors", "and", "potential", "for", "cancer", "polypharmacology", "." ]

[ "CHEMICAL", "GENE-Y" ]

anthra[1,2-d]imidazole-6,11-dione is a CHEMICAL, telomerase is a GENE-Y

23279865_task1

Sentence: Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology. Instructions: please typing these entity words according to sentence: anthra[1,2-d]imidazole-6,11-dione, telomerase Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]

Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.

[ "Structure", "-", "based", "design", ",", "synthesis", "and", "evaluation", "of", "novel", "anthra[1,2-d]imidazole-6,11-dione", "derivatives", "as", "telomerase", "inhibitors", "and", "potential", "for", "cancer", "polypharmacology", "." ]

[ "CHEMICAL", "GENE-Y" ]

anthra[1,2-d]imidazole-6,11-dione, telomerase

23279865_task2

Sentence: Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O" ]

Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.

[ "Structure", "-", "based", "design", ",", "synthesis", "and", "evaluation", "of", "novel", "anthra[1,2-d]imidazole-6,11-dione", "derivatives", "as", "telomerase", "inhibitors", "and", "potential", "for", "cancer", "polypharmacology", "." ]

[ "CHEMICAL", "GENE-Y" ]

Chirurgie is an umlsterm, Krankenhausbau is an umlsterm, Klinikorganisation is an umlsterm

DerChirurg.80690105.ger.abstr_task0

Sentence: Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus .

[ "Zusammenfassung", ".", "Die", "Zwickauer", "Klinik", "bildete", "seit", "ihrer", "Erbauung", "durch", "Heinrich", "Braun", ",", "den", "Schoepfer", "der", "modernen", "Lokalanaesthesie", ",", "ein", "weithin", "bekanntes", "chirurgisches", "Zentrum", ".", "Seine", "direkten", "Nachfolger", "Kulenkampff", "und", "Mayer", "haben", "Brauns", "Lebenswerk", "bewahrt", ",", "fortgesetzt", "und", "ergaenzt", ".", "Von", "der", "Zwickauer", "Chirurgie", "gingen", "wichtige", "Impulse", "fuer", "die", "Allgemein-", "und", "Lokalanaesthesie", ",", "fuer", "den", "Krankenhausbau", "und", "die", "Klinikorganisation", "sowie", "fuer", "die", "chirurgische", "Lehre", "in", "Wort", "und", "Bild", "aus", "." ]

[ "umlsterm" ]

Chirurgie is an umlsterm, Krankenhausbau is an umlsterm, Klinikorganisation is an umlsterm

DerChirurg.80690105.ger.abstr_task1

Sentence: Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus . Instructions: please typing these entity words according to sentence: Chirurgie, Krankenhausbau, Klinikorganisation Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus .

[ "Zusammenfassung", ".", "Die", "Zwickauer", "Klinik", "bildete", "seit", "ihrer", "Erbauung", "durch", "Heinrich", "Braun", ",", "den", "Schoepfer", "der", "modernen", "Lokalanaesthesie", ",", "ein", "weithin", "bekanntes", "chirurgisches", "Zentrum", ".", "Seine", "direkten", "Nachfolger", "Kulenkampff", "und", "Mayer", "haben", "Brauns", "Lebenswerk", "bewahrt", ",", "fortgesetzt", "und", "ergaenzt", ".", "Von", "der", "Zwickauer", "Chirurgie", "gingen", "wichtige", "Impulse", "fuer", "die", "Allgemein-", "und", "Lokalanaesthesie", ",", "fuer", "den", "Krankenhausbau", "und", "die", "Klinikorganisation", "sowie", "fuer", "die", "chirurgische", "Lehre", "in", "Wort", "und", "Bild", "aus", "." ]

[ "umlsterm" ]

Chirurgie, Krankenhausbau, Klinikorganisation

DerChirurg.80690105.ger.abstr_task2

Sentence: Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Zwickauer Klinik bildete seit ihrer Erbauung durch Heinrich Braun , den Schoepfer der modernen Lokalanaesthesie , ein weithin bekanntes chirurgisches Zentrum . Seine direkten Nachfolger Kulenkampff und Mayer haben Brauns Lebenswerk bewahrt , fortgesetzt und ergaenzt . Von der Zwickauer Chirurgie gingen wichtige Impulse fuer die Allgemein- und Lokalanaesthesie , fuer den Krankenhausbau und die Klinikorganisation sowie fuer die chirurgische Lehre in Wort und Bild aus .

[ "Zusammenfassung", ".", "Die", "Zwickauer", "Klinik", "bildete", "seit", "ihrer", "Erbauung", "durch", "Heinrich", "Braun", ",", "den", "Schoepfer", "der", "modernen", "Lokalanaesthesie", ",", "ein", "weithin", "bekanntes", "chirurgisches", "Zentrum", ".", "Seine", "direkten", "Nachfolger", "Kulenkampff", "und", "Mayer", "haben", "Brauns", "Lebenswerk", "bewahrt", ",", "fortgesetzt", "und", "ergaenzt", ".", "Von", "der", "Zwickauer", "Chirurgie", "gingen", "wichtige", "Impulse", "fuer", "die", "Allgemein-", "und", "Lokalanaesthesie", ",", "fuer", "den", "Krankenhausbau", "und", "die", "Klinikorganisation", "sowie", "fuer", "die", "chirurgische", "Lehre", "in", "Wort", "und", "Bild", "aus", "." ]

[ "umlsterm" ]

Isofluran is an umlsterm, Dopplersonographie is an umlsterm, Patienten is an umlsterm, Blutdruck is an umlsterm, Koerpertemperatur is an umlsterm, Isofluran is an umlsterm, Konzentrationsstufe is an umlsterm, Isofluran is an umlsterm, Student is an umlsterm, Varianzanalysen is an umlsterm, ANOVA is an umlsterm

DerAnaesthesist.70460029.ger.abstr_task0

Sentence: Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde .

[ "Die", "Einfluesse", "von", "Sevofluran", "im", "Vergleich", "zu", "Isofluran", "auf", "die", "Messgroessen", "der", "transkraniellen", "Dopplersonographie", "(", "TCD", ")", "wurden", "an", "30", "Patienten", "untersucht", ".", "Neben", "den", "TCD", "-", "Parametern", "wurden", "simultan", "arterieller", "Blutdruck", ",", "Herzfrequenz", "und", "Koerpertemperatur", "registriert", ".", "Messungen", "erfolgten", "vor", "Narkoseeinleitung", ",", "unter", "kontrollierter", "Beatmung", "mit", "0,5", ",", "1,0", "und", "1,5", "MAC", "Sevofluran", "bzw", ".", "Isofluran", "in", "Sauerstoff", "/", "Luft", ",", "anschliessend", "mit", "1,5", ",", "1,0", "und", "0,5", "MAC", "in", "Sauerstoff", "/", "Lachgas", "sowie", "nach", "Extubation", ".", "Waehrend", "jeder", "Konzentrationsstufe", "von", "Sevofluran", "bzw", ".", "Isofluran", "wurde", "zunaechst", "normoventiliert", ",", "anschliessend", "hyperventiliert", ".", "Die", "statistische", "Auswertung", "erfolgte", "mit", "dem", "t", "-", "Test", "nach", "Student", "und", "Varianzanalysen", "(", "ANOVA", ")", ",", "wobei", "p", "0,05", "als", "signifikant", "betrachtet", "wurde", "." ]

[ "umlsterm" ]

Isofluran is an umlsterm, Dopplersonographie is an umlsterm, Patienten is an umlsterm, Blutdruck is an umlsterm, Koerpertemperatur is an umlsterm, Isofluran is an umlsterm, Konzentrationsstufe is an umlsterm, Isofluran is an umlsterm, Student is an umlsterm, Varianzanalysen is an umlsterm, ANOVA is an umlsterm

DerAnaesthesist.70460029.ger.abstr_task1

Sentence: Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde . Instructions: please typing these entity words according to sentence: Isofluran, Dopplersonographie, Patienten, Blutdruck, Koerpertemperatur, Isofluran, Konzentrationsstufe, Isofluran, Student, Varianzanalysen, ANOVA Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde .

[ "Die", "Einfluesse", "von", "Sevofluran", "im", "Vergleich", "zu", "Isofluran", "auf", "die", "Messgroessen", "der", "transkraniellen", "Dopplersonographie", "(", "TCD", ")", "wurden", "an", "30", "Patienten", "untersucht", ".", "Neben", "den", "TCD", "-", "Parametern", "wurden", "simultan", "arterieller", "Blutdruck", ",", "Herzfrequenz", "und", "Koerpertemperatur", "registriert", ".", "Messungen", "erfolgten", "vor", "Narkoseeinleitung", ",", "unter", "kontrollierter", "Beatmung", "mit", "0,5", ",", "1,0", "und", "1,5", "MAC", "Sevofluran", "bzw", ".", "Isofluran", "in", "Sauerstoff", "/", "Luft", ",", "anschliessend", "mit", "1,5", ",", "1,0", "und", "0,5", "MAC", "in", "Sauerstoff", "/", "Lachgas", "sowie", "nach", "Extubation", ".", "Waehrend", "jeder", "Konzentrationsstufe", "von", "Sevofluran", "bzw", ".", "Isofluran", "wurde", "zunaechst", "normoventiliert", ",", "anschliessend", "hyperventiliert", ".", "Die", "statistische", "Auswertung", "erfolgte", "mit", "dem", "t", "-", "Test", "nach", "Student", "und", "Varianzanalysen", "(", "ANOVA", ")", ",", "wobei", "p", "0,05", "als", "signifikant", "betrachtet", "wurde", "." ]

[ "umlsterm" ]

Isofluran, Dopplersonographie, Patienten, Blutdruck, Koerpertemperatur, Isofluran, Konzentrationsstufe, Isofluran, Student, Varianzanalysen, ANOVA

DerAnaesthesist.70460029.ger.abstr_task2

Sentence: Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Einfluesse von Sevofluran im Vergleich zu Isofluran auf die Messgroessen der transkraniellen Dopplersonographie ( TCD ) wurden an 30 Patienten untersucht . Neben den TCD-Parametern wurden simultan arterieller Blutdruck , Herzfrequenz und Koerpertemperatur registriert . Messungen erfolgten vor Narkoseeinleitung , unter kontrollierter Beatmung mit 0,5 , 1,0 und 1,5 MAC Sevofluran bzw. Isofluran in Sauerstoff/Luft , anschliessend mit 1,5 , 1,0 und 0,5 MAC in Sauerstoff/Lachgas sowie nach Extubation . Waehrend jeder Konzentrationsstufe von Sevofluran bzw. Isofluran wurde zunaechst normoventiliert , anschliessend hyperventiliert . Die statistische Auswertung erfolgte mit dem t-Test nach Student und Varianzanalysen ( ANOVA ) , wobei p 0,05 als signifikant betrachtet wurde .

[ "Die", "Einfluesse", "von", "Sevofluran", "im", "Vergleich", "zu", "Isofluran", "auf", "die", "Messgroessen", "der", "transkraniellen", "Dopplersonographie", "(", "TCD", ")", "wurden", "an", "30", "Patienten", "untersucht", ".", "Neben", "den", "TCD", "-", "Parametern", "wurden", "simultan", "arterieller", "Blutdruck", ",", "Herzfrequenz", "und", "Koerpertemperatur", "registriert", ".", "Messungen", "erfolgten", "vor", "Narkoseeinleitung", ",", "unter", "kontrollierter", "Beatmung", "mit", "0,5", ",", "1,0", "und", "1,5", "MAC", "Sevofluran", "bzw", ".", "Isofluran", "in", "Sauerstoff", "/", "Luft", ",", "anschliessend", "mit", "1,5", ",", "1,0", "und", "0,5", "MAC", "in", "Sauerstoff", "/", "Lachgas", "sowie", "nach", "Extubation", ".", "Waehrend", "jeder", "Konzentrationsstufe", "von", "Sevofluran", "bzw", ".", "Isofluran", "wurde", "zunaechst", "normoventiliert", ",", "anschliessend", "hyperventiliert", ".", "Die", "statistische", "Auswertung", "erfolgte", "mit", "dem", "t", "-", "Test", "nach", "Student", "und", "Varianzanalysen", "(", "ANOVA", ")", ",", "wobei", "p", "0,05", "als", "signifikant", "betrachtet", "wurde", "." ]

[ "umlsterm" ]

Population is an umlsterm, demographic transitions is an umlsterm, world 's is an umlsterm, health is an umlsterm, needs is an umlsterm, Chronic diseases is an umlsterm, population is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, deaths is an umlsterm

ZfuerGerontologie+Geriatrie.9032s080.eng.abstr_task0

Sentence: Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions .

[ "Population", "aging", "is", "a", "global", ".", "These", "demographic", "transitions", "have", "brought", "about", "dramatic", "changes", "in", "the", "world", "'s", "health", "needs", "and", "status", ".", "Chronic", "diseases", "of", "aging", "account", "for", "nearly", "half", "of", "population", "morbidity", "and", "mortality", "in", "the", "developing", "regions", "of", "the", "world", "85", "%", "of", "deaths", "and", "disability", "in", "developed", "regions", "." ]

[ "umlsterm" ]

Population is an umlsterm, demographic transitions is an umlsterm, world 's is an umlsterm, health is an umlsterm, needs is an umlsterm, Chronic diseases is an umlsterm, population is an umlsterm, morbidity is an umlsterm, mortality is an umlsterm, deaths is an umlsterm

ZfuerGerontologie+Geriatrie.9032s080.eng.abstr_task1

Sentence: Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions . Instructions: please typing these entity words according to sentence: Population, demographic transitions, world 's, health, needs, Chronic diseases, population, morbidity, mortality, deaths Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions .

[ "Population", "aging", "is", "a", "global", ".", "These", "demographic", "transitions", "have", "brought", "about", "dramatic", "changes", "in", "the", "world", "'s", "health", "needs", "and", "status", ".", "Chronic", "diseases", "of", "aging", "account", "for", "nearly", "half", "of", "population", "morbidity", "and", "mortality", "in", "the", "developing", "regions", "of", "the", "world", "85", "%", "of", "deaths", "and", "disability", "in", "developed", "regions", "." ]

[ "umlsterm" ]

Population, demographic transitions, world 's, health, needs, Chronic diseases, population, morbidity, mortality, deaths

ZfuerGerontologie+Geriatrie.9032s080.eng.abstr_task2

Sentence: Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Population aging is a global . These demographic transitions have brought about dramatic changes in the world's health needs and status . Chronic diseases of aging account for nearly half of population morbidity and mortality in the developing regions of the world 85 % of deaths and disability in developed regions .

[ "Population", "aging", "is", "a", "global", ".", "These", "demographic", "transitions", "have", "brought", "about", "dramatic", "changes", "in", "the", "world", "'s", "health", "needs", "and", "status", ".", "Chronic", "diseases", "of", "aging", "account", "for", "nearly", "half", "of", "population", "morbidity", "and", "mortality", "in", "the", "developing", "regions", "of", "the", "world", "85", "%", "of", "deaths", "and", "disability", "in", "developed", "regions", "." ]

[ "umlsterm" ]

Therapie is an umlsterm, Kreuzbandverletzung is an umlsterm, Krankengut is an umlsterm, Rupturen is an umlsterm, Kombinationsverletzungen is an umlsterm, Bandes is an umlsterm, Trevira - Band is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Rupturen is an umlsterm, Verletzungen is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Kombinationsverletzungen is an umlsterm, Trevira - Band is an umlsterm

DerUnfallchirurg.91020763.ger.abstr_task0

Sentence: Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt .

[ "Bei", "der", "Therapie", "der", "hinteren", "Kreuzbandverletzung", "(", "HKB", "-", "Verletzung", ")", "konkurrieren", "konservative", "wiederherstellende", "und", "ersetzende", "Verfahren", ".", ",", "Im", "eigenen", "Krankengut", "von", "1993", "-", "1997", "wurden", "49", "HKB", "-", "Verletzungen", "operativ", "stabilisiert", ",", "21", "Rupturen", "ohne", "weitere", "Begleitverletzungen", "und", "28", "Kombinationsverletzungen", ".", "Die", "Stabilisierung", "erfolgte", "in", "allen", "Faellen", "mit", "ligamentaerer", "Zerreissung", "durch", "Naht", "des", "Bandes", "und", "Augmentation", "mit", "3", "mm", "Trevira", "-", "Band", ",", "knoecherne", "Verletzungen", "wurden", "mittels", "Osteosynthese", "refixiert", ".", "Nachuntersucht", "wurden", "36", "Patienten", ",", "davon", "15", "mit", "isolierten", "ligamentaeren", "Rupturen", ".", "Die", "knoechernen", "Verletzungen", "ergaben", "in", "allen", "Faellen", "gute", "Stabilitaet", ",", "die", "ligamentaeren", "Verletzungen", "zeigten", "in", "7", "von", "15", "Faellen", "gute", "Stabilitaet", ",", "in", "8", "Faellen", "eine", "deutliche", "hintere", "Schublade", ".", "Im", "Lysholm", "-", "Score", "wurde", "eine", "mittlere", "Punktzahl", "von", "76,8", "(", "+", "/-", "21,6", ")", "Punkten", "erzielt", ",", "im", "OAK", "-", "Score", "fanden", "sich", "2", "sehr", "gute", ",", "5", "gute", ",", "3", "maessige", "und", "5", "schlechte", "Ergebnisse", ",", "im", "IKDC", "-", "Score", "3", "sehr", "gute", ",", "4", "gute", ",", "2", "maessige", "und", "6", "schlechte", "Ergebnisse", ".", "In", "der", "subjektiven", "Einschaetzung", "beurteilten", "10", "Patienten", "das", "Ergebnis", "als", "gut", "oder", "sehr", "gut", ",", "2", "als", "maessig", ",", "3", "als", "schlecht", ".", "Die", "Kombinationsverletzungen", "ergaben", "nur", "in", "40", "%", "der", "Faelle", "sehr", "gute", "oder", "gute", "Ergebnisse", ".", "Die", "Augmentationsnaht", "der", "ligamentaeren", "HKB", "-", "Ruptur", "mit", "3", "mm", "Trevira", "-", "Band", "erscheint", "alternativ", "zu", "den", "primaeren", "Ersatzverfahren", "gerechtfertigt", "." ]

[ "umlsterm" ]

Therapie is an umlsterm, Kreuzbandverletzung is an umlsterm, Krankengut is an umlsterm, Rupturen is an umlsterm, Kombinationsverletzungen is an umlsterm, Bandes is an umlsterm, Trevira - Band is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Rupturen is an umlsterm, Verletzungen is an umlsterm, Verletzungen is an umlsterm, Patienten is an umlsterm, Kombinationsverletzungen is an umlsterm, Trevira - Band is an umlsterm

DerUnfallchirurg.91020763.ger.abstr_task1

Sentence: Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt . Instructions: please typing these entity words according to sentence: Therapie, Kreuzbandverletzung, Krankengut, Rupturen, Kombinationsverletzungen, Bandes, Trevira - Band, Verletzungen, Patienten, Rupturen, Verletzungen, Verletzungen, Patienten, Kombinationsverletzungen, Trevira - Band Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt .

[ "Bei", "der", "Therapie", "der", "hinteren", "Kreuzbandverletzung", "(", "HKB", "-", "Verletzung", ")", "konkurrieren", "konservative", "wiederherstellende", "und", "ersetzende", "Verfahren", ".", ",", "Im", "eigenen", "Krankengut", "von", "1993", "-", "1997", "wurden", "49", "HKB", "-", "Verletzungen", "operativ", "stabilisiert", ",", "21", "Rupturen", "ohne", "weitere", "Begleitverletzungen", "und", "28", "Kombinationsverletzungen", ".", "Die", "Stabilisierung", "erfolgte", "in", "allen", "Faellen", "mit", "ligamentaerer", "Zerreissung", "durch", "Naht", "des", "Bandes", "und", "Augmentation", "mit", "3", "mm", "Trevira", "-", "Band", ",", "knoecherne", "Verletzungen", "wurden", "mittels", "Osteosynthese", "refixiert", ".", "Nachuntersucht", "wurden", "36", "Patienten", ",", "davon", "15", "mit", "isolierten", "ligamentaeren", "Rupturen", ".", "Die", "knoechernen", "Verletzungen", "ergaben", "in", "allen", "Faellen", "gute", "Stabilitaet", ",", "die", "ligamentaeren", "Verletzungen", "zeigten", "in", "7", "von", "15", "Faellen", "gute", "Stabilitaet", ",", "in", "8", "Faellen", "eine", "deutliche", "hintere", "Schublade", ".", "Im", "Lysholm", "-", "Score", "wurde", "eine", "mittlere", "Punktzahl", "von", "76,8", "(", "+", "/-", "21,6", ")", "Punkten", "erzielt", ",", "im", "OAK", "-", "Score", "fanden", "sich", "2", "sehr", "gute", ",", "5", "gute", ",", "3", "maessige", "und", "5", "schlechte", "Ergebnisse", ",", "im", "IKDC", "-", "Score", "3", "sehr", "gute", ",", "4", "gute", ",", "2", "maessige", "und", "6", "schlechte", "Ergebnisse", ".", "In", "der", "subjektiven", "Einschaetzung", "beurteilten", "10", "Patienten", "das", "Ergebnis", "als", "gut", "oder", "sehr", "gut", ",", "2", "als", "maessig", ",", "3", "als", "schlecht", ".", "Die", "Kombinationsverletzungen", "ergaben", "nur", "in", "40", "%", "der", "Faelle", "sehr", "gute", "oder", "gute", "Ergebnisse", ".", "Die", "Augmentationsnaht", "der", "ligamentaeren", "HKB", "-", "Ruptur", "mit", "3", "mm", "Trevira", "-", "Band", "erscheint", "alternativ", "zu", "den", "primaeren", "Ersatzverfahren", "gerechtfertigt", "." ]

[ "umlsterm" ]

Therapie, Kreuzbandverletzung, Krankengut, Rupturen, Kombinationsverletzungen, Bandes, Trevira - Band, Verletzungen, Patienten, Rupturen, Verletzungen, Verletzungen, Patienten, Kombinationsverletzungen, Trevira - Band

DerUnfallchirurg.91020763.ger.abstr_task2

Sentence: Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Bei der Therapie der hinteren Kreuzbandverletzung ( HKB-Verletzung ) konkurrieren konservative wiederherstellende und ersetzende Verfahren . , Im eigenen Krankengut von 1993-1997 wurden 49 HKB-Verletzungen operativ stabilisiert , 21 Rupturen ohne weitere Begleitverletzungen und 28 Kombinationsverletzungen . Die Stabilisierung erfolgte in allen Faellen mit ligamentaerer Zerreissung durch Naht des Bandes und Augmentation mit 3 mm Trevira-Band , knoecherne Verletzungen wurden mittels Osteosynthese refixiert . Nachuntersucht wurden 36 Patienten , davon 15 mit isolierten ligamentaeren Rupturen . Die knoechernen Verletzungen ergaben in allen Faellen gute Stabilitaet , die ligamentaeren Verletzungen zeigten in 7 von 15 Faellen gute Stabilitaet , in 8 Faellen eine deutliche hintere Schublade . Im Lysholm-Score wurde eine mittlere Punktzahl von 76,8 ( +/- 21,6 ) Punkten erzielt , im OAK-Score fanden sich 2 sehr gute , 5 gute , 3 maessige und 5 schlechte Ergebnisse , im IKDC-Score 3 sehr gute , 4 gute , 2 maessige und 6 schlechte Ergebnisse . In der subjektiven Einschaetzung beurteilten 10 Patienten das Ergebnis als gut oder sehr gut , 2 als maessig , 3 als schlecht . Die Kombinationsverletzungen ergaben nur in 40 % der Faelle sehr gute oder gute Ergebnisse . Die Augmentationsnaht der ligamentaeren HKB-Ruptur mit 3 mm Trevira-Band erscheint alternativ zu den primaeren Ersatzverfahren gerechtfertigt .

[ "Bei", "der", "Therapie", "der", "hinteren", "Kreuzbandverletzung", "(", "HKB", "-", "Verletzung", ")", "konkurrieren", "konservative", "wiederherstellende", "und", "ersetzende", "Verfahren", ".", ",", "Im", "eigenen", "Krankengut", "von", "1993", "-", "1997", "wurden", "49", "HKB", "-", "Verletzungen", "operativ", "stabilisiert", ",", "21", "Rupturen", "ohne", "weitere", "Begleitverletzungen", "und", "28", "Kombinationsverletzungen", ".", "Die", "Stabilisierung", "erfolgte", "in", "allen", "Faellen", "mit", "ligamentaerer", "Zerreissung", "durch", "Naht", "des", "Bandes", "und", "Augmentation", "mit", "3", "mm", "Trevira", "-", "Band", ",", "knoecherne", "Verletzungen", "wurden", "mittels", "Osteosynthese", "refixiert", ".", "Nachuntersucht", "wurden", "36", "Patienten", ",", "davon", "15", "mit", "isolierten", "ligamentaeren", "Rupturen", ".", "Die", "knoechernen", "Verletzungen", "ergaben", "in", "allen", "Faellen", "gute", "Stabilitaet", ",", "die", "ligamentaeren", "Verletzungen", "zeigten", "in", "7", "von", "15", "Faellen", "gute", "Stabilitaet", ",", "in", "8", "Faellen", "eine", "deutliche", "hintere", "Schublade", ".", "Im", "Lysholm", "-", "Score", "wurde", "eine", "mittlere", "Punktzahl", "von", "76,8", "(", "+", "/-", "21,6", ")", "Punkten", "erzielt", ",", "im", "OAK", "-", "Score", "fanden", "sich", "2", "sehr", "gute", ",", "5", "gute", ",", "3", "maessige", "und", "5", "schlechte", "Ergebnisse", ",", "im", "IKDC", "-", "Score", "3", "sehr", "gute", ",", "4", "gute", ",", "2", "maessige", "und", "6", "schlechte", "Ergebnisse", ".", "In", "der", "subjektiven", "Einschaetzung", "beurteilten", "10", "Patienten", "das", "Ergebnis", "als", "gut", "oder", "sehr", "gut", ",", "2", "als", "maessig", ",", "3", "als", "schlecht", ".", "Die", "Kombinationsverletzungen", "ergaben", "nur", "in", "40", "%", "der", "Faelle", "sehr", "gute", "oder", "gute", "Ergebnisse", ".", "Die", "Augmentationsnaht", "der", "ligamentaeren", "HKB", "-", "Ruptur", "mit", "3", "mm", "Trevira", "-", "Band", "erscheint", "alternativ", "zu", "den", "primaeren", "Ersatzverfahren", "gerechtfertigt", "." ]

[ "umlsterm" ]

Lipidsenker is an umlsterm, Rolle is an umlsterm, Koronararteriosklerose is an umlsterm, Myopathien is an umlsterm, Pharmaka is an umlsterm

ZfuerHerzThoraxGefaesschirurgie.80120201.ger.abstr_task0

Sentence: Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind .

[ "Lipidsenker", "vom", "Typ", "der", "HMG", "-", "CoA", "-", "Reduktasehemmer", "spielen", "eine", "wesentliche", "Rolle", "in", "der", "Prophylaxe", "der", "Koronararteriosklerose", ".", "Eine", "moegliche", "Nebenwirkung", "besteht", "in", "der", "Ausloesung", "von", "Myopathien", ",", "die", "vorwiegend", "bei", "Interaktion", "mit", "anderen", "Pharmaka", "beschrieben", "sind", "." ]

[ "umlsterm" ]

Lipidsenker is an umlsterm, Rolle is an umlsterm, Koronararteriosklerose is an umlsterm, Myopathien is an umlsterm, Pharmaka is an umlsterm

ZfuerHerzThoraxGefaesschirurgie.80120201.ger.abstr_task1

Sentence: Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind . Instructions: please typing these entity words according to sentence: Lipidsenker, Rolle, Koronararteriosklerose, Myopathien, Pharmaka Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind .

[ "Lipidsenker", "vom", "Typ", "der", "HMG", "-", "CoA", "-", "Reduktasehemmer", "spielen", "eine", "wesentliche", "Rolle", "in", "der", "Prophylaxe", "der", "Koronararteriosklerose", ".", "Eine", "moegliche", "Nebenwirkung", "besteht", "in", "der", "Ausloesung", "von", "Myopathien", ",", "die", "vorwiegend", "bei", "Interaktion", "mit", "anderen", "Pharmaka", "beschrieben", "sind", "." ]

[ "umlsterm" ]

Lipidsenker, Rolle, Koronararteriosklerose, Myopathien, Pharmaka

ZfuerHerzThoraxGefaesschirurgie.80120201.ger.abstr_task2

Sentence: Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Lipidsenker vom Typ der HMG-CoA-Reduktasehemmer spielen eine wesentliche Rolle in der Prophylaxe der Koronararteriosklerose . Eine moegliche Nebenwirkung besteht in der Ausloesung von Myopathien , die vorwiegend bei Interaktion mit anderen Pharmaka beschrieben sind .

[ "Lipidsenker", "vom", "Typ", "der", "HMG", "-", "CoA", "-", "Reduktasehemmer", "spielen", "eine", "wesentliche", "Rolle", "in", "der", "Prophylaxe", "der", "Koronararteriosklerose", ".", "Eine", "moegliche", "Nebenwirkung", "besteht", "in", "der", "Ausloesung", "von", "Myopathien", ",", "die", "vorwiegend", "bei", "Interaktion", "mit", "anderen", "Pharmaka", "beschrieben", "sind", "." ]

[ "umlsterm" ]

Theileria annulata is a mono_cell, matrix metalloproteinase 9 is a protein_molecule, transcription factor is a protein_family_or_group, AP-1 is a protein_molecule, bovine leucocytes is a cell_type

8908_task0

Sentence: Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: mono_cell, cell_type, protein_family_or_group, protein_molecule

[ "O", "O", "B-mono_cell", "I-mono_cell", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]

Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes.

[ "Infection", "with", "Theileria", "annulata", "induces", "expression", "of", "matrix", "metalloproteinase", "9", "and", "transcription", "factor", "AP-1", "in", "bovine", "leucocytes", "." ]

[ "other_name", "cell_type", "protein_molecule", "protein_family_or_group", "mono_cell", "DNA_family_or_group", "multi_cell", "RNA_family_or_group" ]

Theileria annulata is a mono_cell, matrix metalloproteinase 9 is a protein_molecule, transcription factor is a protein_family_or_group, AP-1 is a protein_molecule, bovine leucocytes is a cell_type

8908_task1

Sentence: Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes. Instructions: please typing these entity words according to sentence: Theileria annulata, matrix metalloproteinase 9, transcription factor, AP-1, bovine leucocytes Options: mono_cell, cell_type, protein_family_or_group, protein_molecule

[ "O", "O", "B-mono_cell", "I-mono_cell", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]

Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes.

[ "Infection", "with", "Theileria", "annulata", "induces", "expression", "of", "matrix", "metalloproteinase", "9", "and", "transcription", "factor", "AP-1", "in", "bovine", "leucocytes", "." ]

[ "other_name", "cell_type", "protein_molecule", "protein_family_or_group", "mono_cell", "DNA_family_or_group", "multi_cell", "RNA_family_or_group" ]

Theileria annulata, matrix metalloproteinase 9, transcription factor, AP-1, bovine leucocytes

8908_task2

Sentence: Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-mono_cell", "I-mono_cell", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "O" ]

Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes.

[ "Infection", "with", "Theileria", "annulata", "induces", "expression", "of", "matrix", "metalloproteinase", "9", "and", "transcription", "factor", "AP-1", "in", "bovine", "leucocytes", "." ]

[ "other_name", "cell_type", "protein_molecule", "protein_family_or_group", "mono_cell", "DNA_family_or_group", "multi_cell", "RNA_family_or_group" ]

Gastric ulcer is a Participant_Condition, human epidermal growth factor is a Intervention_Pharmacological, intravenous human epidermal growth factor ( hEGF ) is a Intervention_Pharmacological, cetraxate hydrochloride ( CH ) is a Intervention_Pharmacological, gastric ulcers is a Outcome_Physical, rate of ulcer healing is a Outcome_Physical, 67/86 is a Participant_Sample-size, healing rate is a Outcome_Physical, pain relief is a Outcome_Pain, blood examination is a Outcome_Physical, adverse reactions is a Outcome_Adverse-effects, hydroxypropyl cellulose is a Intervention_Pharmacological, residual mEGF levels is a Outcome_Physical, healing of rat gastric ulcers is a Outcome_Physical

82758_task0

Sentence: Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Pain, Outcome_Physical, Participant_Sample-size

[ "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial .

[ "Gastric", "ulcer", "treatment", "with", "intravenous", "human", "epidermal", "growth", "factor", ":", "a", "double", "-", "blind", "controlled", "clinical", "study", ".", "We", "introduced", "a", "double", "-", "blind", "controlled", "clinical", "study", "to", "compare", "intravenous", "human", "epidermal", "growth", "factor", "(", "hEGF", ")", "to", "cetraxate", "hydrochloride", "(", "CH", ")", ",", "an", "antiulcer", "drug", ",", "for", "their", "healing", "effect", "on", "gastric", "ulcers", ".", "We", "also", "prospected", "an", "oral", "use", "of", "EGF", "on", "the", "basis", "of", "our", "experimental", "evidence", ".", "In", "the", "clinical", "trial", ",", "the", "rate", "of", "ulcer", "healing", "within", "8", "weeks", "was", "77.9", "%", "(", "67/86", ")", "in", "patients", "receiving", "6", "micrograms", "EGF", "intravenously", "twice", "a", "week", ",", "being", "significantly", "greater", "than", "51.7", "%", "(", "45/87", ")", "in", "those", "given", "CH", ".", "Taking", "together", "all", "aspects", "assessed", "including", "the", "healing", "rate", ",", "pain", "relief", ",", "blood", "examination", "and", "adverse", "reactions", ",", "we", "judged", "the", "hEGF", "to", "be", "a", "useful", "and", "safe", "anticuler", "drug", ".", "In", "rats", ",", "50", "micrograms", "/", "kg", "mouse", "EGF", "(", "mEGF", ")", "and", "2", "%", "hydroxypropyl", "cellulose", "(", "HPC", ")", "or", "1.0", "g", "/", "kg", "sucralfate", "given", "by", "gastric", "intubation", "significantly", "raised", "the", "residual", "mEGF", "levels", "in", "both", "gastric", "luminal", "content", "(", "HPC", ":", "x", "30", ";", "sucralfate", ":", "x", "300", "as", "high", "as", "those", "in", "EGF", "alone", ")", "and", "tissue", "(", "HPC", ":", "x", "60", ";", "sucralfate", ":", "x", "100", ")", ".", "In", "addition", ",", "the", "combined", "treatments", "significantly", "promoted", "healing", "of", "rat", "gastric", "ulcers", "whereas", "each", "agent", "alone", "had", "no", "significant", "effect", "as", "compared", "with", "control", "(", "saline", ")", ".", "This", "indicated", "the", "beneficial", "effect", "on", "ulcers", "of", "oral", "administration", "of", "EGF", "with", "agents", "allowing", "it", "to", "remain", "at", "high", "levels", "in", "the", "stomach", ",", "whereas", "most", "reports", "suggested", "less", "effect", "of", "oral", "EGF", "on", "healing", "of", "gastroduodenal", "ulcers", ".", "Subsequent", "to", "the", "clinical", "study", ",", "evaluation", "of", "oral", "use", "of", "EGF", "may", "be", "expected", "as", "the", "next", "step", "in", "the", "treatment", "of", "ulcers", ".", "The", "experimental", "evidence", "above", "would", "possibly", "be", "a", "guide", "for", "such", "trial", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Pain", "Participant_Sample-size" ]

Gastric ulcer is a Participant_Condition, human epidermal growth factor is a Intervention_Pharmacological, intravenous human epidermal growth factor ( hEGF ) is a Intervention_Pharmacological, cetraxate hydrochloride ( CH ) is a Intervention_Pharmacological, gastric ulcers is a Outcome_Physical, rate of ulcer healing is a Outcome_Physical, 67/86 is a Participant_Sample-size, healing rate is a Outcome_Physical, pain relief is a Outcome_Pain, blood examination is a Outcome_Physical, adverse reactions is a Outcome_Adverse-effects, hydroxypropyl cellulose is a Intervention_Pharmacological, residual mEGF levels is a Outcome_Physical, healing of rat gastric ulcers is a Outcome_Physical

82758_task1

Sentence: Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial . Instructions: please typing these entity words according to sentence: Gastric ulcer, human epidermal growth factor, intravenous human epidermal growth factor ( hEGF ), cetraxate hydrochloride ( CH ), gastric ulcers, rate of ulcer healing, 67/86, healing rate, pain relief, blood examination, adverse reactions, hydroxypropyl cellulose, residual mEGF levels, healing of rat gastric ulcers Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Pain, Outcome_Physical, Participant_Sample-size

[ "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial .

[ "Gastric", "ulcer", "treatment", "with", "intravenous", "human", "epidermal", "growth", "factor", ":", "a", "double", "-", "blind", "controlled", "clinical", "study", ".", "We", "introduced", "a", "double", "-", "blind", "controlled", "clinical", "study", "to", "compare", "intravenous", "human", "epidermal", "growth", "factor", "(", "hEGF", ")", "to", "cetraxate", "hydrochloride", "(", "CH", ")", ",", "an", "antiulcer", "drug", ",", "for", "their", "healing", "effect", "on", "gastric", "ulcers", ".", "We", "also", "prospected", "an", "oral", "use", "of", "EGF", "on", "the", "basis", "of", "our", "experimental", "evidence", ".", "In", "the", "clinical", "trial", ",", "the", "rate", "of", "ulcer", "healing", "within", "8", "weeks", "was", "77.9", "%", "(", "67/86", ")", "in", "patients", "receiving", "6", "micrograms", "EGF", "intravenously", "twice", "a", "week", ",", "being", "significantly", "greater", "than", "51.7", "%", "(", "45/87", ")", "in", "those", "given", "CH", ".", "Taking", "together", "all", "aspects", "assessed", "including", "the", "healing", "rate", ",", "pain", "relief", ",", "blood", "examination", "and", "adverse", "reactions", ",", "we", "judged", "the", "hEGF", "to", "be", "a", "useful", "and", "safe", "anticuler", "drug", ".", "In", "rats", ",", "50", "micrograms", "/", "kg", "mouse", "EGF", "(", "mEGF", ")", "and", "2", "%", "hydroxypropyl", "cellulose", "(", "HPC", ")", "or", "1.0", "g", "/", "kg", "sucralfate", "given", "by", "gastric", "intubation", "significantly", "raised", "the", "residual", "mEGF", "levels", "in", "both", "gastric", "luminal", "content", "(", "HPC", ":", "x", "30", ";", "sucralfate", ":", "x", "300", "as", "high", "as", "those", "in", "EGF", "alone", ")", "and", "tissue", "(", "HPC", ":", "x", "60", ";", "sucralfate", ":", "x", "100", ")", ".", "In", "addition", ",", "the", "combined", "treatments", "significantly", "promoted", "healing", "of", "rat", "gastric", "ulcers", "whereas", "each", "agent", "alone", "had", "no", "significant", "effect", "as", "compared", "with", "control", "(", "saline", ")", ".", "This", "indicated", "the", "beneficial", "effect", "on", "ulcers", "of", "oral", "administration", "of", "EGF", "with", "agents", "allowing", "it", "to", "remain", "at", "high", "levels", "in", "the", "stomach", ",", "whereas", "most", "reports", "suggested", "less", "effect", "of", "oral", "EGF", "on", "healing", "of", "gastroduodenal", "ulcers", ".", "Subsequent", "to", "the", "clinical", "study", ",", "evaluation", "of", "oral", "use", "of", "EGF", "may", "be", "expected", "as", "the", "next", "step", "in", "the", "treatment", "of", "ulcers", ".", "The", "experimental", "evidence", "above", "would", "possibly", "be", "a", "guide", "for", "such", "trial", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Pain", "Participant_Sample-size" ]

Gastric ulcer, human epidermal growth factor, intravenous human epidermal growth factor ( hEGF ), cetraxate hydrochloride ( CH ), gastric ulcers, rate of ulcer healing, 67/86, healing rate, pain relief, blood examination, adverse reactions, hydroxypropyl cellulose, residual mEGF levels, healing of rat gastric ulcers

82758_task2

Sentence: Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial . Instructions: please extract entity words from the input sentence

[ "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial .

[ "Gastric", "ulcer", "treatment", "with", "intravenous", "human", "epidermal", "growth", "factor", ":", "a", "double", "-", "blind", "controlled", "clinical", "study", ".", "We", "introduced", "a", "double", "-", "blind", "controlled", "clinical", "study", "to", "compare", "intravenous", "human", "epidermal", "growth", "factor", "(", "hEGF", ")", "to", "cetraxate", "hydrochloride", "(", "CH", ")", ",", "an", "antiulcer", "drug", ",", "for", "their", "healing", "effect", "on", "gastric", "ulcers", ".", "We", "also", "prospected", "an", "oral", "use", "of", "EGF", "on", "the", "basis", "of", "our", "experimental", "evidence", ".", "In", "the", "clinical", "trial", ",", "the", "rate", "of", "ulcer", "healing", "within", "8", "weeks", "was", "77.9", "%", "(", "67/86", ")", "in", "patients", "receiving", "6", "micrograms", "EGF", "intravenously", "twice", "a", "week", ",", "being", "significantly", "greater", "than", "51.7", "%", "(", "45/87", ")", "in", "those", "given", "CH", ".", "Taking", "together", "all", "aspects", "assessed", "including", "the", "healing", "rate", ",", "pain", "relief", ",", "blood", "examination", "and", "adverse", "reactions", ",", "we", "judged", "the", "hEGF", "to", "be", "a", "useful", "and", "safe", "anticuler", "drug", ".", "In", "rats", ",", "50", "micrograms", "/", "kg", "mouse", "EGF", "(", "mEGF", ")", "and", "2", "%", "hydroxypropyl", "cellulose", "(", "HPC", ")", "or", "1.0", "g", "/", "kg", "sucralfate", "given", "by", "gastric", "intubation", "significantly", "raised", "the", "residual", "mEGF", "levels", "in", "both", "gastric", "luminal", "content", "(", "HPC", ":", "x", "30", ";", "sucralfate", ":", "x", "300", "as", "high", "as", "those", "in", "EGF", "alone", ")", "and", "tissue", "(", "HPC", ":", "x", "60", ";", "sucralfate", ":", "x", "100", ")", ".", "In", "addition", ",", "the", "combined", "treatments", "significantly", "promoted", "healing", "of", "rat", "gastric", "ulcers", "whereas", "each", "agent", "alone", "had", "no", "significant", "effect", "as", "compared", "with", "control", "(", "saline", ")", ".", "This", "indicated", "the", "beneficial", "effect", "on", "ulcers", "of", "oral", "administration", "of", "EGF", "with", "agents", "allowing", "it", "to", "remain", "at", "high", "levels", "in", "the", "stomach", ",", "whereas", "most", "reports", "suggested", "less", "effect", "of", "oral", "EGF", "on", "healing", "of", "gastroduodenal", "ulcers", ".", "Subsequent", "to", "the", "clinical", "study", ",", "evaluation", "of", "oral", "use", "of", "EGF", "may", "be", "expected", "as", "the", "next", "step", "in", "the", "treatment", "of", "ulcers", ".", "The", "experimental", "evidence", "above", "would", "possibly", "be", "a", "guide", "for", "such", "trial", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Pain", "Participant_Sample-size" ]

Kinderwunsches is an umlsterm, Techniken is an umlsterm, Techniken is an umlsterm, Behandlung is an umlsterm

DerGynaekologe.00330782.ger.abstr_task0

Sentence: Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind .

[ "Die", "ungewollt", "kinderlosen", "Paare", "hoffen", "auf", "die", "Erfuellung", "des", "Kinderwunsches", "fast", "ausschliesslich", "unter", "Anwendung", "reproduktionsmedizinischer", "Techniken", ".", "Im", "Diskurs", "um", "die", "Anwendung", "und", "die", "Entwicklungen", "reproduktiver", "Techniken", "treten", "die", "Erlebensaspekte", "der", "Betroffenen", "in", "den", "Hintergrund", ".", "Hilfe", "ausserhalb", "der", "medizinischen", "Behandlung", "wird", "von", "vielen", "erst", "zu", "einem", "Zeitpunkt", "angefragt", ",", "an", "dem", "sie", "von", "den", "erfolglosen", "Behandlungsversuchen", "erschoepft", "oder", "sehr", "enttaeuscht", "sind", "." ]

[ "umlsterm" ]

Kinderwunsches is an umlsterm, Techniken is an umlsterm, Techniken is an umlsterm, Behandlung is an umlsterm

DerGynaekologe.00330782.ger.abstr_task1

Sentence: Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind . Instructions: please typing these entity words according to sentence: Kinderwunsches, Techniken, Techniken, Behandlung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind .

[ "Die", "ungewollt", "kinderlosen", "Paare", "hoffen", "auf", "die", "Erfuellung", "des", "Kinderwunsches", "fast", "ausschliesslich", "unter", "Anwendung", "reproduktionsmedizinischer", "Techniken", ".", "Im", "Diskurs", "um", "die", "Anwendung", "und", "die", "Entwicklungen", "reproduktiver", "Techniken", "treten", "die", "Erlebensaspekte", "der", "Betroffenen", "in", "den", "Hintergrund", ".", "Hilfe", "ausserhalb", "der", "medizinischen", "Behandlung", "wird", "von", "vielen", "erst", "zu", "einem", "Zeitpunkt", "angefragt", ",", "an", "dem", "sie", "von", "den", "erfolglosen", "Behandlungsversuchen", "erschoepft", "oder", "sehr", "enttaeuscht", "sind", "." ]

[ "umlsterm" ]

Kinderwunsches, Techniken, Techniken, Behandlung

DerGynaekologe.00330782.ger.abstr_task2

Sentence: Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die ungewollt kinderlosen Paare hoffen auf die Erfuellung des Kinderwunsches fast ausschliesslich unter Anwendung reproduktionsmedizinischer Techniken . Im Diskurs um die Anwendung und die Entwicklungen reproduktiver Techniken treten die Erlebensaspekte der Betroffenen in den Hintergrund . Hilfe ausserhalb der medizinischen Behandlung wird von vielen erst zu einem Zeitpunkt angefragt , an dem sie von den erfolglosen Behandlungsversuchen erschoepft oder sehr enttaeuscht sind .

[ "Die", "ungewollt", "kinderlosen", "Paare", "hoffen", "auf", "die", "Erfuellung", "des", "Kinderwunsches", "fast", "ausschliesslich", "unter", "Anwendung", "reproduktionsmedizinischer", "Techniken", ".", "Im", "Diskurs", "um", "die", "Anwendung", "und", "die", "Entwicklungen", "reproduktiver", "Techniken", "treten", "die", "Erlebensaspekte", "der", "Betroffenen", "in", "den", "Hintergrund", ".", "Hilfe", "ausserhalb", "der", "medizinischen", "Behandlung", "wird", "von", "vielen", "erst", "zu", "einem", "Zeitpunkt", "angefragt", ",", "an", "dem", "sie", "von", "den", "erfolglosen", "Behandlungsversuchen", "erschoepft", "oder", "sehr", "enttaeuscht", "sind", "." ]

[ "umlsterm" ]

precipitinas is a PROTEINAS, IgG is a PROTEINAS, antígeno galactomanano is a PROTEINAS, voriconazol is a NORMALIZABLES, precipitinas is a PROTEINAS

414_task0

Sentence: Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O" ]

Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas.

[ "Varón", "de", "45", "años", ",", "trabajador", "en", "canteras", "durante", "15", "años", ".", "Diagnosticado", "de", "silicosis", "complicada", "en", "FMP", ".", "Exfumador", "desde", "hace", "dos", "años", ",", "de", "25", "paquetes", "/", "año", ".", "Tuberculosis", "pulmonar", "en", "2007", ".", "Acudió", "al", "Servicio", "de", "Urgencias", "en", "marzo", "2009", "con", "hemoptisis", "amenazante", ",", "precedida", "de", "tos", "y", "expectoración", "marronácea", "de", "4", "semanas", "de", "evolución", ".", "En", "la", "exploración", "física", "destacar", "constantes", "vitales", "dentro", "de", "la", "normalidad", "y", "roncus", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sérica", "destacar", "leucocitosis", "(", "11.280", "células", "/", "μl", "con", "80", "%", "de", "neutrófilos", ")", "sin", "otras", "alteraciones", ".", "La", "fibrobroncoscopia", "permitió", "ver", "un", "gran", "coágulo", "en", "bronquio", "de", "lóbulo", "superior", "derecho", ".", "La", "TAC", "mostraba", "afectación", "intersticial", "micronodular", "bilateral", "y", "difusa", ",", "algunos", "nódulos", "calcificados", ",", "de", "predominio", "en", "lóbulos", "superiores", "y", "conglomerados", "que", "habían", "aumentado", "respecto", "a", "estudios", "previos", ",", "con", "aparición", "de", "material", "en", "su", "interior", ",", "así", "como", "engrosamiento", "pleural", "nodular", "y", "difuso", ".", "El", "cultivo", "fue", "positivo", "para", "Aspergillus", "fumigatus", "en", "esputo", "y", "en", "aspirado", "bronquial", ".", "En", "sangre", "las", "precipitinas", "IgG", "resultaron", "positivas", "y", "el", "antígeno", "galactomanano", "negativo", ".", "Se", "realizó", "embolización", "de", "arterias", "bronquiales", "del", "LSI", "con", "control", "de", "la", "hemoptisis", "y", "se", "instauró", "tratamiento", "con", "voriconazol", "con", "buena", "evolución", "al", "año", "de", "tratamiento", "con", "negativización", "de", "las", "precipitinas", "séricas", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES" ]

precipitinas is a PROTEINAS, IgG is a PROTEINAS, antígeno galactomanano is a PROTEINAS, voriconazol is a NORMALIZABLES, precipitinas is a PROTEINAS

414_task1

Sentence: Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas. Instructions: please typing these entity words according to sentence: precipitinas, IgG, antígeno galactomanano, voriconazol, precipitinas Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O" ]

Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas.

[ "Varón", "de", "45", "años", ",", "trabajador", "en", "canteras", "durante", "15", "años", ".", "Diagnosticado", "de", "silicosis", "complicada", "en", "FMP", ".", "Exfumador", "desde", "hace", "dos", "años", ",", "de", "25", "paquetes", "/", "año", ".", "Tuberculosis", "pulmonar", "en", "2007", ".", "Acudió", "al", "Servicio", "de", "Urgencias", "en", "marzo", "2009", "con", "hemoptisis", "amenazante", ",", "precedida", "de", "tos", "y", "expectoración", "marronácea", "de", "4", "semanas", "de", "evolución", ".", "En", "la", "exploración", "física", "destacar", "constantes", "vitales", "dentro", "de", "la", "normalidad", "y", "roncus", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sérica", "destacar", "leucocitosis", "(", "11.280", "células", "/", "μl", "con", "80", "%", "de", "neutrófilos", ")", "sin", "otras", "alteraciones", ".", "La", "fibrobroncoscopia", "permitió", "ver", "un", "gran", "coágulo", "en", "bronquio", "de", "lóbulo", "superior", "derecho", ".", "La", "TAC", "mostraba", "afectación", "intersticial", "micronodular", "bilateral", "y", "difusa", ",", "algunos", "nódulos", "calcificados", ",", "de", "predominio", "en", "lóbulos", "superiores", "y", "conglomerados", "que", "habían", "aumentado", "respecto", "a", "estudios", "previos", ",", "con", "aparición", "de", "material", "en", "su", "interior", ",", "así", "como", "engrosamiento", "pleural", "nodular", "y", "difuso", ".", "El", "cultivo", "fue", "positivo", "para", "Aspergillus", "fumigatus", "en", "esputo", "y", "en", "aspirado", "bronquial", ".", "En", "sangre", "las", "precipitinas", "IgG", "resultaron", "positivas", "y", "el", "antígeno", "galactomanano", "negativo", ".", "Se", "realizó", "embolización", "de", "arterias", "bronquiales", "del", "LSI", "con", "control", "de", "la", "hemoptisis", "y", "se", "instauró", "tratamiento", "con", "voriconazol", "con", "buena", "evolución", "al", "año", "de", "tratamiento", "con", "negativización", "de", "las", "precipitinas", "séricas", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES" ]

precipitinas, IgG, antígeno galactomanano, voriconazol, precipitinas

414_task2

Sentence: Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "B-PROTEINAS", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O" ]

Varón de 45 años, trabajador en canteras durante 15 años. Diagnosticado de silicosis complicada en FMP. Exfumador desde hace dos años, de 25 paquetes/año. Tuberculosis pulmonar en 2007. Acudió al Servicio de Urgencias en marzo 2009 con hemoptisis amenazante, precedida de tos y expectoración marronácea de 4 semanas de evolución. En la exploración física destacar constantes vitales dentro de la normalidad y roncus bilaterales en la auscultación pulmonar. En la analítica sérica destacar leucocitosis (11.280 células/μl con 80% de neutrófilos) sin otras alteraciones. La fibrobroncoscopia permitió ver un gran coágulo en bronquio de lóbulo superior derecho. La TAC mostraba afectación intersticial micronodular bilateral y difusa, algunos nódulos calcificados, de predominio en lóbulos superiores y conglomerados que habían aumentado respecto a estudios previos, con aparición de material en su interior, así como engrosamiento pleural nodular y difuso. El cultivo fue positivo para Aspergillus fumigatus en esputo y en aspirado bronquial. En sangre las precipitinas IgG resultaron positivas y el antígeno galactomanano negativo. Se realizó embolización de arterias bronquiales del LSI con control de la hemoptisis y se instauró tratamiento con voriconazol con buena evolución al año de tratamiento con negativización de las precipitinas séricas.

[ "Varón", "de", "45", "años", ",", "trabajador", "en", "canteras", "durante", "15", "años", ".", "Diagnosticado", "de", "silicosis", "complicada", "en", "FMP", ".", "Exfumador", "desde", "hace", "dos", "años", ",", "de", "25", "paquetes", "/", "año", ".", "Tuberculosis", "pulmonar", "en", "2007", ".", "Acudió", "al", "Servicio", "de", "Urgencias", "en", "marzo", "2009", "con", "hemoptisis", "amenazante", ",", "precedida", "de", "tos", "y", "expectoración", "marronácea", "de", "4", "semanas", "de", "evolución", ".", "En", "la", "exploración", "física", "destacar", "constantes", "vitales", "dentro", "de", "la", "normalidad", "y", "roncus", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sérica", "destacar", "leucocitosis", "(", "11.280", "células", "/", "μl", "con", "80", "%", "de", "neutrófilos", ")", "sin", "otras", "alteraciones", ".", "La", "fibrobroncoscopia", "permitió", "ver", "un", "gran", "coágulo", "en", "bronquio", "de", "lóbulo", "superior", "derecho", ".", "La", "TAC", "mostraba", "afectación", "intersticial", "micronodular", "bilateral", "y", "difusa", ",", "algunos", "nódulos", "calcificados", ",", "de", "predominio", "en", "lóbulos", "superiores", "y", "conglomerados", "que", "habían", "aumentado", "respecto", "a", "estudios", "previos", ",", "con", "aparición", "de", "material", "en", "su", "interior", ",", "así", "como", "engrosamiento", "pleural", "nodular", "y", "difuso", ".", "El", "cultivo", "fue", "positivo", "para", "Aspergillus", "fumigatus", "en", "esputo", "y", "en", "aspirado", "bronquial", ".", "En", "sangre", "las", "precipitinas", "IgG", "resultaron", "positivas", "y", "el", "antígeno", "galactomanano", "negativo", ".", "Se", "realizó", "embolización", "de", "arterias", "bronquiales", "del", "LSI", "con", "control", "de", "la", "hemoptisis", "y", "se", "instauró", "tratamiento", "con", "voriconazol", "con", "buena", "evolución", "al", "año", "de", "tratamiento", "con", "negativización", "de", "las", "precipitinas", "séricas", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES" ]

brain damage is a ADVERSE

example-399_task0

Sentence: Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful.

[ "Iatrogenic", "intravenous", "medication", "errors", "reported", "to", "the", "PIC", "Erfurt", ".", " ", "BACKGROUND", ":", "We", "investigated", "the", "iatrogenic", "intravenous", "medication", "errors", "(", "IIME", ")", "reported", "to", "the", "Poisons", "Information", "Center", "(", "PIC", ")", "Erfurt", ".", "METHODS", ":", "All", "IIME", "over", "a", "ten", "year", "period", "were", "analyzed", "retrospectively", "and", "categorized", "into", "error", "types", ",", "age", "groups", ",", "drugs", "involved", ",", "and", "estimated", "risk", "of", "toxicity", ".", "RESULTS", ":", "From", "1997", "to", "2006", "the", "PIC", "Erfurt", "registered", "132", "cases", "of", "IIME", ".", "They", "increased", "from", "7", "in", "1997", "to", "31", "in", "2006", ".", "Children", "accounted", "for", "31.1", "%", "of", "the", "patients", "affected", "and", "adults", "for", "68.9", "%", ".", "The", "drug", "classes", "(", "ATC", "classification", ")", "involved", "most", "frequently", "were", "antipsychotics", "(", "9.8", "%", ")", "and", "antihistamines", "for", "systemic", "use", "(", "7.5", "%", ")", ".", "The", "main", "types", "of", "IIME", "were", "overdose", "(", "53.1", "%", ")", "and", "incorrect", "route", "of", "administration", "(", "29.7", "%", ")", ".", "The", "estimated", "risk", "of", "toxicity", "was", ":", "14.4", "%", "none", ",", "71.2", "%", "risk", "of", "toxicity", ",", "and", "14.4", "%", "unpredictable", "risk", ".", "Medical", "treatment", "was", "recommended", "in", "82", "%", ".", "The", "outcome", "of", "104", "of", "the", "132", "(", "78.8", "%", ")", "courses", "was", "unknown", ".", "In", "the", "28", "cases", "followed", "to", "a", "known", "outcome", ",", "9", "(", "32", "%", ")", "were", "asymptomatic", "and", "19", "(", "68", "%", ")", "symptomatic", "with", "minor", "(", "9", "cases", ")", ",", "moderate", "(", "1", "case", ")", ",", "and", "severe", "features", "(", "6", "cases", ")", "but", "mostly", "complete", "recovery", ".", "Two", "IIME", "resulted", "in", "hypoxia", "-", "induced", "brain", "damage", "and", "one", "in", "death", "despite", "of", "resuscitation", ".", "CONCLUSION", ":", "Approximately", "0.1", "%", "of", "all", "calls", "registered", "by", "the", "PIC", "Erfurt", "from", "1997", "to", "2006", "concerned", "IIME", ".", "Thirty", "-", "two", "percent", "of", "IIME", "followed", "to", "a", "known", "outcome", "resulted", "in", "severe", "symptoms", ".", "These", "data", "show", "that", "IIME", "can", "be", "harmful", "." ]

[ "ADVERSE" ]

brain damage is a ADVERSE

example-399_task1

Sentence: Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful. Instructions: please typing these entity words according to sentence: brain damage Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful.

[ "Iatrogenic", "intravenous", "medication", "errors", "reported", "to", "the", "PIC", "Erfurt", ".", " ", "BACKGROUND", ":", "We", "investigated", "the", "iatrogenic", "intravenous", "medication", "errors", "(", "IIME", ")", "reported", "to", "the", "Poisons", "Information", "Center", "(", "PIC", ")", "Erfurt", ".", "METHODS", ":", "All", "IIME", "over", "a", "ten", "year", "period", "were", "analyzed", "retrospectively", "and", "categorized", "into", "error", "types", ",", "age", "groups", ",", "drugs", "involved", ",", "and", "estimated", "risk", "of", "toxicity", ".", "RESULTS", ":", "From", "1997", "to", "2006", "the", "PIC", "Erfurt", "registered", "132", "cases", "of", "IIME", ".", "They", "increased", "from", "7", "in", "1997", "to", "31", "in", "2006", ".", "Children", "accounted", "for", "31.1", "%", "of", "the", "patients", "affected", "and", "adults", "for", "68.9", "%", ".", "The", "drug", "classes", "(", "ATC", "classification", ")", "involved", "most", "frequently", "were", "antipsychotics", "(", "9.8", "%", ")", "and", "antihistamines", "for", "systemic", "use", "(", "7.5", "%", ")", ".", "The", "main", "types", "of", "IIME", "were", "overdose", "(", "53.1", "%", ")", "and", "incorrect", "route", "of", "administration", "(", "29.7", "%", ")", ".", "The", "estimated", "risk", "of", "toxicity", "was", ":", "14.4", "%", "none", ",", "71.2", "%", "risk", "of", "toxicity", ",", "and", "14.4", "%", "unpredictable", "risk", ".", "Medical", "treatment", "was", "recommended", "in", "82", "%", ".", "The", "outcome", "of", "104", "of", "the", "132", "(", "78.8", "%", ")", "courses", "was", "unknown", ".", "In", "the", "28", "cases", "followed", "to", "a", "known", "outcome", ",", "9", "(", "32", "%", ")", "were", "asymptomatic", "and", "19", "(", "68", "%", ")", "symptomatic", "with", "minor", "(", "9", "cases", ")", ",", "moderate", "(", "1", "case", ")", ",", "and", "severe", "features", "(", "6", "cases", ")", "but", "mostly", "complete", "recovery", ".", "Two", "IIME", "resulted", "in", "hypoxia", "-", "induced", "brain", "damage", "and", "one", "in", "death", "despite", "of", "resuscitation", ".", "CONCLUSION", ":", "Approximately", "0.1", "%", "of", "all", "calls", "registered", "by", "the", "PIC", "Erfurt", "from", "1997", "to", "2006", "concerned", "IIME", ".", "Thirty", "-", "two", "percent", "of", "IIME", "followed", "to", "a", "known", "outcome", "resulted", "in", "severe", "symptoms", ".", "These", "data", "show", "that", "IIME", "can", "be", "harmful", "." ]

[ "ADVERSE" ]

brain damage

example-399_task2

Sentence: Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Iatrogenic intravenous medication errors reported to the PIC Erfurt. BACKGROUND: We investigated the iatrogenic intravenous medication errors (IIME) reported to the Poisons Information Center (PIC) Erfurt. METHODS: All IIME over a ten year period were analyzed retrospectively and categorized into error types, age groups, drugs involved, and estimated risk of toxicity. RESULTS: From 1997 to 2006 the PIC Erfurt registered 132 cases of IIME. They increased from 7 in 1997 to 31 in 2006. Children accounted for 31.1% of the patients affected and adults for 68.9%. The drug classes (ATC classification) involved most frequently were antipsychotics (9.8%) and antihistamines for systemic use (7.5%). The main types of IIME were overdose (53.1%) and incorrect route of administration (29.7%). The estimated risk of toxicity was: 14.4% none, 71.2% risk of toxicity, and 14.4% unpredictable risk. Medical treatment was recommended in 82%. The outcome of 104 of the 132 (78.8%) courses was unknown. In the 28 cases followed to a known outcome, 9 (32%) were asymptomatic and 19 (68%) symptomatic with minor (9 cases), moderate (1 case), and severe features (6 cases) but mostly complete recovery. Two IIME resulted in hypoxia-induced brain damage and one in death despite of resuscitation. CONCLUSION: Approximately 0.1% of all calls registered by the PIC Erfurt from 1997 to 2006 concerned IIME. Thirty-two percent of IIME followed to a known outcome resulted in severe symptoms. These data show that IIME can be harmful.

[ "Iatrogenic", "intravenous", "medication", "errors", "reported", "to", "the", "PIC", "Erfurt", ".", " ", "BACKGROUND", ":", "We", "investigated", "the", "iatrogenic", "intravenous", "medication", "errors", "(", "IIME", ")", "reported", "to", "the", "Poisons", "Information", "Center", "(", "PIC", ")", "Erfurt", ".", "METHODS", ":", "All", "IIME", "over", "a", "ten", "year", "period", "were", "analyzed", "retrospectively", "and", "categorized", "into", "error", "types", ",", "age", "groups", ",", "drugs", "involved", ",", "and", "estimated", "risk", "of", "toxicity", ".", "RESULTS", ":", "From", "1997", "to", "2006", "the", "PIC", "Erfurt", "registered", "132", "cases", "of", "IIME", ".", "They", "increased", "from", "7", "in", "1997", "to", "31", "in", "2006", ".", "Children", "accounted", "for", "31.1", "%", "of", "the", "patients", "affected", "and", "adults", "for", "68.9", "%", ".", "The", "drug", "classes", "(", "ATC", "classification", ")", "involved", "most", "frequently", "were", "antipsychotics", "(", "9.8", "%", ")", "and", "antihistamines", "for", "systemic", "use", "(", "7.5", "%", ")", ".", "The", "main", "types", "of", "IIME", "were", "overdose", "(", "53.1", "%", ")", "and", "incorrect", "route", "of", "administration", "(", "29.7", "%", ")", ".", "The", "estimated", "risk", "of", "toxicity", "was", ":", "14.4", "%", "none", ",", "71.2", "%", "risk", "of", "toxicity", ",", "and", "14.4", "%", "unpredictable", "risk", ".", "Medical", "treatment", "was", "recommended", "in", "82", "%", ".", "The", "outcome", "of", "104", "of", "the", "132", "(", "78.8", "%", ")", "courses", "was", "unknown", ".", "In", "the", "28", "cases", "followed", "to", "a", "known", "outcome", ",", "9", "(", "32", "%", ")", "were", "asymptomatic", "and", "19", "(", "68", "%", ")", "symptomatic", "with", "minor", "(", "9", "cases", ")", ",", "moderate", "(", "1", "case", ")", ",", "and", "severe", "features", "(", "6", "cases", ")", "but", "mostly", "complete", "recovery", ".", "Two", "IIME", "resulted", "in", "hypoxia", "-", "induced", "brain", "damage", "and", "one", "in", "death", "despite", "of", "resuscitation", ".", "CONCLUSION", ":", "Approximately", "0.1", "%", "of", "all", "calls", "registered", "by", "the", "PIC", "Erfurt", "from", "1997", "to", "2006", "concerned", "IIME", ".", "Thirty", "-", "two", "percent", "of", "IIME", "followed", "to", "a", "known", "outcome", "resulted", "in", "severe", "symptoms", ".", "These", "data", "show", "that", "IIME", "can", "be", "harmful", "." ]

[ "ADVERSE" ]

prostaglandin D synthase is a GENE-Y

8415655_task0

Sentence: Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.

[ "Dominant", "expression", "of", "mRNA", "for", "prostaglandin", "D", "synthase", "in", "leptomeninges", ",", "choroid", "plexus", ",", "and", "oligodendrocytes", "of", "the", "adult", "rat", "brain", "." ]

[ "GENE-Y", "CHEMICAL" ]

prostaglandin D synthase is a GENE-Y

8415655_task1

Sentence: Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Instructions: please typing these entity words according to sentence: prostaglandin D synthase Options: GENE-Y

[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.

[ "Dominant", "expression", "of", "mRNA", "for", "prostaglandin", "D", "synthase", "in", "leptomeninges", ",", "choroid", "plexus", ",", "and", "oligodendrocytes", "of", "the", "adult", "rat", "brain", "." ]

[ "GENE-Y", "CHEMICAL" ]

prostaglandin D synthase

8415655_task2

Sentence: Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain.

[ "Dominant", "expression", "of", "mRNA", "for", "prostaglandin", "D", "synthase", "in", "leptomeninges", ",", "choroid", "plexus", ",", "and", "oligodendrocytes", "of", "the", "adult", "rat", "brain", "." ]

[ "GENE-Y", "CHEMICAL" ]

Jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, Jacalin is a DRUG_N

3871459_task0

Sentence: Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG_N

[ "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.

[ "Jacalin", ":", "an", "IgA", "-", "binding", "lectin", ".", "We", "previously", "reported", "that", "seeds", "of", "Artocarpus", "integrifolia", "(", "jackfruit", ")", "contain", "a", "lectin", ",", "which", "we", "call", "jacalin", ",", "that", "is", "both", "a", "potent", "T", "cell", "mitogen", "and", "an", "apparently", "T", "cell", "-", "independent", "activator", "of", "human", "B", "cells", "for", "the", "secretion", "of", "immunoglobulins", ".", "During", "the", "above", "experiments", "we", "noted", "a", "massive", "precipitation", "in", "cell", "cultures", "stimulated", "with", "greater", "than", "or", "equal", "to", "100", "micrograms", "of", "lectin", ".", "In", "this", "paper", ",", "we", "show", "that", "the", "precipitate", "is", "formed", "after", "the", "interaction", "of", "jacalin", "and", "the", "serum", "protein", "added", "to", "the", "culture", "medium", ".", "More", "importantly", ",", "we", "demonstrate", "that", "IgA", "is", "probably", "the", "major", "serum", "constituent", "precipitated", "by", "the", "lectin", "and", "that", "no", "IgG", "or", "IgM", "can", "be", "detected", "in", "the", "precipitates", ".", "In", "secretions", "such", "as", "colostrum", ",", "IgA", "is", "the", "only", "protein", "precipitated", "by", "jacalin", ".", "On", "the", "basis", "of", "this", "specificity", "we", "describe", "a", "simple", "and", "reliable", "affinity", "chromatography", "procedure", "for", "the", "purification", "of", "both", "human", "serum", "and", "colostrum", "IgA.", "Jacalin", "is", "a", "D", "-", "Gal", "binding", "lectin", "and", "should", "be", "a", "useful", "tool", "for", "studying", "of", "serum", "and", "secretory", "IgA." ]

[ "DRUG_N" ]

Jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, jacalin is a DRUG_N, Jacalin is a DRUG_N

3871459_task1

Sentence: Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA. Instructions: please typing these entity words according to sentence: Jacalin, jacalin, jacalin, jacalin, Jacalin Options: DRUG_N

[ "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.

[ "Jacalin", ":", "an", "IgA", "-", "binding", "lectin", ".", "We", "previously", "reported", "that", "seeds", "of", "Artocarpus", "integrifolia", "(", "jackfruit", ")", "contain", "a", "lectin", ",", "which", "we", "call", "jacalin", ",", "that", "is", "both", "a", "potent", "T", "cell", "mitogen", "and", "an", "apparently", "T", "cell", "-", "independent", "activator", "of", "human", "B", "cells", "for", "the", "secretion", "of", "immunoglobulins", ".", "During", "the", "above", "experiments", "we", "noted", "a", "massive", "precipitation", "in", "cell", "cultures", "stimulated", "with", "greater", "than", "or", "equal", "to", "100", "micrograms", "of", "lectin", ".", "In", "this", "paper", ",", "we", "show", "that", "the", "precipitate", "is", "formed", "after", "the", "interaction", "of", "jacalin", "and", "the", "serum", "protein", "added", "to", "the", "culture", "medium", ".", "More", "importantly", ",", "we", "demonstrate", "that", "IgA", "is", "probably", "the", "major", "serum", "constituent", "precipitated", "by", "the", "lectin", "and", "that", "no", "IgG", "or", "IgM", "can", "be", "detected", "in", "the", "precipitates", ".", "In", "secretions", "such", "as", "colostrum", ",", "IgA", "is", "the", "only", "protein", "precipitated", "by", "jacalin", ".", "On", "the", "basis", "of", "this", "specificity", "we", "describe", "a", "simple", "and", "reliable", "affinity", "chromatography", "procedure", "for", "the", "purification", "of", "both", "human", "serum", "and", "colostrum", "IgA.", "Jacalin", "is", "a", "D", "-", "Gal", "binding", "lectin", "and", "should", "be", "a", "useful", "tool", "for", "studying", "of", "serum", "and", "secretory", "IgA." ]

[ "DRUG_N" ]

Jacalin, jacalin, jacalin, jacalin, Jacalin

3871459_task2

Sentence: Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA. Instructions: please extract entity words from the input sentence

[ "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Jacalin: an IgA-binding lectin. We previously reported that seeds of Artocarpus integrifolia (jackfruit) contain a lectin, which we call jacalin, that is both a potent T cell mitogen and an apparently T cell-independent activator of human B cells for the secretion of immunoglobulins. During the above experiments we noted a massive precipitation in cell cultures stimulated with greater than or equal to 100 micrograms of lectin. In this paper, we show that the precipitate is formed after the interaction of jacalin and the serum protein added to the culture medium. More importantly, we demonstrate that IgA is probably the major serum constituent precipitated by the lectin and that no IgG or IgM can be detected in the precipitates. In secretions such as colostrum, IgA is the only protein precipitated by jacalin. On the basis of this specificity we describe a simple and reliable affinity chromatography procedure for the purification of both human serum and colostrum IgA. Jacalin is a D-Gal binding lectin and should be a useful tool for studying of serum and secretory IgA.

[ "Jacalin", ":", "an", "IgA", "-", "binding", "lectin", ".", "We", "previously", "reported", "that", "seeds", "of", "Artocarpus", "integrifolia", "(", "jackfruit", ")", "contain", "a", "lectin", ",", "which", "we", "call", "jacalin", ",", "that", "is", "both", "a", "potent", "T", "cell", "mitogen", "and", "an", "apparently", "T", "cell", "-", "independent", "activator", "of", "human", "B", "cells", "for", "the", "secretion", "of", "immunoglobulins", ".", "During", "the", "above", "experiments", "we", "noted", "a", "massive", "precipitation", "in", "cell", "cultures", "stimulated", "with", "greater", "than", "or", "equal", "to", "100", "micrograms", "of", "lectin", ".", "In", "this", "paper", ",", "we", "show", "that", "the", "precipitate", "is", "formed", "after", "the", "interaction", "of", "jacalin", "and", "the", "serum", "protein", "added", "to", "the", "culture", "medium", ".", "More", "importantly", ",", "we", "demonstrate", "that", "IgA", "is", "probably", "the", "major", "serum", "constituent", "precipitated", "by", "the", "lectin", "and", "that", "no", "IgG", "or", "IgM", "can", "be", "detected", "in", "the", "precipitates", ".", "In", "secretions", "such", "as", "colostrum", ",", "IgA", "is", "the", "only", "protein", "precipitated", "by", "jacalin", ".", "On", "the", "basis", "of", "this", "specificity", "we", "describe", "a", "simple", "and", "reliable", "affinity", "chromatography", "procedure", "for", "the", "purification", "of", "both", "human", "serum", "and", "colostrum", "IgA.", "Jacalin", "is", "a", "D", "-", "Gal", "binding", "lectin", "and", "should", "be", "a", "useful", "tool", "for", "studying", "of", "serum", "and", "secretory", "IgA." ]

[ "DRUG_N" ]

Intraokularlinsen is an umlsterm, Lichtaufteilung is an umlsterm, Lichtmenge is an umlsterm, Lichtmenge is an umlsterm

DerOpthalmologe.90960578.ger.abstr_task0

Sentence: Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung .

[ "Hintergrund", ":", "Multifokale", "Intraokularlinsen", "(", "MIOL", ")", "werden", "seit", "Jahren", "mit", "gutem", "Erfolg", "implantiert", ".", "Bedingt", "durch", "die", "Lichtaufteilung", "auf", "mehrere", "Brennpunkte", "steht", "fuer", "jedes", "Bild", "eine", "geringere", "Lichtmenge", "zur", "Verfuegung", ".", "Eine", "zusaetzliche", "Reduktion", "der", "Lichtmenge", "oder", "Streulichteffekte", "durch", "eine", "Kapselfibrose", "fuehren", "moeglicherweise", "fruehzeitig", "zu", "einer", "Sehverschlechterung", "." ]

[ "umlsterm" ]

Intraokularlinsen is an umlsterm, Lichtaufteilung is an umlsterm, Lichtmenge is an umlsterm, Lichtmenge is an umlsterm

DerOpthalmologe.90960578.ger.abstr_task1

Sentence: Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung . Instructions: please typing these entity words according to sentence: Intraokularlinsen, Lichtaufteilung, Lichtmenge, Lichtmenge Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung .

[ "Hintergrund", ":", "Multifokale", "Intraokularlinsen", "(", "MIOL", ")", "werden", "seit", "Jahren", "mit", "gutem", "Erfolg", "implantiert", ".", "Bedingt", "durch", "die", "Lichtaufteilung", "auf", "mehrere", "Brennpunkte", "steht", "fuer", "jedes", "Bild", "eine", "geringere", "Lichtmenge", "zur", "Verfuegung", ".", "Eine", "zusaetzliche", "Reduktion", "der", "Lichtmenge", "oder", "Streulichteffekte", "durch", "eine", "Kapselfibrose", "fuehren", "moeglicherweise", "fruehzeitig", "zu", "einer", "Sehverschlechterung", "." ]

[ "umlsterm" ]

Intraokularlinsen, Lichtaufteilung, Lichtmenge, Lichtmenge

DerOpthalmologe.90960578.ger.abstr_task2

Sentence: Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hintergrund : Multifokale Intraokularlinsen ( MIOL ) werden seit Jahren mit gutem Erfolg implantiert . Bedingt durch die Lichtaufteilung auf mehrere Brennpunkte steht fuer jedes Bild eine geringere Lichtmenge zur Verfuegung . Eine zusaetzliche Reduktion der Lichtmenge oder Streulichteffekte durch eine Kapselfibrose fuehren moeglicherweise fruehzeitig zu einer Sehverschlechterung .

[ "Hintergrund", ":", "Multifokale", "Intraokularlinsen", "(", "MIOL", ")", "werden", "seit", "Jahren", "mit", "gutem", "Erfolg", "implantiert", ".", "Bedingt", "durch", "die", "Lichtaufteilung", "auf", "mehrere", "Brennpunkte", "steht", "fuer", "jedes", "Bild", "eine", "geringere", "Lichtmenge", "zur", "Verfuegung", ".", "Eine", "zusaetzliche", "Reduktion", "der", "Lichtmenge", "oder", "Streulichteffekte", "durch", "eine", "Kapselfibrose", "fuehren", "moeglicherweise", "fruehzeitig", "zu", "einer", "Sehverschlechterung", "." ]

[ "umlsterm" ]

lymph node dissection is an umlsterm, patients scheduled is an umlsterm, prostatectomy is an umlsterm, radiation therapy is an umlsterm, lymph nodes is an umlsterm, patient is an umlsterm, patients is an umlsterm, metastatic disease is an umlsterm, lymph nodes is an umlsterm, time is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, one - stage is an umlsterm, procedure is an umlsterm, overall is an umlsterm, complication is an umlsterm, open is an umlsterm, patients is an umlsterm, Postoperative is an umlsterm, hospital is an umlsterm, patients is an umlsterm, lymph node dissection is an umlsterm, invasive procedure is an umlsterm, patients is an umlsterm, lymph node is an umlsterm, metastases is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, radiation therapy is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, hospital is an umlsterm, period is an umlsterm, convalescence is an umlsterm

DerUrologeA.60350413.eng.abstr_task0

Sentence: Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence .

[ "Laparoscopic", "pelvic", "lymph", "node", "dissection", "was", "performed", "in", "120", "patients", "scheduled", "to", "undergo", "either", "radical", "perineal", "prostatectomy", "or", "radiation", "therapy", ".", "On", "average", "13", "lymph", "nodes", "were", "resected", "in", "each", "patient", ",", "and", "21", "patients", "were", "found", "to", "have", "metastatic", "disease", "in", "1", "-", "9", "lymph", "nodes", ".", "After", "an", "initial", "learning", "curve", ",", "mean", "operative", "time", "was", "reduced", "significantly", ",", "allowing", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "prostatectomy", "to", "be", "performed", "as", "a", "one", "-", "stage", "procedure", ".", "The", "overall", "complication", "rate", "was", "10", "%", ";", "open", "revisions", "were", "necessary", "in", "only", "2", "of", "120", "patients", ".", "Postoperative", "hospital", "stay", "was", "2", "days", "in", "patients", "undergoing", "laparoscopic", "lymph", "node", "dissection", "only", ".", "This", "minimally", "invasive", "procedure", "is", "particularly", "beneficial", "to", "patients", "with", "lymph", "node", "metastases", "not", "undergoing", "radical", "prostatectomy", ",", "as", "well", "as", "to", "patients", "planned", "to", "be", "treated", "by", "radiation", "therapy", ".", "The", "combination", "of", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "perineal", "prostatectomy", "avoids", "an", "abdominal", "incision", "and", "thus", "shortens", "both", "the", "hospital", "stay", "and", "the", "period", "of", "convalescence", "." ]

[ "umlsterm" ]

lymph node dissection is an umlsterm, patients scheduled is an umlsterm, prostatectomy is an umlsterm, radiation therapy is an umlsterm, lymph nodes is an umlsterm, patient is an umlsterm, patients is an umlsterm, metastatic disease is an umlsterm, lymph nodes is an umlsterm, time is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, one - stage is an umlsterm, procedure is an umlsterm, overall is an umlsterm, complication is an umlsterm, open is an umlsterm, patients is an umlsterm, Postoperative is an umlsterm, hospital is an umlsterm, patients is an umlsterm, lymph node dissection is an umlsterm, invasive procedure is an umlsterm, patients is an umlsterm, lymph node is an umlsterm, metastases is an umlsterm, prostatectomy is an umlsterm, patients is an umlsterm, radiation therapy is an umlsterm, lymph node dissection is an umlsterm, prostatectomy is an umlsterm, hospital is an umlsterm, period is an umlsterm, convalescence is an umlsterm

DerUrologeA.60350413.eng.abstr_task1

Sentence: Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence . Instructions: please typing these entity words according to sentence: lymph node dissection, patients scheduled, prostatectomy, radiation therapy, lymph nodes, patient, patients, metastatic disease, lymph nodes, time, lymph node dissection, prostatectomy, one - stage, procedure, overall, complication, open, patients, Postoperative, hospital, patients, lymph node dissection, invasive procedure, patients, lymph node, metastases, prostatectomy, patients, radiation therapy, lymph node dissection, prostatectomy, hospital, period, convalescence Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence .

[ "Laparoscopic", "pelvic", "lymph", "node", "dissection", "was", "performed", "in", "120", "patients", "scheduled", "to", "undergo", "either", "radical", "perineal", "prostatectomy", "or", "radiation", "therapy", ".", "On", "average", "13", "lymph", "nodes", "were", "resected", "in", "each", "patient", ",", "and", "21", "patients", "were", "found", "to", "have", "metastatic", "disease", "in", "1", "-", "9", "lymph", "nodes", ".", "After", "an", "initial", "learning", "curve", ",", "mean", "operative", "time", "was", "reduced", "significantly", ",", "allowing", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "prostatectomy", "to", "be", "performed", "as", "a", "one", "-", "stage", "procedure", ".", "The", "overall", "complication", "rate", "was", "10", "%", ";", "open", "revisions", "were", "necessary", "in", "only", "2", "of", "120", "patients", ".", "Postoperative", "hospital", "stay", "was", "2", "days", "in", "patients", "undergoing", "laparoscopic", "lymph", "node", "dissection", "only", ".", "This", "minimally", "invasive", "procedure", "is", "particularly", "beneficial", "to", "patients", "with", "lymph", "node", "metastases", "not", "undergoing", "radical", "prostatectomy", ",", "as", "well", "as", "to", "patients", "planned", "to", "be", "treated", "by", "radiation", "therapy", ".", "The", "combination", "of", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "perineal", "prostatectomy", "avoids", "an", "abdominal", "incision", "and", "thus", "shortens", "both", "the", "hospital", "stay", "and", "the", "period", "of", "convalescence", "." ]

[ "umlsterm" ]

lymph node dissection, patients scheduled, prostatectomy, radiation therapy, lymph nodes, patient, patients, metastatic disease, lymph nodes, time, lymph node dissection, prostatectomy, one - stage, procedure, overall, complication, open, patients, Postoperative, hospital, patients, lymph node dissection, invasive procedure, patients, lymph node, metastases, prostatectomy, patients, radiation therapy, lymph node dissection, prostatectomy, hospital, period, convalescence

DerUrologeA.60350413.eng.abstr_task2

Sentence: Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Laparoscopic pelvic lymph node dissection was performed in 120 patients scheduled to undergo either radical perineal prostatectomy or radiation therapy . On average 13 lymph nodes were resected in each patient , and 21 patients were found to have metastatic disease in 1-9 lymph nodes . After an initial learning curve , mean operative time was reduced significantly , allowing laparoscopic lymph node dissection and radical prostatectomy to be performed as a one-stage procedure . The overall complication rate was 10 % ; open revisions were necessary in only 2 of 120 patients . Postoperative hospital stay was 2 days in patients undergoing laparoscopic lymph node dissection only . This minimally invasive procedure is particularly beneficial to patients with lymph node metastases not undergoing radical prostatectomy , as well as to patients planned to be treated by radiation therapy . The combination of laparoscopic lymph node dissection and radical perineal prostatectomy avoids an abdominal incision and thus shortens both the hospital stay and the period of convalescence .

[ "Laparoscopic", "pelvic", "lymph", "node", "dissection", "was", "performed", "in", "120", "patients", "scheduled", "to", "undergo", "either", "radical", "perineal", "prostatectomy", "or", "radiation", "therapy", ".", "On", "average", "13", "lymph", "nodes", "were", "resected", "in", "each", "patient", ",", "and", "21", "patients", "were", "found", "to", "have", "metastatic", "disease", "in", "1", "-", "9", "lymph", "nodes", ".", "After", "an", "initial", "learning", "curve", ",", "mean", "operative", "time", "was", "reduced", "significantly", ",", "allowing", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "prostatectomy", "to", "be", "performed", "as", "a", "one", "-", "stage", "procedure", ".", "The", "overall", "complication", "rate", "was", "10", "%", ";", "open", "revisions", "were", "necessary", "in", "only", "2", "of", "120", "patients", ".", "Postoperative", "hospital", "stay", "was", "2", "days", "in", "patients", "undergoing", "laparoscopic", "lymph", "node", "dissection", "only", ".", "This", "minimally", "invasive", "procedure", "is", "particularly", "beneficial", "to", "patients", "with", "lymph", "node", "metastases", "not", "undergoing", "radical", "prostatectomy", ",", "as", "well", "as", "to", "patients", "planned", "to", "be", "treated", "by", "radiation", "therapy", ".", "The", "combination", "of", "laparoscopic", "lymph", "node", "dissection", "and", "radical", "perineal", "prostatectomy", "avoids", "an", "abdominal", "incision", "and", "thus", "shortens", "both", "the", "hospital", "stay", "and", "the", "period", "of", "convalescence", "." ]

[ "umlsterm" ]

tolerance is a Outcome_Other, bronchoprotective effect is a Outcome_Physical, salmeterol / fluticasone is a Intervention_Pharmacological, salmeterol / fluticasone propionate is a Intervention_Pharmacological, early airway response ( EAR ) is a Outcome_Physical, placebo is a Intervention_Control, allergen challenge ( T1 ) is a Intervention_Pharmacological, single dose of salmeterol / fluticasone is a Intervention_Pharmacological, allergen challenge ( T2 ) is a Intervention_Pharmacological, allergen challenge ( T3 ) is a Intervention_Pharmacological, FEV1 is a Outcome_Physical, MaxDeltaFEV1 % is a Outcome_Physical, area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge is a Outcome_Physical, significantly greater is a Outcome_Other, No difference is a Outcome_Other, area under the curve is a Outcome_Physical, protected against EAR is a Outcome_Physical, protected against EAR . is a Outcome_Physical, tolerance to the protective effect is a Outcome_Physical

24706_task0

Sentence: Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Physical, Intervention_Control

[ "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge . In order to assess whether the administration of salmeterol/fluticasone propionate combination ( 50/250 mcg by Diskus ) for 1 week induces tolerance to the bronchoprotective effect of salmeterol on allergen challenge , a single-blind , cross-over study was carried out . We studied nine subjects ( eight men and one woman ; mean age+/-SD : 31.3+/-11.0 yr ) with mild intermittent allergic asthma , never treated with regular beta2-agonists or inhaled corticosteroids . In a previous allergen challenge all subjects had shown a positive early airway response ( EAR ) to allergen . They underwent allergen challenge after 1-week treatment with placebo and a single dose of placebo immediately before allergen challenge ( T1 ) , or 1-week treatment with placebo and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T2 ) , or 1-week treatment with salmeterol/fluticasone combination bid and a single dose of salmeterol/fluticasone immediately before allergen challenge ( T3 ) . EAR was evaluated both as maximum decrease in FEV1 ( MaxDeltaFEV1 % ) after allergen challenge and as area under FEV1 -time curve . MaxDeltaFEV1 % during allergen challenge protected by placebo ( T1 ) was significantly greater than MaxDeltaFEV1 % during allergen challenges protected by single dose of salmeterol/fluticasone ( T2 ) and by salmeterol/fluticasone 1-week treatment ( T3 ) . No difference was found in MaxDeltaFEV1 % between T2 and T3 . The same results were observed also after computing the area under the curve for each challenge . When individually considered , all subjects were protected against EAR ( protection index > or = 80 % ) at T2 , while at 3 seven out of nine subjects were still protected against EAR . In conclusion , the simultaneous administration of salmeterol and fluticasone in the same device prevents in almost 80 % of examined subjects the development of tolerance to the protective effect of salmeterol on allergen challenge . This observation may contribute to explain the positive interaction between inhaled beta2-agonists and corticosteroids in the long-term treatment of asthma .

[ "Minimal", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "inhaled", "salmeterol", "/", "fluticasone", "combination", "on", "allergene", "challenge", ".", "In", "order", "to", "assess", "whether", "the", "administration", "of", "salmeterol", "/", "fluticasone", "propionate", "combination", "(", "50/250", "mcg", "by", "Diskus", ")", "for", "1", "week", "induces", "tolerance", "to", "the", "bronchoprotective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ",", "a", "single", "-", "blind", ",", "cross", "-", "over", "study", "was", "carried", "out", ".", "We", "studied", "nine", "subjects", "(", "eight", "men", "and", "one", "woman", ";", "mean", "age+/-SD", ":", "31.3+/-11.0", "yr", ")", "with", "mild", "intermittent", "allergic", "asthma", ",", "never", "treated", "with", "regular", "beta2-agonists", "or", "inhaled", "corticosteroids", ".", "In", "a", "previous", "allergen", "challenge", "all", "subjects", "had", "shown", "a", "positive", "early", "airway", "response", "(", "EAR", ")", "to", "allergen", ".", "They", "underwent", "allergen", "challenge", "after", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "placebo", "immediately", "before", "allergen", "challenge", "(", "T1", ")", ",", "or", "1-week", "treatment", "with", "placebo", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T2", ")", ",", "or", "1-week", "treatment", "with", "salmeterol", "/", "fluticasone", "combination", "bid", "and", "a", "single", "dose", "of", "salmeterol", "/", "fluticasone", "immediately", "before", "allergen", "challenge", "(", "T3", ")", ".", "EAR", "was", "evaluated", "both", "as", "maximum", "decrease", "in", "FEV1", "(", "MaxDeltaFEV1", "%", ")", "after", "allergen", "challenge", "and", "as", "area", "under", "FEV1", "-time", "curve", ".", "MaxDeltaFEV1", "%", "during", "allergen", "challenge", "protected", "by", "placebo", "(", "T1", ")", "was", "significantly", "greater", "than", "MaxDeltaFEV1", "%", "during", "allergen", "challenges", "protected", "by", "single", "dose", "of", "salmeterol", "/", "fluticasone", "(", "T2", ")", "and", "by", "salmeterol", "/", "fluticasone", "1-week", "treatment", "(", "T3", ")", ".", "No", "difference", "was", "found", "in", "MaxDeltaFEV1", "%", "between", "T2", "and", "T3", ".", "The", "same", "results", "were", "observed", "also", "after", "computing", "the", "area", "under", "the", "curve", "for", "each", "challenge", ".", "When", "individually", "considered", ",", "all", "subjects", "were", "protected", "against", "EAR", "(", "protection", "index", ">", "or", "=", "80", "%", ")", "at", "T2", ",", "while", "at", "3", "seven", "out", "of", "nine", "subjects", "were", "still", "protected", "against", "EAR", ".", "In", "conclusion", ",", "the", "simultaneous", "administration", "of", "salmeterol", "and", "fluticasone", "in", "the", "same", "device", "prevents", "in", "almost", "80", "%", "of", "examined", "subjects", "the", "development", "of", "tolerance", "to", "the", "protective", "effect", "of", "salmeterol", "on", "allergen", "challenge", ".", "This", "observation", "may", "contribute", "to", "explain", "the", "positive", "interaction", "between", "inhaled", "beta2-agonists", "and", "corticosteroids", "in", "the", "long", "-", "term", "treatment", "of", "asthma", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Intervention_Control" ]